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1.1 TARGETING INTEGRINS 
 
Integrins are the major family of adhesion receptors known in the kingdom Animalia, 
being involved in cell adhesion to extracellular matrix proteins and also playing 
important roles in cell-cell adhesion. In addition to mediating cell adhesion, integrins 
make transmembrane connections to the cytoskeleton and activate many intracellular 
signaling pathways. Since the recognition of the integrin receptor family around 20 
years ago,1 they have become the best-understood cell adhesion receptors. Integrins and 
their ligands play key roles in the pathogenesis of inflammatory diseases, leukocyte 
traffic, aggregation, tumor progression as well as osteoporosis and macular 
degeneration. The role of integrins in pathological conditions makes them attractive as 
pharmacological targets.2 
Research in the last two decades has been directed to the discovery and the 
development of integrin antagonists for clinical applications.3 The early discovery of the 
structural basis of the recognition between integrins and their natural ligands by means 
of short amino acid sequences,4 together with outstanding crystallographic, electron 
microscopy, and computational analyses5,6 on selected integrin subfamilies provided a 
breakthrough for the rational design of a wide variety of class-selective or promiscuous 
integrin inhibitors. 
 
1.1.1 -   Integrins: family, function, structure 
Integrins are heterodimeric membrane glycoproteins comprising non-covalently 
associated - and -subunits, mediating dynamic linkages between extracellular 
adhesion molecules and the intracellular actin cytoskeleton. They are expressed by all 
multicellular animals, but their diversity varies widely among species; for example, 18 
 and 8  subunit genes are present in mammals, encoding for 25 diﬀerent 
heterodimers, whereas the Drosophila and Caenorhabditis genomes encode only five 
and two integrin  and  subunits, respectively. 
Each integrin subunit consists of an extracellular domain, a single transmembrane 
region, and a short  cytoplasmic region (∼30–40 amino acids). Figure 1.1.1 depicts the 
mammalian subunits and their  associations; 8  subunits can assort with 18  
subunits to form 24 distinct integrins.7 
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Figure 1.1.1 - Integrin family. 
The N-terminus of the -chain consists of a -propeller domain that is formed by seven 
repeats of 60 amino acids each.8 The -propeller domain is linked to the transmembrane 
domain by three regions that have been named the Thigh, Calf-1, and Calf-2 domains 
(Figure 1.2 a). In addition, a highly flexible region is present between the Thigh and 
Calf-1 domains.5 Half of all -chains have an additional 200-amino acid inserted 
domain between repeats two and three of the - propeller (the I-domain, Figure 1.1.2 
a).9 The I-domain functions as the major ligand-binding site in those integrins where it 
is present, whereas the -propeller serves as the ligand binding in integrins without I-
domains.10 Cytoplasmic tail domains of individual -subunits are well-conserved across 
species boundaries.11 
The N-terminal region of the -subunit consists of a cysteine-rich region termed the 
plexin-semaphorin-integrin (PSI) domain. C-terminal to this domain is an 
evolutionarily conserved I-like domain flanked on either side by immunoglobulin folds 
called hybrid domains. The membrane proximal region of the -subunit contains four 
EGF-like repeats. The -subunit also has a flexible ‚knee‛ region, which is formed by 
the hybrid domain and the first two EGF-like repeats (Figure1.1.2 b).10 The intracellular 
regions of the -subunits are more conserved between subunits than are the -subunit 
cytoplasmic tails.12 These -chain cytoplasmic tails play significant roles in regulating 
integrin activity.5b 
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Figure 1.1.2 - Integrin structure. a) Primary structure of integrin -subunits. Half of the -subunits also 
have an I-domain inserted between -propeller repeats 2 and 3; b) Primary structure of integrin -
subunits. 
Each -chain combines with a -chain to form a unique heterodimer with selectivity for 
ECM proteins, cell surface molecules, plasma proteins, or microorganisms.13 Integrins 
bind to their ligands in a divalent cation-dependent fashion.14 Although some integrins 
recognize primarily a single ECM protein ligand (e.g., 51 recognizes primarily 
fibronectin), others can bind several ligands (e.g., integrin v3 binds vitronectin, 
fibronectin, fibrinogen, denatured or proteolyzed collagen, and other matrix proteins). 
Many integrins recognize the tripeptide Arg–Gly–Asp (RGD) (e.g. v3, 51, IIb3, v6, 
and 31), but sequences flanking the RGD peptide are also important for selectivity.13a,b 
Other integrins recognize alternative short peptide sequences (e.g., integrin 41 
recognizes Glu lle Leu Asp Val [EILDV] and Arg Glu Asp Val [REDV] in alternatively 
spliced CS-1 fibronectin and IIb3 binds KQAGDV in the fibrinogen  chain).15 In 
addition, some integrins can also bind cell surface receptors to induce cell–cell 
adhesion.13b,c 
The ligands bound by common integrins and integrin clinical targets are shown in 
Table 1.1.1.16  
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Table 1.1.1 - Integrin subfamilies cluster major therapeutic indications and main ligands. 
Integrin class Clinically targeted in: Main ligandsa 
 
α4- Family 
α4β1  MS, autoimmune, Crohn’s, IBD  VCAM-1, FN 
α4β7  MS, autoimmune, arthritis  MAd-CAM-1 
α9β1  Cancer  VCAM-1, Opn, VEGF-C,-D 
 
Leukocyte cell adhesion 
αLβ2 
 Inflammation, psoriasis, stroke, ischemia,   
fibrosis 
 ICAM-1,-2,-3 
αMβ2  Inflammation, autoimmune iC3b, Fbg 
αXβ2  Inflammation iC3b, Fbg 
αDβ2  Inflammation  ICAM-3, VCAM-1 
αEβ7  Inflammation  E-cadherin 
 
RGD-binding 
gpIIbIIIa  Thrombosis, stroke, myocardial ischemia  Fbg, vWf 
α5β1  Cancer, AMD  FN 
α8β1  None  Npn, FN, VN 
αnβ1  Cancer  VN, FN 
αnβ3  Cancer, osteoporosis  VN, Opn, vWf, FN, Fbgb 
αnβ5  Cancer  VN 
αnβ6  Fibrosis, transplant rejection, cancer  FN, TGF-b1,-3 
αnβ8  Cancer  FN, TGF-b1,-3 
 
I domain: collagen binding 
α1β1  Fibrosis, cancer  Col 
α2β1  Fibrosis, cancer  Col 
α10β1, α11β1  None  Col 
 
LN binding 
α3β1  None  LN-5 
α6β1, α7β1  None  LN-1, -2 
α6β4  None  LN-2, -4, -5 
a Abbreviations: VCAM-1, vascular cell adhesion molecule 1; Mad-CAM-1, mucosal vascular addressin 
cell adhesion molecule 1; ICAM, Intercellular Adhesion Molecule 1; iC3b, complement regulatory 
protein; TGF, transforming growth factor;  Col, collagens; Fbg, fibrinogen; FN, Fibronectin; LN, laminin; 
Npn, nephronectin; Opn, osteopontin; VN, vitronectin; vWF, von Willebrand factor. 
b Among many other ligands. 
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Integrins are not constitutively active, but rather exist in multiple activation states 
(Figure 1.1.3).17 Integrin activation status is regulated by the delicate balance in a 
bidirectional signaling mechanism which drives reversible changes in integrin 
conformation and affinity for their ligands. Both extra- and intracellular stimuli are 
allowed to regulate activation.7,18 
 
Figure 1.1.3 - Representation of integrin activation states. 
High affinity binding of integrins to ligands is promoted in response to intracellular 
signaling events converging on the cytoplasmic domain that alter the tertiary and 
quaternary structure of the extracellular region, making the integrin ligand-competent 
(inside-out signaling). 
Extracellular factors that influence integrin activation are ligand binding, divalent 
cation concentration, chemokine signaling and mechanical stress. Integrins transmit 
signals to the cell interior, which regulate organization of the cytoskeleton, activate 
kinase signaling cascades, and modulate the cell cycle and gene expression (outside-in 
signaling). Through this mechanism, integrins behave as mechanochemical transducers, 
orchestrating a synergic cross-talk with other extracellular matrix constituents and 
providing anchorage for endothelial cells. 
The integrin tails serve as a site for the docking of various kinases and related adaptor 
proteins that comprise focal adhesions. Signals emanating from focal adhesions have 
been shown to promote survival, differentiation and proliferation.19 In the absence of 
integrin ligation, these processes are abrogated, and therefore pharmacological 
inhibition of integrin ligation is of great interest for the therapy of numerous diseases 
resulting from aberrant integrin mediated signaling. 
Integrins are transducing information both into and out of the cell to promote cell 
adhesion, spreading and motility. Disruption of focal adhesions prevents integrin-
mediated cell adhesion and impairs cell motility and migration. Prolonged integrin 
inhibition in adhesion-dependent cells results in anoikis, apoptotic cell death due to 
ECM deprivation.20 
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1.1.2 Role in Human Diseases 
1.1.2.1 Role in Angiogenesis 
Angiogenesis is the process whereby new vessels form from pre-existing vessels. The 
growth of new blood vessels promotes embryonic development, wound healing, the 
female reproductive cycle, and also plays a key role in the pathological development of 
solid tumors, hemangiomas, diabetic retinopathy, age-related macular degeneration, 
psoriasis, gingivitis, rheumatoid arthritis, and possibly osteoarthritis and inflammatory 
bowel disease.21 
Several cell types within tumors, including tumor cells, monocytes, and fibroblasts, 
secrete growth factors, such as VEGF, that induce blood vessel growth into tumors 
(Figure 1.1.4).22 
Studies have shown that angiogenesis plays a major role in tumor growth and that 
inhibiting angiogenesis can inhibit tumor progression and metastasis. Although growth 
factors and their receptors play key roles in angiogenic sprouting, adhesion to the ECM 
also regulates angiogenesis. 
Formation of new vasculature requires endothelial cell attachment and migration on 
ECM proteins. One ECM protein, fibronectin, is associated with vascular proliferation.23 
As integrins are critical for the cell to bind ECM, many integrins play crucial roles in 
regulating vascular growth, both during embryonic development and in various 
pathologies. Proliferating endothelial cells express several integrins that are not 
expressed on quiescent blood vessels. 
Recent studies suggest that inhibition of both v3 and 51 may be required for optimal 
effects on angiogenesis.24 
 
 
 
Figure 1.1.4 - Angiogenesis: a) secretion of 
growth factors and Chemokines from 
tumor cells in vicinity of already existing 
blood vessels; b) activation or expression 
upregulation of integrins such as 11, 
21, 41, 51 and V3 on blood vessels; 
c) integrins promoting endothelial cell 
migration and survival during invasion of 
tumour tissue. New vessel sprouts are 
produced promoting tumour growth and 
providing a way to metastasis to local and 
distant sites, such as lung. 
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Integrins IIb3 
IIb3 integrin (GPIIa/IIIb) is highly expressed on the surface of platelets,25 comprising 
approximately 80% of the total surface proteins found on platelets. The final common 
pathway in blood coagulation involves the engagement of this integrin induced by 
platelet activation. Under normal conditions integrin IIb3 is maintained in the 
inactivated state. Soluble factors in the blood such as thrombin, bind their respective 
platelet receptors to activate inside-out signalling pathways that cause conformational 
changes in IIb3 integrin.25 Changes in conformation lead to increases in receptor 
affinity and avidity, which promote platelet aggregation and clot formation through 
increased cell-to-cell contacts and cell-matrix contacts. Aberrant platelet aggregation or 
thrombosis is central to the pathophysiology of multiple Acute Coronary Syndromes 
(ACS), unstable angina, ischemic stroke and sickle cell anemia. Inhibition of IIb3 
prevents platelet aggregation and therefore has shown efficacy in the prevention of 
thrombosis for the treatment of ACS. Some IIb3 integrin targeted drugs have already 
been approved so far. 
The complete ectodomain structure of integrin IIb3 was determined,26 thus living 
information about its binding site, better understanding its binding mode and 
conformation (Figure 1.1.5). The binding mode of RGD-based IIb3 antagonists was 
established through mutagenesis experiments27 and crystallographic analysis of the 
platelet fibrinogen receptor.28 
 
 
Figure 1.1.5 - Crystal structure of the extracellular segment of integrin IIb3. 
IIb3 
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Integrins v3 andv5 
Integrin v3 is expressed on angiogenic blood vessels but not on resting vessels.29 
Antibodies that inhibit v3 block angiogenesis in a variety of animal models. A key role 
of v3 in vasculogenesis and angiogenesis has been outlined. Peptide and antibody 
antagonists of v3 also block tumor angiogenesis and growth. Further analysis showed 
tumor regression related to apoptosis in the vasculature, induced by these antagonists.30 
Different members of the integrin v subfamily transduce angiogenic signals by 
different growth factors. In vivo angiogenesis assays showed that bFGF or TNF- 
depend on v3 to initiate angiogenesis, whereas v5 is required for TGF-- and VEGF-
mediated angiogenesis.31 These data, taken together, have established a role for v3 
integrins in angiogenesis and as important therapeutic targets. 
One study showed that animals lacking 3 or 3 and 5 subunits displayed increased 
tumor angiogenesis.32 This led to the controversial conclusion that v3/v5 integrins 
might actually be involved in suppressing angiogenesis. However, it is likely that the 
apoptotic mechanism, which is generally induced by unligated integrins and controls 
tumor vascular growth, is responsible for the increased vascularization in 3 - and 5 -
deficient tumors.16,33 
The complete crystal structure of v3 integrin ectodomain including an  
transmembrane fragment has been very recently determined.34 The earlier 
determination of the crystal structure of the ectodomain of v3 (∆TM-v3, Figure 
1.1.6a) in the absence and presence of a prototypical RGD ligand (Cilengitide, Figure 
1.1.6b), already revealed the modular nature of integrins and pivotal information on its 
divalent cation–mediated binding interactions with extracellular ligands. 
 
 
Figure 1.1.6 - Crystal structures of V3 integrin: a) Crystal structure of the extracellular segment of 
integrin V3; b) Crystal structure of the extracellular segment of V3 integrin in complex with the cyclic 
pentapeptide ligand Cilengitide, in its binding conformation. 
V3 
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A homology model for the closely related V5 receptor was developed. The two 
integrins were found to mostly differ in the region comprising residues 159-188 in the 3 
subunit. A ‘roof’ was described for V5 integrin featuring Tyr and Lys residues, which 
would hamper the binding of compounds containing bulky substituents nearby their 
Asp-mimicking group. Because of this difference, a few inhibitors of V3 integrin 
displaying selectivity over V5 have actually been found,35 but specific inhibitors of 
V5 integrins have not been described yet. 
 
Integrin 51 
Integrin 51 is significantly upregulated in tumor angiogenesis in both mice and 
humans, but is not expressed on quiescent endothelium. Antagonists of 51 also 
inhibited tumor angiogenesis in chicks and mice, thus leading to tumor regression.23 
Integrin 51-mediated adhesion promotes endothelial cell survival in vivo and in vitro33 
by suppressing the activity of protein kinase A (PKA). Integrin 51 antagonists activate 
both PKA and caspase-8, thereby inducing apoptosis and inhibiting angiogenesis.36 
Although inhibition of integrin ligation can prevent cell attachment to the ECM, recent 
studies show that integrin 51 antagonists also actively suppress signal transduction 
that leads to cell survival. Antagonists of 51 suppress cell migration and survival on 
vitronectin, but not cell attachment to vitronectin, indicating that these antagonists 
affect the migration and survival machinery rather than integrin receptors for 
vitronectin.16,37 The three-dimensional structure of the ligand-binding headpiece of 
integrin 51 complexed with fragments of its physiological ligand fibronectin was 
determined by means of a molecular electron microscopy. The density map for the 
unliganded 51 headpiece shows a ‘closed’ conformation similar to that seen in the V3 
crystal structure. By contrast, binding to fibronectin induces an ‘open’ conformation 
(Figure 1.1.7).38 
 
 
Figure 1.1.7 - Surface-rendered density maps of the 51 headpiece: a) the unliganded closed and b) the 
ligand-bound open conformation. 
a) b) a) 
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The lack of reliable structural data in the past, however, excluded 51 as target for 
structure based drug design. However, the high homology between the different 
integrin subtypes makes them promising targets for homology modeling, which was 
achieved for αVβ5 integrin by Kessler and co-workers.39,35b Homology modeling of 
proteins is considered to be possible for a homology of 40% or greater.40 This 
precondition is met by the integrins αvβ3 and α5β1 with 53% homology for αv/α5 and 
55% for β3/β1. Recently the α5β1 crystal structure was published, providing the necessary 
knowledge for structure based drug design.41 In particular Takagi and coworkers 
reported the crystal structure of a ligand-binding fragment of human α5β1 integrin, a 
prototypic integrin that functions as an RGD-dependent fibronectin receptor. The 
structure, solved as a complex with a Fab fragment of the anti-β1inhibitory antibody 
SG/19, revealed high similarity to the ligand unbound form of αVβ3 and αIIbβ3 integrins 
(Figure 1.1.8). Surprisingly, the RGD peptide can be introduced into the binding pocket 
by soaking, without causing any conformational change in integrin except for an ~1 Å 
shift of one residue and the dissociation of Ca2+ from the adjacent to the MIDAS 
(ADMIDAS). Docking simulations and structure-based mutagenesis identified a single 
α5 residue responsible for the strong preference of α5β1 for fibronectin, establishing a 
basis for the combinatorial roles played by each subunit during the specific recognition 
of protein ligands. 
 
 
Figure 1.1.8 - Structure of the α5β1 integrin 
headpiece in complex with SG/19Fab: A) 
Ribbon presentation of the overall structure 
with disulfide bonds in stick model. Individual 
domains are differently colored in magenta (β-
propeller), red (thigh), cyan (βA), blue 
(hybrid), and purple (PSI), and bound metal 
ions are shown as spheres (yellow for Ca2+ and 
purple for Mg2+). SG/19 Fab is colored in gray 
(light chain) and wheat (heavy chain), with 
their CDR loop regions highlighted in green 
and yellow, respectively. B) Close-up view of 
the SG/19-binding interface. SG/19 Fab and β1 
chain are shown in surface and ribbon 
presentations, respectively, with the same 
color code used in A. CDR regions and 
important interface residues are labeled. C) 
Superposition of three integrin headpiece 
structures in the ligand unbound form. Blue, 
α5β1; red, αvβ3 (3IJE); green, αIIbβ3 (3FCS). On 
the right is a blowup of the region around the 
metal-binding sites in the β1 (blue) and β3 
(green; 3FCS) βA domains. 
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1.1.2.2 Role in hemostasis and thrombosis 
Thrombosis is a disease-related process consisting in the formation of a blood clot 
inside a blood vessel. It occurs when platelets adhere to damaged blood vessels and 
become activated.42 These activated platelets recruit other platelets, resulting in the 
formation of a haemostatic plug. This is an essential mechanism for preventing blood 
loss, but inappropriate thrombus formation can lead to a stroke or to a heart attack. It is 
probably the first clearly integrin associated process. 
In this context, integrin αIIBβ3 is responsible for platelet aggregation and this feature 
made it the first integrin to be identified as therapeutic target. In the 1990s, three αIIBβ3 
integrin inhibitors were approved to reduce the risk of ischaemic events in patients with 
acute coronary syndromes and those undergoing percutaneous coronary intervention. 
They were the antibody fragment abciximab and the small-molecule inhibitors 
eptifibatide 1 and tirofiban 2 (Figure 1.1.9), all of which are administered 
intravenously.43 
 
 
Figure 1.1.9 - αIIBβ3 integrin inhibitors. 
 
However, despite initial expectations that antagonists targeting this integrin would be 
blockbuster drugs, attempts to develop oral antagonists for more convenient 
administration were not successful, and the use of the approved intravenous inhibitors 
has largely been restricted to high-risk patients.  
Instead, clopidogrel (commercially known also as PLAVIX®), an orally active ADP 
receptor antagonist, filled the market that was expected for αIIBβ3 integrin antagonists 
and became the second biggest-selling drug globally.44 
The failure of oral αIIBβ3 antagonists was probably due to multiple factors.45 There were 
severe problems, in particular a poor bioavailability and the lack complete 
understanding of the αIIBβ3 integrin role in thrombosis and signalling. 
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1.1.2.3  Immune system disorders 
Beside the studies on blood diseases, a great number of attempts have been made to 
find efficient antagonists of integrins involved in immune system disorders. 
In particular, both β1 and β2 integrins are important in immune function, where they 
have essential roles in localizing the immune response to the site of inflammation.46 
Moreover a defect in β2 integrins leads to a life-threatening immune dysfunction (that 
is, leukocyte adhesion deficiency).47 
In this context, αLβ2 and α4β1 have been the first integrins to be therapeutically targeted. 
In particular Karin and coworkers reported that α4β1 integrin has a key role in the 
migration of lymphocytes to inflamed regions of the central nervous system in rodent 
models of multiple sclerosis.48 
Monoclonal antibody binding the α4 integrin subunit (natalizumab, approved in 2004) 
was effective in the treatment of multiple sclerosis, and also for the inflammatory bowel 
disorder Crohn’s disease.49Although natalizumab showed substantial efficacy in clinical 
trials,50 several patients developed a fatal progressive multifocal leukoencephalopathy 
after treatment,51 and the drug was withdrawn from the market in 2005. However, after 
reassessment in 2010, the European Medicines Agency (EMA) concluded that the 
benefits outweighed the risks for patients treated with natalizumab, and it was re-
approved with implementation of appropriate warning and safety measures. Several 
small-molecule inhibitors of α4 integrins are in development as followers of 
natalizumab. 
 
1.1.2.4  Osteoporosis 
Osteoporosis occurs when the balance between bone formation and degradation is 
disturbed. Integrins have an important role in the function of osteoclasts, which 
mediate bone resorption. Osteoclast α1β1 integrin is responsible for the adhesion of 
osteoclasts to collagen.52  The αVβ3 integrin is also important in osteoclast function, and 
polymorphisms in this receptor are also associated with increased rate of fracture.53 An 
antagonist of this receptor (L-000845704) showed an increased bone density in 
postmenopausal women in a Phase II clinical study.54 However, it seems that neither 
this antagonist or any other anti-integrin is currently in clinical development for 
osteoporosis. 
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1.1.3 RGD and isoDGR recognition motifs 
The arginine-glycine-aspartic acid (RGD) cell adhesion sequence was discovered in 
fibronectin 27 years ago.55 Other adhesion proteins such as vitronectin, fibrinogen, von 
Willebrand factor, thrombospondin, laminin, entactin, tenascin, osteopontin, bone 
sialoprotein, and, under some conditions, collagens were then discovered to include 
RGD sites. It was soon confirmed with regard to fibronectin and then extended to other 
proteins that the RGD sequence is the endogenous recognition motif for cell attachment 
to proteins. 
Cells expressing several V integrins (e.g. 1,3,5,6 and 8), as well as integrins IIb3, 
51 and 81, recognize the ubiquitous RGD sequence in their ligands. Naturally 
occurring integrin inhibitor proteins bearing the RGD motif are showing an extremely 
varied selectivity and potency in targeting RGD-recognizing integrins. Elucidations on 
their structure suggest that proper restriction of the RGD flexibility can lead to integrin 
inhibition.56 
Hence, monomeric linear or confomationally constrained RGD-containing cyclic 
peptides, pseudo-peptides, and mimetics thereof displaying high potency and 
selectivity were conceived. The most significant advances in this field have led to the 
development of agents targeting IIb3 integrin on platelets for inhibiting thrombosis57 
and inhibitors of V3 andV5 integrins against angiogenesis, cancer and bone 
resorption.58 Among these, it is important to recall the nanomolar V3/V5 binder 
cyclic pentapeptide c-RGD-(D-Phe)-N-methyl-V developed by Kessler (known as 
Cilengitide or EMD121974), which is currently tested in phase II clinical investigation 
(‚CORE‛ trials) for patients with newly diagnosed glioblastoma multiforme and 
unmethylated MGMT gene promoter, while it has been withdrawn from phase III 
clinical investigation (‚CENTRIC‛ trials, Cilengitide in combination with 
Temozolomide and Radiotherapy in newly diagnosed glioblastoma).58p  
As already mentioned, a crucial enhancement in this field was achieved with the crystal 
structure resolution of the ectodomain of V3 integrin, both unligated and complexed 
with Cilengitide,5b as well as the better crystal structure resolution of IIb3 integrin 
complexed with the synthetic anti-trombotic drug Eptifibatide.6d,59 
 
Besides the well-defined RGD and other binding motifs, it has been proposed that the 
NGR and DGR sequences might also have a role in integrin recognition. Controversial 
results have however been reported. 
The importance of the isoDGR sequence as an integrin binding motif was discovered by 
serendipity by Corti research group (S.Raffaele/MolMed).60 
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The NGR sequence, present in several endogenous molecules as well as in fibronectin 
FN-I5 and FN-I7, can easily deamidate (also in vivo) on asparagine, giving isoDGR and 
DGR (Scheme 1.1.1). Although protein modifications typically causes loss of 
activity/function, it was recently suggested that isoDGR formation at NGR or DGR sites 
might result in a gain of function. The isoDGR sequence can in fact mimic RGD and 
interact with the RGD-binding site of integrins.61 
 
 
Scheme 1.1.1 - Formation of DGR and isoDGR sequences by asparagine deamidation. 
 
isoDGR containing peptides can recognize members of the RGD-dependent integrin 
family, such as v3, v5, v6, v8 and 51, but not other.62 Both affinity and specificity 
of the interaction between isoDGR and integrin binding site is reported to be highly 
dependent on the flanking residues. 
Notably, isoDGR docks onto the integrin binding site in an inverted orientation respect 
to RGD. This orientation allows isoDGR to bind to the v3  binding pocket maintaining 
all the typical electrostatic-clamp interactions of the RGD motif. The acidic and basic 
residues are at the correct distance and orientation to engage stabilizing interactions 
with the polar regions of integrin: the isoAspartic carboxylic side chain is interacting 
with MIDAS, Asn215, Tyr122 and Arg214, while Arginine guanidinium interacts with 
Asp218, Asp150 and Gln180. Moreover, additional stabilizing interactions are present: 
glycine recognizes the receptor via polar interactions and an H-bond between its amide 
and carbonyl of Arg216.61 Therefore, isoDGR can be considered as a natural fit for the 
RGD binding pocket of v3 integrin, suggesting that the naturally occurring 
transformation of NGR and DGR into isoDGR functions as a molecular switch able to 
activate integrin recognition. 
Although isoDGR- and RGD-containing ligands can share the same integrin binding 
site, their effects on integrin function might not be necessarily the same.63  
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1.1.3.1 RGD integrin ligands: state of the art 
The potential of v3  inhibitor EMD121974 (3, Cilengitide, Figure 1.1.10) by Kessler was 
soon recognized by various clinical programs, opening the era of the integrin inhibitor 
class as investigational agents for antiangiogenic and anticancer therapies. The crystal 
structure analysis of the ectodomain of v3 complexed with Cilengitide offered the first 
clear picture of the RGD binding mode, which revealed a Cilengitide conformation 
featuring an inverse -turn centred on Asp, and a distorted II'-turn with Gly and Asp 
at the i+1 and i+2 positions, respectively. A distance of 8.9 Å between the C of Asp and 
Arg, accounting for an almost extended conformation of the RGD motif were observed. 
The most important interactions between the ligand and the receptor involved the Arg 
guanidinium group, which was forming salt bridges with Asp150 and Asp218 in the 
subunit, and the Asp carboxylic group of the ligand, which interacts with the Mn2+ ion 
at MIDAS (Metal-Ion-Dependent Adhesion Site) in the subunit. Moreover, several 
hydrophobic interactions were engaging the Gly residue, positioned at the interface 
between the and subunits. 
An earlier example of RGD-based cyclic peptide had already been identified by Kessler, 
c(RGDfV)64 4 (Figure 1.1.10), which can be considered as an ancestor of Cilengitide. This 
compound was selectively active against V3 integrin, and its overall conformation 
allowed the lateral chains of Asp and Arg to adopt a unstretched arrangement (distance 
C(Asp)- C(Arg) 6.9 Å). 
Representative examples of semipeptidic V3 inhibitors, bearing a non-peptidic and 
rigid turn-inducing motif to appropriately constrain the RGD motif, are reported in the 
literature. 
Classic bicyclic, but also monocyclic scaffolds and simple linear tethers have been used 
to properly fold the RGD sequence within a macrocyclic template, to better fit within 
V3 integrin binding site.65 
Bicyclic heterocycles stand among the most popular constrained mimetics of natural 
amino acids in the structure-based design of peptidomimetics. Various successful 
examples of peptide are validating their use as preferred conformation inducing 
scaffolds.66 
Kessler exploited azabicycloalkane and spyrocyclic systems, traditionally known as -
turn inducers, to prepare cyclic RGD-containing peptidomimetics.67 The most active and 
less constrained compound of the series (5, Figure 1.1.10) was a fully promiscuous 
antagonist. 
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Figure 1.1.10 
 
A library of RGD pentapeptide mimetics incorporating 5,6- and 5,7-fused 
azabicycloalkane amino acids was generated by the group of Scolastico.68 Among the 
high affinity ligands found within the collection, the most active compounds 
demonstrated low nanomolar binders of V3 and V5 integrins. 6 was completely 
selective towards V3 integrin respect toV5 integrin. Moreover, significant 
antiangiogenic activity of this compound emerged from in vitro experiments showing 
inhibition of the proliferation of endothelial cells.69 
 
 
Figure 1.1.11 
 
A strong dependence of the overall conformation of the cyclic peptides on the lactam 
ring size and stereochemistry was revealed. Almost the same interactions observed in 
the crystal structure of V3 complexed with Cilengitide 3 were maintained. They 
observed an average distance between Arg and Asp C of 8.8 Å in the case of 6, and 8.5 
Å in 7, indicative of an almost extended conformation of the RGD sequence. 
Cyclopeptide 8 (Figure 1.1.11) emerged as a nanomolar antagonist of both V3 and V5 
integrins comparable to ST1646 7. Docking studies revealed that the conformations 
containing an inverse -turn on Asp conserved the main contacts observed in the X-ray 
crystal structure with Cilengitide 3.70 
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Also monocyclic turn-inducing scaffolds were used in the search for non peptidic RGD-
containing systems, based on II'/ arrangement with the -turn centered on Gly. 
Kessler inserted amino pyrrolidinone based motifs to hold the RGD moiety, providing 
macrocycles 9a and 9b (Figure 1.1.12).71 A II' turn conformation with Gly at the i+1 
position was unexpectedly observed for  these compounds. 9a was a moderate and 
selective antagonist of V3 integrin, while 9b proved to be a more active V3 inhibitor, 
even though aspecific. The main difference between the two analogues was the 
orientation of the lactam bond in the turn-motif, which was found to be rotated by 180° 
in the two isomers, and involved in a H-bond with the receptor in the case of 9b. 
 
 
Figure 1.1.12 
D- and L-morpholines were exploited by Guarna and co-workers to replace the N-Me-
Val motif of Cilengitide 3, grafting compounds 10 (Figure 1.1.13).72 The different 
conformation of the peptide bond between D-Phe and the morpholine scaffold provided 
distinct structural arrangements for the two compounds. 10b showed in particular a cis 
conformation in the docking analysis, with an RGD sequence arrangement comparable 
to that observed in the V3-Cilengitide complex. 
 
 
Figure 1.1.13 
 
Kessler and Overhand designed several pyranoid and furanoid sugar - and -amino 
acid based compounds. Due to their high flexibility, they proved to be aspecific 
antagonists of V3 and IIb3 integrins. This aspecificity was also supported by the 
conformational analysis of this compounds, which showed an arrangement standing in 
between the typical kinked conformation of V3-selective antagonists and the extended 
one required for targeting IIb3  integrin. The two most representative members of this 
class of compounds are sketched in Figure 1.1.14 (11, 12).73,58k 
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Casiraghi and colleagues, following an analogous inspiration, exploited furanoid 
carbasugar -amino acid equivalents to generate four stereoisomeric macrocycles (most 
active members 13, Figure 1.1.14). Although an improvement in the affinity towards 
V3 and V5 was observed, their activity surprisingly proved to be almost irrespective 
of the configuration at the carbons bearing the amino acid functions. An inverted -turn, 
centered on Asp was revealed by NMR, displaying a C(Asp)- C(Arg) distance in the 
range of 8.0-8.4 Å.74 
 
 
Figure 1.1.14 
The same group incorporated 4-amino proline (Amp) scaffolds into a library of RGD 
peptides, to further extend these findings.75 The compounds reported in Figure 1.1.15 
(14 a-d) displayed exceptionally high affinity towards V3 and V5 integrins. A 
picomolar activity was observed for V3 integrin in the high affinity status. A 
preferential conformation featuring an inverse -turn motif around Asp for the 
macrocycles containing a cis-disposed -amino acid motif was detected by NMR 
conformational analysis. On the contrary the macrocycles proved to be more flexible 
when a trans -amino acid was present. All the macrocycles showed a C(Asp)- C(Arg) 
distance in the 7.8-8.2 Å range. The most active analogues maintain the relevant key 
interactions observed for Cilengitide 3. Compound 14a was stabilized by a strong H-
bonding contact between the NH in the aminoproline motif and Tyr178. Quite 
interestingly, the alkyl and acyl chains of 14 b and c provided additional contacts for 
binding, pointing towards a large hydrophobic hollow rich with aromatic residues.  
 
 
Figure 1.1.15 
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Pseudopentapeptides containing both enantiomers of cis--
aminocyclopropanecarboxylic acid (-Acc) were conceived, the most interesting of the 
two being sketched in Figure 1.1.15 (15).58e 
Compound 15 resulted more active towards both V3 and 51 integrins, respect to the 
reference compound c(RGDfV) 4. The C(Asp)- C(Arg) distance found for compound 
15 resulted considerably shorter than expected (7.06 Å). Moreover, a -turn centered on 
Gly and a pseudo -turn wherein (+)--Acc occupied the i+1 position were observed. 
 
Despite the impressive work dedicated to the identification of semipeptide analogues, 
Cilengitide (3) is the only investigational agent of this class that has been developed for 
clinical testing on cancer patients. The growth inhibitory activity of Cilengitide 
observed in the clinic is likely due to a combination of multifaceted mechanisms. These 
might depend on whether the drug is administered alone or in combination, and 
include  inhibition of angiogenesis, direct cytotoxic activity on tumor cells, increase of 
endothelial cell permeability, and inhibition of cell adhesion, migration and invasion.65,76  
Very recently, a paradoxical proangiogenic activity of low doses of Cilengitide was 
observed in certain preclinical studies (see also Chapter 2.1 for further discussion).77 
 
1.1.3.2  isoDGR integrin ligands 
As regards isoDGR-containing cyclic peptides or pseudo-peptides, not many examples 
appeared in the literature so far.  
 
 
Figure 1.1.16 
Being a relatively young research field (the earliest evidences dating back to 2006),78 
there is still a need to understand  the structural basis for the interaction of isoDGR with 
the RGD-binding site of integrins, the molecular switch ability of the NGR sequence to 
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isoDGR and its possible applications in the discovery of innovative drugs. Still, 
extensive efforts in the understanding of the isoDGR motif potential need to be 
profused. 
The most interesting examples appeared in the literature are reported in Figure 1.1.16. 
Compound 16a was the first to be discovered, by Corti and co-workers.60,61 The efficacy 
of the cyclic motif CisoDGRC was demonstrated exchanging cysteine residues with 
glycine, and analogues such as 16b were also prepared, obtaining enhanced affinity 
towards most of the integrins tested.62  
These compounds have been tested for their competitive binding with ACDCRGDCFC-
TNF to V3 integrin. Being ACDCRGDCFC-TNF a quite weak ligand of V3 integrin, 
the strikingly low nanomolar activity of these compounds should not be compared to 
other already shown activities. 
 
Kessler and colleagues started an investigation in the field, synthesizing a small library 
of compounds based on the retrosequence of the highly active integrin-binding cyclic 
peptide c(RGDfV) 4, for example c(VfisoDGR), obtaining moderate to poor results. Far 
better results were obtained flanking the isoDGR moiety with an aromatic amino acid 
and a glycine (17-19, Figure 1.1.16). Hints on the importance of the flanking residues 
and, in particular, on the effects of a flanking aromatic moiety were given, and 
interesting selectivity towards 51 integrin respect to V3 integrin were obtained.79 
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1.2 PREVIOUS W ORK OF OUR  RESEARCH  GROUP IN  THE FIELD  
 
1.2.1 Diketopiperazines (DKP) scaffolds 
Recently, our group developed the synthesis of a new class of bifunctional DKP 
scaffolds (DKP-1, DKP-2, DKP-3, Figure 1.2.1), formally derived from aspartic acid and 
2,3-diaminopropionic acid, bearing a carboxylic acid and an amino functionalities.80,81 As 
a consequence of the absolute configuration of the two α-amino acids forming the cyclic 
dipeptide unit, the two reactive functionalities (amino and carboxylic acid) are locked in 
a cis- (DKP-1) or trans-configuration (DKP-2, DKP-3). In addition, while being derived 
from α-amino acids, these DKP scaffolds can be seen as a conformationally constrained 
dipeptide formed by two β-amino acids (see Figure 1.2.1), and in particular a β2- and a 
β3-amino acids (following Seebach’s nomenclature).82 
 
Figure 1.2.1 - Structure of bifunctional DKP scaffolds highlighting the conformationally constrained β2–
β3 dipeptide sequence. 
DKP-1, DKP-2 and DKP-3 (bearing a benzyl group at nitrogen N-4, Figure 1.2.1) were 
prepared making use of the serine ligation strategy exemplified in Scheme 1.2.1.83 These 
scaffolds differs into the stereocenters at C3-C6 (Figure 1.2.1) and the synthetic sequence 
started from either (R)- or (S)-N-(tert-butoxycarbonyl)aspartic acid β-allyl ester 2084 and 
either (R)- or (S)-N-benzylserine methyl ester 21 (Scheme 1.2.1).85 Direct coupling of 
these fragments (HATU, iPr2NEt or EDC, DMAP) led to the isopeptides 22 in high 
yield, rather than forming the expected dipeptides 23. As a matter of fact, selective O-
acylation of the unprotected -hydroxyl group of N-benzylserine methyl ester is 
preferred to the formation of the tertiary amide and the resulting ester bond is stable in 
solution to O,N-acyl transfer.83 The O,N-acyl migration was then triggered by cleavage 
of the Boc protecting group and treatment with a base, which also promoted the 
simultaneous cyclization to the diketopiperazines 24. The introduction of the nitrogen 
functionality was then realized through a Mitsunobu-type reaction using HN3·Tol in a 
toluene / dichloromethane solution, thus obtaining azides 25 in a moderate (51%; cis: 
S,S) to good yield (80%; trans: S,R or R,S).86 Finally, a one pot Staudinger reduction – 
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Boc protection87 yielded the DKP scaffold allyl esters 26, which was de-allylated88 to 
give the amino acid derivatives DKP-1, DKP-2 and DKP-3 in a quantitative yield. 
 
 
Scheme 1.2.1 - Synthesis of DKP-1, DKP-2 and DKP-3 via the serine ligation strategy. a) EDC·HCl, 
DMAP, CH2Cl2, 94%; b) TFA/CH2Cl2 1:2; c) DIPEA, iPrOH, 90% over two steps; d) HN3, DIAD, PPh3, 
CH2Cl2/toluene, 51% (S,S), 80% (S,R or R,S); e) Me3P, BocON, THF, 76%; f) pyrrolidine, PPh3, [Pd(PPh3)4], 
CH2Cl2, 99%. 
 
In addition, our group developed the synthesis of two functionalized (f) trans 
diketopiperazines (i.e., DKP-f2 and DKP-f3), varying the absolute stereochemistry at C-
3 and C-6 (Figure 1.2.2).89 These DKPs were used for the synthesis of cyclo[DKP-f-RGD] 
integrin ligands (Chapter 1.4), bearing a p-aminomethylbenzyl N-substituent as 
anchoring point for further conjugation for the synthesis of dual action compounds 
(Chapter 2). The Mtr protecting group for the p-aminomethylbenzyl N-substituent 
(Figure 1.2.2) was chosen because of its stability and orthogonality with the methyl, 
benzyl, allyl, tBu, Boc, and Cbz protecting groups. 
 
 
Figure 1.2.2 - Structure of functionalized (f) DKP-f scaffolds highlighting the p-aminomethylbenzyl N-
substituent as anchorage point for further conjugations. 
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Also in this case, for the preparation of the functionalized trans diketopiperazines 
DKP-f2 and DKP-f3, the serine ligation strategy was used (Scheme 1.2.2). (R)- and (S)-
Serine were protected as methyl ester and reductively alkylated with aldehyde 27 and 
sodium triacetoxyborohydride to afford the amines 28 (Scheme 1.2.2). From this step, 
the synthesis is identical to that described in Scheme 1.2.1 (Scheme 1.2.2, yields are also 
comparable). 
 
 
Scheme 1.2.2 - Synthesis of DKP-f2 and DKP-f3 via the serine ligation strategy. a) LiAlH4, THF, 8 h, 
reflux, 70%; b) Mtr-Cl, i-Pr2NEt, THF, 6 h, room temp., 85%; c) MnO2, THF, overnight, room temp., 
quant.; d) MeOH, AcCl, quant.; e) aldehyde 27, NaBH(OAc)3, THF, 3 h, room temp., quant.; f) HATU, 
HOAT, iPr2NEt, DMF, 3 h, 0 °C to room temp., 86%; g) TFA/DCM 1:2, 3 h, 0 °C to room temp.; h) iPr2NEt, 
iPrOH, 6 h, room temp., 93% over two steps; i) HN3.Tol, DIAD, Ph3P, DCM/Tol 1:2, 7 h, -20 °C, 86%; j) 
Me3P, BOC-ON, THF, 6 h, -20 °C to room temp., 88%; k) pyrrolidine, PPh3, [Pd(PPh3)4], DCM, 4 h, room 
temp., quant. 
 
 
 
 
 
 
 
   1 | Integrin Ligands 
 
 
25 
1.2.2 c[DKP-RGD] integrin ligands 
Starting from these scaffolds, our group previously developed the synthesis of cyclic 
RGD-peptidomimetics c[DKP-1-RGD], c[DKP-2-RGD], c[DKP-3-RGD], c[DKP-f2-
RGD] and c[DKP-f3-RGD] (Figure 1.2.3), containing the bifunctional diketopiperazine 
scaffolds DKP-1, DKP-2, DKP-3, DKP-f2 and DKP-f3 (Figure 1.2.3).81,89,90 
 
 
Figure 1.2.3 - Cyclic RGD peptidomimetics containing scaffolds DKP-1, DKP-2, DKP-3, DKP-f2 and 
DKP-f3.  
 
Diketopiperazines DKP-1, DKP-2, DKP-3, DKP-f2 and DKP-f3 were used as scaffolds 
for the synthesis of functionalized c[DKP-RGD] integrin ligands, following a solution-
phase strategy (Scheme 1.2.3). 
 
Scheme 1.2.3 
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Conformational studies of cyclic RGD peptidomimetics c[DKP-1-RGD], c[DKP-2-
RGD], c[DKP-3-RGD] were performed by NMR spectroscopy (1H-NMR and NOESY 
spectra of dilute H2O/D2O 9:1 solutions) and by computational methods [Monte 
Carlo/Stochastic Dynamics (MC/SD) simulations]. Their biological activities were 
evaluated in v3/5 isolated receptor binding assay (see chapter 1.4.3 and 1.4.4 for more 
details).  
 
During my PhD thesis I expanded this library of previously developed ligands, 
developing new DKP scaffolds (Chapter 1.3) and new corresponding c[DKP-RGD] 
integrin ligands (Chapter 1.4). The 7 new scaffolds of the prepared library were used as 
templates in the synthesis of cyclic integrin ligands containing either the RGD- 
recognition sequences. The development of this library has provided a detailed SAR 
analysis of new integrin ligands based on DKP scaffolds, affording to a comprehensive 
view for this new class of integrin ligands. 
 
Furthermore, the functionalized ligands c[DKP-f2-RGD], c[DKP-f3-RGD] and the new 
functionalized ligands described in Chapter 1.4.2 were used to synthesize integrin-
targeting compounds conjugated to Paclitaxel and other dual-action conjugates 
(Chapter 2). 
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1.3  N EW  DKP SCAFFOLDS 
1.3.1 Design of the library 
On the basis of the goals previously achieved by our research group (see Chapter 1.2), 
the library of bifunctional diketopiperazines reported in Figure 1.3.1 was expanded, 
with the second-generation scaffolds DKP-4-8 and DKP-f4-6,  each differing in their 
stereochemistry and substitution pattern, to be used as templating moiety for the RGD 
sequence. Since the cis stereochemistry provided low affinity integrin ligand (see 
Chapter 1.4.3 for further discussion), the new scaffolds were developed only with the 
trans stereochemistry. 
 
 
Figure 1.3.1 - Previously developed library of bifunctional diketopiperazine scaffolds (either 
functionalized or not) and second generation scaffolds (either functionalized or not). 
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DKP-1, DKP-2, DKP-3, DKP-f2 and DKP-f3 already turned out to be interesting and 
valuable constrained rigid scaffolds which, owing to their  carboxylic acid and amino 
functionalities, could be successfully employed as secondary structure inducers for the 
RGD sequence. Moreover, functionalized scaffolds bear also a protected amino moiety 
that could be further employed for the synthesis of dual action compounds (Chapter 2). 
Tiny variations in their stereochemistry, ring substitutions or degrees of freedom, may 
dramatically change the behavior of these scaffolds when inserted into a 
peptidomimetic moiety.  Having a wide range of scaffolds available may be of great 
impact expecially when aiming at the modulation of a biological target. For these 
reasons a library of new seven diketopiperazines (Figure 1.3.1) was conceived. 
The new five unfunctionalized trans scaffolds differ for their absolute stereochemistry 
[either 3R,6S (DKP-4, DKP-5) or 3S,6R (DKP-6, DKP-7, DKP-8)], for the substitution at 
the endocyclic nitrogens, which can be either hydrogen or benzyl (DKP-4, DKP-6, 
DKP-8, DKP-5, DKP-7), and for the length of side-arm bearing the carboxylic group, 
which can be either carboxymethyl (DKP-4-7) or carboxyethyl (DKP-8). The new two 
functionalized trans scaffolds DKP-f4 and DKP-f6 differ for their absolute 
stereochemistry [3R,6S for (DKP-f4) and 3S,6R for (DKP-f6)]. 
 
1.3.2 Synthesis of DKP-4, DKP-6, DKP-f4 and DKP-f6 
A retrosynthetic analysis of scaffolds DKP-4 and DKP-6 (bearing a benzyl group at 
nitrogen N-1) suggested that, also in this case, the diketopiperazine ring could be 
obtained from suitably protected aspartic acid and serine in the correct relative 
configuration (Scheme 1.3.1, see for comparison Scheme 1.2.1 and Scheme 1.2.2): 
 
 
Scheme 1.3.1 
Since the isopeptide route (see Scheme 1.2.1 and ref. 83) could not be applied for these 
scaffolds, the coupling of commercially available Boc-D-serine tert-butyl ether to N-
benzyl-L-aspartic acid dimethylester 29a91 was initially developed for the preparation of 
diketopiperazine DKP-4 (bearing a benzyl group at nitrogen N-1) (Scheme 1.3.2). 
Among the different coupling methodologies used (from the ‚classic‛ ones, based on 
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HATU and PyBrOP, till the more sophisticated such as cyanuric fluoride), the only one 
that was effective consisted in the pre-formation of the symmetric Boc-D-Ser(OtBu) 
anhydride (using DCC)92 and then coupling to N-Bn-L-Asp dimethyl ester 29a, leading 
to the corresponding dipeptide 30a in a satisfactory 75% yield. Treatment of dipeptide 
30a with trifluoroacetic acid (to deprotect both the amino and the hydroxy group of 
serine) and subsequent ring closing reaction in methanol, led to diketopiperazine 31a 
(Scheme 1.3.2). 
 
 
Scheme 1.3.2 - First-generation synthesis of diketopiperazine 31a; Reagents and conditions: a) CH3COCl, 
MeOH, 24h, 100%; b) PhCHO, NaCNBH3, MeOH, 4h, 67%; c) DCC, CH2Cl2, 1h, 100%; d) 29a, CH2Cl2, 18h, 
75%; e) TFA/CH2Cl2 1:1, 2h; f) iPr2NEt, MeOH, 85% over two steps. 
With the aim to transform the hydroxy group of 31a in a protected amino group, we ran 
a Mitsunobu reaction under the same conditions used for the synthesis of scaffolds 
DKP-1-3 (toluene/DCM, -20 °C, Scheme 1.2.1), but we only recovered starting material. 
Hence we tried to run the reaction again increasing temperature gradually, from -20 °C 
to 0 °C, without any results. Finally, the Mitsunobu reaction performed at r.t. led to 
azide 32a, although major product resulted to be the -elimination derivative 33a (ratio 
32a/33a 1:4) (Scheme 1.3.3). 
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Scheme 1.3.3  
Aiming at improving the poor yield obtained with the Mitsunobu reaction, we tried to 
introduce the azido moiety through the mesylate/sodium azide synthetic route (Scheme 
1.3.4). Unfortunately, also in this case 21% of conversion was obtained at best, with the 
-elimination derivative 33a as major product. 
 Scheme 1.3.4 
At this point, aiming at scaling up the syntheses of both DKP-4 and DKP-6, we tried to 
circumvent the problem of -elimination, by performing the Mitsunobu reaction on Boc-
Ser-OMe (either L or D)93 (34), thus directly transforming the Ser OH group into the 
azide. This could also contribute to simplify the synthetic sequence avoiding the use of 
an additional protecting group (OtBu). These scaffolds differs into the stereocenters at 
C3-C6 (Scheme 1.3.1) and the synthetic sequence was carried out starting from both the 
enantiomeric forms of serine (Scheme 1.3.5). 
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Scheme 1.3.5 - Synthesis of symmetric anhydrides 37: a) CH3COCl, MeOH, 95%; b) Boc2O, THF/H2O 1:1, 
85%; c) HN3, DIAD, PPh3, THF, 78%; d) LiOH, THF/H2O 1:1, 100%; e) DCC, CH2Cl2, 100%. 
The Mitsunobu reaction with HN3 proceeded uneventfully in good  yield (78%) to give 
compounds 35, which were then saponified with LiOH.94 Treatment of freshly prepared 
acids 36 with DCC afforded the symmetric anhydrides 37 in a quantitative yield, which 
were isolated by filtering off DCU and evaporating the solvent, and immediately used 
in the next synthetic step without further purification (Scheme 1.3.5). 
Coupling of 3-azido-2-N-tert-butoxycarbonylaminopropionic anhydrides (37) to either 
(S)- or (R)- N-benzyl-aspartic acid dimethylester (29) to give dipeptides 38 occurred in a 
very good 80% yield, while the subsequent Boc cleavage and cyclization to 
diketopiperazines 39 were nearly quantitative (Scheme 1.3.6). 
 
 
Scheme 1.3.6 - Synthesis of diketopiperazines 39: a) CH2Cl2, 80%; b) Et3SiH, TFA/DCM 1:2; c) iPr2NEt, 
iPrOH, 90% over two steps. 
 
Dipeptides 38 were now obtained easily in gram scale, allowing thus a significant scale 
up of scaffolds DKP-4 and DKP-6, but also DKP-5 and DKP-7 (see Chapter 1.3.3). 
Spectroscopic analysis (1H and 13C NMR) on dipeptides 38 revealed the presence of two 
rotamers (4:1 ratio in CD2Cl2 at r.t., see also the Experimental Section) due to the 
hindered rotation of the tertiary amide bond (cis and trans amide bond rotamers). 
The same Staudinger-type reaction used for the synthesis of DKP-1-3 (see Scheme 1.2.1) 
could be employed to reduce azides 39. Moreover, the absence, in this case, of an allyl 
ester, allowed us to use the more reliable catalytic hydrogenation, which provides 
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amines 40, followed by a Boc protection, giving compounds 41. A final hydrolysis of the 
methyl ester provided diketopiperazines DKP-4 and DKP-6 in 90% overall yield 
(Scheme 1.3.7). 
 
 
Scheme 1.3.7 - Synthesis of DKP-4 and DKP-6: a) H2, Pd/C, THF; b) Boc2O, THF; c) LiOH, THF/H2O 1:1, 
90% over three steps. 
Diketopiperazine scaffolds DKP-4 and DKP-6 were then employed as templating 
structures for the RGD sequence (see Chapter 1.4).  
 
The symmetric anhydride synthetic route leading to dipeptides featuring an azido 
moiety described above, allowed us to synthesize also two new functionalized DKP 
scaffolds, DKP-f4 and DKP-f6 (Scheme 1.3.8). 
The synthetic steps and the functional group interconversion were the same described 
for the synthesis of DKP-4 and DKP-6. Detailed experimental procedures for each step 
and compounds characterization are reported in the Experimental Section. The only 
substantial difference consisted in the moderate yield (40%) for the symmetric 
anhydride coupling step.   Yield optimization was pursued by extensively varying the 
reaction conditions (equivalents, solvents, temperature, time) but all the attempts were 
unsuccessful, in spare contrast with the analogous reaction run on N-benzyl-aspartic 
acid dimethylester (see Scheme 1.3.6) where the yield was uniformly higher (80%). A 
possible explanation could be attributed to the lower nucleophilicity of compounds 42, 
probably due to the electronic effect of the aryl sulphonamide group (EWG) or to an 
intramolecular hydrogen bond between the acidic sulphonamide proton and the benzyl 
amine moiety. 
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Scheme 1.3.8 - Reagents and conditions: a) MeOH, AcCl, 100%; b) aldehyde 27 [Scheme 1.2.2], NaCNBH3, 
MeOH, 4 h, 66%; c) CH2Cl2, 18h, 40%; d) TFA, Et3SiH, CH2Cl2; e) iPr2NEt, iPrOH, 6 h, 92% over two steps; 
f) H2, 10% Pd/C, THF, 4 h; g) Boc2O, iPr2NEt, DCM, 6 h, room temp., 96% over two steps; h) LiOH, 
THF/H2O 1:1, 100%. 
Also in this case, scaffolds DKP-f4 and DKP-f6 were then employed as templating 
structures for the RGD sequence (see Chapter 1.4), allowing further conjugation with 
other molecular entities. 
 
1.3.3 Synthesis of DKP-5 and DKP-7 
The synthesis of scaffolds DKP-5 and DKP-7 can in principle be achieved through the 
benzylation of the second diketopiperazine nitrogen of an advanced intermediate in the 
synthesis of either DKP-2 and DKP-4, or DKP-3 and DKP-6, respectively (Figure 1.3.2, 
see Scheme 1.2.1 and 1.3.7). Aiming at minimizing the use of protecting groups, the only 
suitable intermediate for a nitrogen alkylation was identified in the azide derivative 
(namely, compounds 25 and 39). Indeed, the diketopiperazine intermediates bearing a 
free hydroxyl group or a Boc protected amino functionality could in fact give over-
alkylated by-products. The azido group might serve as a protecting group here, being 
stable under the reaction conditions. 
 
1 | Integrin Ligands 
 
34 
 
Figure 1.3.2 
 
As we had intermediates 39 available (Scheme 1.3.7), we started to investigate N-
benzylation on these substrates. 
Nitrogen N-4 alkylation was first attempted using sodium hydride and benzyl bromide 
in dimethylformamide. This classic experimental procedure generally provides good 
yields for amide benzylation but, unfortunately, our major product proved to be an 
elimination derivative (compounds 33, Scheme 1.3.4). –N3 acted as leaving group in 
presence of a strong non-hindered base, such as NaH. Better results were obtained 
using hindered KHMDS (potassium bis(trimethylsilyl)amide) in presence of benzyl 
bromide and lowering temperature of reaction between -70°C and -40°C (Scheme 1.3.8).  
Bis-benzylated azides 46 are subjected to a one pot Staudinger reduction – Boc 
protection, providing N-Boc protected amines 47. Methyl ester hydrolysis finally 
afforded the desired products DKP-5 and DKP-7 (Scheme 1.3.8). 
 
 
 
Scheme 1.3.4 - Synthesis of DKP-5 and DKP-7, starting from intermediates 39a and 39b, respectively:  a) 
BnBr, KHMDS, THF/DMF 7:3, 86%; b) PMe3, Boc-ON, THF, 90%; c) LiOH, THF/H2O 1:1, 100%. 
 
For a synthetic comparison, azides 25 (Scheme 1.2.1) were also converted into DKP-5 
and DKP-7 following the same protocols, a part of the last deprotection step (Tsuji-
Trost-like ester deallylation, Scheme 1.3.5). 
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Scheme 1.3.5 - Synthesis of DKP-5 and DKP-7, starting from intermediates 25: a) KHMDS, BnBr, 
THF/DMF 7:3, 76%; b) Me3P, Boc-ON, THF, 65%; c) pyrrolidine, PPh3, [Pd(PPh3)4], DCM, 100%. 
The former approach (Scheme 1.3.4) is significantly better than the latter (Scheme 1.3.5): 
the overall yield for the first synthetic route is 77% over three steps, while for the 
second route is 49% over three steps. Moreover, methyl ester hydrolysis is an effective 
and transition metal free step, suitable also for substantial scale up of the synthesis. 
 
The two bis-benzylated scaffolds DKP-5 and DKP-7  so obtained were then employed 
in the synthesis of cyclic RGD integrin ligands (Chapter 1.4)  
 
1.3.4 Synthesis of DKP-8 
Scaffold DKP-8, bearing a carboxyethyl side chain, was obtained through a synthetic 
strategy similar to the one adopted in the case of compounds DKP-1-3 (see Chapter 
1.2.1), starting from (S)-N-benzylserine methyl ester 21 (Scheme 1.2.1) and (R)-N-(tert-
butoxycarbonyl)glutamic acid -methyl ester 48.95 In this case too, direct coupling of 
these fragments afforded isopeptide 49 (see scheme 1.3.6 and ref.83). Diagnostic of this 
outcome were the NMR spectra for compound 49: (i) in the 1H NMR spectrum, the O-
CH2 protons of serine were rather deshielded [4.47 (dd, J = 11.0, 4.9 Hz, 1H), 4.30 (dd, J 
= 11.0, 4.9 Hz, 1H) (CDCl3)]; (ii) in the HMBC (Heteronuclear Multiple Bond Coherence) 
spectrum of both compounds, a long range coupling (through three bonds) was clearly 
evident between the O-CH2 protons of serine and the -carbonyl carbon of glutamic 
(Figure 1.3.3). 
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Figure 1.3.3 - a) HMBC spectra of isopeptides 49 (CDCl3), highlighting the long range coupling (through 
three bonds) between the O-CH2 protons of Ser and the -carbonyl carbon of Glu; b) scheme representing 
the long range couplings highlighted from the HMBC spectra. 
 
Isopeptide 49 was then deprotected and cyclized to diketopiperazine 50. Azidation of 
the -CH2OH group via a Mitsunobu reaction (51), reduction by catalytic hydrogenation 
(52), protection with Boc2O (53) and final hydrolysis of the methyl ester afforded DKP-8 
(Scheme 1.3.6). 
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Scheme 1.3.6 - a) 21, HATU, HOAt, DIPEA, DMF; b) TFA/CH2Cl2 1:2; c) DIPEA, iPrOH; d) HN3, DIAD, 
PPh3, CH2Cl2/toluene/DMF; e) H2, Pd-C, THF; f) Boc2O, THF; g) LiOH, THF/30% H2O2 1:1. 
This latest step was at first performed in the conditions already described for the 
synthesis of DKP-4-7, treating 53 with LiOH in a 1:1 mixture of THF and water. The 
reaction did not proceed as fast and completely as observed in the other cases and, 
moreover, extensive racemization problems were detected in the 13C spectrum of DKP-8 
thus obtained. Hence a milder yet more selective procedure involving the in situ 
formation of LiOOH was adopted. Enantiomerically pure DKP-8 was this time obtained 
quantitatively. 
 
Also this last scaffold DKP-8 was then employed as templating structure for the RGD 
sequence (see Chapter 1.4). 
 
1.3.5 Considerations on DKP scaffolds 
It is noteworthy to say that scaffolds DKP-4, DKP-f4, DKP-5, DKP-6, DKP-f6 and DKP-
7 will allow, as discussed in next chapter 1.4, a detailed SAR of this kind of 
diketopiperazine templating agent. However, it should be underlined that this new 
synthetic route (symmetric anhydride as key step) is less atom-economic compared to 
the previously developed isopeptide route (see 1.2.1 and 1.3.4). For this reason, in our 
research group it was chosen, at the end of this DKP SAR analysis, to scale up (multi-
gram scale) the synthesis of DKP-3 and DKP-f3 (and its functionalized integrin ligand 
c[DKP-f3-RGD], see 1.2.2), to store a relevant amount of these useful scaffolds for 
further applications (see 1.5 and Chapter 2). 
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1.4 CYCLIC [DKP-RGD] INTEGRIN  LIGANDS 
1.4.1 Synthesis of ligands c[DKP-4-8-RGD]  
The synthesis of six new RGD-containing integrin ligands was performed starting from 
the new DKP scaffolds described in the previous chapter (1.3) (Figure 1.4.1). 
 
 
Figure 1.4.1 
 
The presence of two diastereomers of c[DKP-7-RGD]-A and -B will be explained below. 
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The synthetic route leading to these new ligands was adapted from the previous work 
on DKP-containing integrin ligands (Scheme 1.4.1) (see Experimental Part for detailed 
yields and conditions): 
 
Scheme 1.4.1 - Synthesis of cyclic RGD peptidomimetics c[DKP-4-8-RGD] containing scaffolds DKP-4-8: 
a) Cs2CO3, MeOH; b) BnBr, DMF: 95% o.t.s.; c) TFA/DCM 1:2; d) HBTU, HOBt, DIPEA, DMF; e) 
TFA/DCM 1:2; f) HATU, HOAt, iPr2EtN, DMF; g) TFA/DCM 1:2; h) Cbz-Asp(OtBu)-OH, HATU, HOAt, 
iPr2EtN, DMF; i) H2, Pd/C, THF/H2O 1:1; j) HATU, HOAt, iPr2EtN, DMF, 1.4mM; k) TFA 90%, thioanisol 
5%, EDT 3%, anisol 2%. 
Diketopiperazines DKP-4-8 were incorporated into the cyclic RGD derivatives c[DKP-
4-8-RGD] (Scheme 1.4.1). A solution phase synthetic strategy was adopted, using Boc-
Arg(Mtr), Gly-OBn and Cbz-Asp(OtBu)-OH. The dipeptide Boc-Arg(Mtr)-Gly-OBn was 
Boc-deprotected and coupled to the acid of the appropriate diketopiperazine scaffold. 
Subsequent Boc deprotection of the DKP amino group and coupling of the aspartic 
derivative Cbz-Asp(OtBu)-OH afforded the linear peptidomimetic Cbz-Asp(OtBu)-
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DKP-Arg(Mtr)-Gly-OBn, which was deprotected by hydrogenolysis (Cbz and Bn): 
initially, during the synthesis of c[DKP-4-RGD],  this reaction was performed in 
methanol and surprisingly the formation of N-methylated derivatives (up to 30% of the 
total yield) was observed (Scheme 1.4.2), leading to a troublesome HPLC separation of 
this byproduct after the macrolactamization step. The unexpected outcome of this 
reaction was then found out in literature with a similar procedure (Pd/C in methanol) 
specific for the synthesis of N-methylated amino acids.96 
 
Scheme 1.4.2 - a) H2, Pd/C, CH3OH; b) H2, Pd/C, THF/H2O 1:1. 
 
To overcome this problem, we decided to avoid the use of alcoholic solvents and we set 
up a solvent mixture capable of both dissolving the starting material (THF) and the 
hydrogenated product (H2O) (Scheme 1.4.2). 
Deprotected compounds were subjected to macrolactamization. Several methodologies 
were screened for the ring closure, and the best yields were obtained for all the 
products using HATU/HOAT as coupling agents in a 1:4:4:6 
substrate/HATU/HOAT/iPr2NEt molar ratio and a substrate concentration = 1.4 mM in 
DMF. Purification and isolation of these products were achieved both through a simple 
flash column chromatography (DCM/MeOH) or through reverse phase BiotageTM 
purification on C18 cartridge, in case of complex mixture of formed byproducts. 
A final side-chain deprotection (TFA/thioanisole/ethanedithiol/anisole 90:5:3:2) and 
preparative HPLC purification afforded the desired compounds c[DKP-4-8-RGD]. 
 
The N-dibenzyl derivatives c[DKP-5-RGD] and c[DKP-7-RGD] can exist as two 
different separable conformers (diastereomers) due to hindered rotation of one ring 
around the other, in a way reminiscent of the ansa-cyclopeptides97 (i.e., the DKP N-
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benzyl group cannot pass inside the macrolactam ring). In the case of c[DKP-5-RGD], 
we were able to isolate only one diastereomer (either because it was formed exclusively 
or because it was formed predominantly) and the minor one was not detected. 
The two diastereomers of c[DKP-7-RGD] (A and B), formed in the macrolactamization 
step, were isolated in a 2:1 ratio (Figure 1.4.2). Although two sets of peaks (2:1 ratio) 
were visible in the 1H NMR spectrum (see Experimental Section for full peaks 
assignement), the two diastereomers could not be separated by HPLC because they had 
the same elution time. However, after protecting groups side-chain deprotection, the 
two diastereomers could be separated, analyzed and subjected to the binding assays 
(vide infra). 
 
 
 
c[DKP-7-RGD]-A
c[DKP-7-RGD]-B
 
Figure 1.4.2 - Upper: non-interconverting diastereoisomers c[DKP-7-RGD]-A and –B; lower: HPLC trace 
after the protecting groups side-chain deprotection step. 
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1.4.2 Synthesis of functionalized ligands c[DKP-f4-RGD] and c[DKP-f6-RGD] 
The synthesis of two new functionalized RGD-containing integrin ligands was 
performed starting from the new DKP-f4 and DKP-f6 scaffolds described in the 
previous chapter (1.3.2) (Figure 1.4.3). 
 
 
Figure 1.4.3 
 
The tripeptide R-G-D decoration on these scaffolds was performed using the same 
synthetic route described in Chapter 1.4.1 (Scheme 1.4.3) (see Experimental Section for 
yields and detailed conditions). 
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Scheme 1.4.3 - a) TFA/DCM 1:2; b) HATU, HOAT, iPr2NEt, DMF; c) TFA/DCM 1:2; d) Cbz-Asp(OtBu)-
OH, HATU, HOAT, iPr2NEt, DMF; e) H2, 10% Pd/C, THF/H2O 1:1; f) HATU, HOAT, iPr2NEt, 1.4 mM in 
DMF; g) TFA/TMSBr/thioanisol/EDT/phenol 70:14:10:5:1. 
 
The side-chain deprotection turned out to be more challenging with respect to the 
previously reported unfunctionalized ligands: while the OtBu and the Mtr on the 
arginine were easily deprotected, the Mtr on the benzylic amine turned out to be very 
stable (see Scheme 1.4.4). 
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Scheme 1.4.4 - a) ‚Reagent K‛: TFA/phenol/water/TIPS, 88/5/5/2; b) ‚Reagent R‛: 
TFA/thioanisole/EDT/anisole, 90/5/3/2; c) ‚Reagent P+‛: TFA/phenol/methanesulfonic acid, 95/2.5/2.5; d) 
TFA/TMSBr/thioanisole/EDT/phenol 70/14/10/5/1. 
 
During the synthesis of c[DKP-f4-RGD], several cleavage cocktails were screened and 
the more classical ones98 (‚Reagent K‛, ‚Reagent R‛ and ‚Reagent P+‛) failed, giving 
the mono-protected compound as main product (the Mtr on the amine was still 
present), with a low yield (5-20%) of the desired totally deprotected product, even after 
48 h. Finally, with the use of TFA/TMSBr/thioanisole/EDT/phenol (70/14/10/5/1) 
cleavage cocktail at room temperature for 2 h, fully deprotected compound c[DKP-f4-
RGD] was obtained in 70% isolated yield.  
 
The benzylic amine moiety contained in the c[DKP-f4/f6-RGD] ligands allowed, as 
described in Chapter 2, further conjugation with other molecular entities (dual-action 
conjugates). To this end, we have developed a reliable synthetic protocol to react only 
the free amine without side reactions on the guanidine moiety (free Arg side-chain) 
(Scheme 1.4.5) (see Chapter 2 and Experimental Section for further details). 
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Scheme 1.4.5 
 
The amine functionalization allows to elongate the integrin ligands through a new 
amide bond: the carboxylic acid can be activated both with the simple N-
hydroxysuccinimmide (NHS) protocol or through the sulpho- N-hydroxysuccinimmide 
(sulpho-NHS)  methodology, a more water soluble activating agent. In both case, the 
reaction must be conducted in a H2O/CH3CN solvent (1:1 ratio), adjusting pH = 7.5 
(Scheme 1.4.5). 
 
Integrin ligands c[DKP-f4-RGD] and c[DKP-f6-RGD] were employed in a drug-
targeting approach with Paclitaxel (dual-action conjugates), further described in 
Chapter 2.1.  
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1.4.3 Biological evaluation 99 
The new cyclic RGD peptidomimetics were examined in vitro for their ability to inhibit 
biotinylated vitronectin binding to the purified v3 and v5 receptors (Table 1.4.1, in 
comparison with the previously reported c[DKP-RGD] ligands). 
  
Table 1.4.1. Inhibition of biotinylated vitronectin binding to v3 and v5 receptors 
Compound V3 IC50 [nM]a V5 IC50 [nM]a 
c[DKP-1-RGD]  3898 ± 418 > 104 
c[DKP-2-RGD]  3.2 ± 2.7 114 ± 99 
c[DKP-3-RGD]  4.5 ± 1.1 149 ± 25 
c[DKP-4-RGD]  7.6 ± 4.3 216 ±  5 
c[DKP-5-RGD] 12.2 ± 5.0 131 ± 29 
c[DKP-6-RGD]  2.1 ± 0.6 79 ±  3 
c[DKP-7-RGD]-A 220.2 ± 82.3 > 104 
c[DKP-7-RGD]-B 0.2 ± 0.09 109 ± 15 
c[DKP-8-RGD] 7.5 ± 0.6 > 103 
c(RGDfV)b 3.2 ± 1.3 7.5 ± 4.8 
ST1646b 1.0 ± 0.5 1.4 ± 0.8 
aIC50 values were calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± SD of 
triplicate determinations; b see Chapter 1.1.3.1. 
 
Screening assays were performed by incubating the immobilized integrin receptors 
with various concentrations (10-10 – 10-5 M) of the c[DKP-RGD] ligands in the presence 
of biotinylated vitronectin (1 µg/mL), and measuring the concentration of bound 
vitronectin in the presence of the competitive ligands. The ability of the new 
compounds to inhibit the binding of vitronectin to the isolated v3 and v5 receptors 
was compared with that of the reference compounds c(RGDfV)  and ST164669 (see 
Chapter 1.1.3.1). 
Low nanomolar values were obtained with all the ligands except c[DKP-1-RGD], which 
incorporates a cis-DKP and ligand c[DKP-7-RGD]-A. The behaviour of this last ligand 
is peculiar, considering that the diastereomeric compound c[DKP-7-RGD]-B  (see 1.4.2) 
is the most potent ligand of this series, as it effectively inhibits the binding of 
vitronectin to the isolated v3 receptor in subnanomolar concentration. Interestingly, 
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unlike reference compounds c(RGDfV) and ST1646, the RGD-peptidomimetics c[DKP-
RGD] were ca. 10-1000-fold more selective for the v3 integrin with respect to the v5, 
in this kind of assay. 
 
Functionalized ligands c[DKP-f-RGD] were not tested in this kind of assay, as their 
integrin affinity was evaluated once they were conjugated to other molecular entities 
(see Chapter 2). 
 
1.4.4 Spectroscopic and computational studies 100 
The spectroscopic and computational studies are here reported for integrin ligands 
c[DKP-4-8-RGD]  in comparison also with the already synthesized ligands c[DKP-1-3-
RGD] (see 1.2.2). 
The structure and connectivity of ligands c[DKP-4-8-RGD] and of their fully protected 
precursors were unambiguously assigned by means of mono- and bidimensional 1H- 
and 13C-NMR spectra. 
The preferred conformations of the cyclic RGD peptidomimetics c[DKP-4-8-RGD]  in 
aqueous solution were then investigated, with the aim of rationalizing the affinity of 
these compounds for the v3 receptor at a molecular level. In fact, as already 
mentioned, the high activity and selectivity of Cilengitide 3 has been attributed to an 
extended conformation of the RGD motif displaying a distance of ca. 9 Å between the 
C atoms of Asp and Arg. In such extended conformations, the carboxylate and 
guanidinium groups are properly positioned to effectively exert their function of 
electrostatic clamp. Monodimensional 1H-NMR experiments were conducted to detect 
intramolecular hydrogen bonds, by measuring the chemical shift of the N–H protons 
and their temperature coefficients (/T). NOESY spectra were recorded to investigate 
both sequential and long-range NOEs that provide evidence of preferred 
conformations. The relevant NMR data are summarized in Table 1.4.2. 
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Table 1.4.2 - 1H-NMR and NOE data of cyclic RGD-peptidomimetics in water. 
 
 
 NH1 NH4 NH10 NHArg NHGly NHAsp 
Significant 
NOE contacts 
c[DKP-1-RGD] 
 (ppm) 8,35 - 7,46 8,40 8,75 8,10 
NHAsp-NH10; 
NHAsp-NHGly 
 
(ppb/K) 
-7.3 - -2.0 -7.0 -8.0 -3.7 
c[DKP-2-RGD] 
 (ppm) 8.35 - 8.78 8.57 8.18 8.29 
NHArg-NHGly  
(ppb/K) 
-8.7 - -10.7 -7.0 -5.7 -7.7 
c[DKP-3-RGD] 
(ppm) 8.10 - 8.28 8.80 8.00 7.85 
NHArg-NHGly  
(ppb/K) 
-5.7 - -8.5 -6.0 -4.5 -3.5 
c[DKP-4-RGD] 
(ppm) - 8.17 7.59 8.29 8.27 8.88 
--  
(ppb/K) 
- -9.1 -0.7 -9.3 -8.2 -9.3 
c[DKP-5-RGD] 
(ppm) - - 8.58 8.48 8.23 8.42 
NHArg-NHGly  
(ppb/K) 
- - -11.0 -7.5 -4.7 -8.2 
c[DKP-6-RGD] 
 (ppm) - 8.07 7.90 8.32 8.35 8.80 
NHAsp-NH10; 
NH4-NH10; 
 
(ppb/K) 
- -4.9 -5.1 -7.6 -6.7 -8.0 
c[DKP-7-RGD] 
A 
(ppm) - - 8.04 8.66 7.93 7.76 
NHArg-NHGly; 
NHAsp-NHGly 
 
(ppb/K) 
- - -7.5 -5.0 -3.0 -1.0 
c[DKP-7-RGD] 
B 
 (ppm) - - 7.72 8.34 8.45 8.55 
NHAsp-NH10  
(ppb/K) 
- - -4.0 -7.0 -7.0 -5.0 
c[DKP8-RGD] 
 (ppm) 7.82 - 7.43 8.64 8.04 7.90 
-  
(ppb/K) 
-8.0 - -6.0 -6.8 -4.4 -5.2 
 
As already reported in the literature,90  ligand c[DKP-1-RGD] exists as an equilibrium of 
two different preferred conformations. The NOESY spectrum shows two mutually 
exclusive long-range NOE contacts. The cross peak between DKP-NH10 and NHAsp 
(strong) is indicative of a -turn conformation at Gly-Asp stabilized by a hydrogen 
bond between DKP-NH10 and Arg-C=O (Type I H-bonding pattern, Figure 1.4.4 A). The 
chemical shift value (7.46 ppm) and the /T value (-2 ppb/K) of the amide proton 
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DKP-NH10 indicate that this proton is strongly locked in an intramolecularly H-bonded 
state. The cross peak between NHGly and NHAsp (medium) is indicative of an alternative 
-turn conformation at Arg-Gly, stabilized by a hydrogen bond between Asp-NH and 
C(8)=O (Type II H-bonding pattern, Figure 1.4.4 B). 
 
 
Figure 1.4.4 - Preferred intramolecular hydrogen-bonding pattern proposed for compound c[DKP-1-
RGD]  on the basis of spectroscopic data. The arrows indicate significant NOE contacts. A) Type I H-
bonding pattern, Gly-Asp β-turn motif. B) Type II H- H-bonding pattern, Arg-Gly β-turn motif . 
Ligands c[DKP-2-RGD] and c[DKP-3-RGD] are characterized by a high conformational 
equilibrium, as ascertained by the values of chemical shifts and Δδ/ΔT reported in Table 
1.4.2. On the other hand, the presence in both cases of a NOE contact between NHGly 
and NHArg suggests the formation of a -turn motif at DKP-Arg, stabilized by a 
hydrogen bond between NHGly and C(5)=O (appointed as Type III H-bonding pattern, 
Figure 3.18). The presence of this H-bond is also supported by the rather upfield 
chemical shift value of NHGly in these two ligands (8.18 and 8.00 ppm for c[DKP-2-
RGD] and c[DKP-3-RGD], respectively) and the relatively low temperature 
dependence (-5.7 and -4.5 ppb/K, respectively). The similarity of the NMR data and 
hence of the conformation of these two ligands is quite surprising, considering the 
opposite configuration of the diketopiperazine scaffold (DKP-2, 3R,6S; DKP-3, 3S,6R) 
which should impart a different stereochemical orientation to the two side arms of the 
diketopiperazine. This conformational similarity can be interpreted in terms of a quasi-
enantiomeric structure of the two ligands (excluding the configuration of the remote RD 
amino acid side chains, Figure 1.4.5).  
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Figure 1.4.5 - Preferred intramolecular hydrogen-bonding pattern proposed for compound c[DKP-2-
RGD] and c[DKP-3-RGD] on the basis of spectroscopic data. The arrows indicate significant NOE 
contacts. The DKP-Arg β-turn motif is referred as Type III H-bonding pattern.  
Ligands c[DKP-4-RGD] and c[DKP-6-RGD], featuring the diketopiperazine scaffolds 
DKP-4 (3R,6S) and DKP-6 (3S,6R) respectively (with the benzyl substitution at the 
endocyclic nitrogen N1, instead of N4), show a different NMR pattern. In particular, 
ligand c[DKP-6-RGD] is characterized by a rather strong NOE contact between NHAsp 
and NH10 and a moderate/weak one involving NH4 and NH10. These two contacts are 
mutually exclusive and hence indicative of an equilibrium between two different 
conformations, respectively Type I and Type IV H-bonding patterns (Figure 1.4.6 A and 
B).  
 
Figure 1.4.6 - Preferred intramolecular 
hydrogen-bonded pattern proposed for 
compound c[DKP-6-RGD] on the basis of 
spectroscopic data. A) Type I H-bonding 
pattern is characterized by a -turn motif at 
Gly-Asp stabilized by a hydrogen bond 
between NH10 and Arg-C=O. B) Type IV H-
bonding pattern which is characterized by a 
pseudo -turn at Asp-DKP stabilized by a 
hydrogen bond between NH4 and Gly-C=O. 
The arrows indicate significant NOE 
contacts. 
 
The hydrogen bonded status of the two amide protons NH4 and NH10, as indicated by 
their rather low temperature dependence (-4.9 and -5.1 ppb/K, respectively) and quite 
upfield chemical shift values (8.07 and 7.90 ppm, respectively), corroborate this 
assumption. The Type IV H-bonding pattern could feature a pseudo -turn at Asp-DKP 
stabilized by a hydrogen bond between NH4 and Gly-C=O (NOE contact between NH4 
and NH10). 
Ligand c[DKP-4-RGD], on the other hand, is characterized by the absence of relevant 
NOE contacts, a very low temperature dependence (-0.7 ppb/K) and a quite upfield 
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chemical shift value (7.59 ppm) for proton NH10. These two features suggest a Type I H-
bonding pattern, notwithstanding the apparent lack of NOE contact between NHAsp and 
NH10. 
The dibenzylated diketopiperazine containing peptidomimetics c[DKP-5-RGD]  and 
c[DKP-7-RGD]  were eventually studied. Ligand c[DKP-5-RGD] shows NMR features 
similar to ligand c[DKP-2-RGD]   (Type III H-bonding pattern): a NOE contact between 
NHGly and NHArg and a rather shielded NHGly (8.23 ppm) with a relatively low 
temperature coefficient (-4.7 ppb/K). As discussed above (Chapter 1.4.2), ligand c[DKP-
7-RGD] was obtained as a mixture of two diastereomers A and B, whose conformations 
in solution were studied separately. In particular, c[DKP-7-RGD]-A displays two 
mutually exclusive NOE contacts between NHArg and NHGly and between NHAsp and 
NHGly. These three protons, on the other hand, show also a rather strong hydrogen 
bonded status, as indicated by their low temperature dependence and, at least for 
NHAsp and NHGly, their upfield chemical shift (Table 1.4.2). These data indicate an 
equilibrium between two different conformations: one displaying a Type III H-bonding 
pattern and a second one showing a Type II H-bonding pattern (-turn at Arg-Gly), like 
the low-affinity ligand c[DKP-1-RGD]. Finally, ligand c[DKP-7-RGD]-B shows a single 
NOE contact between NHAsp and NH10 and a hydrogen bonded status for NH10 ( 7.72 
ppm and T -4 ppb/K, see Table 1.4.2). These values are indicative of a Type I H-
bonding pattern. 
No NOE contacts were identified for compound c[DKP-8-RGD], containing the 
superior omologous of DKP-3 (i.e. DKP-8). Moreover, also temperature coefficients of  
the amide protons are not relevant for the identification of H-bonds. 
 
1.4.4.1 Conformational analysis 
Conformational studies of the cyclic RGD-peptidomimetics were performed by mixed-
mode Metropolis Monte Carlo/Stochastic Dynamics (MC/SD) simulations, using the 
implicit water GB/SA solvation model2 and the OPLS_2001 force field. 
As already reported in a preliminary communication,90  three-dimensional structures 
satisfying long-range NOE contacts were generated for RGD peptidomimetic c[DKP-1-
RGD] performing two 10 ns restrained MC/SD simulations and applying the DKP-
NH10/NHAsp or the NHAsp/NHGly distance restraint derived from NOESY spectra. 
More than 90% of the conformations sampled during the first simulation adopted a 
non-extended arrangement of the RGD sequence characterized by a -turn at Gly-Asp 
and the presence of the corresponding hydrogen bond between DKP-NH10 and Arg-
C=O. In addition, the formation of a -turn at Gly stabilized by the hydrogen bond 
between NHAsp and Arg-C=O was observed for 40% of the simulation. A C(Arg)–
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C(Asp) average distance of 7.4 Å was obtained during this MC/SD calculation. A 
representative energy minimized conformation selected by cluster analysis and 
featuring both H-bonds is shown in Figure 1.4.7 A (Type I-cis H-bonding pattern). 
Approximately 60% of the conformations sampled during the simulation of c[DKP-1-
RGD] featuring the NHAsp/NHGly distance restraint, adopted a non-extended 
arrangement of the RGD sequence characterized by a -turn at Arg-Gly and the 
corresponding hydrogen bond between NHAsp and C(8)=O. In addition, the formation of 
a -turn at Arg stabilized by the hydrogen bond between NHGly and C(8)=O was 
observed for 40% of the simulation. The C(Arg)–C(Asp) average distance in this 
MC/SD calculation was 6.8 Å. A representative energy minimized conformation 
selected by cluster analysis and featuring both H-bonds is shown in Figure 1.4.7 B (Type 
II H-bonding pattern). 
 
 
Figure 1.4.7 - Structures of c[DKP-1-RGD] as obtained by restrained MC/SD simulations based on 
experimental distance information, after energy minimization. A) Type I-cis H-bonding pattern, -turn at 
Gly and II’-turn at Gly-Asp [CArg)–C(Asp)=7.9 Å]. B) Type II H-bonding pattern, -turn at Arg and 
II’-turn at Arg-Gly [C(Arg)–C(Asp)=6.6 Å]. 
The NOESY spectra of compounds c[DKP-2-RGD], c[DKP-3-RGD] and c[DKP-5-RGD] 
show only one relevant long-range interaction between NHGly and NHArg: this NOE 
is indicative of a -turn motif at DKP-Arg stabilized by a hydrogen bond between 
NHGly and C(5)=O (Figure 1.4.5, Type III H-bonding pattern). The distance restraint 
corresponding to the NOE contact between NHGly and NHArg was applied in the 10 
ns MC/SD simulations of compounds c[DKP-2-RGD], c[DKP-3-RGD] and c[DKP-5-
RGD]. More than 90% of the conformations sampled during each of these simulations 
adopted an extended arrangement of the RGD sequence characterized by a pseudo -
turn at DKP-Arg and the formation of the corresponding hydrogen bond between the 
NHGly and C(5)=O. Interestingly, only for compound c[DKP-3-RGD], the additional 
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formation of a -turn at Arg-Gly stabilized by the hydrogen bond between NHAsp and 
C(8)=O was observed for 15% of the simulation. These results and the NMR data 
(showing  7.85 ppm and T -3.5 ppb/K for NHAsp of c[DKP-3-RGD]) suggest the 
contribution of a Type II/Type III H-bonding pattern to the conformational equilibrium 
of c[DKP-3-RGD] (mainly populated by a Type III H-bonding pattern).  
C(Arg)-C(Asp) average distances of 9.3, 8.8, and 9.1 Å were obtained during the 
MC/SD calculations of c[DKP-2-RGD], c[DKP-3-RGD] and c[DKP-5-RGD], 
respectively. A representative energy minimized conformation selected by cluster 
analysis and featuring the H-bond between the Gly-NH and C(5)=O (Type III H-
bonding pattern) is shown in Figure 1.4.8 for RGD peptidomimetic c[DKP-2-RGD]. 
 
Figure 1.4.8 - Structure of c[DKP-2-RGD] as obtained by restrained MC/SD simulations based on 
experimental distance information, after energy minimization (Type III H-bonding pattern, distorted 
inverse -turn at Asp and pseudo -turn at DKP-Arg, CArg)–C(Asp)=9.4 Å). 
Due to the absence of relevant long-range NOE contacts, several 10 ns runs of 
unconstrained MC/SD simulations were performed for RGD peptidomimetic c[DKP-4-
RGD] starting from different 3D structures. Most of the conformations sampled during 
these simulations adopted an extended arrangement of the RGD sequence (C(Arg)-
C(Asp) average distance of 8.8 Å) and approximately 40% of them are characterized by 
a -turn at Gly-Asp and the presence of the corresponding hydrogen bond between 
DKP-NH10 and Arg-C=O. These results provide a structural model in agreement with 
NMR data showing a low temperature dependence (-0.7 ppb/K) and an upfield 
chemical shift value (7.59 ppm) for proton NH10. It is worth noting how the combination 
of the trans DKP-4 scaffold with the Gly-Asp -turn occurs by generating an extended 
RGD arrangement, while the combination of the cis DKP-1 scaffold with the same 
secondary motif resulted in a non-extended RGD disposition (see above, Figure 1.4.7 
A). Accordingly, two Type I H-bonding patterns have been defined, depending on the 
cis or trans relative stereochemistry of the diketopiperazine scaffold. 
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Three-dimensional structures satisfying long-range NOE contacts were generated for 
RGD peptidomimetic c[DKP-6-RGD] performing two 10 ns restrained MC/SD 
simulations and applying the DKP-NH10/NHAsp or the NH4/NH10 distance restraint 
derived from NOESY spectra (Table 1.4.2, Figure 1.4.6). 
Most of the conformations sampled during the first simulation adopted an extended 
arrangement of the RGD sequence (C(Arg)-C(Asp) average distance of 9.0 Å) and 
approximately 40% of them are characterized by a -turn at Gly-Asp and the 
corresponding hydrogen bond between DKP-NH10 and Arg-C=O. A representative 
energy minimized conformation selected by cluster analysis and featuring this H-bond 
is shown in Figure 1.4.9 A (Type I-trans H-bonding pattern). Approximately 70% of the 
conformations sampled during the simulation of c[DKP-6-RGD] featuring the 
NH4/NH10 distance restraint, adopted an extended arrangement of the RGD sequence 
(C(Arg)-C(Asp) average distance of 8.8 Å) characterized by a pseudo -turn at Asp-
DKP and the corresponding hydrogen bond between NH4 and Gly-C=O. In addition, 
the formation of a -turn at Asp stabilized by the hydrogen bond between NH10 and 
Gly-C=O was observed for 50% of the simulation A representative energy minimized 
conformation selected by cluster analysis and featuring these H-bonds is shown in 
Figure 1.4.9 B (Type IV H-bonding pattern). 
 
 
Figure 1.4.9 - Structures of c[DKP-6-RGD]  as obtained by restrained MC/SD simulations based on 
experimental distance information, after energy minimization. A) Type I-trans H-bonding pattern, inverse 
-turn at Asp and distorted II’-turn at Gly-Asp [CArg)–C(Asp)=9.0 Å]. B) Type IV H-bonding pattern, 
inverse -turn at Asp and pseudo -turn at Asp-DKP [C(Arg)–C(Asp)=8.8 Å]. 
 
Three-dimensional structures satisfying long-range NOE contacts were generated for 
RGD peptidomimetic c[DKP-7-RGD] performing three 10 ns restrained MC/SD 
simulations and applying the distance restraints derived from NOESY spectra of 
diastereoisomers A and B (Table 1.4.2): in the first simulation NHArg/NHGly relevant in 
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c[DKP-7-RGD]-A, in the second simulation NHAsp/NHGly also relevant in c[DKP-7-
RGD]-A, and in the third simulation DKP-NH10/NHAsp relevant in c[DKP-7-RGD]-B. 
All the conformations sampled during the first two simulations adopted a non-
extended arrangement of the RGD sequence [C(Arg)-C(Asp) average distance of 6.6 
Å] characterized by the simultaneous presence of different turn motifs (pseudo -turn 
at DKP-Arg, -turn at Gly and pseudo -turn centered at the DKP unit). The structural 
models provided by these restrained MC/SD simulations differ from the conformations 
hypothesized on the basis of NMR data of c[DKP-7-RGD]-A [equilibrium between 
Type III (pseudo -turn at DKP-Arg) and Type II (-turn at Arg-Gly) H-bonding 
patterns, see the NMR section]. However, also the calculated structures are able to 
provide an explanation for the NOE contacts and the NMR temperature coefficients 
observed for c[DKP-7-RGD]-A. 
The distance restraint corresponding to the NOE contact between DKP-NH10 and NHAsp 
(observed in the NOESY spectrum of c[DKP-7-RGD]-B) was applied in the third 10 ns 
MC/SD simulation of compound c[DKP-7-RGD]. Most of the conformations sampled 
during this simulation adopted an extended arrangement of the RGD sequence 
(C(Arg)-C(Asp) average distance of 9.0 Å) and approximately 50% of them are 
characterized by a -turn at Gly-Asp and the corresponding hydrogen bond between 
DKP-NH10 and Arg-C=O. A representative energy minimized conformation selected by 
cluster analysis and featuring this H-bond is shown in Figure 1.4.10 (Type I-trans H-
bonding pattern). 
Contrary to what observed for the other cyclic RGD peptidomimetics containing DKP 
scaffolds, rotation of the DKP ring can not be observed during the simulations 
performed on compound c[DKP-7-RGD], confirming c[DKP-7-RGD]-A and c[DKP-7-
RGD]-B as two different separable conformers (diastereomers) due to hindered rotation 
of one ring around the other. 
 
 
Figure 1.4.10 - Structure of c[DKP-7-RGD]-B as obtained by restrained MC/SD simulations based on 
experimental distance information, after energy minimization (Type I-trans H-bonding pattern, distorted 
inverse -turn at Asp and II’-turn at Gly-Asp, CArg)–C(Asp)=9.2 Å). 
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Due to the absence of relevant long-range NOE contacts, two 10 ns runs of 
unconstrained MC/SD simulations were performed for RGD peptidomimetic c[DKP-8-
RGD].  
 
Figure 1.4.11 - Structure of c[DKP-8-RGD] as obtained by MC/SD simulations, after energy minimization 
(CArg)–C(Asp)=9.5 Å). 
All the conformations sampled during these simulations adopted an extended 
arrangement of the RGD sequence (C(Arg)-C(Asp) average distance of 9.8 Å) 
characterized by the formation of hydrogen bonds between NHAsp and C(2)=O and 
between NH1 and Arg-C=O. 
A representative energy minimized conformation selected by cluster analysis and 
featuring these H-bonds is shown in Figure 1.4.11 for RGD peptidomimetic c[DKP-8-
RGD]. 
1.4.4.2 Molecular docking 
In order to rationalize, on a molecular basis, the affinity of cyclic RGD peptidomimetics 
for the v3 receptor, docking studies were performed starting from the representative 
conformations obtained from the MC/SD simulations. The crystal structure of the 
extracellular segment of integrin v3 complexed with the cyclic pentapeptide 
Cilengitide (1L5G, pdb code) was taken as a reference model for the interpretation of 
the docking results in terms of ligand-protein interactions. In the X-ray complex, 
Cilengitide binds to the interface of the  and  units forming specific electrostatic 
interactions. The acid and basic pharmacophoric groups and their orientation are 
essential for binding to the v3 because they act like an electrostatic clamp, interacting 
with charged regions of the receptor binding site. 
Docking calculations starting from geometries featuring the Type I-cis and Type II H-
bonding patterns produced top-ranked poses conserving optimal interactions only with 
the  subunit of the v3 receptor. Probably, the short C(Arg)-C(Asp) distances 
(values less than 8 Å) of these geometries prevent the guanidine and carboxylic groups 
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from achieving the required separation for binding to the v3 integrin. On the other 
hand, docking calculations starting from the RGD extended conformations featuring the 
Type I-trans, Type III and Type IV H-bonding patterns, produced top-ranked poses 
conserving all the important interactions of the X-ray complex (Figure 1.4.12).  
 
 
Figure 1.4.12 - Top-ranking binding mode of compounds A) c[DKP-3-RGD] and B) c[DKP-7-RGD]-B 
into the crystal structure of the extracellular domain of αVβ3 integrin overlaid on the bound conformation 
of Cilengitide (green).  
The positively charged Arg guanidinium group of the ligand interacts with the 
negatively charged side chains of Asp218 and Asp150 in the  unit, one carboxylate 
oxygen of the ligand Asp side chain is coordinated to the metal cation in the metal-ion-
dependent adhesion site (MIDAS) region of the  unit, while the second carboxylate 
oxygen forms hydrogen bonds with the backbone amides of Asn215 and Tyr122 in the  
unit. Further stabilizing interaction involves the formation of a hydrogen bond between 
the ligand backbone NH of the Asp residue and the backbone carbonyl group of Arg216 
in the  unit. 
In light of all these considerations, the micromolar affinity of RGD peptidomimetics 
c[DKP-1-RGD] and c[DKP-7-RGD]-A (3.9 and 0.2 M, respectively) for v3 (Table 
1.4.1) can be explained in terms of their low pre-organization for binding. In fact, as 
determined by the computational and NMR studies, these compounds in solution 
mainly feature non-extended RGD conformations which, according to the docking 
results, are not able to properly fit into the v3 receptor. On the contrary, the 
nanomolar affinity of RGD peptidomimetics c[DKP-2-RGD], c[DKP-3-RGD],  c[DKP-
4-RGD], c[DKP-5-RGD], c[DKP-6-RGD], c[DKP-7-RGD]-A, c[DKP-8-RGD] for v3 
can be attributed to their high structural pre-organization. In fact, as determined by the 
computational and NMR studies, these compounds in solution mainly feature extended 
RGD conformations (principally determined by Type I-trans, Type III and Type IV H-
bonding patterns) similar to the RGD bound conformation of Cilengitide. 
A B 
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1.5 CYCLIC [DKP-isoDGR] INTEGRIN LIGANDS 
 
Given the interesting results appeared in literature recently (see 1.1.3.2), during my 
thesis I planned to synthesize a new class of cyclic isoDGR integrin ligands, starting 
from the already reported diketopiperazine scaffolds DKP-2 and DKP-3 (see 1.2.1 and 
1.3.5 for the choice of DKP scaffolds).  
We synthesized two cyclic isoDGR peptidomimetics (c[DKP-2-isoDGR] and c[DKP-3-
isoDGR]; Figure 1.5.1) containing the bifunctional diketopiperazine scaffolds 
mentioned above, and investigated their conformation in solution and their ability to 
compete with biotinylated vitronectin for binding to the purified v3 and v5 
receptors. 
 
 
Figure 1.5.1 - Cyclic isoDGR peptidomimetics containing the bifunctional diketopiperazine scaffolds. 
 
1.5.1 Synthesis of c[DKP-isoDGR] ligands 
The synthesis was conveniently performed on solid phase (Fmoc strategy) using 
SASRINTM resin, following the strategy shown in Scheme 1.5.1. Fmoc-glycine was 
loaded onto the resin and Fmoc-aspartic acid -tert-butyl ester was coupled. The DKP-2 
and DKP-3 scaffolds (either 3R,6S or 3S,6R) were then coupled to the supported 
dipeptide. The DKP-scaffolds are normally obtained as N-Boc protected amino acids 
(see 1.2.1) and thus they are unsuitable for solid phase synthetic applications. In order 
to avoid an exchange of the nitrogen protecting group, involving a deprotection-
reprotection sequence, an intermediate of DKP synthesis, namely the azido-acids 63 
were used in this case. The azide reduction on resin was performed using 
trimethylphosphine in dioxane-water and Cbz-Arg(Mtr) was finally coupled. The linear 
precursors were cleaved from the resin under controlled acidic conditions (to avoid 
deprotection of the t-butyl ester and the Mtr group) affording carboxylic acids 64 that, 
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after hydrogenolysis of the benzyloxycarbonyl group (65), were subjected to 
macrolactamization (66). Final protecting groups side-chain deprotection and 
purification by RP-HPLC afforded the cyclic isoDGR peptidomimetics c[DKP-2-
isoDGR] and c[DKP-3-isoDGR] ready for biological studies and conformational 
analysis. 
 
 
Scheme 1.5.1 - a) Fmoc-Gly-OH, DIC, cat. DMAP, DMF, 2h; b) 20% piperidine in DMF; c) Fmoc-
Asp(OH)-OtBu, DIC, HOAt, DMF; d) 2% piperidine and 2% DBU in DMF; e) 63a or 63b, DIC, HOAt, 
DMF, 18h; f) Me3P, dioxane/water 4:1; g) Cbz-Arg(Mtr)-OH, DIC, HOAt, DMF; h) 1% TFA in DCM; i) H2, 
10% Pd/C, THF/water 1:1; j) HATU, HOAt, DIPEA, 1.4 mM, DMF; k) TFA/thioanisole/EDT/anisole 
90:5:3:2. 
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1.5.2 Biological evaluation 99 
Cyclic isoDGR peptidomimetics c[DKP-2-isoDGR] and c[DKP-3-isoDGR] were 
examined in vitro for their abilities to compete with biotinylated vitronectin for binding 
to the purified v3 and v5 receptors (Table 1.5.1). Screening assays were performed 
by incubating the immobilized integrins v3, v5 and 51 with increasing 
concentrations (10-12–10-5 M) of the two isoDGR ligands in the presence of biotinylated 
vitronectin (for integrins v3 and v5) and biotinylated fibronectin (for integrin 51), 
and measuring the concentration of bound vitronectin or fibronectin in the presence of 
the competitive ligands.  
Table 1.5.1 - Inhibition of biotinylated vitronectin or fibronectin binding to v3, v5 and 51 receptors. 
Ligand v3 
IC50 [nM][a] 
v5 
IC50 [nM][a] 
51 
IC50 [nM][a] 
c[DKP-2-isoDGR] 46.7 ± 18.2 220 ± 84 4246 ± 2586 
c[DKP-3-isoDGR] 9.2 ± 1.1 312 ± 21 1066 ± 228 
c[GisoDGRphg] [b] 89 ± 19 [c] n.d. 406 ± 191 [c] 
c[phg-isoDGR-G] [b] > 103 [c] n.d. 19 ± 4 [c] 
c[DKP-3-RGD] 4.5 ± 1.1 149 ± 25 532 ± 35 
c[RGDfV] 3.2 ± 1.3 7.5 ± 4.8 166 ± 28 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin or fibronectin binding as estimated by GraphPad Prism software; all values are 
the arithmetic mean ± SD of triplicate determinations; [b] See 1.1.3.2; [c] determined by a solid phase 
binding assay using supported vitronectin, soluble integrin, specific primary and secondary antibodies. 
 
The v3  IC50 values of compounds c[DKP-2-isoDGR] and c[DKP-3-isoDGR] reported 
in Table 1.5.1 compare favorably with other isoDGR ligands, such as the 
cyclopentapeptide c[GisoDGRphg] recently published by Kessler and coworkers,79 as 
well as with known RGD ligands, such as our c[DKP-3-RGD] (see 1.2.2) and the 
standard cyclopentapeptide cyclo(RGDfV) (see 1.1.3.1). In particular, the new ligand 
c[DKP-3-isoDGR]  is ten times more potent in binding integrin v3 than 
c[GisoDGRphg] and only two-three times less potent than the powerful RGD ligands 
c[DKP-3-RGD] and c[RGDfV]. The IC50 value of c[GisoDGRphg] can be compared with 
the IC50 values of c[DKP-2-isoDGR] and c[DKP-3-isoDGR]  despite the binding assays 
were realized using two different protocols. Indeed, i) vitronectin is used as a 
competitive natural ligand in both assays, and ii) Cilengitide, i.e. c[RGDf(N-Me)V], 
gives the same IC50 value using both assays (0.54 nM79 and 0.58 nM101). 
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Interestingly, the synthesized ligands c[DKP-2-isoDGR] and c[DKP-3-isoDGR]  show 
no selectivity with respect to 51 integrin, unlike for some isoDGR ligands (i.e. c[phg-
isoDGR-G] in Table 1.5.1) developed by Kessler and coworkers.79 
1.5.3 Spectroscopic and computational studies 100 
The structure and connectivity of compounds c[DKP-2-isoDGR] and c[DKP-3-
isoDGR] were unambiguously assigned by means of mono- and bidimensional 1H and 
13C NMR spectra. The preferred conformations c[DKP-2-isoDGR] and c[DKP-3-
isoDGR] were investigated by 1H NMR spectroscopy of dilute H2O/D2O 9:1 solutions 
and by computational methods, with the aim of rationalizing the affinity of these 
compounds for the v3 receptor at a molecular level. One-dimensional 1H NMR 
experiments were conducted to detect intramolecular hydrogen bonds, by measuring 
the chemical shift of the amide N-H protons, their temperature coefficients (/T) and 
their chemical exchange rate in the presence of D2 (see Table 1.5.2). NOESY spectra were 
also recorded to investigate both sequential and long-range NOE signals that provide 
evidences of preferred conformations. Three-dimensional structures satisfying long-
range NOE contacts were generated by restrained mixed-mode Metropolis Monte 
Carlo/Stochastic Dynamics (MC/SD) simulations, using the implicit water GB/SA 
solvation model. 
 
Table 1.5.2 - List of the temperature coefficients, chemical shifts and chemical exchange rates for c[DKP-
2-isoDGR] and c[DKP-3-isoDGR]. 
 
 
Ligand c[DKP-2-isoDGR] c[DKP-3-isoDGR] 
 (ppm) 
T 
(ppb/K) 
Chemical 
Exchange rates 
(ppm) 
T 
(ppb/K) 
Chemical 
Exchange rates 
NH1 8.34 -6.99 0 min 7.60 -1.70 0 min 
NH10 8.43 -8.57 20 min 8.46 -8.02 1h27min 
NHAsp 8.23 -4.90 0 min 8.63 -7.03 12 min 
NHGly 7.88 -4.76 0 min 8.16 -7.20 7 min 
NHArg 8.26 -6.87 5-10 min 8.27 -6.92 12-17 min 
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The data obtained from the NMR experiments show that compound c[DKP-2-isoDGR] 
(Figure 1.5.2) is characterized by a high conformational flexibility. Indeed, the T 
values range from -4.7 ppb K-1 (Gly-NH)  to -8.5 ppb K-1 (DKP-NH10) and the N-H 
chemical shifts indicate that the amide protons of 1 are all solvent exposed. However, 
the strong NOE contact between isoAsp-NH and Gly-NH (see Figure 1.5.2, structure on 
the left) indicates a preferred folding through the formation of a pseudo -turn 
stabilized by an intramolecular hydrogen bond between Gly-NH and DKP-C(5)=O. 
 
 
Figure 1.5.2 - Left: Preferred intramolecular 
hydrogen-bonded pattern proposed for c[DKP-2-
isoDGR], on the basis of spectroscopic data. The 
arrow indicates the NOE contact. Right: 3D 
structure of c[DKP-2-isoDGR] as obtained by 
restrained MC/SD simulations based on 
experimental distance information, after energy 
minimization [pseudo -turn at DKP-isoAsp, 
C(Arg)–COO-(Asp) distance = 8.8 Å].  
 
The distance restraint corresponding to the NOE contact between isoAsp-NH and Gly-
NH was applied in the MC/SD simulations of compound c[DKP-2-isoDGR]. 
Approximately 50% of the conformations sampled during the simulations adopted an 
extended arrangement of the isoDGR sequence characterized by a pseudo -turn at 
DKP-isoAsp and the formation of the corresponding hydrogen bond between Gly-NH 
and C(5)=O. A C(Arg)–COO-(Asp) average distance of 8.6 Å was obtained during the 
MC/SD calculations. A representative energy minimized conformation featuring the 11-
membered ring hydrogen bond between Gly-NH and C(5)=O is shown in Figure 1.5.2 
(structure on the right). 
NMR experiments performed on the isoDGR peptidomimetic c[DKP-3-isoDGR]  
suggest a different conformational preference. Indeed, compound c[DKP-3-isoDGR]  
exists in two preferred conformations, as shown in Figure 1.5.3 (A and B). The NOESY 
cross peak between DKP-NH10 and Arg-NH (strong) is indicative of a -turn 
conformation stabilized by a hydrogen bond between DKP-NH10 and isoAsp-C=O 
(Figure 1.5.3 A), while the NOESY cross peak between Gly-NH and isoAsp-NH (weak) 
is indicative of a pseudo -turn motif (Figure 1.5.3 B) similar to that observed for 
compound c[DKP-2-isoDGR]. 
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Figure 1.5.3 - Preferred intramolecular hydrogen-
bonded patterns proposed for the cyclic isoDGR 
peptidomimetic c[DKP-3-isoDGR], on the basis of 
spectroscopic data. The arrows indicate the NOE 
contacts. (A) -turn at Gly-Arg. (B) pseudo -turn 
at DKP-isoAsp.  
 
 
Only the distance restraint corresponding to the strong NOE contact between DKP-
NH10 and Arg-NH (shown in Figure 1.5.3 A) was applied in the MC/SD simulations of 
compound c[DKP-3-isoDGR]. It is worth noting that approximately 80% of the 
conformations sampled during the simulations adopted an extended arrangement of 
the isoDGR sequence, characterized by a pseudo -turn at DKP-isoAsp and the 
formation of the corresponding hydrogen bond between Gly-NH and C(5)=O (shown in 
Figure 1.5.3 B). In addition, the formation of a distorted -turn at Gly-Arg (shown in 
Figure 1.5.3 A), characterized by hydrogen bond distances of ca. 3.5 Å between DKP-
NH10 and isoAsp-C=O, was observed for 10% of the simulations. A C(Arg)–COO-
(Asp) average distance of 10.7 Å was obtained during the MC/SD calculations of 
compound c[DKP-3-isoDGR]. Two representative energy minimized conformations 
featuring the two hydrogen bond patterns compatible with the strong NOE contact 
between DKP-NH10 and Arg-NH are shown in Figure 1.5.4.  
 
 
Figure 1.5.4 -  3D structures of compound c[DKP-3-
isoDGR] as obtained by restrained MC/SD 
simulations based on experimental distance 
information, after energy minimization. (A) 
distorted -turn at Gly-Arg, populated for 10% of 
the simulation, C(Arg)–COO-(Asp) distance = 10.7 
Å. (B) pseudo -turn at DKP-isoAsp, populated for 
80% of the simulation, C(Arg)–COO-(Asp) 
distance = 10.8 Å. 
 
In order to rationalize, on a molecular basis, the affinity of compounds c[DKP-2-
isoDGR] and c[DKP-3-isoDGR] for the v3 receptor, docking studies were performed 
starting from the representative conformations obtained from the restrained MC/SD 
simulations. The crystal structure of the extracellular segment of integrin v3 
complexed with the cyclic pentapeptide Cilengitide (1L5G pdb code) was taken as a 
reference model for the interpretation of the docking results in terms of ligand-protein 
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interactions. In the X-ray complex, Cilengitide (3) binds to the interface of the  and 
units forming specific electrostatic interactions. The acid and basic pharmacophoric 
groups and their orientation are essential for binding to v3 because they act like an 
electrostatic clamp, interacting with charged regions of the receptor binding site. 
 
Docking calculations starting from the pseudo -turn DKP-isoAsp geometries of 
compound c[DKP-2-isoDGR]  (Figure 1.5.2, right) and from the distorted -turn Gly-
Arg conformations of compound c[DKP-3-isoDGR]  (Figure 1.5.4 A), produced top-
ranked poses conserving the key electrostatic interactions but lacking further stabilizing 
hydrogen bond interactions with the -subunit (e.g. hydrogen bonds of ligand 
carboxylate oxygen with the backbone amides of Asn215 and Tyr122, and hydrogen 
bonds between ligand backbone N-H and protein backbone carbonyl groups). 
On the contrary, docking calculations starting from the pseudo -turn DKP-isoAsp 
geometries of compound c[DKP-3-isoDGR] (Figure 1.5.4 B) produced top-ranked poses 
conserving all the important interactions of the X-ray complex (see Figure 1.5.5).  
 
 
Figure 1.5.5 -  Best pose of compound c[DKP-3-
isoDGR] (atom colour tube representation, 
pseudo -turn at DKP-isoAsp) into the crystal 
structure of the extracellular domain of v3 
integrin ( unit red and  unit blue wire 
representation) overlaid on the bound 
conformation of Cilengitide (green tube 
representation). Only selected integrin residues 
involved in the interactions with the ligand are 
shown. The metal ion in the MIDAS region is 
represented by a magenta sphere. Non-polar 
hydrogens were removed for clarity. 
 
The positively charged Arg guanidinium group of the ligand interacts with the 
negatively charged carboxylates of Asp218 and Asp150 in the  unit, one carboxylate 
oxygen of the ligand is coordinated to the metal cation in the metal-ion-dependent 
adhesion site (MIDAS) region of the  unit, while the second carboxylate oxygen forms 
hydrogen bonds with the backbone amides of Asn215 and Tyr122 in the  unit. Further 
stabilizing interaction involves the formation of a hydrogen bond between the ligand 
backbone NH of the Gly residue and the backbone carbonyl group of Arg216 in the  
unit. The isoDGR sequence of compound c[DKP-3-isoDGR] can fit into the RGD-
binding pocket of v3 integrin, establishing the same electrostatic clamp as well as 
additional key-interactions. 
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1.6 CONCLUSIONS 
 
A library of 7 new bifunctional 2,5-diketopiperazine scaffolds (DKP-4-8, DKP-f4, DKP-
f6) was designed and prepared, in addition to the previously reported scaffolds DKP-1-
3 and DKP-f2-f3.  
All the DKP scaffolds feature a carboxylic acid functionality and a single amino moiety 
(DKP-4-8) or a double protected amino moiety (DKP-f4, DKP-f6). Moreover, the DKP 
scaffolds differ each from the other for the substitution at the intracyclic nitrogens (N-1, 
N-4), as they are either mono (DKP-4, DKP-6, DKP-f4, DKP-f6, DKP-8) or bis-
benzylated (DKP-5, DKP-7). While being derived from -amino acids, they can be seen 
as a constrained dipeptide formed by two - or a - and a -amino acids. 
 
A different synthetic strategy, compared to the isopeptide strategy, was devised: the 
synthesis to obtain these scaffolds occurred via dipeptide. The -hydroxy group of 
serine was converted into azide by a Mitsunobu-type reaction before the formation of 
the symmetric anhydride, which was used in the coupling with a N-benzyl dimethyl 
aspartate derivative. Bis N-benzyl substituted scaffolds (DKP-5, DKP-7) could be easily 
accessed by benzylation of mono-substituted advanced intermediates. 
 
The 7 new scaffolds of the prepared library were used as templates in the synthesis of 
cyclic integrin ligands containing the RGD- recognition sequences.  
The development of this library has provided a detailed SAR analysis of new integrin 
ligands based on DKP scaffolds, affording to a comprehensive view for this new class of 
integrin ligands. 
  
In particular, an efficient synthesis in solution of constrained peptides containing the 
Arg-Gly-Asp (RGD) motif and the 7 diketopiperazine scaffolds was developed and 
optimized. Notably, two different separable conformers (diastereomers) formed during 
the cyclization of compound c[DKP-7-RGD], containing bis-benzylated scaffold DKP-7, 
due to hindered rotation of  one ring around the other. 
 
Ligands c[DKP-4-8-RGD] were tested for their ability to inhibit biotinylated vitronectin 
binding to αvβ3 and αvβ5 receptors. All the ligands, except for c[DKP-7-RGD]-A, 
displayed low nanomolar affinity for both αVβ3 and αVβ5 integrins, with a slight 
selectivity towards the former receptor. Interestingly, the two diastereomeric 
compounds showing atropoisomerism (c[DKP-7-RGD]-A, c[DKP-7-RGD]-B) are the 
least and the most selective and potent of the series. 
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The conformational preferences of ligands c[DKP-4-8-RGD] were investigated by NMR 
spectroscopy in water, detecting H-bonds and long-range NOE contacts. In addition, 
three-dimensional structures satisfying long-range NOE contacts were generated by 
restrained MC/SD simulations. These high affinity ligands display well-defined 
preferred conformations featuring intramolecular hydrogen-bonded turn motifs and an 
extended arrangement of the RGD sequence [C(Asp)-C (Arg) average distance ca. 9 
Å]. Docking studies were performed, starting from the representative conformations 
obtained from the MC/SD simulations and taking as a reference model the crystal 
structure of the extracellular segment of integrin αVβ3 complexed with the cyclic 
pentapeptide Cilengitide. The highest affinity ligands produced top-ranked poses 
conserving all the important interactions of the X-ray complex. 
 
Besides the well-defined RGD motif, it was proposed that also the isoDGR sequence 
might be involved in integrin recognition. In fact, isoDGR sequence can mimic RGD and 
interact with RGD binding site of integrins (such as v3, v5 and 51) in an inverted 
orientation, maintaining all the typical electrostatic-clamp interactions of the RGD motif 
and presenting additional stabilizing interactions. Hence, two constrained peptides 
(c[DKP-2-isoDGR] and c[DKP-3-isoDGR]) containing the isoAsp-Gly-Arg (isoDGR) 
motif and diketopiperazine scaffolds DKP-2 and DKP-3 were prepared, combining a 
new solid phase and an homogeneous synthetic approach. Low nanomolar values were 
obtained for their ability to inhibit biotinylated vitronectin binding to αvβ3 and αvβ5 
receptors and also in this case the recognition sequence of compound c[DKP-2-3-
isoDGR] can fit into the RGD-binding pocket of v3 integrin, establishing the same 
electrostatic clamp as well as additional key-interactions. Interestingly, the synthesized 
ligands c[DKP-2-isoDGR] and c[DKP-3-isoDGR]  show no selectivity with respect to 
51 integrin. Further studies will be conducted to develop the synthesis of c[DKP-
isoDGR] ligands including also the newly prepared DKP scaffolds. 
 
In addition, the two new functionalized integrin ligands c[DKP-f4-RGD] and c[DKP-f6-
RGD] were employed in a drug-targeting approach with Paclitaxel (dual-action 
conjugates), further described in Chapter 2.1.  These compounds were the basis for the 
work described in Chapter 2:  since αv integrins are involved in tumor angiogenesis and 
are overexpressed on the surface of cancer cells, integrin ligands can be usefully 
employed to design dual-action conjugates, able to exploit its integrin affinity to exert a 
site-directed delivery of other payloads. 
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2.1 TUM OR TARGETING STRATEGY  
 
 
2.1.1   State of the art 
 
Chemotherapy has been one of the main approaches for the treatment of cancer for 
more than half a century and is based on the administration of drugs which often 
interfere with fundamental cellular functions (e.g., DNA replication, cell division). The 
antitumor efficacy of anticancer drugs is thus limited by their nonspecific toxicity to 
normal cells, especially to rapidly growing cells such as blood, bone marrow and 
mucous membrane cells, resulting in a low therapeutic index and serious side-effects. 
The efficacy of chemotherapy is further limited by the occurrence or development of 
drug resistance: tumor cells can be regarded as a rapidly changing target because of 
their genetic instability, heterogeneity, and high rate of mutation, leading to selection 
and overgrowth of a drug-resistant tumor cell population.1 In principle, the efficiency of 
the treatment can be improved by increasing the doses, but this approach commonly 
results in severe toxicity. Therefore, selective tumor targeting of chemotherapeutic 
agents represents a major goal, and various drug delivery systems have been recently 
developed,2 including the use of liposomes, microspheres, micelles, polymers, protein- 
or antibody-drug conjugates, and pro-drugs (Figure 2.1.1).3  
Considerable efforts are currently being made in this domain to such an extent that 
leaders of major pharmaceutical companies foresee that >60% of all existing drugs will 
be targeted in less than two decades.4  
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Figure 2.1.1 - Pharmaceutical nano-carriers for drug targeting: A) Structural design of a ligand-targeted 
drug conjugate; B) i) ligand-drug conjugate obtained by a direct linkage between the ligand and the drug 
or ii) connected through a linker. 
Integrins are ideal pharmacological targets based on their key role in angiogenesis and 
tumor development and on their easy accessibility as cell surface receptors interacting 
with extracellular ligands.5 They are also involved in tissue integrity and cell trafficking, 
growth, differentiation, proliferation and migration (see relevant discussion in Chapter 
1.1).6  As a consequence of their role in so many fundamental processes, integrin 
malfunction is connected to a large variety of diseases such as thrombosis, osteoporosis, 
inflammation, and cancer.7 The tripeptide sequence arginine-glycine-aspartate (RGD) 
has been identified as the common motif used by several endogenous ligands to 
recognize and bind a group of integrins, including V3, V5, 51, which are crucial in 
angiogenesis, tumor progression and metastasis, and IIb3, which is involved in platelet 
aggregation.8 
As mentioned in Chapter 1.1.3.1, the potent V3 integrin ligand, cyclo[Arg-Gly-Asp-D-
Phe-N(Me)-Val] (Cilengitide) developed by Kessler and co-workers,9,10 is currently in 
phase II clinical trials (‚CENTRIC‛) as an angiogenesis inhibitor for patients with 
glioblastoma multiforme.11 
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It is currently emerging that antiangiogenic therapy alone is not sufficient to fight and 
eradicate tumors: recent pre-clinical findings of a paradoxical pro-angiogenic activity of 
RGD-mimetic agents (like Cilengitide) at low concentrations have stimulated the debate 
on the use of antiangiogenetics as single drugs.12 The presence of complex biological 
processes inside the cell system (among them, the integrins ‚cross-talk‛ with other 
extracellular receptors, Chapter 2.3.2) seems to suggest that the antiangiogenic therapy 
based only on integrin ligands will not lead to promising applications. After 25 years of 
research on integrins as pharmacological targets, only four drugs are currently on the 
market (cut-off: November 2012) (see Table 2.1.1 and Figure 2.1.2). 
Table 2.1.1 - Integrin inhibitors in late-stage (Market, Phase III or Phase II) clinical studies. 
 
bAbbreviations: A, trials active; AP, angina pectoris; cPep, cyclic peptide; Chi-mAb-Fab, chimeric 
monoclonal antibody, Fab’ fragment; Diag, diagnostic reagent; HIV, human immunodeficiency virus; Hu-
mAb, humanized monoclonal antibody; IS, ischemic stroke; L, launched/drug approved for clinical use; 
mAb, monoclonal antibody; MS, multiple sclerosi, ndr, no development reported, drug not discontinued, 
but trials not apparently active; oSM, orally available small molecule; Pep-der, peptide derivative; PF, 
pulmonary fibrosis; RA, rheumatoid arthritis; SM, small molecule; TR, transplant rejection; UC, ulcerative 
colitis. c x indicates that all associated  chains are targeted. 
2 | Dual-Action Conjugates 
 
 
77 
Although it initially appeared a promising strategy, successful therapeutic inhibition of 
integrins has proven to be elusive, despite the discovery of highly potent inhibitors. 
This is due to a number of reasons, including redundancy among the integrins, the 
importance of integrins in key physiological systems and antagonists that had less than 
optimal properties.13 
 
 
Figure 2.1.2 - The current distribution of integrins as therapeutic targets and the stages of related clinical 
trials. If targeting affects all  chains (‘x’) or all  chains (‘x’) the trial is classified accordingly (e.g., 
intetumumab affects all v integrins independently of associated  chains – and is classed under vx). 
Trials discontinued (light blue); at Phase I (dark blue); at Phase II (pale orange); at Phase III (mid orange); 
or approved drugs (red). Symbols: small molecules and peptides (circles yellow); antibodies (triangles); 
biologicals (cubes). Symbols with black centers represent discontinued trials. 
 
Since V integrins, which can be internalized by cells, are involved in tumor 
angiogenesis and are overexpressed on the surface of cancer cells, integrin ligands can 
be usefully employed as tumor-homing peptidomimetics for site-directed delivery of 
cytotoxic drugs.14 During the past fifteen years, a number of RGD-small molecules drug 
conjugates have been developed (Table 2.1.2). 
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Table 2.1.2 - Integrin targeted delivery of therapeutic small molecules. 
 
 
In a pioneering work Arap and co-workers used a phage display library to isolate 
peptides that home specifically to tumor blood vessels.15a Recovery of phage from 
tumors led to identification of RGD-4C as best candidates. To determinate if this RGD-
compound could be used to improve the therapeutic index of cancer 
chemotherapeutics, they coupled the RGD-4C ligand to doxorubicin (a well-known 
anticancer agent). The RGD-4C-doxorubicin conjugate (see Figure 2.1.3) was used to 
treat mice bearing tumors derived from human MDA-MB-435 breast carcinoma cells. 
An enhanced efficacy and reduced toxicity of the drug against the human breast cancer 
xenografts in nude mice were observed. These results demonstrated the utility of 
targeted chemotherapy strategies based on selective expression of receptors in tumor 
vasculature. The same conjugate (RGD-4C-doxorubicin) was evaluated by Lee and Kim 
in an orthotopic murine hepatoma model. When given intravenously to mice the 
construct suppressed the growth of hepatoma more effectively than free doxorubicin, 
confirming the previously reported results on a different tumor model.15b 
 
 
Figure 2.1.3 - RGD-4C-doxorubicin conjugate. 
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SF1126 (67, Figure 2.1.4) is an RGDS-containing prodrug of LY294002, a PI3K/mTOR 
inhibitor, that targets the cytotoxic portion to stromal end endothelial tumour cells and 
maximizes its clinical efficacy, after cellular internalization of SF1126 and its hydrolysis 
to give cytosolic LY294002.16  The cyclic RGD ligand (Cilengitide)-doxorubicin conjugate 
68 (Figure 2.1.4) was reported to be highly cytotoxic against cancer cells overexpressing 
integrins αVβ3/αVβ5 on their membrane.17 
 
 
Figure 2.1.4 - RGD-based cytotoxic conjugates. 
 
 
In this field, an attractive avenue for selective tumor targeting are hybrid molecules 
designed to bind to specific over-expressed receptors on cancer cells, such as integrins.18 
Clearly, the success of this approach is heavily dependent on the rational selection of 
appropriate biological objectives. 
 
In the next Paragraph (2.1.2), the previous work of our research group in the tumor 
targeting field is presented; in Paragraph 2.2, a new class of dual-action conjugates 
(integrin ligand-proapoptotic compound) will be discussed. 
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2.1.2   Previous work of our research group in the field 
Recently, our research group reported a small library of four (69-72, Figure 2.1.5)  
integrin ligand - Paclitaxel conjugates (c[DKP-RGD]-PTX), with the aim of using c[DKP-
RGD] peptidomimetics as recognition motif for ‚tumor homing drug delivery‛.19 
 
 
Figure 2.1.4 
 
I contributed directly to the design and synthesis of two functionalized 
diketopiperazine scaffolds (DKP-f4, DKP-f6) and their relative integrin ligands (c[DKP-
f4-RGD], c[DKP-f6-RGD]) (see Chapter 1). In order to prepare cyclic RGD-
peptidomimetics covalently linked to Paclitaxel, four functionalized (f) trans 
diketopiperazines (i.e., DKP-f2, DKP-f3, DKP-f4, DKP-f6) were synthesized (see 
Chapter 1.2.1 and 1.3.2), varying the position of the p-aminomethylbenzyl N-substituent 
(N-1 or N-4) and the absolute stereochemistry at C-3 and C-6. These DKPs were used for 
the synthesis of c[DKP-RGD] integrin ligands (see Chapter 1.2.2 and 1.4.2), which were 
finally conjugated to 2’-succinyl Paclitaxel (Scheme 2.1.1). 
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Scheme 2.1.1 - Synthesis of c[DKP-RGD]-PTX conjugates 69-72. Reagents and conditions: a) succinic 
anhydride, Py, DCM, overnight, 0 °C to room temp., 94%; b) N-hydroxysulfosuccinimide sodium salt, 
DIC, DMF, overnight, room temp.; c) c[DKP-f2-RGD], c[DKP-f3-RGD], c[DKP-f4-RGD] or c[DKP-f6-
RGD], CH3CN, aq. phosphate buffer, pH = 7.3, 10 h at 0 °C then 8 h at room temp., 60-70%. 
 
All the Paclitaxel-RGD constructs 69-72 inhibited biotinylated vitronectin binding to the 
purified V3 receptor at low nanomolar concentration (Table 2.1.3), showing that the 
enormous increase of steric hindrance in the conjugates, due to presence of the linker 
bearing Paclitaxel and of the succinate tether, did not influence the high affinity for the 
integrin receptors. Quite surprisingly, the worst inhibition values derive from the 
‚unconjugated‛ integrin ligand c[DKP-f3-RGD] (see Chapter 2.2.2.3 for further 
discussion). 
Table 2.1.3 - Inhibition of biotinylated vitronectin binding to v3 and v5 receptors. 
Compound v3  
IC50 [nM]a 
v5  
IC50 [nM]a 
69 8.5 ± 0.8 518 ± 10 
70 5.2 ± 2.3 219 ± 124 
71 0.9 ± 0.6 76 ± 32 
72 1.1 ± 0.1 22 ± 3 
c[DKP-f3-RGD]b 26.4 ± 3.7 > 5∙103 
 
 
 
 
aIC50 values were calculated as the 
concentration of compound required 
for 50% inhibition of biotinylated 
vitronectin binding as estimated by 
GraphPad Prism software; all values 
are the arithmetic mean ± SD of 
triplicate determinations. bSee Chapter 
1.2.2. 
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Conjugates 69-72 showed in vitro cytotoxic activity against a panel of human tumor cell 
lines similar to that of Paclitaxel.19 Among the cell lines, the cisplatin-resistant IGROV-
1/Pt1 cells express high levels of integrin V3, and thus they are an attractive target for 
in vivo tests. c[DKP-f3-RGD]-PTX 70 (Scheme 2.1.1) displayed sufficient stability in 
physiological solution and in both human and murine plasma to be a good candidate 
for in vivo testing. In tumor-targeting experiments against the IGROV-1/Pt1 human 
ovarian carcinoma xenotransplanted in nude mice, compound 70 exhibited better 
effects than Paclitaxel in terms of tumor volume inhibition, despite the lower (ca. half) 
molar dosage used. The superior in vivo activity of c[DKP-f3-RGD]-PTX 70 as compared 
to Paclitaxel supports the view that integrin ligands are promising tools to improve 
delivery of cytotoxic drugs. 
 
On the base of these positive results, we designed two new classes of dual-action 
conjugates. The first class of conjugates (Chapter 2.2)  exploits the integrin-mediated 
site-directed delivery of pro-apoptotic compounds for the consequent intracellular 
release of SMAC mimetics; the second class (Chapter 2.4) targets simultaneously two 
different extracellular receptors (integrin V3 and VEGFR), both involved in tumor 
growth and angiogenesis. 
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2.2  cycloRGD-SM AC  M IM ETIC DUAL-ACTION CONJUGATES 
 
2.2.1 Apoptosis 
 
Apoptosis is started by stimuli received from within the cell, or from the external 
environment.20 Degradation of cellular protein components is carried out by Cysteine 
ASPartic acid-specific proteASEs (caspases).21 Initiator caspases start the apoptotic 
process, and executioner caspases carry out protein degradation in 
intrinsic/mitochondrial22 and extrinsic/death receptor-dependent23 caspase-dependent 
apoptosis. The family of Inhibitor of Apoptosis Proteins (IAPs)24 bind, through their 
baculovirus inhibitor repeat (BIR) domains, the initiator CASP-9 (BIR3) and the 
executioner CASP-3 and CASP-7 (linker-BIR2): IAP binding blocks caspases in their 
inactive forms and antagonizes apoptosis.25 The endogenous SMAC protein26,27 (Second 
Mitochondria-derived Activator of Caspases, also called DIABLO) binds to the primary-
BIR3 domain of IAPs28 and prevents linker-BIR2 - CASP-3/-7 interactions, through a 
weaker BIR2-SMAC interaction (see Figure 2.2.1).29  
Thus, SMAC is a pro-apoptotic IAP ligand able to restore caspase-dependent apoptosis. 
 
 
Figure 2.2.1 - The biological cycle that regulates apoptosis. 
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X-ray30 and NMR studies31 showed that the N-terminal sequence of SMAC (AVPI 
peptide sequence, see 72 in Figure 2.2.2) binds to BIR2 and BIR3 domains of XIAP, 
cIAP1 and cIAP2 (the most relevant IAP proteins) with nanomolar affinity. 
 
 
 
 
Figure 2.2.2 – AVPI binding epitope on SMAC protein and its interaction with BIR3 domain.  
 
Starting from the natural sequence, chemists developed mimetics of the AVPI sequence, 
aiming at reproducing the pro-apoptotic effect.  
SMAC binds XIAP as a dimer on the same binding sites of caspase 9 (BIR3 domain).32 
Smac interferes also with the XIAP binding site of caspases 3 and 7 (linker-BIR2 
domain), promoting both the extrinsic and intrinsic apoptosis paths.33 The delicate 
balance of this binding equilibrium is altered in various diseases; for example, several 
tumor cell lines show overexpression of XIAP and, consequently, a caspase-dependent 
resistance to enter apoptosis.34,35 Thus, XIAP inhibition via Smac mimetics’ binding is 
considered a validated mechanism for intervention in cancer therapy.36 
Pro-apoptotic N-AVPI mimetics such as 73 (Figure 2.2.3) are undergoing preclinical and 
clinical evaluation as anticancer agents.37 The research group of Prof. P. Seneci and 
colleagues introduced monomeric 4-substituted aza-bicyclo[5.3.0]decane derivatives 
(74, 75, 76, Figure 2.2.3), endowed with good cell-free potency against IAPs and 
moderate cytotoxicity.38,39 
 
 
Figure 2.2.3 -  Pro-apoptotic SMAC mimetics. 
 
The dimeric SMAC mimetic 77 (Figure 2.2.4) is a potent pro-apoptotic anticancer agent 
where two identical N-AVPI mimetic units are connected via a suitable linker. 40 As for 
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the natural SMAC ligand, a first binding event between an N-AVPI mimetic unit and 
the BIR3 primary binding site on IAPs is followed by the intra-molecular binding of the 
other unit and the linker-BIR2 binding site.  
Starting from monomeric SMAC mimetics 74, 75 and 76 (Figure 2.2.3), the research 
group of Prof. P. Seneci reported the synthesis41 and biological evaluation42 of head-head 
(78, Figure 2.2.4) and tail-tail dimers (79, Figure 2.2.4). The linker joining the monomeric 
units is long and flexible enough to allow binding to both IAP BIR domains. Amines 
and alcohols in position 4 of 74, 75 and 76 contribute to their IAP/BIR affinity.43 Such 
amines and alcohols can be further reacted with bifunctional reagents without loss of 
IAP/BIR affinity, providing head-head SMAC dimers 78.44 The pro-(S)-phenyl group in 
the CONH-CHPh2 amide of 74 and 75 does not participate to BIR binding45 and can be 
replaced: functionalization of such group with bifunctional reagents provides access to 
tail-tail SMAC dimers 79.41  
 
 
 
Figure 2.2.4 -  Dimeric pro-apoptotic SMAC mimetics. 
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2.2.2 SMAC-RGD conjugates 
Starting a collaboration with the research group of Prof. P. Seneci (Università degli 
Studi di Milano), we reasoned that, by replacing one of the N-AVPI mimetic units in 78 
and 79 with a cyclic RGD ligand, dual action conjugates targeting tumor cell 
overexpressed receptors (cyclic RGD unit) and apoptosis (SMAC unit) could be created 
(Figure 2.2.5). We designed the dual-action conjugates aiming at exploring: (i) the 
influence of head-like (in compounds c[DKP-RGD]-O/N-SMAC), and tail-like (in 
compound 80) connections as anchoring points on the SMAC mimetic unit, (ii) the 
influence of the ring size of the cyclic RGD ligand unit (15-membered in compounds 
c[DKP-RGD]-O/N-SMAC and 17-membered in compound 80), and (iii) the presence of 
an ester (less stable bond, in c[DKP-RGD]-O-SMAC) or of an amide (more stable bond, 
in c[DKP-RGD]-N-SMAC, 80) in the linker connecting the cyclic RGD and SMAC 
portions (Figure 2.2.5).  
 
Figure 2.2.5 - Targeted cyclic RGD ligand- SMAC mimetic conjugates: head-like compounds c[DKP-
RGD]-O/N-SMAC and tail-like compound 80. 
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The targeted delivery of SMAC mimetics (cytotoxic agents) relies on the αvβ3-mediated 
internalization of the dual-action RGD/SMAC conjugate. Upon the binding, the 
complex ligand-drug-receptor is internalized by the cell (receptor-mediated 
endocytosis); αvβ3 integrin is internalized in a caveolin 1-dependent manner and can 
also enter the cell in clathrin-coated structures. Proteins caveolin and clathrin are able to 
interact with the integrin tails and trigger the vesicles formation. Payload compound 
(i.e., the SMAC unit) is then released inside the cell, able to exploit its pro-apoptotic 
effect through the IAP proteins binding. 
 
P. T. Caswell, S. Vadrevu, J. C. Norman, Nat. Rev. Mol. Cell Biol. 2009, 10, 843-853; P. Caswell, J. Norman, Trends Cell Biol. 2009, 18, 257-263.
 
  
 
During my PhD thesis I synthesized the two dual action conjugates c[DKP-RGD]-O/N-
SMAC, and we performed biological evaluation on this new class of SMAC-RGD 
conjugates, including also compound 80 (prepared by the research group of Prof. P. 
Seneci). 
 
The synthesis of c[DKP-RGD]-O/N-SMAC conjugates started with the analysis of a 
small-molecule SMAC mimetics library recently reported by Prof. Seneci’ group (Figure 
2.2.6).39 
 
Figure 2.2.6 
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We modified the synthesis of this class of ligands to introduce an anchor point for 
further elongation with a linker and conjugation with our functionalized integrin ligand 
c[DKP-f3-RGD] (see Chapter 1.2.2) (Scheme 2.2.1). 1,4-Butanedioic acid was used as a 
relatively short linker, because the distance between the DKP and the SMAC scaffolds 
(21 atoms, including two phenyl groups) was largely determined by the DKP-nitrogen 
p-aminomethylbenzyl and the SMAC p-O/N-methylbenzylaminoethyl substitutions. 
 
 
Scheme 2.2.1 
 
The synthesis of intermediate 81 (Scheme 2.2.1) was already reported,39 and is briefly 
presented at the beginning of Paragraph 2.2.2.1. We decided to use c[DKP-f3-RGD] as 
integrin ligand (among the other functionalized ligands prepared, see Paragraph 1.2.2 
and 1.4.2), for the synthesis of SMAC-RGD conjugates, because of its good affinity to 
integrin receptors (see Paragraph 1.4.3) and because a multi-gram scale synthesis of this 
ligand was already accomplished in our laboratory. 
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2.2.2.1 Synthesis of c[DKP-RGD]-O/N-SMAC conjugates 
As already mentioned, the synthesis of intermediate 81 was already reported: we 
repeated the synthetic pathway shown in Scheme 2.2.2 with an overall yield (from 82 to 
81) of 50% over 9 steps. Starting material 82 was kindly provided by research group of 
Prof. P. Seneci. 
 
Scheme 2.2.2 - a) TFA, Et3SiH, DCM, rt;  b) Ph2CHNH2·HCl, EDC·HCl, HOAt, DIPEA, DCM, N2, rt, 82% 
over 2 steps; c) H2 (H-CubeTM)10bar, Pd/C, EtOH/H2O, rt; d) (Boc)2O, DIPEA, DCM, rt, 92% over 2 steps; 
e) MsCl, DIPEA, DCM, rt; f) n-Bu4N+CN-, DMF, M.W. (80°C), 86% over 2 steps; g) MsOH, THF, 25°C; h) 
Boc-NMe-Abu, HATU, HOAt, DIPEA, DMF, 90% over 2 steps; i) H2 (H-CubeTM) 60bar, Ni Raney, citric 
acid, EtOH, H2O, 60°C, 55% (86% b.o.r.s.m.). 
 
The only tricky point encountered in this synthesis was the unexpected and selective 
formation, during the methansulfonic acid-assisted Boc removal of intermediate 83 and 
in the conditions described in literature, of amidine byproduct 84 (Scheme 2.2.3): 
 
Scheme 2.2.3 - a) workup conditions: residue dissolved in CH2Cl2 and washed with 1 M NaOH; b) 
workup conditions: residue dissolved in AcOEt and washed with NaHCO3 aq. 
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Only a detailed analysis of 13C NMR spectrum revealed the formation of this byproduct, 
since 1H NMR spectrum and MS profile are identical both for the undesired amidine 84 
and for the expected free amine 85. The amidine formation seems to be linked to a too 
basic workup condition (Scheme 2.2.3). 
 
Having in hands amine 81, we synthesized the two aldehydes necessary for the 
ester/amide diversification strategy described in Scheme 2.2.1 (Scheme 2.2.4). 
 
Scheme 2.2.4 - a) NaBH4 (0.25 eq.), THF/EtOH/H2O (60:38:2), 6h, -5 °C to 0 °C, 76%; b) CbzCl, iPr2EtN, 
THF, 0 °C, 71%; c) MnO2, THF, r.t., 97%. 
 
Our synthetic strategy to the ester-connected conjugate c[DKP-RGD]-O-SMAC started 
from amine 81 (Scheme 2.2.2). In a first approach, amine 81 was submitted to a two-
steps reductive alkylation (Scheme 2.2.5) with 4-hydroxymethyl benzaldehyde 86. The 
only product recovered was the amine-borane adduct 88, that was stable also to a 
reported decomplexation procedure.46 
 
Scheme 2.2.5 - a) 86, iPr2EtN, THF, r.t., 5h; b) NaBH4 , 5h, 43% over 2 steps; c) Raney-Ni, 1-hexene, MeOH, 
18h, r.t., 5%. 
 
Repeating the reaction changing the solvent for the imine formation step (MeOH 
instead of THF) and reducing time and NaBH4 equivalents for the reduction step (2 eq 
added over 30 min instead of 10 eq left to react in 5h) afforded aminoalcohol 89 in good 
yield (80%) (Scheme 2.2.6). The resulting aminoalcohol 89 is chemoselectively N-Boc 
protected, and finally bis-N-Boc protected benzyl alcohol 90 is acylated with succinic 
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anhydride to yield the key SMAC mimetic-linker construct 91 (Scheme 2.2.6). The 
overall yield for the reaction steps from 81 to 91 is a rather good 62%. A single direct 
phase chromatographic column (step b) is needed to purify the reaction products. 
 
 
Scheme 2.2.6 – a) 86, iPr2EtN, MeOH, r.t., 5h; b) NaBH4, r.t., 30min, 80% over two steps; c) Boc2O, iPr2EtN, 
CH2Cl2, 0°C to r.t., 24h, 87%; d) succinic anhydride, iPr2EtN, DMAP, CH2Cl2, 0°C to r.t., 2h, 90%. 
 
Construct 91 is then coupled to the previously described c[DKP-f3-RGD] (see Chapter 
1.2.2), to give the bis-N-Boc protected, ester-connected dual compound 92 (Scheme 
2.2.7). The multi-functional nature of both coupling partners and the presence of 
potentially reactive functions (e.g., the guanidine and carboxylate functions in c[DKP-
f3-RGD]) requires the initial activation of the carboxylic group of 91 (step a), followed 
by its coupling with the amino group of c[DKP-f3-RGD]  (step b) under carefully 
controlled conditions. Namely, coupling at pH 7.5 largely prevents side reactions 
involving the unprotected functionalities in c[DKP-f3-RGD], and yields an acceptable 
40% overall yield. Finally, acidic hydrolysis of the N-Boc groups leads to quantitative 
deprotection and isolation of target c[DKP-RGD]-O-SMAC dual action conjugate 
(Scheme 2.2.7).  
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Scheme 2.2.7 - a) N-hydroxysulfosuccinimide, DIC, DMF, r.t., 18h; b) c[DKP-f3-RGD], CH3CN, 
phosphate buffer, pH 7.5, 0°C, 18h, 40% over 2 steps; c) TFA, CH2Cl2, r.t., 50min, 99%. 
 
HPLC purification is needed to obtain N-protected 92 and target c[DKP-RGD]-O-
SMAC as pure compounds. HPLC purification of step b (Scheme 2.2.7) allowed to 
recover both the unreacted SMAC and RGD counterpart (yield was up to 75% based on 
recovery of starting material) (Figure 2.2.7). 
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c[DKP-f3-RGD]
c[DKP-RGD]-O-SMAC
91
 
Figure 2.2.7 – HPLC trace of step b purification (See Scheme 2.2.7). 
 
Synthesis of amide-connected conjugate c[DKP-RGD]-N-SMAC only differs for the 
aldehyde employed (87, Scheme 2.2.4) and for deprotection step d (Scheme 2.2.8). The 
overall yield for the reaction steps from 81 to 96 is an excellent 82% and amide-
connected dual action conjugate c[DKP-RGD]-N-SMAC was obtained, in the last 3 
conjugation steps, in a good 49% overall yield.  However, the yield reaches 87% if the 
recovery of starting material for step g is taken into account (Scheme 2.2.8). 
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Scheme 2.2.8 - a) 87, iPr2EtN, MeOH, r.t., 5h; b) NaBH4, r.t., 30min, 83% over two steps; c) Boc2O, iPr2EtN, 
CH2Cl2, 0°C to r.t., 24h, 100%; d) H2, Pd/C 10%, THF/H2O, r.t., 18h, 100%; e) succinic anhydride, iPr2EtN, 
DMAP, CH2Cl2, 0°C to r.t., 2h, 99%; f) N-hydroxysulfosuccinimide, DIC, DMF, r.t., 18h; g) c[DKP-f3-
RGD], CH3CN, phosphate buffer, pH 7.5, 0°C, 18h, 49% over 2 steps; h) TFA, CH2Cl2, r.t., 50min, 100%. 
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2.2.2.2 Cell-free assays – BIR domains/IAPs 47 
Three BIR domain-based IAP portions were used to test the affinity of the cyclic RGD 
ligand-SMAC mimetics c[DKP-RGD]-O-SMAC, c[DKP-RGD]-N-SMAC and 80 
(Figure 2.2.5). The primary BIR3 binding site/domain from XIAP and cIAP2 was 
selected to observe the affinity for two of the most therapeutically relevant IAPs.48 The 
bi-functional linker-BIR2-BIR3 portion from IAP was selected to determine any SMAC 
dimer-like behaviour of the cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-
SMAC and 80.49 The standard monomeric SMAC mimetics 74, 75, 76 (Figure 2.2.3), were 
tested for comparison. Their IC50 values are reported in Table 2.2.1. 
 
Table 2.2.1 - IC50 of selected compounds on BIR portions from IAPs. 
Compound 
BIR3, XIAP 
IC50 [nM] 
l-BIR2-BIR3, XIAP 
IC50 [nM] 
BIR3, cIAP2 
IC50 [nM] 
c[DKP-RGD]-O-SMAC 52.0 ± 4.5 50.5 ± 7.8 1.33 ± 0.3 
c[DKP-RGD]-N-SMAC 25.5 ± 1.7 57.5 ± 5.8 0.73 ± 0.1 
80 a 680.0 ± 77.3 504.3 ± 251.4 7.97 ± 2.8 
74 b 120 ± 18.6 55 ± 13.1 n.t.c 
75 b 110 ± 26.4 27 ± 12.4 n.t.c 
76 b 760 ± 99.2 190 ± 49.1 n.t.c 
a see Figure 2.2.5  
b see Figure 2.2.3 
c n.t.: not tested 
 
These results clearly show that for the head-like connected cyclic RGD ligand-SMAC 
mimetics c[DKP-RGD]-O/N-SMAC, the attachment of a linker and a cyclic RGD ligand 
onto the SMAC mimetic unit is not affecting its affinity for IAPs. Indeed these 
conjugates show lower IC50 values than reference compounds. On the contrary, tail-like 
connected cyclic RGD ligand-SMAC mimetics 80 is less potent than reference 
compounds. In this case, we can explain this loss in affinity with the presence of a less 
favourable phenylglycinamide moiety – XIAP portion interaction, similar to the C-
terminus phenylglycinamide ester reference compound 76. Moreover, the higher 
affinity of dual action conjugates c[DKP-RGD]-O/N-SMAC and 80 for cIAP proteins is 
also common for monomeric SMAC mimetics.39 
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2.2.2.3 Cell-free assays – αvβ3/αvβ5 integrins 
50  
The cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-SMAC and 80 were tested 
in vitro for their ability to inhibit biotinylated vitronectin binding to the purified αvβ3 
and αvβ5 receptors. The standard monomeric, integrin ligands c[DKP-3-RGD], c[DKP-
f3-RGD] and 98 (Figure 2.2.8), were tested for comparison. Their IC50 values are 
reported in Table 2.2.2. 
 
Table 2.2.2 - Inhibition of biotinylated vitronectin binding to v3 and v5 receptors by selected 
compounds. 
Compound 
v3  
IC50 [nM] 
v5  
IC50 [nM] 
c[DKP-RGD]-O-SMAC 70.1 ± 0.1 900 ± 380 
c[DKP-RGD]-N-SMAC 36.5 ± 0.6 1500 ± 700 
80 a 105.2 ± 3.4 649 ± 25 
 98 b 20.2 ± 1.9 205 ± 34 
c[DKP-3-RGD] b 4.5 ± 1.1 149 ± 25 
c[DKP-f3-RGD] b 26.4 ± 3.7 > 5∙10
3
 
a see Figure 2.2.5  
b see Figure 2.2.8 
 
 
Figure 2.2.8 
 
Although the three cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-SMAC and 
80 show nanomolar affinity for both αvβ3 (stronger interaction) and αvβ5 integrin 
(weaker interaction), their potency is reduced compared to the reference compounds 
c[DKP-3-RGD] and 98. A possible explanation for this is that the free amine moiety 
(NMe-Abu) present in compounds c[DKP-RGD]-O/N-SMAC and 80 interferes with the 
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integrin recognition mechanism (the electrostatic clamp of the carboxylate and 
guanidinium groups). The free amines of the SMAC mimetic moieties could compete 
with the arginine guanidinium group of the RGD counterpart (see Chapter 1.1.1). This 
explanation is supported also by the reduced binding affinity of unconjugated ligand 
c[DKP-f3-RGD] (containing a free amine, see Table 2.2.2 and Figure 2.2.8) and other 
examples of reduced affinity of RGD ligand containing a free amine.51 To assess if this 
hypothesis could be true, we tested in this kind of assay compound 97, an available 
intermediate of the synthesis described in Scheme 2.2.8. Compound 97, having both the 
free amine protected as Boc, should improve its binding affinity, if the hypothesis 
described before is correct. As shown in Figure 2.2.9, IC50 values for intermediate 97 
turned out to be higher than reference compound c[DKP-RGD]-N-SMAC. Thus we 
could conclude that the presence of charged amines, in this specific case, is not relevant 
for the higher IC50 values measured. 
 
 
 
Compound 
v3  
IC50 [nM] 
v5  
IC50 [nM] 
97 82.6 ± 5.7 2100 ± 600 
c[DKP-RGD]-N-SMAC 36.5 ± 0.6 1500 ± 700 
Figure 2.2.9 
 
 
Although the affinity of the c[DKP-RGD]-O/N-SMAC dual-action conjugates for the 
V3 integrin receptor is reduced with respect to the RGD ligands alone taken as 
reference compounds, their residual binding strength is surely sufficient to target them 
towards integrin-expressing tumor cells. Thus, we decided to examine the cytotoxic 
activity of the three cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-SMAC and 
80. 
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2.2.2.4 Cytotoxicity – Tumor cells 47 
The cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-SMAC and 80 were tested 
in cellular assays for their ability to kill tumor cells, either expressing integrin receptors 
on their surface or relying on IAP proteins to impair the physiological apoptotic 
process. We selected ovarian IGROV-1 carcinoma cells as representatives for the former, 
and breast cancer MDA-MB-231 cells for the latter group. The standard monomeric, 
integrin ligands c[DKP-3-RGD] and 98 (Figure 2.2.8) and IAP inhibitors 74, 75, 76 
(Figure 2.2.3), were tested for comparison. Their IC50 values are reported in Table 2.2.3. 
 
Table 2.2.3 - Cytotoxicity of selected compounds. 
Compound MDA-MB-231 
IC50 [M] 
IGROV-1 
IC50 [M] 
c[DKP-RGD]-O-SMAC 9.7 ± 1.6 > 25 
c[DKP-RGD]-N-SMAC > 25 > 25 
80  20.5 ± 2.2 11.5 ± 2.5 
98 n.t. a > 25 
c[DKP-3-RGD] n.t. a > 25 
74 13.5 ± 1.6 > 25 
75 8.1 ± 0.9 > 25 
76 > 25 > 25 
a n.t.: not tested 
 
The results show that cyclic RGD ligand-SMAC mimetics c[DKP-RGD]-O/N-SMAC 
and 80 are endowed with moderate cytotoxic activity. Namely, cytotoxicity for ester-
connected c[DKP-RGD]-O-SMAC and reference SMAC mimetic 74, 75 may be due to 
ester hydrolysis and SMAC mimetic unit release, since they are similarly potent against 
MDA-MB-231 cells. The loss of cytotoxicity for amide-connected c[DKP-RGD]-N-
SMAC may be due to the non-internalization of this dual-action conjugate and 
consequent missed SMAC mimetic unit release. Amide connected 80 shows moderate 
cytotoxicity both on MDA-MB-231 and, interestingly, also on IGROV-1 cells, although 
no hydrolysis and SMAC unit release can easily take place. As expected, reference cyclic 
RGD ligands c[DKP-3-RGD] and 98 per se do not show any cytotoxicity against 
integrin-rich IGROV-1 cells,19,52 and the same is true for reference SMAC mimetics 74, 
75, 76.53 Surprisingly, amide-connected cyclic RGD ligand-SMAC mimetic 80 shows 
cytotoxicity on IGROV-1 cells, possibly suggesting an advantage for tail connected 
dual-action conjugates in terms of cellular activity: the cytotoxic activity of the dual-
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action conjugate 80 on integrin-rich IGROV-1 cells indicates a possible tumor targeting 
effect. 
 
In conclusion, considering the obtained results for these three dual-action SMAC/RGD 
conjugates, influences of linker composition, of steric hindrance and of overall physico-
chemical and electronic properties (e.g., substituents on the SMAC mimetic unit, 
especially the RGD-unit anchoring point) seem to be of primary importance for the 
development of potent SMAC-RGD dual-action conjugates. 
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2.3  INTEGRINS AND VEGFRS 
 
2.3.1 The VEGF-VEGFR system biology 
2.3.1.1 Vascular endothelial growth factors and their receptors 
Vascular endothelial growth factors (VEGFs) are crucial regulators of vascular 
development during embryogenesis (vasculogenesis) as well as blood-vessel formation 
(angiogenesis) in the adult. In mammals, five VEGF ligands, which occur in several 
different splice variants and processed forms, have been identified so far. These ligands 
bind in an overlapping pattern to three receptor tyrosine kinases (RTKs), known as 
VEGF receptor-1, -2 and -3 (VEGFR1–3), as well as to co-receptors (defined as VEGF-
binding molecules that lack established VEGF-induced catalytic function), such as 
heparan sulphate proteoglycans (HSPGs) and neuropilins.54 In certain respects, VEGFs 
share regulatory mechanisms with other well-characterized RTKs, such as the platelet-
derived growth-factor receptors (PDGFRs) and the epidermal growth-factor receptors 
(EGFRs). These mechanisms include receptor dimerization and activation of the 
tyrosine kinase, as well as creation of docking sites for signal transducers. Moreover, 
the VEGFRs induce cellular processes that are common to many growth-factor 
receptors, including cell migration, survival and proliferation.  
However, the VEGFRs also seem to be unique, for example, in their ability to transduce 
signals that form the three-dimensional vascular tube, and in regulating vascular 
permeability that leads to oedema and swelling of tissues. VEGFR1 is a positive 
regulator of monocyte and macrophage migration, and has been described as a positive 
and negative regulator of VEGFR2 signalling capacity. Negative regulation is exerted, at 
least in part, by an alternatively spliced soluble VEGFR1 variant that binds to VEGF and 
thereby prevents VEGF from binding to VEGFR2. VEGFR2 is implicated in all aspects of 
normal and pathological vascular-endothelial-cell biology, whereas VEGFR3 is 
important for lymphaticendothelial- cell development and function. Recently, tumor 
therapies that are based on neutralizing anti-VEGF antibodies and small-molecular-
weight tyrosine-kinase inhibitors that target the VEGFRs have been developed (see 
Paragraph 2.3.1.2 for further discussion).  
The members of VEGF family are dimeric glycoproteins of approximately 40 kDa. In 
mammals, the VEGF family consists of five members, VEGFA, B, C, D and placenta 
growth factor (PLGF). In addition, proteins that are structurally related to the VEGFs 
exist in parapoxvirus (VEGFE) and snake venom (a group of proteins known as 
VEGFFs).55 VEGFA, B and PLGF bind to VEGFR1, VEGFA and E bind to VEGFR2, and 
2 | Dual-Action Conjugates 
 
 
101 
VEGFC and D bind to VEGFR3. Proteolytic processing of the human VEGFC and D 
allows for binding to VEGFR2, however, these factors bind to VEGF2 with lower 
affinity than to VEGFR3 (see FIG. 1a for mammalian ligand–receptor interactions). The 
VEGFFs interact with both VEGFR1 and 2 (Figure 2.3.1).56 
 
 
Figure 2.3.1 - VEGF receptor-binding properties and signalling complexes: a) Mammalian VEGFs bind to 
the three VEGFR tyrosine kinases, leading to the formation of VEGFR homodimers and heterodimers. 
Proteolytic processing of VEGF-C and D allows for binding to VEGFR-2. b) VEGFR signalling is 
modulated by different co-receptors. VEGFs as well as VEGFRs bind to co-receptors such as heparan 
sulphate proteoglycans (HSPGs) and neuropilins. These interactions can influence VEGFR-mediated 
responses, for example, affecting the half-life of the receptor complex. c) Mechanosensory complex 
formation. Blood flow might activate VEGFRs in a ligand-independent manner, by the formation of 
mechanosensory complexes that consist of platelet-endothelial-cell adhesion molecule-1 (PECAM1), 
vascular endothelial (VE)–cadherin, VEGFRs and integrins. PlGF, placenta growth factor. 
 
Structurally, the VEGFs are related to the PDGF family of growth factors, with 
intrachain and interchain disulfide bonds between eight cysteine residues in conserved 
positions. The crystal structure of VEGFA revealed two monomers that are organized in 
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an anti-parallel fashion to form a dimer, with the receptor-binding sites located at each 
pole of the dimer.57 The VEGFs preferentially form homodimers, although VEGFA and 
PLGF heterodimers have been identified. Alternative splicing of several of the VEGF 
family members gives rise to isoforms with different biological activities. The human 
isoforms are denoted VEGFA121, VEGFA145, VEGFA165, VEGFA189 and VEGFA206. The 
mouse isoforms are one amino-acid residue shorter than the corresponding human 
isoform, and they are denoted VEGFA120 and so forth. The activities of the VEGFA 
isoforms are dictated by their different abilities to interact with VEGFR co-receptors, 
such as neuropilins and HSPGs. The bioactivity of VEGF family members is also 
regulated by proteolytic processing. This mechanism might enable specific interactions 
with different types of receptor. For example, in humans, processed VEGFC and D bind 
to VEGFR2, as well as to VEGFR3.  
The VEGFRs are members of the RTK superfamily and they belong to the same subclass 
as receptors for PDGFs and fibroblast growth factors (FGFs). The VEGFRs are equipped 
with an approximately 750-amino-acid-residue extracellular domain, which is 
organized into seven immunoglobulin (Ig)-like folds. Structural and functional studies 
have yielded insights into how the distinct domains contribute to VEGFR activity. The 
crystal structure of part of the extracellular domain of VEGFR1, alone and in complex 
with ligand, shows that the Ig domain-2 constitutes the ligand-binding site on the 
receptor.58 In addition, biochemical analyses showed that the Ig domain-3 in VEGFR2 is 
important for the determination of ligand-binding specificity.59 Alternative splicing or 
proteolytic processing of VEGFRs give rise to secreted variants of VEGFR1 and 
VEGFR2, and in humans, to a C-terminal truncated VEGFR3.60  
 
2.3.1.2 Anti-angiogenic therapy via suppression of the VEGF/VEGFR system 
Tumor angiogenesis is an attractive target for the treatment of cancer: solid tumors 
often become hypoxic due to a rapid growth of tumor cells. The VEGFRs, particularly 
VEGFR-2, are also up-regulated to some extent under hypoxia. 
A VEGF-neutralizing antibody (Bevacizumab, AvastinTM by Genentech Inc., San 
Francisco, CA) was developed for the treatment of solid tumours, including colorectal, 
lung (non-epithelial, NSCLC) and breast cancers as well as glioblastomas. In the USA, 
the FDA approved Bevacizumab in 2008 for the treatment of breast cancer because of a 
statistically significant efficacy in improving overall survival; however, it was 
withdrawn in late 2011 due to a lack of clear efficacy data in recent large-scale phase III 
studies. On the other hand, other countries such as EU and Japan approved 
Bevacizumab for breast cancer treatment based on a statistically significant 
improvement in progression-free survival . Other anti-VEGF-VEGFR drugs, such as 
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VEGF-Trap (a VEGFR-1-VEGFR-2 fusion protein) and VEGFR-neutralizing antibodies, 
have been developed and are now under clinical trials.61  
Papo and co-workers created a dual-specific therapeutic protein (scVEGF ‚fusion-
protein‛, Figure 2.3.2 left) that does not rely on associating domains or physical linkage, 
but rather is based on a naturally occurring ligand (VEGF) into which an additional 
high affinity receptor binding epitope (RGD) has been introduced without disrupting 
the original function.62 Authors showed that dual-specific scVEGF variants can 
simultaneously bind to both VEGFR and αVβ3 integrin, leading to antagonism of 
immediate signalling events (VEGFR-2 phosphorylation) and downstream processes 
(proliferation), particularly in the presence of vitronectin. A specific scVEGF variant  
exhibited increased binding to HUVECs and was a more potent inhibitor of biological 
activity compared to its mono-specific counterparts, highlighting the effects of the dual 
functionality engineered into this protein: remarkably, the dual-specific mutant scVEGF 
(variant 7I), but not the mono-specific variants scVEGFmut or scVEGF m27I (Figure 
2.3.2, left), exhibited nearly complete inhibition of VEGF-mediated murine blood vessel 
formation within implanted Matrigel plugs. (Figure 2.3.2, right). 
 
 
 
Hemoglobin (Hb) content within Matrigel plugs 
was quantified and depicted as the percent of Hb 
compared to VEGF165 / heparin (gray bar). 
 
Figure 2.3.2 – Dual-specific ‚fusion protein‛ scVEGF (left) and its anti-angiogenic activity in vivo (right) 
 
This inhibition could be due to biological effects mediated by blocking both VEGFR2 
and αVβ3 integrin, or through blocking receptor cross-talk (see Paragraph 2.3.2). These 
results provide a basis for further clinical development of dual-specific VEGFR-2/αVβ3 
integrin antagonists (see Paragraph 2.4).  
VEGF function can also be inhibited by small molecules that block or prevent activation 
of VEGF-A receptor tyrosine kinases (receptor intracellular segments) and consequently 
interfere with the VEGF signal transduction pathway.63 Sunitinib (98, Figure 2.3.2, 
SutentTM by Sugen-Pfizer), is a multikinase indol-2-one inhibitor targeting VEGFR-1 and 
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VEGFR-2, PDGFRβ, and other kinases, including FLT3, which has been shown to be 
involved, especially in mutated forms, in acute leukemia.64 Sunitinib was approved in 
2006 by the FDA for the treatment of RCC and of GIST.65 Sorafenib (99, Figure 2.3.2, 
NexavarTM by Bayer and Onyx Pharmaceuticals), is a biarylurea multitargeted kinase 
inhibitor. It inhibits VEGFR-2 ,VEGFR-3 and PDGFRβ.  Sorafenib was approved by U.S. 
FDA in 2005 for the treatment of advanced renal cell carcinoma (RCC) and in 2007 for 
the treatment of hepatocellular carcinoma (HCC).66 
 
Figure 2.3.3 
 
Another class of small molecules that can effectively block the VEGF receptors is 
represented by peptides or peptidic derivatives that bind to the VEGFR extracellular 
segment. Among the successful ligands, the VEGFR2-binding peptoids 100 and 101,67 
the helical peptides 102, 103 derived from VEGF and Vammin hotspots,68 the 17-amino 
acid cyclopeptide 10469 and α/β-peptide 105 by Gellman70 can be mentioned (Figure 
2.3.2). 
 
Figure 2.3.4 
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In 2005 D’Andrea and co-workers published synthesis, structural characterization and 
biological evaluations of QK (106), a 15-mer peptide reproducing the VEGF 17–25 helix 
region (Figure 2.3.3). The -helix conformation of peptide 106 was stabilized 
introducing N- and C-capping sequences (amino acids with intrinsic helix propensity 
and favorable electrostatic interactions). The results demonstrated that 106 binds to 
VEGF receptors in vitro and showed that, quite surprisingly, it promotes capillary 
formation and organization in in vitro assais on matrigel, thus revealing to be a potent 
agonist for angiogenesis.71 
 
 
Figure 2.3.5 
 
Moving from the QK sequence, D’Andrea and co-workers designed a novel peptide, 
called MA (Figure 2.3.3).72 Authors showed that MA assumes in water a well-defined -
helical conformation, binds to VEGF receptors, and inhibits the VEGF biological activity 
on ECs. Furthermore, in vivo experiments showed that MA inhibits VEGF-induced 
capillary formation and tumor growth.  
 
 
Figure 2.3.6 
 
The peptides 106 and MA differ only for two amino acids: Met5 and Ala11 residues in 
MA and Gln5 and Lys11 residues in 106. It is noteworthy that a two amino acid change 
in a 15-mer VEGFR binder peptide induces so different biological responses. A 
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structural approach was adopted to verify if the two different amino acids induce a 
diverse peptide conformation.  Superposition of MA and 106 representative structures 
(Figure 2.3.4) indicates that the two peptides fold very similarly but nonetheless exhibit 
structural differences at the N-terminus. This small difference affects the conformation 
and probably the orientation of the Trp4 side chain that together with Met5, Tyr8, Gln9, 
and Tyr12 is likely involved in the interaction with VEGF receptor. It is possible that 
this different peptide arrangement could effectively affect the receptor molecular 
recognition or receptor activation, but this hypothesis needs further computational 
and/or experimental proof. Furthermore, it is possible to speculate that a different 
conformational arrangement of the bound receptor, ending up in an opposite receptor 
activation state, could be induced by a direct role of the two different amino acids.  
 
Figure 2.3.7 - NMR structure of MA: superposition of 106 (blue) and MA (red) representative structures. 
The residues potentially involved in the interaction with VEGF are shown.72a 
 
This simple 15-mer peptide (MA) represents a good candidate for the treatment of 
diseases associated with excessive VEGF dependent angiogenesis. Among the all other 
examples found in literature, the VEGFR ligand MA proved to be the most accessible, 
from a synthetic point of view, also for further structure modifications, aiming at 
designing a novel dual-action conjugate to target both integrin (RGD motif) and VEGF 
receptors (MA sequence) (Chapter 2.4). 
The rationale behind the VEGFR/integrin multi-target system project will be deeply 
explained in the next Paragraph (2.3.2) 
 
2.3.2 Integrin-VEGFR cross-talk 
Cross-talk between integrins and growth factor or cytokine receptors on both tumor 
and host cell types is vital for many aspects of tumor progression. Mechanisms of cross-
talk include both direct and indirect association of integrins with growth factor or 
cytokine receptors, which affects the expression, ligand affinity and signalling of the 
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receptors. Tumor growth and invasion probably depend on integrin cross-talk with 
growth factor receptors or oncogenes in both tumor cells and tumor associated cells. 
Recent studies have demonstrated that some growth factors and oncogenes require 
specific integrins for tumor initiation and progression. These studies highlight the 
importance of understanding cross-talk mechanisms, as they could influence the tumor 
response to inhibitors of growth factor or integrin signalling. Growing evidence 
supports a central role for cooperative signalling between integrins, growth factor 
receptors and cytokine receptors in many aspects of tumour progression (Figure 2.3.5).73 
 
 
Figure 2.3.8 - Integrin–growth factor and integrin–cytokine receptor cross-talk. Cooperation between integrin 
and growth factor signalling or integrin and cytokine signalling is crucial to tumour progression. Several 
cross-talk mechanisms have so far been elucidated. Integrin ligation may lead directly to the increased 
secretion of growth factors and/or cytokines, which can then bind to their receptors in an autocrine or 
paracrine manner to further induce signalling. In addition, signalling induced by either integrin ligation 
or growth factor binding may activate common downstream pathways resulting in enhanced signalling 
overall compared with the activation of either receptor alone. This signalling seems to most commonly 
converge on kinases such as Src family kinases (SFKs), scaffolding proteins such as p130 CRK-associated 
substrate (p130CAS), and GTPases, such as the Ras family. Alternatively, both chemokine and growth 
factor signalling may regulate integrin function by directly controlling integrin expression levels. ECM, 
extracellular matrix; EGF, epidermal growth factor; FAK, focal adhesion kinase; SDF1, stromal cell-
derived factor 1; RTK, receptor tyrosine kinase. 
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Integrin cross-talk not only regulates tumour cell adhesion, migration, invasion and 
survival, but also affects many aspects of the host response to cancer, particularly in the 
angiogenic endothelium. Another mechanism by which VEGF influences integrin αVβ3 
signalling is through regulating the affinity state, or activation of the integrin: the 
activation of integrin αVβ3 can in turn increase tumour cell secretion of VEGF, providing 
a feedback loop resulting in increased tumour growth. Therefore, signalling through 
distinct integrin–growth factor receptor pairs has crucial roles in tumour angiogenesis.74 
 
Figure 2.3.9 - Four possible mechanisms responsible for the complex formation between VEGFR-2 and 
αVβ3 on the surface of endothelial cells and the functional consequences of this cross-talk. 
 
In a pioneer study published by Roushlati and coworkers, their main goal was to 
localize the sites of the αvβ3 integrin that interact with PDGFRb and VEGFR2.75 The 
main new finding in this work is that both PDGFRb and VEGFR2 associate with the 
extracellular domain of the β3 integrin subunit. Ligand binding and phosphorylation of 
the RTKs do not seem to be required for the integrin interaction. The exact nature of the 
complex containing αvβ3 and the RTKs is unclear: both direct interaction and binding 
mediated by a third component are viable possibilities. This result strongly suggests 
that the integrin RTK extracellular domain interactions described in this work are the 
physical basis of the functional cooperativity between αvβ3 and RTKs. 
The research group of Byzova and coworkers deeply investigated the integrin/VEGFR 
cross talk system.76 In a paper published in 2008, they showed that EC stimulation by 
VEGF induced formation of the high affinity (activated) state of αvβ3 in a monolayer 
and activated αvβ3 was co-localized with VEGF receptor-2 (VEGFR-2).76d Most 
importantly, activated αvβ3 was detected on endothelial cells of tumor vasculature 
(Figure 2.3.7).  
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Figure 2.3.10 - αvβ3 integrin and VEGFR-2 co-localize on endothelial cells. HUVECs were serum-starved 
overnight then stimulated with 20 ng/mL VEGF for 5 minutes. These cells were stained with WOW-1 (a 
genetically engineered antibody used as a probe to detect αvβ3 in its high affinity state on the cell 
surface) and anti-VEGFR-2 antibodies, followed by the incubation with goat anti-mouse IgG labeled with 
Alexa Fluor 488 and goat anti-rabbit IgG conjugated with Alexa Fluor 594. Without a stimulatory signal 
(upper), very little co-localization of αvβ3 integrin and VEGFR-2 was observed. Upon VEGF stimulation 
(lower), the affinity of αvβ3 increases and co-localizes with VEGFR-2. 
 
Activation of αvβ3 was substantially increased in highly-vascularized tumors as 
compared to normal tissues. Activated αvβ3 was co-localized with VEGFR-2 on 
endothelial cells of proliferating blood vessels. Together, these results show the unique 
role of αvβ3 integrin in cross-talk with VEGFR-2 in the context of pathological 
angiogenesis. 
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2.4 DUAL-ACTION  CONJUGATES TARGETING INTEGRIN  V3 AND VEGFR  
 
 
As suggested from the experimental evidences reported above (Paragraph 2.3), a 
dual integrin-VEGFR ligand could significantly improve the anti-angiogenic activity 
associated to the simultaneous inhibition of these extracellular receptors and at the 
same time elucidate the intracellular signalling deriving from the inhibition of this 
cross-talk.  
We decided to investigate this field designing a novel class of small-molecule dual 
action conjugates capable of binding both to the v3 integrin receptor and to VEGF 
receptors. So far, the only example known in literature is the already mentioned dual 
specific fusion protein scVEGFmut (see Paragraph 2.3.1.2). 
We decided to use our potent v3 integrin ligand c[DKP-f3-RGD] (see Paragraph 1.2.2) 
and the recently reported VEGFR1 ligand MA (see Paragraph 2.3.1.2) to develop an 
efficient synthesis of constructs MA-RGD and Ac-MA-RGD (Figure 2.4.1). 
 
 Figure 2.4.1 
 
The retrosynthetic analysis of MA-RGD and Ac-MA-RGD is illustrated in Figure 2.4.2 
and shown in Scheme 2.4.1: 
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Figure 2.4.2 
 
Scheme 2.4.1 
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First of all, we modified the MA peptide (Figure 2.4.3) introducing the alkyne moiety 
necessary for the CuAAC reaction strategy (see Figure 2.4.2 and Scheme 2.4.1): 
 
 
Figure 2.4.3 
 
The N- and C-capping motifs (see also Paragraph 2.3.1.2) were chosen to introduce the 
modifications needed, as these amino acid residues do not participate in the binding 
epitopes of the MA peptide (Figure 2.4.3). We decided to introduce a variation 
(acetylation) on the Lys13 residue (affording thus Ac-MA peptide) in order to prevent 
the possible electrostatic interactions that a free charged amine might create with the 
RGD-ligand counterpart. Indeed these interactions could perturb the interaction with 
the integrin receptor that is based on an electrostatic clamp (see Chapter 1.1). Then we 
chose the side chain of Lys1 as the anchorage point for further derivatization and 
conjugation to the c[DKP-f3-RGD] counterpart (Figure 2.4.3), and we elongated it with 
but-3-ynoic acid (see Paragraph 2.4.1.1 for further details). 
 
On the other hand, in order to perform the CuAAC reaction, the RGD ligand c[DKP-f3-
RGD] must bear an azide moiety (Scheme 2.4.1). We decided to introduce the azide 
through a bi-functional PEG-8 linker (see Paragraph 2.4.1.2 for further details). A critical 
aspect was the choice of the polyethylene glycol chain length: the PEG-8 linker has a 
medium length, hopefully able to exploit the proximity of VEGFR and integrin 
receptors, due to cross-talk induced physical clustering of these receptors (see Chapter 
2.3.2). In addition, the chosen PEG-8 linker presents a mono-dispersed structure profile 
(the longest mono-dispersed bi-functional linker sold by major chemicals suppliers). 
Mono-dispersion is a fundamental property for the linker because it allows to have a 
precise structure of the product (necessary for HPLC purifications and mass analysis) 
rather than a statistical mixture of products differing only for the PEG chain length.  
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2.4.1 Synthesis 
2.4.1.1 Synthesis of VEGFR ligand counterparts 
The MA and Ac-MA peptides were synthesized as reference compounds by 
microwave-assisted solid phase peptide synthesis (MW SPPS) with Biotage Initiator™ 
Microwave Synthesizer, using Rink Amide MHBA Resin and the Fmoc strategy 
(Scheme 2.4.2). 
 
Scheme 2.4.2 
 
Fmoc-Lys(Ac)-H (Novabiochem Ltd.) was used to synthesize on bead-peptide 107 
and fully cleaved peptide Ac-MA. Each coupling step was carried out under N2 
atmosphere and at 70 °C under microwave irradiation. The use of microwaves allowed 
to speed up the coupling reactions on solid phase: decapentapeptides 106 and 107 were 
synthesized in only three days. The power curve maintained by the Biotage Initiator™ 
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Microwave Synthesizer for desired temperature (70 °C) during the coupling step is 
reported in Figure 2.4.4 . 
 
Figure 2.4.4 - Temperature-power curve. The temperature curve (°C) is reported in blue, the power curve 
(W) is reported in red. 
 
The Mtt protecting group on the Lys1 (Scheme 2.4.2) was chosen to perform its 
selective removal with respect to the other protective groups present in 106 and 107. 
Indeed, a single batch of on bead-peptides 106 and 107 was synthesized, and each batch 
was then split into two portions that were treated differently (Scheme 2.4.3). In 
particular, as already shown in Scheme 2.4.2, full side chains deprotection and cleavage 
from resin were accomplished to obtain the reference peptides MA and Ac-MA (see 
Scheme 2.4.3). Alternatively, the on bead-peptides 106 and 107 were selectively Mtt-
deprotected (and maintained on resin) in order to allow their conjugation with but-3-
ynoic acid (see Scheme 2.4.3 and discussion above). 
 
 
Scheme 2.4.3 
 
2 | Dual-Action Conjugates 
 
 
115 
The selective Mtt-removal on the on bead-peptides 106 and 107 was not easy and 
required optimization: it was necessary to establish a procedure to confirm the correct 
outcome of the selective deprotection reaction. The optimization was performed on 
petide 106: as shown in Scheme 2.4.4, 106 was treated with the cleavage cocktail 
TFA/TIS/DCM (1:2:97 v/v/v, 2.3 mL for 0.05 mmol of resin) and subsequently with a 
solution of Ac2O in DMF (1:3, 3.0 mL) to effect the acetylation of the ε-amino moiety of 
Lys1. The acetylation step was performed in order to verify whether the selective 
removal (and selective acetylation) of the Mtt group had taken place. Indeed, at this 
point only the Lys1 side chain –NH2 should be deprotected, whereas all the others side 
chain functional groups should be still protected (and thus impossible to be acetylated). 
The last step was the full cleavage of the peptide from the resin, removing all the 
protecting groups still present on the residues side chains. MS analysis on the fully 
deprotected peptide gave no evidence of the desired product. Instead it revealed the 
ineffectiveness of the selective Mtt-removal: the MS spectrum showed the m/z value of 
the MA peptide, without the Ac group on the Lys1 side chain expected in the case of 
successful selective cleavage of Mtt. Moreover also a Kaiser test on some beads (after 
the expected selective cleavage) gave a negative result, i.e. no presence of free amine 
moieties, thus demonstrating the ineffectiveness of the Mtt-selective cleavage 
procedure. 
  
 
Scheme 2.4.4 – First attempt (failed) to selectively remove the Lys1 Mtt-protecting group. 
 
To overcome this problem, a different selective procedure for the Mtt-removal was 
followed: 106 was treated with cocktail TFA/TIS/DCM (1:5:94 v/v/v) 12 times, 2 min and 
3 mL for each time. Final full cleavage gave 110, whose MS analysis confirmed the 
presence of acetylated Lys1 and thus the effectiveness of this procedure (Scheme 2.4.5). 
Moreover, a Kaiser test, just after the selective cleavage, gave a qualitative evidence of 
the presence of free amino groups. 
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Scheme 2.4.5 – Optimized procedure to selectively remove the Lys1 Mtt-protecting group. 
 
The efficacy of the new procedure is probably due to the repeated additions of fresh 
cleavage cocktail every 2 minutes, instead of a single passage lasting 30 minutes, as in 
the first Mtt-removal attempt. 
 
Once established an effective procedure for the selective Mtt group removal, we 
synthesized the Lys1-deprotected peptides 108 and 109 (Scheme 2.4.6), that will be 
employed in the synthesis of the dual action conjugates described in Paragraph 2.4.1.3. 
 
 
Scheme 2.4.6 
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2.4.1.2 Synthesis of RGD ligand counterpart 
The functionalization of RGD-ligand counterpart c[DKP-f3-RGD] started with the 
amino-PEG-8-azide 111 (Sigma-Aldrich) elongation through reaction with succinic 
anhydride: azide 112 was purified by RP-HPLC and isolated in 96% yield. The next 
steps consisted in the activation of the carboxylic acid 112 with DIC and N-
hydroxysuccinimide and subsequent coupling of the activated ester with c[DKP-f3-
RGD] (see Paragraph 1.4.2 for further details). The desired product 113 was purified via 
RP-HPLC (Scheme 2.4.7). 
 
Scheme 2.4.7 - a) succinic anhydride, DMAP, DIPEA, CH2Cl2, r.t., 18h, 96%; b) N-hydroxysuccinimide, 
DIC, DMF, r.t., 2h; c) c[DKP-f3-RGD], CH3CN, phosphate buffer, pH 7.5, 0°C, 18h, 65% over 2 steps. 
 
2.4.1.3 Synthesis of MA-RGD and Ac-MA-RGD 
As described at the beginning of Paragraph 2.4, the dual action conjugates bearing and 
integrin and VEGFR recognition motifs were synthesized by CuAAC reaction. This 
kind of reaction has been widely adopted to conjugate complex molecules and to obtain 
highly branched and elaborate products.77 Some CuAAC reactions performed with solid 
supported substrates were also reported in literature.78 
Regarding the synthesis of  Ac-MA-RGD, the CuAAC reaction was planned to be 
performed on solid phase: we decided to set up a reaction model for the optimization of 
the on-bead click reaction, in order to avoid to waste the valuable azide 113. The on-
bead peptide 109 (Scheme 2.4.6) was used for the optimization: first of all, alkyne 114 
was coupled to Lys1-free peptide 109, thus affording the on-bead alkyne-bearing 
peptide 115. Then model-azide 116 was synthesized starting from cinnamyl alcohol 
(Scheme 2.4.8). 
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Scheme 2.4.8 - a) CrO3, H2SO4 conc., acetone/H2O 1:5, 0°C, 3.5h, 26%; b) HATU, HOAt, DIPEA, DMF, r.t., 
18h; c) Pd/C 10%, H2, CH3OH, r.t., 18h, 96%; d) MsCl, DIPEA, CH2Cl2, 0°C, r.t.; e) NaN3, DMF, 30°C, 24h, 
80% over 2 steps. 
 
A Kaiser test on some beads of 115 was carried out, and the negative result confirmed 
the absence of free amino moiety on the resin, and the effectiveness of the coupling 
reaction. Then, alkyne 115 was reacted with the model azide 116, performing the 
CuAAC reaction on solid phase. The expected peptide 117 was then cleaved from the 
resin and purified by RP-HPLC (Scheme 2.4.9). 
 
Scheme 2.4.9 - a) 116, Cu(I), sodium ascorbate, DMF/piperidine 4:1, r.t., 42h; b) TFA/EDT/H2O/TIS 
(94:2.5:2.5:1  v/v/v/v), 3 h, r.t. 
 
The HPLC chromatogram of the crude CuAAC reaction to give 117 was upsetting and 
full of unexpected peaks (Figure 2.4.5). 
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Figure 2.4.5 - HPLC chromatogram of the crude reaction CuAAC for the model conjugate 17. 
 
The formation of so many by-products could be related to the high reactivity of the acid 
114, which is prone to give the corresponding allene. The allene formation can be due to 
a base (piperidine, present in the reaction mixture) or a metal (copper, present in a 
catalytic amount) which coordinates the triple bond and guides the addition of a proton 
to the terminal alkyne –CH (Scheme 2.4.10).79 
 
 
Scheme 2.4.10 
 
To overcome this problem, we decided to use the homologous pent-4-ynoic acid 118 
(Sigma-Aldrich), which has an extra carbon between the alkyne and the carboxylic acid 
moieties, compared to 114. The reaction conditions for the new alkyne coupling and 
CuAAC reaction are described in Scheme 2.4.11. 
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Scheme 2.4.11 – a) HATU, HOAt, DIPEA, DMF, r.t., 18h; b) 116, CuI, sodium ascorbate, DMF/piperidine 
4:1, r.t., 72h; c) TFA/EDT/H2O/TIS (94:2.5:2.5:1  v/v/v/v), 3 h, r.t. 
 
The HPLC chromatogram of the crude reaction to give the model-peptide 120 is 
reported in Figure 2.4.6. The main peak was confirmed, by MS analysis, to be the 
desired product 120. 
 
  
Figure 2.4.6 - HPLC chromatogram of the crude reaction affording to 120.The main peak corresponds to 
compound 120 
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Having optimized the reaction conditions, the CuAAC reaction was performed 
between azide 113 (Scheme 2.4.7) and alkyne 119 (Scheme 2.4.12). 
 
Scheme 2.4.12 - a) 113, CuI, sodium ascorbate, DMF/piperidine 4:1, r.t., 18h; b) TFA/EDT/H2O/TIS 
(94:2.5:2.5:1  v/v/v/v), 3 h, r.t. 
 
The HPLC chromatogram showed the presence of two peaks in a 6:1 ratio. The 
major peak was assigned to the desired product Ac-MA-RGD by MALDI-TOF-MS 
analysis (Figure 2.4.7) 
 
Figure 2.4.7 - MS spectrum of the conjugate product Ac-MA-RGD (MALDI-TOF-MS analysis, HCCA 
matrix). The spectrum shows the m/z value corresponding to the [M+H]+ ion: the experimental value 
[3172.5 amu] corresponded to the calculated value [3171.63 amu]. 
 
The MS analysis on the minor peak showed a higher m/z value (3346.6 amu) with 
respect to that expected for the desired product. It can be hypothesized that this is a by-
product deriving from the addition of dehydroascorbate, the oxidised form of 
ascorbate, to the already formed Ac-MA-RGD, leading to Ac-MA-RGD-Asc (Scheme 
2.4.13). It is reasonable to assume that the dehydroascorbate (deriving from the 
reduction of Cu(II) to Cu(I)) could be prone to participate to the main click reaction as 
an electrophile. This probably happens in the last step of the catalytic cycle, when an 
electrophile (E+) is required (Scheme 2.4.13). Although this explanation is reasonable, no 
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studies on this side reaction pathway were conducted to deeply investigate why the by-
product formed. 
 
Scheme 2.4.13 
 
Considering the problems found performing the CuAAC reaction on solid phase, it 
was decided to carry out the synthesis of the other dual action ligand MA-RGD in 
solution phase, also to have better control on the stoichiometry and to compare the 
outcome of the reactions, if conducted in solution or on solid phase. Moreover, since 
reaction was conducted in solution phase, the excess of azide 113 was no longer 
necessary, and it was also easier to control the undesired addition of ascorbate to the 
final product.  To avoid this side reaction it was also decided to use CuSO4 as copper 
source, in order to have the reduction of Cu(II) to Cu(I) in situ by ascorbate. 
 
Peptide 108 (Scheme 2.4.6) was coupled to alkyne 118 and alkyne-bearing peptide 121 
was removed from resin (fully deprotection of side chain groups) and purified by RP-
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HPLC, affording alkyne 122. This compound was coupled to azide 113 by Cu(II) click 
reaction, affording, after RP-HPLC purification, the dual action ligand MA-RGD in 25% 
yield (Scheme 2.4.14). 
 
 
Scheme 2.4.14 - a) HATU, HOAt, DIPEA, DMF, r.t., 18h; b) TFA/EDT/H2O/TIS (94:2.5:2.5:1  v/v/v/v), 3 h, 
r.t; c) 113, CuSO4, sodium ascorbate, DIPEA, DMF, r.t., 48h, 25%.  
 
 
 
MALDI-TOF-MS analysis confirmed the mass value for the desired product MA-RGD 
(Figure 2.4.8). 
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Figure 2.4.8 - MS spectrum of MA-RGD (MALDI-TOF-MS analysis, SIN matrix). The spectrum shows the 
m/z value corresponding to the [M+H]+ ion: the experimental value [3130.5 amu] corresponded to the 
calculated value [3129.62 amu]. 
 
 
2.4.2 Circular dichroism analysis 80 
The CD spectroscopy was used to investigate the structural properties of the 
synthesized compounds and to have a more general view of their behaviour in relation 
with their biological activity. 
The CD spectrum arises from the sum of the dichroic contributes of each amide 
moiety present in the peptide. When a peptide folds into a helical conformation, the 
spatial distribution and orientation of its chromophores generate a CD spectrum which 
usually consists of two major bands, corresponding to the π→π* and n→π* electronic 
transitions, located at about 208 and 220 nm (the wavelength values can be different 
due to the helix type, α-helix or 310 helix). The ellipticity sign (positive or negative) in 
correspondence of these focal wavelengths depends on the rotatory direction of the 
helix: in the presence of a right-handed helical structure the ellipticity assumes negative 
values and positive values for the left-handed ones. 
The ratio between the two maxima intensities at 220 and 208 nm is defined as R and 
its value is usually used to evaluate the alpha-helix content in the sample: the higher the 
R value is, the bigger is the fraction of the sample which folds into a α-helix 
conformation. 
 
First the CD spectra of reference compounds MA and Ac-MA peptides (Chapter 
2.4.1.1) were registered in methanol and in trifluoroethanol (TFE), solvents which were 
expected to better solubilize the two compounds (Figure 2.4.9): in Table 2.4.1 the 
experimental data obtained are shown. 
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Figure 2.4.9 - MA and Ac-MA CD spectra in MeOH and TFE. 
Table 2.4.1 - Experimental data for MA and Ac-MA CD spectra in MeOH and TFE. 
Peptide Solvent [θ]
T
 x 10
-3
 (208 nm) [θ]
T
 x 10
-3
 (220 nm) R [θ]220/ [θ]208 
MA 
MeOH -175.30 -139.38 0.80 
TFE -196.45 -162.81 0.83 
Ac-MA 
MeOH -162.50 -136.33 0.84 
TFE -141.13 -124.07 0.88 
Since the CD spectrum derives from a sum of various contributes, the data reported 
above can be used to determine the secondary structure of the compounds only when 
two conditions are fulfilled: 
1 the peptide contains a sufficient number of amide bonds, so that they generate a 
reliable CD spectrum; 
2 the peptide has no other chromophores, different from the amide moiety, which 
absorb the radiation in absorption range of the amide bonds, so that their 
contribute does not alter the spectrum making it unreliable. 
For MA and Ac-MA it is possible to consider reliable the corresponding values of R 
indicating that the α-helix content in the structures of these two peptides is high. 
The CD spectra of MA and Ac-MA were registered also in water for two main 
reasons: 
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1. the cell environment is aqueous, thus it is more useful study the synthesized 
compounds in water; 
2. methanol and TFE are solvents with a well-known ability to induce the helical 
conformation and this effect could invalidate the experimental results. 
 In Figure 2.4.10 the CD spectra in water of MA and Ac-MA are shown. The two 
spectra are very similar, but in the MA spectrum a slightly higher helical content is 
shown: the MA peptide seems to assume a more ordered helical conformation. For the 
Ac-MA peptide, this helical content decrease can be attributed to a greater population 
of unordered structure. 
The only difference between the two sequences is the non-acetylated Lys13 in MA: 
the positive charge of its free amino group could form a salt bridge with the Glu6 
residue. In fact, the two amino acids are at the right distance (seven residues, 
corresponding to two helix turns) to be on the same side of the -helix, thus stabilizing 
the secondary structure. The distance between these two residues is about 11 Å, 
corresponding to two helix turns: Lys and Glu have long side chains and they could get 
close enough to maintain the stabilizing electrostatic interaction. In Table 2.4.2 the 
experimental data obtained are reported. 
 
Figure 2.4.10 - MA and Ac-MA CD spectra in H2O. 
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Table 2.4.2 - Experimental data for MA and Ac-MA CD spectra in H2O. 
Peptide Solvent [θ]
T
 x 10
-3
 (208 nm) [θ]
T
 x 10
-3
 (220 nm) R [θ]220/ [θ]208 
MA H2O -67.55 -46.58 0.69 
Ac-MA H2O -71.28 -38.94 0.55 
In the MA CD spectrum the negative maximum of the   * transition for the amidic 
cromophore (parallel component) is centred at 205 nm, but in the Ac-MA spectrum this 
transition slides down to 203 nm. The classic right-handed α-helix is characterized by 
two negative maxima of roughly equivalent intensity, centred at 208 nm (parallel 
component of the transition   * for the amidic chromophore) and at 222 nm 
(transition n  *). Therefore, the position of the two negative maxima in the spectrum 
of Ac-MA and their intensities indicate the predominant presence of a helical structure 
of type α, with a significant participation of disordered structures, also called 
"polyproline type-II", which move the left band at about 203 nm and determine the 
intensity decrease of the right band. 
 
The CD spectra in water of c[DKP-f3-RGD] and 113 (Chapter 2.4.1.2) are reported 
in Figure 2.4.11. The two curves have the form usually attributed to type β folding, in 
particular β-turn type II, characterized by two maxima: a positive maximum at ≈203 nm 
and a negative one at ≈226 nm. In fact, this kind of spectra was observed in cyclic tri-
peptides that form β-turn structures. Notably, the modest differences, consisting of 
variations in the sign and position of the two maxima between the two curves suggest 
that the PEG-8 moiety does not alter significantly the structure of compound 113.  
 
Figure 2.4.11 - c[DKP-f3-RGD] and N3-PEG8-c[DKP-f3-RGD] CD spectra in H2O. 
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In these two compounds the cyclic peptide RGD is too short to assume a well-defined 
secondary structure: the R values are not meaningful in these cases. 
In Paragraph 1.5.3 has been already demonstrated, via NMR and computational 
studies, that  c[DKP-3-RGD] forms pseudo-β-turn structures. 
 
Figure 2.4.12 shows the superimposed CD spectra of MA, Ac-MA and Ac-MA-RGD in 
TFE and in MeOH. In Table 2.4.3 the experimental data for these CD spectra are 
reported. 
 
Figure 2.4.12 - MA, Ac-MA and Ac-MA-RGD stacked CD spectra in TFE (on the left) and in MeOH (on 
the right). 
Table 2.4.3 - Experimental data for MA, Ac-MA and Ac-MA-RGD CD spectra in TFE and in MeOH. 
Peptide Solvent [θ]
T
 x 10
-3
 (208 nm) [θ]
T
 x 10
-3
 (220 nm) R [θ]220/ [θ]208 
MA 
MeOH -175.30 -139.38 0.80 
TFE -196.45 -162.81 0.83 
Ac-MA 
MeOH -162.50 -136.33 0.84 
TFE -141.13 -124.07 0.88 
Ac-MA-RGD 
MeOH -168.07 -207.57 1.23 
TFE -146.35 -157.61 1.08 
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In TFE and MeOH the Ac-MA-RGD conjugate presents a high helical content, as 
demonstrated by the R values. However, as explained before, these two solvents have a 
well-known ability to induce the helical conformation, for this reason the Ac-MA-RGD 
CD spectrum was recorded also in water (Figure 2.4.13 left).  
The sum CD spectrum of Ac-MA + 113 superimposed to the Ac-MA-RGD CD spectrum 
is reported in Figure 2.4.13 (right). The sum spectrum is obtained by summing the 
molar ellipticities [θ] of the two spectra, i.e. it consisted in the sum of the experimental 
data at the various wavelengths. 
 
Figure 2.4.13 - Ac-MA-RGD CD spectrum in H2O. (on the right) Sum CD spectrum Ac-MA+N3-PEG8-
c[DKP-f3-RGD] stacked to the Ac-MA-RGD CD spectrum. 
 
Also for the other dual-action conjugate, the CD spectrum of MA-RGD in water is 
shown in Figure 2.4.14; on the right  the sum spectrum of MA+113 superimposed to the 
MA-RGD CD spectrum is reported. 
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Figure 2.4.14 - MA-RGD CD spectrum in H2O. (on the right) Sum CD spectrum MA+N3-PEG8-c[DKP-f3-
RGD] stacked to the MA-RGD CD spectrum. 
 
The experimental data for the CD spectra of MA, Ac-MA, MA-RGD and Ac-MA-
RGD in water are summarized in Table 2.4.4 
Table 2.4.4 - Experimental data for MA, Ac-MA, MA-RGD and Ac-MA-RGD CD spectra in H2O. 
Compound Solvent [θ]
T
 x 10
-3
 (208 nm) [θ]
T
 x 10
-3
 (220 nm) R [θ]220/ [θ]208 
MA H2O -67.55 -46.58 0.69 
Ac-MA H2O -71.28 -38.94 0.55 
MA-RGD H2O -51.41 -81.38 1.58 
Ac-MA-RGD H2O -53.52 -92.71 1.73 
Regarding the MA-RGD and Ac-MA-RGD final products, the presence of the PEG-8-
RGD branch makes the R values meaningless because of its contribute to the CD 
spectra: indeed, in both the two sum spectra reported in Figure 2.4.13 and 2.4.14 (for Ac-
MA-RGD and MA-RGD respectively), it is possible to observe the contributions of the 
PEG-8-RGD counterpart to the negative maxima at about 220 nm. The dotted lines 
(which refer to the CD spectra given by the sums of the two parts, the peptide and the 
DKP-RGD moieties) have a maximum more negative with respect to the curves of the 
relative conjugates Ac-MA-RGD and MA-RGD: in this wavelength region the 
character of the CD spectrum curve is dominated by some contributions deriving from 
the 113 counterpart (see also Figure 2.4.11, in which the negative maximum at about 220 
nm is clearly visible). 
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2.4.3 Binding assays on isolated receptors 50 
Since the dual action conjugates MA-RGD and Ac-MA-RGD should exert their 
function on both integrin and VEGF receptors, two separate binding assays on isolated 
receptors were planned. 
  
The ability of the new compounds to inhibit (IC50) vitronectin binding to the isolated 
αVβ3 and αVβ5 receptors is shown in Table 2.4.5, compared also to other conjugated and 
unconjugated integrin ligands. 
Table 2.4.5 - Inhibition of biotinylated vitronectin binding to V3 and V5 receptors. 
Ligand 
αVβ3 
IC50 [nM][a] 
αVβ5 
IC50 [nM][a] 
MA-RGD 50.2 ± 6.2 1700 ± 100 
Ac-MA-RGD 97.5 ± 30.8 4100 ± 1800 
c[DKP-3-RGD][b] 4.5 ± 1.1 149 ± 25 
c[DKP-f3-RGD]-PTX[c] 5.2 ± 2.3 219 ± 124 
c[DKP-RGD]-N-SMAC[d] 36.5 ± 0.6 1500 ± 700 
c[RGDfV] [e] 3.2 ± 1.3 7.5 ± 4.8 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic 
mean ± SD of triplicate determinations; [b] see Chapter 1.2.2; [c] see Chapter 2.1.2; [d] see Chapter 2.2.2.1; [e] 
see Chapter 1.1.3.1 
Although the affinity of MA-RGD and Ac-MA-RGD dual-action conjugates for the 
αVβ3 integrin receptor is reduced compared to the reference compounds c[DKP-f3-
RGD] and c[DKP-3-RGD] and to other dual-action conjugates (c[DKP-f3-RGD]-PTX 
and c[DKP-RGD]-N-SMAC), their residual binding strength (still nanomolar !) is 
surely sufficient to target them towards integrin receptors. It was thought that the free 
ε-amino moiety present on Lys13 in the MA-RGD could have affected negatively the 
results, due to a destabilizing interaction of the positive charge on the electrostatic 
clamp that steers the RGD action mechanism. In order to avoid this problem, the Ac-
MA-RGD conjugate was synthesized with the ε-amine acetylated: the lower IC50 values 
for MA-RGD indicates that, against our expectation, this positive charge does not affect 
the electrostatic clamp. 
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The chemiluminescent assays relying on competition between tested compounds and 
biotinylated VEGF165 for binding to the extracellular domain of recombinant VEGFR-1 
(isolated receptor D1–D7, full ECD) are still on-going. As a reference for these assays it 
will be possible to use the Kd value reported by D’Andrea and co-workers: they 
performed a NMR titration using the second domain of VEGFR-1 (VEGFR-1D2) and the 
Kd of the MA/VEGFR-1D2 complex was estimated to be in the micromolar range (≈46 ± 13 
µM) after an analysis of the NMR titration curves of selected VEGFR-1D2 residues.72b  
We decided to test our compounds on the isolated VEGFR-1 through the competitive 
binding assay reported in Figure 2.4.15.81 The compounds are tested for their ability to 
compete with biotinylated VEGF165 (btVEGF165), an endogenous ligand of VEGFR-1. The 
compound to test and btVEGF165 are added to VEGFR-1 and left in incubation to allow 
equilibration. First Streptavidin-HRP (Horseradish Peroxidase) and then the substrate 
for HRP are added: the chemiluminescence deriving from the subsequent reaction is 
read. The competition between the tested compound and btVEGF165 affects the 
chemiluminesce extent: less chemiluminescence is observed in the presence of a better 
VEGFR-1 ligand respect to btVEGF165. 
 
 
 
Figure 2.4.15 - In vitro binding assay on isolated VEGFR-1. This is a competition assay between the tested 
compound and biotynilated VEGF165 (btVEGF165) on the extracellular domain of recombinant VEGFR-1 
(D1–D7 full ECD). The inhibition is read via chemiluminescence. 
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2.4.4 In vitro tube formation assays 82 
The synthesized compounds were tested for their capacity to block angiogenesis 
with in vitro morphogenesis assays. One of the most specific tests for angiogenesis is the 
measurement of the ability of endothelial cells to form three-dimensional structures 
(tube formation). Endothelial cells of all origins appear able to form tubules 
spontaneously, when enough time is left in order to allow the appropriate extracellular 
matrix components to lay down. Tube formation can be enhanced by use of collagen or 
fibrin clots to coat plastic culture dishes. Tube formation on these clots reflects the in 
vivo situation, and the formation of tight junctions can be confirmed by electron 
microscopy. With the discovery that Matrigel (a matrix-rich product prepared from 
Engelbreth–Holm–Swarm –EHS- tumour cells whose primary component is laminin) 
can evoke endothelial cell tube formation within 24 h, tube formation assays have 
achieved a prominent place in the array of angiogenesis measures (Figure 2.4.16). 
However, one word of caution is that cultured cells of non-endothelial origin, such as 
fibroblasts, may also exhibit a response to Matrigel. It is also critical to control the 
protein concentration of the Matrigel used, because not all commercial preparations of 
Matrigel promote tube formation in vitro.83 
 
 
Figure 2.4.16 - Tube formation on Matrigel. Murine myocardium-derived endothelial cells were seeded 
on Matrigel. Tube formation was observed within 24 h. 
 
The less the tube extent is formed, the more the anti-angiogenic activity of the tested 
compound is high. So, the quantification in this kind of assay is carried out by an 
operator, which counts manually the number of formed tubes, or by special software. 
The qualitative result is very easy to see and understand, evaluating the thickness of the 
tubes network. Figure 2.4.17 reports three pictures taken during the in vitro Matrigel 
assays of the tested compounds. In the picture on the left, where only VEGF was added, 
the three-dimensional network is clearly visible. In the central picture, also the c[DKP-
3-RGD] and Ac-MA were added (co-administration) together with VEGF: the tube 
network is less developed with respect to the photo on the left. On the right the picture 
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corresponding to the addition of Ac-MA-RGD and VEGF to HUVE cells is reported: as 
in the central photo the network is poorly formed, qualitatively less than the other two 
assays. 
 
Figure 2.4.17 -  In vitro Matrigel angiogenesis assays. On the left: HUVEC+VEGF (10-8 M). In the middle: 
HUVEC+VEGF (10-8 M) + c[DKP-3-RGD] (10-9 M) + Ac-MA (10-9 M). On the right: HUVEC+VEGF (10-8 M) 
+ Ac-MA-RGD (10-9 M). To assess angiogenic activity, HUVEC 2.5x104 cells were seeded in a 24-well 
plate coated with 100 µL/well of BD-Matrigel previously polymerized for 1 h at 37 °C. Cells were treated 
with the reported compounds and incubated for 5 h at 37 °C in a moist atmosphere of 5% CO2. Tube‐like 
structure formation was evaluated by phase‐contrast microscopy using a fluorescence microscope 
(Axiovert 40CFL, Carl Zeiss S.p.A. Milan, Italy). The total tube length (pixels) was quantified using 
Adobe Photoshop CS4 (Adobe). 
 
In Figure 2.4.18, in vitro tube formation assay results are reported: all the tested 
compounds (MA, Ac-MA, c[DKP-3-RGD], Ac-MA-RGD) showed a potent anti-
angiogenic activity, giving comparable results in terms of total tubule length. 
HUVEC+BM (EndoGRO Basal Medium) was used as control. The assays on the MA-
RGD compound are still on-going. 
 
Figure 2.4.19 - In vitro angiogenesis assays on Matrigel. HUVEC+BM (EndoGRO Basal Medium) was 
taken as control. The assays on MA-RGD compound are still on-going. 
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These similar results underline a very complex angiogenesis regulation system in the 
examined cell biology. Indeed the integrin ligand c[DKP-3-RGD] showed a very high 
anti-angiogenic activity, as well as the MA peptide, known to be a potent VEGF 
antagonist and its derivative Ac-MA. The c[DKP-3-RGD] compound is an integrin 
ligand and it could block angiogenesis by a pathway involving also the VEGFR 
signalling system (see Paragraph 2.3.2). The dual action conjugate Ac-MA-RGD blocks 
angiogenesis with similar efficacy respect to: (i) the co-administered ligands Ac-MA 
and c[DKP-3-RGD]; (ii) the single administration of integrin ligand c[DKP-3-RGD] and 
VGFR ligand Ac-MA. Thus it appears that the covalently linked dual action conjugate 
Ac-MA-RGD could not improve, in this kind of assay, the anti-angiogenic effects of its 
precursors. Moreover, the marked anti-angiogenic activity of the integrin ligand c[DKP-
3-RGD] was quite unexpected: this strong biological activity could be due to a 
αVβ3/VEGFR-1 cross-talk which disables the VEGFR signalling system when integrin 
receptors are blocked. It is noteworthy to say that, in in vivo  experiments, Cilengitide, at 
very low concentrations (10-9 -10-10 M) exhibited a marked pro-angiogenic effect (see also 
Chapter 2.1.1).12 In this kind of assay (in vitro Matrigel study), the integrin ligand 
c[DKP-3-RGD] showed always an anti-angiogenic effect (up to 10-12 M). 
It is clear that further studies are necessary to have a more detailed picture of the 
behaviour of these integrin/VEGFR ligands . 
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2.5 CONCLUSIONS 
 
In conclusion,  I have started to explore two new classes of dual-action conjugates.  
 
We reported the synthesis and biological characterization of a new class of dual-action 
SMAC/RGD conjugates, aiming at both targeting cell surface receptors overexpressed 
on tumor cells (integrins) and interfering with cellular proliferation through the action 
of a pro-apoptotic unit (SMAC mimetic). We have successfully confirmed their affinity 
for the molecular target of each monomeric unit (v3/v5 receptors and BIR domains), 
and we have ascertained that the moderate cytotoxicity of their monomeric precursors 
can be maintained, even if these results indicates that influences of linker composition, 
its steric hindrance and of overall physico-chemical (e.g., lipophilicity) and electronic 
properties (e.g., substituents on the SMAC mimetic unit) should be taken in account to 
develop potent cytotoxic SMAC-based dual-action conjugates. In addition, some 
preliminary results (e.g., the cytotoxic activity of one dual-action conjugate on IGROV-1 
cells) indicate that the combination of a tumor targeting cyclic RGD unit with a pro-
apoptotic SMAC mimetic unit may lead to synergistic anticancer effects. 
 
The second class of dual-action conjugates targets simultaneously two different 
extracellular receptors (integrin v3 and VEGFR), both involved, through a cross-talk 
mechanism, in tumor growth and angiogenesis. The synthesis of the two dual-action 
conjugates MA-RGD and Ac-MA-RGD was accomplished after the optimization of the 
CuAAC reaction on solid phase and in solution. The two final conjugates were 
characterized with mass spectrometry, and their secondary structures were investigated 
with circular dichroism spectroscopy: the biologically active α-helical conformation was 
maintained, despite the conjugation of the 15-mer peptides to the integrin ligand. The 
biological activities of both the two compounds were evaluated in vitro with binding 
assays on the isolated receptors αVβ3/αVβ5: the affinity for the integrin αVβ3 was 
maintained. The anti-angiogenic activity of these compounds and their precursors was 
tested in vitro with morphogenesis assays on Matrigel (HUVEC); similar results were 
obtained, underlining a very complex angiogenesis regulation system. αVβ3/VEGFR 
dual-action conjugates can be considered a promising tool to further elucidate the cross-
talk regulation mechanism in the examined cell biology. 
 
In summary, promising results were obtained in both cases, highlighting the potential 
of dual-action conjugates capable of tumor targeting or inhibiting two intertwined 
receptors at the same time. 
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3.1 CHEM ISTRY  
3.1.1 -   General remarks and procedures 
 
MATERIALS AND METHODS: All manipulations requiring anhydrous conditions 
were carried out in flame-dried glassware, with magnetic stirring and under a nitrogen 
atmosphere. All commercially available reagents were used as received. Anhydrous 
solvents were purchased from commercial sources and withdrawn from the container 
by syringe, under a slight positive pressure of nitrogen. (S)-and-(R)-serine methyl ester 
hydrochloride,1 (S)- and (R)-serine methyl ester hydrochloride,2 (2R)- and (2S)-aspartic 
acid β-allyl ester hydrochloride,3 N-(tert-butoxycarbonyl)-(2R)-aspartic acid β-allyl 
ester,3 (S)- and (R)-N-Boc-serine methyl ester,4 (S)- and (R)-methyl 3-azido-2-(tert-
butoxycarbonylamino)propanoate,5 (S)- and (R)-3-azido-2-(tert-butoxycarbonylamino) 
propanoic acid,5 (S)- and (R)-dimethyl aspartate hydrochloride,6 (S)- and (R)-N-benzyl-
dimethyl aspartate,7 -methyl glutamate hydrochloride,8 N-Boc-glycine benzyl ester,9  4-
((4-methoxy-2,3,6-trimethylphenylsulfonyl)aminomethyl)benzaldehyde 27,10 N3-(3R,6S)-
DKP-COOAllyl or N3-(3S,6R)-DKP-COOAllyl,11 8112, c[DKP-f3-RGD]10 were already 
synthesized in our laboratory or were prepared according to literature procedures and 
their analytical data were in agreement with those already published; 83 was kindly 
provided by Prof. P. Seneci and its synthesis was previously scaled up on 100g scale by 
Chorisis S.r.l. (Gerenzano, Italy). Reactions were monitored by analytical thin layer 
chromatography using 0.25 mm pre-coated silica gel glass plates (DURASIL-25 UV254) 
and compounds visualized using UV fluorescence, aqueous potassium permanganate 
or ninhydrin. Flash column chromatography was performed according to the method of 
Still and co-workers13 using Chromagel 60 ACC (40-63 µm) silica gel. Melting points 
were obtained in an open capillary apparatus and are uncorrected. Infrared spectra 
were recorded on a standard FT-IR and peaks are reported in cm–. Optical rotation 
values were measured on an automatic polarimeter with a 1 dm cell at the sodium D 
line and are given in units of 10-1 deg cm2 g-1.  
 
NUCLEAR MAGNETIC RESONANCE (NMR) 
 1H-NMR spectra were recorded on a spectrometer operating at 400.16 MHz. Proton 
chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard. The following 
abbreviations are used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet, br = broad signal, dd = doublet of doublet. 13C-NMR spectra 
were recorded on a spectrometer operating at 100.63 MHz, with complete proton 
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decoupling. Carbon chemical shifts are reported in ppm () relative to TMS with the 
respective solvent resonance as the internal standard. 
HPLC PURIFICATION 
The HPLC purifications were performed on a Dionex Ultimate 3000 instrument 
equipped with a Dionex RS Variable Wavelenght Detector (column: Atlantis® Prep T3 
OBDTM 5 m 19 x 100 mm). The crude reaction mixture was dissolved in H2O or, if 
compounds were insoluble in water, adding first DMF, then diluting slowly with H2O 
until reaching at least a 1:1 mixture DMF/H2O (ultrasonic sonicator was used to assist 
the dissolution). The solution so obtained was filtered (polypropylene, 0.45 µm, 13 mm 
ø, PK/100) and injected in the HPLC, affording purified products. 
HPLC ANALYSIS 
Purity analysis for each of the compounds was carried out on a Waters AcquityTM 
UPLC-MS (ESI ion source) instrument (column: Waters AcquityTM UPLC HSS T3 2.1 x 
50mm; C18 1.8m). All the described compounds showed a purity ≥ 98%, as determined 
by UPLC-MS (UV and MS detectors). Alternatively, purity analysis was carried on a 
Dionex Ultimate 3000 instrument equipped with a Dionex RS Variable Wavelenght 
detector (column: Atlantis® Prep T3 OBDTM 5 m 19 x 100 mm). 1 mg of purified 
product was dissolved in 1 ml of H2O and was injected using the same gradient used in 
the purification step. The analysis of the integrals and the relative percentage of purity 
was performed with the software Cromeleon 6.80 SR11 Build 3161. Each isolated 
product showed a purity ≥ 98%. 
FREEZE-DRYING 
Products were freeze-dried after HPLC purification. The desired compound was 
dissolved in a proper solvent (H2O, H2O + 0.1% TFA, glacial acetic acid or a mixture of 
them, on the base of product solubility), then it was frozen with dry ice for 1h and 
freeze-dried for 48 h at -50 °C and 5·10-3 mbar, through the 5Pascal Lio5P DGT 
instrument. 
MASS ANALYSIS 
High resolution mass spectra (HRMS) were performed on a  Fourier Transform Ion 
Cyclotron  Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker 
Daltonics) – 4.7 T Magnet (Magnex) equipped with ESI source, available at CIGA 
(Centro Interdipartimentale Grandi Apparecchiature) c/o Università degli Studi di 
Milano. 
Low resolution mass spectra (MS) were measured on a Waters AcquityTM UPLC-MS 
(ESI ion source). Alternatively, ESI-MS spectra were recorded on the ion trap mass 
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spectrometer Finnigan LCQ Advantage analysing a solution H2O/CH3CN 1:1 + 0,1% 
TFA. 
MALDI-TOF-MS spectra were recorded on the instrument Bruker Microflex™ LT, 
supporting the sample on the 2,5-dihydroxybenzoic acid (DHB), α-cyano-4-
hydroxycinnamic acid (HCCA) and sinapinic acid (SIN) matrices. The peptide 
calibration standard (300-3000 Da range), which consisted of Angiotensin II, 
Angiotensin I, Substance P, Bombesin; ACTH clip 1-17, ACTH clip 18-39, Somatostatin 
28, was purchased from Bruker Daltonics® and used to calibrate the MALDI-TOF-MS 
instrument. The sample was mixed in equal volumes with the matrix solution: a small 
amount (1 μL) of this mixture was spotted on the target surface. The target matrix was 
dried at room temperature and then analyzed. 
 
GENERAL PROCEDURES FOR SOLUTION PHASE SYNTHESIS: 
 
GENERAL PROCEDURE FOR Boc-DEPROTECTION REACTIONS: 
GP1: To a solution of the N-Boc-protected  amino acid or peptide in CH2Cl2 (0.13 M) 
was added half volume of TFA. The reaction mixture was stirred at for 2 h r.t. and then 
concentrated at reduced pressure. The excess TFA was azeotropically removed from the 
residue with toluene. Diethyl ether was added to the residue and the resulting 
suspension was evaporated under reduced pressure to afford the corresponding TFA 
salt.  
 
GENERAL PROCEDURE FOR COUPLING REACTIONS: 
GP2: To a solution of the N-protected amino acid in DMF, under nitrogen atmosphere 
and at 0 ºC, HATU (1.2 eq.), HOAt (1.2 eq.) and DIPEA (4 eq.) were added successively. 
After 30 min, a solution of the N-deprotected TFA salt of the peptide in DMF was added 
and the reaction mixture was stirred at 0 ºC for 1 h and at r.t. overnight. The mixture 
was afterwards diluted with EtOAc and consecutively washed with 1 M KHSO4 (2×), 
aqueous NaHCO3 (2×) and brine (2×), and dried over Na2SO4. Volatiles were evaporated 
under reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE FOR Cbz AND OBn HYDROGENOLYTIC CLEAVAGE:  
GP3: protected compound (1 eq.) was dissolved in a mixture of THF/H2O (1:1) and 
Pd/C 10% (0.1 eq.) was added. The reaction mixtures were subjected to three 
vacuum/hydrogen cycles and then left stirring overnight at room temperature under 1 
bar of hydrogen. The mixture was filtered through Celite, and the cake thus obtained 
was washed thoroughly with THF/H2O (1:1). The filtrate was concentrated and dried to 
give the crude product as white solid. 
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GENERAL PROCEDURE FOR MACROLACTAMIZATION: 
GP4: to a 1.4 mM solution of deprotected linear compound (1 eq.) in DMF, under 
nitrogen atmosphere and at 0 ºC, HATU (4 eq.), HOAt (4 eq.) and DIPEA (6 eq.) were 
added successively. After stirring the reaction mixture at 0 ºC for 1 h, it was allowed to 
reach r.t., and stirred overnight. DMF was then removed under reduced pressure and 
the residue was purified by flash chromatography on silica gel to afford the product as 
white foam. 
 
GENERAL PROCEDURE FOR Mtr AND OtBu ESTER REMOVAL: 
GP5: protected macrolactams was treated with TFA (0.01 M solution), in the presence of 
ion scavengers: thioanisole (5%), ethanedithiol (3%), anisole (2%). After TFA removal, 
under reduced pressure, the residue was dissolved in a 1:1 mixture of diisopropyl 
ether/water. Phases were separated and the aqueous layer was washed several times 
with diisopropyl ether. The aqueous phase was concentrated under reduced pressure to 
give the crude product, which was purified by HPLC to give the desired compound as 
white solid. 
 
GENERAL PROCEDURES FOR MANUAL SPPS: 
 
GENERAL PROCEDURE FOR CAPPING: 
GP6: A 2 M solution of acetic anhydride in DMF was added to the previously washed 
peptidyl resin, and the reaction vessel was shaken for 20 min at room temperature. The 
solution was sucked away, and the resin was washed in the order with DMF (4x) and 
iPrOH (3x). Kaiser test was performed before proceeding to the next step.  
 
GENERAL PROCEDURE FOR KAISER TEST: 
GP7: Phenol (80% solution in ethanol), ninhydrin (6% solution in ethanol) and pyridine 
(two drops) were added to a small sample of the resin and then heated in a boiling 
water bath for 60 sec. If the color of the solution maintained yellow, quantitative 
coupling was achieved. In the case of a slight blue color, the coupling step was not fully 
completed and had to be repeated. 
 
GENERAL PROCEDURES FOR Fmoc DEPROTECTION: 
GP8: The washed and swollen resin was treated twice with a solution of piperidine 
(2%) and DBU (2%) in DMF (v/v) or with a solution of piperidine (20%) in DMF (v/v), 
for 5 min and 15 min respectively and then washed with DMF (5x), DCM (5x), and 
again DMF (4x).  
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GENERAL PROCEDURE FOR AZIDE REDUCTION: 
GP9: Azidopeptidyl resin (1 eq.) was suspended in a 4:1 mixture of dioxane/water. 
Trimethylphosphine (1 M solution in toluene, 6 eq.) was added and the reaction vessel 
was shaken for 40 min. The resin was then washed with dioxane (3x).  
 
GENERAL PROCEDURES FOR SEMI-AUTOMATIC SPPS: 
 
The semi-automatic SPPS was accomplished through the Biotage® Initiator™ 
synthesizer, assisted by microwaves (MW) irradiations; Fmoc/tBu strategy and Rink 
Amide MHBA Resin (100-200 mesh; loading: 0.5 mmol/g) were used. Each coupling 
step consisted in: (i) manual activation (solution phase) of the Fmoc-protected amino 
acid, (ii) addition of the activated amino acid to the resin in the synthesizer vial and 
perform the automated tasks (coupling reaction, capping, deprotection and washing). 
 
SOLUTIONS AND SOLVENTS 
In order to execute the programs set, the synthesizer required the following solutions: 
25% Ac2O in DMF (v/v) (capping solution), 25% piperidine in DMF (v/v) (deprotection 
solution), methanol (washing solvent) and DMF (washing solvent). 
RESIN PREPARATION  
The resin was weighted in a 10 ml Teflon-vial (Biotage) and processed with the swelling 
task and the swelling-Fmoc deprotection task. At the end of these operations the resin 
was ready for the SPPS. 
ACTIVATION OF FMOC-AA-OH  
To a solution of the desired Fmoc-AA-OH (0.4 mmol, 4.0 eq with respect to the resin [1 
eq.]) in DMF (3.5 mL) DIC (63 μL, 0.4 mmol, 4.0 eq), HOAt (54.4 mg, 0.4 mmol, 4.0 eq) 
and DIPEA (139 μL, 0.8 mmol, 8.0 eq) were added at 0 °C, under stirring and inert 
atmosphere. After 25 min, the reaction mixture was added to the resin in the vial inside 
the synthesizer and a cycle of coupling-capping-deprotection-washing steps was 
effected. At the end of this cycle it is possible to add another residue or effect a capping-
washing cycle if the peptide sequence was completed. 
 
The Biotage® Initiator™ programs “Tasks” used for the semi-automatic SPPS are 
reported below. Each task can be modified in every of its parameters and it is 
performed under mechanical stirring at 1000 rpm. 
SWELLING TASK 
DMF (3.0 mL) was added to the resin: the swelling was accomplished at r.t. in 30 min. 
At the end of the swelling step, the vial was empty. 
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SWELLING-FMOC DEPROTECTION TASK 
DMF (3.5 mL) was added to the resin and the swelling was performed at r.t. for 15 min. 
Then two deprotection steps [25% piperidine in DMF (3.0 mL for each step)] were 
carried out: the reaction was performed at r.t. under inert atmosphere for 5 min and 15 
min for the first and the second deprotection step respectively. The resin was washed 8 
times with DMF (3 mL × 30 s for every wash). At the end of each step, the vial was 
empty. 
COUPLING-CAPPING-FMOC DEPROTECTION TASK 
The activated Fmoc-AA was added to the resin inside the vial and the coupling reaction 
assisted by microwaves was carried out at 70 °C under inert atmosphere for 12 min. The 
beads were washed six times with DMF (2.5 mL × 20 s for every wash). The capping 
solution (3 mL) was added to the resin: the capping step was performed at r.t. under 
inert atmosphere for 15 min. The beads were washed six times with DMF (2.5 mL × 20 s 
for every wash). Two deprotection steps were carried out adding the deptotection 
solution (3.0 mL for each step) to the beads: the reaction was performed at r.t. under 
inert atmosphere for 5 min and 7 min for the first and the second deprotection step 
respectively. The beads were washed twice with DMF, MeOH, DMF, MeOH and DMF 
(3.0 mL × 20 s for every wash; 3.0 mL × 20 s for the last washes in MeOH and DMF). At 
the end of each step, the vial was empty. 
COUPLING-CAPPING TASK 
The activated Fmoc-AA was added to the beads and the coupling reaction assisted by 
microwaves was carried out at 70 °C under inert atmosphere for 12 min. The beads 
were washed six times with DMF (2.5 mL × 20 s for every wash). The capping solution 
(3 mL) was added to the resin: the capping step was performed at r.t. under inert 
atmosphere for 15 min. The beads were washed six times with DMF (2.5 mL × 20 s for 
every wash). The beads were washed twice with DMF, MeOH, DMF, MeOH (3.0 mL × 
20 s for every wash). Eventually, the beads were washed eight times with DMF (3.0 mL 
× 30 s). At the end of each step, the vial was empty. 
CAPPING TASK 
The capping solution (3 mL) was added to the resin: the capping step was performed at 
r.t. under inert atmosphere for 15 min. The beads were washed six times with DMF (2.5 
mL × 20 s for every wash). The beads were washed twice with DMF, MeOH, DMF (3.0 
mL × 20 s for every wash). Eventually, the beads were washed twice with MeOH (3.0 
mL × 30 s) and eight times with DMF (3.0 mL × 30 s). At the end of each step, the vial 
was empty. 
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RESIN STORAGE 
The on bead-peptides were stored at 4 °C in a small volume of DMF, with the last 
amino acid of the sequence still Fmoc-protected. The next  SPPS cycle restarted with a 
swelling-deprotection step before continuing the peptide sequence. 
 
PEPTIDE CLEAVAGE 
All the cleavage reactions from the resin were performed manually, under inert 
atmosphere and with mechanical stirring. Under stirring and inert atmosphere, in a 
round bottom flask the cleavage cocktail was prepared adding TIS (1%V/V), EDT 
(2.5%V/V), H2O (2.5%V/V) and TFA (94%V/V) in a ratio of 3.0 mL of cleavage cocktail per 0.1 
mmol of resin. The cleavage procedure was formed by three cleavage cycles. The on 
resin-peptide, stored in a vial, was swollen first with DMF (3.5 mL), then with DCM (3.5 
mL). The resin was put under inert atmosphere and the cleavage cocktail (3.0 mL per 
0.1 mmol of resin to treat) was added: the reaction was carried out at r.t. under 
mechanical stirring and inert atmosphere. After 1 h, the solution was filtered off under 
nitrogen flow and collected in a round bottom flask, where neat TFA (1.0 mL) used for 
washing the beads was collected too: the filtered mixture was then concentrated. 
Another aliquot of cleavage cocktail was added to the beads and the same procedure 
described above was accomplished: the cleavage was completed after three cycles. All 
the filtered, combined fractions were concentrated and poured into cold Et2O, to 
provoke peptide precipitation. Ether was removed through suction-filtration with a 
syringe. The white solid so obtained was purified with RP-HPLC and freeze-dried. 
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3.1.2 -  Synthesis of diketopiperazine (DKP) scaffolds 
 
Preparation of hydrazoic acid  
 
 
 
In a three-necked flask, NaN3 (3 g) was dissolved in H2O (3 mL). Once completely 
dissolved, toluene (20 mL) was added and the reaction mixture was cooled to 0 °C 
under vigorous stirring. Concentrated H2SO4 (1.2 mL) was added extremely slowly, so 
that the solution temperature did not exceed 10 °C. The reaction was stirred for one 
hour at 0 °C and then filtered on cotton wool. The residue was washed twice with 
toluene. The toluene solution was titrated by diluting 1 mL in distilled water (50 mL), 
and addition of NaOH (0.1 M) with phenolphthalein as indicator. 
 
3.1.2.1 DKP-4, DKP-6  
(S)-dimethyl 2-((R)-N-benzyl-3-tert-butoxy-2-(tert- butoxycarbonylamino) propanamido) 
succinate (30a) 
 (R)-dimethyl 2-((S)-N-benzyl-3-tert-butoxy-2-(tert- butoxycarbonylamino) propanamido) 
succinate (30b) 
 
 
 
DCC (604 mg, 2.93 mmol, 1 eq.) was added to a solution of N-Boc-Ser(OtBu)-OH 
(FluorochemTM) (1.53g, 5.86 mmol, 2 eq.) in 15 ml of CH2Cl2, in one portion. A white 
precipitate (DCU) formed and stirring continued for 1h at r.t.. The mixture was then 
filtered on a cotton wool to remove DCU. The white DCU residue was washed twice 
with cold CH2Cl2. The filtrate was concentrated under reduced pressure at r.t., and 
dried under high vacuum to afford symmetric anhydride as a white foam, which was 
used without further purification. N-Bn-Asp(OMe)-OMe 29 (515.4 mg, 2.05 mmol, 0.7 
eq.) was dissolved in CH2Cl2 (15 ml) and at 0°C was added dropwise a solution of 
symmetric anhydride (1.5 g, 2.93 mmol , 1 eq.) in 20 ml of CH2Cl2. Reaction was left to 
warm to r.t. and stirred for 3 days. Then EtOAc was added (60 ml) and the solution was 
extracted with aqueous 1 M KHSO4 (2x30 ml), aqueous NaHCO3 (2x30 ml) and brine 
(1x30 ml), dried over Na2SO4, and volatiles were removed under reduced pressure. The 
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residue was purified by flash chromatography on silica gel (Petroleum ether/EtOAc, 
7:3) to afford the desired product 30 as a transparent viscous oil (810 mg, 75% yield).  
Rf = 0.40 (Hex/EtOAc, 7:3); 1H NMR (400 MHz, CD2Cl2) (two rotamers) δ 7.48 – 7.18 (m, 
5H), 5.27 (br, 1H), 4.95 (d, 1H, J = 16.7 Hz), 4.83 – 4.46 (m, 3H), 3.69 – 3.58 (m, 6H), 3.51 
(d, 2H, J = 6.6 Hz), 3.27 (dd, 1H, J = 16.8, 8.1 Hz), 2.46 (dd, 1H, J = 16.7, 4.6 Hz), 1.46 (s, 
9H), 1.20 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 172.1, 171.2, 170.1, 136.2, 128.6, 128.1, 
127.8, 127.7, 127.4, 73.4, 62.9, 56.7, 52.4, 52.0, 51.6, 51.1, 34.3, 28.0, 27.1; MS (ESI) m/z calcd 
for [C25H39N2O8]+: 495.27 [M+H]+; found: 495.4. 
 
OH-DKP-4-CO2Me (31a); 
OH-DKP-6-CO2Me (31b) 
 
 
 
To a solution of 30 (179 mg, 0.36 mmol, 1 eq.) in CH2Cl2 (1.8 ml) was added 
trifluoroacetic acid (1.8 ml, 5 ml/mmol). The reaction mixture was stirred for 3 h at r.t. 
and then concentrated at reduced pressure. The excess of TFA was azeotropically 
removed from the residue with toluene. Diethyl ether was added to the residue and the 
resulting suspension was evaporated under reduced pressure to give the TFA salt of 17 
as a white foamy solid in quantitative yield. The TFA salt was dissolved in MeOH (5 
ml) and iPr2EtN (247 μl, 1.44 mmol, 4 eq.) was added at r.t. The reaction was stirred for 
40 h at r.t., monitoring the formation of DKP by TLC (AcOEt/Hexane: 8/2). The solution 
was then concentrated under reduced pressure and the residue was purified by flash 
chromatography on silica gel (Petroleum ether/AcOEt, 75:25) to afford the desired 
product 18 as a transparent foam (93.7 mg, 85% yield).  
Rf = 0.1 (AcOEt/Hexane: 8/2); 1H NMR (400 MHz, CD2Cl2) δ 7.40 – 7.22 (m, 5H), 6.55 (br, 
1H), 5.08 (d, J = 15.3 Hz, 1H), 4.38 (t, J = 5.2 Hz, 1H), 4.25 (d, J = 15.4 Hz, 1H), 4.10 (t, J = 
3.9 Hz, 1H), 4.03 – 3.87 (m, 2H), 3.64 (s, 3H), 3.03 (dd, J = 17.3, 3.7 Hz, 1H), 2.99 – 2.92 (br, 
1H), 2.85 (dd, J = 17.3, 5.1 Hz, 1H); 13C NMR (101 MHz, CD2Cl2) δ 170.3, 167.5, 166.3, 
135.7, 128.8, 127.8, 127.7, 56.0, 55.6, 52.0, 47.3, 34.8; ESI+: m/z calcd for [C15H19N2O5]+: 
307.13 [M+H]+; found: 307.4. 
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N-benzyl-dimethyl aspartate (29) 6,7 
 
 
 
At 0 °C to 50 ml of anhydrous methanol, 3.75 ml (47.5 mmol) of thionly chloride was 
added dropwise. The solution was stirred at 0 °C for 30 min and then 6.332 g (47.5 
mmol) of Asp was added. The reaction mixture was stirred at r.t. for 24 h and TLC 
(CH3Cl/CH3OH, 9:1) indicated complete disappearance of Asp. The reaction mixture 
was evaporated under reduced pressure and the residue was triturated with petroleum 
ether repeatedly to provide 7.495 mg (98%) of HCl·Asp-(OCH3)2 as a white solid which 
was directly used for the next reaction. 
To a vigorously stirred solution of 500 mg (2.54 mmol) of dimethyl aspartate 
hydrochloride and 160 mg (2.54 mmol) of sodium cyanoborohydride in 12 ml of 
methanol at rt was added 265 mg (2.54 mmol) of benzaldehyde in one portion. After 
being stirred for 4 h, the mixture was cooled in an ice bath, and the pH was lowered to 
ca. 1 with 37% HCl. The mixture was then allowed to warm to r.t. for 2 h, and the 
methanol was removed under reduced pressure at r.t.. The white residue was dissolved 
into a minimum volume of water, and the pH was raised to ca. 10 with saturated 
aqueous Na2CO3. After three ethyl acetate extractions, combined organic portions were 
washed with brine, dried over Na2CO3, and evaporated to give 29 (425 mg, 67%) as a 
pale yellow oil. 
 
Methyl 3-azido-2-(tert-butoxycarbonylamino)propanoate (35) 5 
 
 
    
In a round bottom flask were solved (10.0 g, 64.3 mmol, 1 eq.) of serine methyl ester 
hydrochloride1 in 232 mL of THF/water 1:1 solution. The reaction flask was lowered 
into an ice bath and 27 ml (193 mmol, 3 eq.) of triethylamine were added. Then, 16.8 g 
(77.1 mmol, 1.2 eq.) of Boc2O were added and the reaction was stirred at room 
temperature for 24 h. The reaction mixture was then diluted with 200 ml of EtOAc and 
washed with aqueous KHSO4 1M until pH = 3 and brine. The organic phase was dried 
over Na2SO4, filtered and concentrated under reduced pressure. The product was then 
dried under high vacuum for a few hours affording 12.3 g (90 %) of pure Boc-Ser-OMe 
34 as viscous transparent oil, which was used in the next step without purification. 
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To triphenyl phosphine (1.45 g, 5.54 mmol, 1.2 eq.) in THF (11 ml) at -78 °C was added 
DIAD (1 ml, 5.54 mmol, 1.2 eq.) in THF (10 ml) followed by the HN3 solution (1.8 M in 
toluene, 3.1 ml, 5.54 mmol,  1.2 eq.) and Boc-serine methyl ester 34 (1.00 g, 4.62 mmol) in 
THF (10 ml). After the mixture stirred at -78 °C for 30 min and then allowed to slowly 
reach 0 °C (within 3 h). The solvent was evaporated and the residue was 
chromatographed with hexane/EtOAc 9:1 to provide 839 mg (74%) of the azide 35 as a 
mobile oil which crystallizes upon standing in the refrigerator. 
 
3-azido-2-(tert-butoxycarbonylamino)propanoic acid (36) 5 
 
 
    
Compound 35 (350.0 mg, 1.433 mmol) dissolved in THF (6 ml) at 0 °C was treated with 
LiOH monohydrate (84.0 mg, 2.00 mmol) in water (4 ml). After 1 h, the mixture was 
concentrated, diluted with water, washed with ether, acidified with 1 M KHSO4, and 
extracted into DCM, which was dried and evaporated to provide 329.2 mg (quant.) of a 
colorless oil. 
 
(R)-dimethyl-2-((S)-3-azido-N-benzyl-2-(tert-butoxycarbonylamino)propanamido)succinate 
(38a);  
(S)-dimethyl-2-((R)-3-azido-N-benzyl-2-(tert-butoxycarbonylamino)propanamido)succinate          
(38b) 
 
 
 
DCC (1.77 g, 8.56 mmol, 1 eq.) was added to a solution of N-Boc-Ser(N3)-OH (36) (3.94g, 
17.11 mmol, 2 eq.) 60 ml of CH2Cl2, in one portion. A white precipitate (DCU) formed 
and stirring continued for 1h at r.t.. The mixture was then filtered on a cotton wool to 
remove DCU. The white DCU residue was washed twice with cold CH2Cl2. The filtrate 
was concentrated under reduced pressure at r.t., and dried under high vacuum to 
afford symmetric anhydride 37 as a pale yellow foam, which was used without further 
purification. N-benzyl-aspartic acid dimethylester 29 (1.51 g, 6.01 mmol, 0.7 eq.) was 
dissolved in CH2Cl2 (50 ml) and the mixture was cooled to 0°C. To this mixture, a 
solution of symmetric anhydride in 50 ml of CH2Cl2 was then added dropwise, very 
slowly. The reaction mixture was let to reach r.t. and stirred overnight. The solvent was 
afterwards removed under reduced pressure and the residue was purified by flash 
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chromatography on silica gel (Hexane/EtOAc, 8:2) to afford the desired product 38 as a 
viscous transparent oil (2.22 g, 80%). 
Rf = 0.37 (Hexane/EtOAc, 7:3);  20Dα =-38.6 (38a, c=1.0 in CHCl3); 1H NMR (400 MHz, 
CD2Cl2) (rotamers ratio in CD2Cl2 A/B = 4:1) δ 7.51 – 7.11 (m, 5H), 5.61 – 5.50 (m, 1HB), 
5.40 – 5.28 (m, 1HB, overlapping with solvent signal), 5.17 (t, 1HB, J = 7.1 Hz), 5.07 – 4.99 
(m, 1HB), 4.86 – 4.69 (m, 3HA, 1HB), 4.54 – 4.38 (m, 1HA, 1HB), 3.74 (dd, 1HB, J = 12.3, 5.4 
Hz), 3.69 – 3.65 (m, 3HA, 1HB), 3.63 (s, 3HA), 3.52 (dd, 1HA, J = 12.4, 6.3 Hz), 3.41 (dd, 
1HA, J = 12.3, 6.0 Hz), 3.28 (dd, 1HA, J = 16.9, 7.4 Hz), 3.05 (dd, 1HB, J = 17.1, 7.0 Hz), 2.71 
(dd, 1HB, J = 17.2, 7.3 Hz), 2.55 (dd, 1HA, J = 16.1, 6.1 Hz), 1.45 (s, 9H); 13C NMR (101 
MHz, CD2Cl2) δ 171.9, 171.3, 170.4, 155.5, 136.3, 129.5, 129.3, 129.2, 129.1, 129.0, 128.8, 
128.2, 128.0, 127.9, 80.9, 58.0, 56.9, 56.6, 53.4, 53.1, 53.0, 52.6, 52.4, 51.4, 48.1, 35.3, 34.9, 
28.6; IR (neat): νmax 3343, 2979, 2953, 2106, 1739, 1712, 1651, 1497, 1438, 1367, 1289, 1250, 
1166; MS (ESI) m/z calcd for [C21H29N5NaO7]+: 486.20 [M+Na]+; found: 486.3. 
 
N3-DKP-4-CO2Me (39a);  
N3-DKP-6-CO2Me (39b) 
  
 
 
Dipeptide 38 (1.44 g, 3.11 mmol, 1 eq.) was deprotected according to general procedure 
GP1, with the addition of Et3SiH (1.24 ml, 7.78 mmol, 2.5 eq.) as an ion scavenger. The 
corresponding trifluoroacetate salt was dissolved in iPrOH (40 ml) and iPr2EtN (2.13 ml, 
12.44 mmol, 4 eq.) was added at r.t.. The reaction was stirred for 5 h at r.t., then the 
solution was concentrated under reduced pressure and the residue was purified by 
flash chromatography on silica gel (EtOAc/Hexane, 8:2) to afford the desired product as 
a white foam (927.4 mg, 90%). 
Rf = 0.33 (Hexane/EtOAc 2:8);  20Dα =+32.2 (39a, c=1 in CHCl3); 1H NMR (400 MHz, 
CD2Cl2) δ 7.45 – 7.24 (m, 5H), 6.83 (s, 1H), 5.13 (d, 1H, J = 15.3 Hz), 4.53 – 4.47 (m, 1H), 
4.24 (d, 1H, J = 15.3 Hz), 4.12 (t, 1H, J = 4.7 Hz), 3.91 (dd, 1H, J = 12.5, 5.8 Hz), 3.85 (dd, 
1H, J = 12.5, 3.6 Hz), 3.65 (s, 3H), 3.07 (dd, 1H, J = 17.5, 3.3 Hz), 2.88 (dd, 1H, J = 17.5, 5.0 
Hz); 13C NMR (101 MHz, CD2Cl2) δ 170.4, 167.6, 164.5, 135.6, 128.9, 127.9, 127.8, 56.0, 
54.3, 52.0, 47.4, 34.6; IR (neat): νmax 3249, 3066, 3030, 3007, 2953, 2924, 2852, 2362, 2342, 
2117, 1736, 1558, 1496, 1449, 1372, 1332, 1281, 1204, 1180, 1138; MS (ESI) m/z calcd for 
[C15H18N5O4]+: 332.14 [M+H]+; found: 332.3. 
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NH2-DKP-4-CO2Me (40a);  
NH2-DKP-6-CO2Me (40b) 
 
 
 
Compound 39 (737 mg, 2.22 mmol, 1 eq.) was dissolved in THF (45 ml) and Pd/C (237 
mg, 0.22 mmol, 0.1 eq.) was added. The flask was thoroughly purged with H2, and the 
system was closed. The reaction mixture was stirred at r.t. for 4 h, and then filtered 
through a Celite pad. The cake thus obtained was washed thoroughly with THF. The 
filtrate was concentrated and dried to give the crude product as a transparent paste 
(643.9 mg, 95%) which was used without further purification. 
Rf = 0.13 (CH2Cl2/MeOH 95:5);  20Dα =+83.2 (40a, c=1  in CHCl3); 1H NMR (400 MHz, 
CD2Cl2) δ 7.30 – 7.09 (m, 5H), 6.75 (br s, 1H), 4.99 (d, 1H, J = 15.3 Hz), 4.15 – 4.04 (m, 2H), 
4.00 (br s, 1H), 3.53 (s, 3H), 3.18 (dd, 1H, J = 13.1, 3.6 Hz), 2.99 – 2.84 (m, 2H), 2.73 (dd, 
1H, J = 17.0, 5.1 Hz), 1.33 (s, 2H); 13C NMR (101 MHz, CD2Cl2) δ 170.3, 167.4, 166.2, 136.1, 
128.8, 127.7, 56.3, 55.9, 51.9, 47.2, 44.2, 35.0; IR (neat): νmax 1736, 1685, 1659, 1496, 1449, 
1371, 1318, 1254, 1203, 1179, 1109; MS (ESI) m/z calcd for [C15H20N3O4]+: 306.14 [M+H]+; 
found: 306.3. 
 
NHBoc-DKP-4-CO2Me (41a);  
NHBoc-DKP-6-CO2Me (41b) 
 
 
 
To a solution of 40 (586 mg, 1.92 mmol, 1 eq.) in THF (35 ml), Boc2O (461 mg, 2.11 mmol, 
1.1 eq.) was added in one portion. After stirring the mixture at r. t. overnight, EtOAc (60 
ml) was added. The solution was washed with 1 M KHSO4 (4x) and brine (1x). The 
organic phase was dried over Na2SO4 and volatiles were removed under reduced 
pressure, to afford the desired product as a white foam (739.5 mg, 95%), which was 
used without further purification. 
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Rf = 0.23 (EtOAc/Hex 7:3);  20Dα =+82.2 (41a, c=1  in CHCl3); 1H NMR (400 MHz, CD2Cl2) δ 
7.33 – 7.06 (m, 5H), 6.69 (br s, 1H), 5.12 (br s, 1H), 4.96 (d, 1H, J = 15.2 Hz), 4.26 (s, 1H), 
4.14 (d, 1H, J = 15.3 Hz), 4.00 (s, 1H), 3.68 – 3.57 (m, 3H), 3.56 – 3.45 (m, 4H), 2.86 (d, 1H, 
J = 16.9 Hz), 2.72 (dd, 1H, J = 17.1, 4.9 Hz), 1.35 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 
170.3, 167.3, 166.0, 146.7, 135.9, 128.8, 127.8, 127.6, 79.9, 56.6, 55.9, 51.9, 47.7, 42.2, 35.1, 
28.0; IR (neat): νmax 3328, 3004, 2979, 2953, 2934, 1809, 1737, 1690, 1586, 1508, 1497, 1450, 
1393, 1368, 1333, 1250, 1208, 1168, 1119; MS (ESI) m/z calcd for [C20H28N3O6]+: 406.20 
[M+H]+; found: 406.3. 
 
NHBoc-DKP-4-COOH (DKP-4);  
NHBoc-DKP-6-COOH (DKP-6) 
 
 
 
Compound 41 (710 mg, 1.75 mmol, 1 eq.) was dissolved in THF (60 ml) and the mixture 
was cooled to 0 °C. A solution of LiOH·H2O (183.7 mg, 4.38 mmol, 2.5 eq.) in H2O (30 
ml) was added dropwise. The resulting solution was let reacting for 1 h at 0 °C. Then, 
maintaining the temperature at 0 °C, the mixture was acidified with HCl 1M to pH = 1-
2, and extracted with CH2Cl2 (4x). The collected organic phases were dried over Na2SO4 
and volatiles removed under reduced pressure. Either DKP-4 or DKP-6 were afforded 
as a white foam (685 mg, 100%), which was used in subsequent steps without further 
purification. 
 
3.1.2.2 DKP-f4, DKP-f6 
(S)-dimethyl-2-(4-((4-methoxy-2,3,6-trimethylphenylsulfonamido)methyl)benzylamino)  
succinate 109 
(R)-dimethyl-2-(4-((4-methoxy-2,3,6-trimethylphenylsulfonamido)methyl)benzylamino) 
succinate 110 
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To a vigorously stirred solution of (S)- or (R)-dimethylaspartate hydrochloride (490 mg, 
2.5 mmol, 1 equiv) and sodium cyanoborohydride (160 mg, 2.5 mmol, 1 equiv) in 
methanol (12 mL), aldehyde 2710 (870 mg, 2.5 mmol, 1 equiv) was added in one portion 
at rt under N2. After being stirred for 4 h, the mixture was cooled to 0 °C and the pH 
was lowered to approximately 1 with a few drops of 37% aqueous HCl (v/v). The 
mixture was allowed to warm and stirred at rt for 2 h. The solvent was removed under 
reduced pressure at rt, the residue was suspended in a small volume of water and the 
pH was adjusted to 7 with an aqueous NaHCO3 solution. AcOEt was added and the 
mixture was stirred for a few minutes. Then, the emulsion was filtered over a small pad 
of celite to afford a separable mixture. The aqueous phase was extracted 3 times with 
AcOEt and the organic phases were collected, dried with Na2SO4 and the solvent was 
evaporated to afford a clear oil.  
This oil was dissolved in THF (50 mL) and treated with an excess of activated MnO2: in 
this way, the small amount (ca. 10%) of benzyl-alcoholic byproduct [i.e. N-(4-
(hydroxymethyl)benzyl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide] was re-
oxidized to aldehyde 27, which is less polar with respect to the alcohol (which co-eluted 
with the desired product). The mixture was stirred for 4 h, filtered over a pad of celite 
and the solvent was evaporated under reduced pressure. The brown oil was purified by 
column chromatography on silica gel (Hexane/AcOEt, 1:1) to afford the desired product 
42 as a viscous transparent oil (800 mg, 66% yield). 
Rf = 0.45 (Hexane/AcOEt, 1:1);  20Dα = -20.5 (42a, c=1.0 in CH3OH); 1H NMR (400 MHz, 
CD2Cl2) δ 7.18 (AB system, 4H), 6.66 (s, 1H), 4.88 (t, 1H, J = 5.6 Hz), 4.06 (d, 2H, J = 6.3 
Hz), 3.90 (s, 3H), 3.85 (d, 1H, J = 13.9 Hz), 3.75 (s, 3H), 3.69-3.61 (m, 5H),  2.77-2.64 (m, 
5H), 2.56 (s, 3H), 2.16 (s, 3H); 13C NMR (101 MHz, CD2Cl2) δ 174.2, 171.5, 159.7, 139.9, 
139.2, 139.0, 135.9, 129.2, 128.6, 128.2, 125.6, 112.5, 57.4, 55.9, 52.3, 52.0, 51.8, 46.9, 38.3, 
24.4, 18.1, 12.1; IR (film) 3356, 2940, 2847, 1736, 1585, 1562, 1308, 1141 cm-1; MS (ESI) m/z 
calcd for. [C24H33N2O7S]+: 493.20 [M+H]+; found: 493.2. 
 
 
(S)-dimethyl-2-((R)-3-azido-2-(tert-butoxycarbonylamino)-N-(4-((4-methoxy-2,3,6-
trimethylphenylsulfonamido)methyl)benzyl)propanamido)succinate (43a); 
(R)-dimethyl-2-((S)-3-azido-2-(tert-butoxycarbonylamino)-N-(4-((4-methoxy-2,3,6-
trimethylphenylsulfonamido)methyl)benzyl)propanamido)succinate (43b) 
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 (S)- or (R)-3-azido-2-(tert-butoxycarbonylamino) propanoic acid 36 (1.84 g, 8.0 mmol, 5 
equiv) was dissolved in CH2Cl2 (12 ml) and then DCC (826 g, 4 mmol, 2.5 equiv) was 
added in one portion. A white precipitate (DCU) was formed and stirring was 
continued for 1h at rt. The mixture was then filtered on cotton funnel to remove DCU, 
which was washed with cold CH2Cl2. The filtrate and the washings were concentrated 
under reduced pressure at rt, to afford symmetric anhydride 37 as a pale yellow foam, 
which was immediately used without further purification.  
(S)- or (R)-N-(N-Mtr-aminomethylbenzyl)-Asp(OMe)-OMe 42  (780 mg, 1.59 mmol, 1 
equiv) was dissolved in CH2Cl2 (12 ml) and cooled to 0 °C. A solution of symmetric 
anhydride in CH2Cl2 (8 ml) was added dropwise and very slowly. The reaction was 
warmed up to rt and stirred overnight. Then solvent was removed under reduced 
pressure and the residue was purified by flash chromatography on silica gel 
(Hexane/AcOEt, 6:4) to afford the desired product 43 as a viscous transparent oil (440 
mg, 40% yield). 
Rf = 0.43 (Hex/AcOEt 1:1);  20Dα = -31.6 (43a, c=0.5 in CH2Cl2); 1H NMR (400 MHz, CD2Cl2) 
(rotamers ratio in CD2Cl2 A/B = 4:1) δ 7.34 – 7.17 (m, 4HA), 7.12 – 7.01 (m, 4HB), 6.66 – 
6.60 (m, 1HA + 1HB), 5.49 (d, 1HB, J = 8.2 Hz), 5.26 (d, 1HA, J = 8.5 Hz), 5.14 – 5.07 (m, 
1HB), 4.99 – 4.92 (m, 1HB), 4.78 (t, 1HA, J = 6.3 Hz), 4.74 – 4.60 (m, 3HA + 1HB), 4.36 (t, 1HA, 
J = 6.4 Hz), 4.29 (d, 1HB, J = 15.9 Hz), 4.05 – 3.96 (m, 2HA + 2HB), 3.85 (s, 3HA + 3HB), 3.71 – 
3.53 (m, 6HA + 8HB), 3.45 (dd, 1HA, J = 12.3, 6.3 Hz), 3.34 (dd, 1HA, J = 12.3, 6.1 Hz), 3.22 
(dd, 1HA, J = 16.9, 7.3 Hz), 2.98 (dd, 1HB, J = 17.3, 7.0 Hz), 2.72 – 2.61 (m, 3HA + 4HB), 2.60 
– 2.45 (m, 4HA + 3HB), 2.14 (s, 3HA + 3HB), 1.50 – 1.35 (m, 9HA + 9HB); 13C NMR (101 MHz, 
CD2Cl2) δ 171.6, 171.0, 170.0, 159.8, 155.2, 139.3, 139.0, 137.3, 135.6, 129.4, 128.8, 128.2, 
127.8, 125.7, 112.5, 80.7, 57.8, 56.7, 55.9, 53.1, 52.8, 52.4, 52.2, 51.1, 50.7, 47.5, 46.7, 35.0, 
34.6, 28.3, 24.4, 18.1, 12.1; IR (film) 3301, 2933, 2112, 1736, 1691, 1670, 1585, 1561, 1307, 
1140 cm-1; MS (ESI) m/z calcd for [C32H45N6O10S]+: 705.29 [M+H]+; found: 705.4. 
 
N3-DKP-f4-COOMe (44a) 
N3-DKP-f6-COOMe (44b) 
 
 
 
Dipeptide-N3 43 (400 mg, 0.57 mmol, 1 equiv) was deprotected according to general 
procedure GP1, with the addition of Et3SiH (0.23 ml, 1.43 mmol, 2.5 equiv) as ion 
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scavenger. The corresponding trifluoroacetate salt  was dissolved in iPrOH (8 ml) and 
iPr2EtN (0.4 ml, 2.28 mmol, 4 equiv) was added at rt. The reaction was stirred for 5 h at 
rt, then the solution was concentrated under reduced pressure and the residue was 
purified by flash chromatography on silica gel (AcOEt/Hexane, 8:2) to afford the 
desired product 44 as a white foam (300 mg, 92% yield). 
Rf = 0.49 (AcOEt);  20Dα = +15.6 (44a, c=0.5 in CH2Cl2); 1H NMR (400 MHz, CD2Cl2) δ  7.17 – 
7.10 (m, 4H), 6.62 (s, 1H), 6.59 (s, 1H), 5.08 (d, 1H, J = 15.3 Hz), 4.92 (t, 1H, J = 6.3 Hz), 
4.46 – 4.40 (m, 1H), 4.08 (d, 1H, J = 15.3 Hz), 4.04 – 3.97 (m, 3H), 3.90 – 3.82 (m, 4H), 3.79 
(dd, 1H, J = 12.6, 3.5 Hz), 3.60 (s, 3H), 3.00 (dd, 1H, J = 17.5, 3.4 Hz), 2.80 (dd, 1H, J = 17.5, 
5.0 Hz), 2.64 (s, 3H), 2.52 (s, 3H), 2.12 (s, 3H); 13C NMR (101 MHz, CD2Cl2) δ 170.7, 167.7, 
164.9, 159.8, 139.3, 139.0, 137.1, 135.5, 128.8, 128.3, 125.7, 112.5, 56.2, 55.9, 54.6, 53.7, 52.4, 
47.3, 46.7, 34.9, 24.4, 18.1, 12.1; IR (film) 3265, 2933, 2110, 1735, 1690, 1671, 1586, 1559, 
1308, 1141 cm-1; MS (ESI) m/z calcd for [C26H33N6O7S]+: 573.21 [M+H]+; found: 573.5. 
 
Boc-DKP-f4-COOMe (45a) 
Boc-DKP-f6-COOMe (45b) 
 
 
 
A solution of azide 44 (300 mg, 0.52 mmol, 1 equiv) in THF (45 ml) was treated with 
10% Pd/C (56 mg, 0.052 mmol, 0.1 equiv), and the flask was purged three times with 
vacuum/H2. The mixture was stirred at rt for 4 h under H2 atmosphere, then filtered 
through a pad of Celite and the Celite cake was washed thoroughly with THF. The 
solvent was removed under vacuum to give the crude amine as a white foam (280 mg, 
99% yield), which was used without further purification. 
To a solution of the crude amine (280 mg, 0.52 mmol, 1 equiv) in DCM (40 ml) at 0 °C, i-
Pr2NEt (0.17 ml, 1.0 mmol, 2 equiv) and Boc2O (132 mg, 0.6 mmol, 1.2 equiv) were 
added. The mixture was stirred at rt for 6 h, the solvent was evaporated and the crude 
compound was purified over a small pad of silica gel with AcOEt as eluent, to afford 
the desired product 45 as a white foam (320 mg, 96% yield). 
Rf = 0.59 (AcOEt);  20Dα =+60.0 (45a, c=1.00 in CH2Cl2); 1H NMR (400 MHz, CD2Cl2) δ 7.17 – 
7.06 (m, 5H), 6.62 (s, 1H), 5.39 (t, 1H, J = 6.0 Hz), 5.27 (t, 1H, J = 5.9 Hz), 4.97 (d, 1H, J = 
15.3 Hz), 4.29 (t, 1H, J = 4.4 Hz), 4.14 (d, 1H, J = 15.3 Hz), 4.03 – 3.96 (m, 3H, J = 6.1 Hz), 
3.85 (s, 3H), 3.66 (ddd, 1H, J = 14.2, 6.6, 4.3 Hz), 3.59 (s, 3H), 3.57 – 3.48 (m, 1H), 2.92 (dd, 
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1H, J = 17.1, 4.1 Hz), 2.76 (dd, 1H, J = 17.1, 5.1 Hz), 2.63 (s, 3H), 2.52 (s, 3H), 2.11 (s, 3H), 
1.41 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 170.7, 167.8, 166.5, 159.7, 157.2, 139.3, 139.1, 
137.1, 135.7, 128.7, 128.1, 125.6, 112.5, 80.1, 56.8, 56.0, 55.9, 52.4, 47.6, 46.6, 42.7, 35.3, 28.4, 
24.4, 18.1, 12.1; IR (film) 3340, 2971, 2937, 1741, 1681, 1650, 1586, 1554, 1455, 1307, 1141 
cm-1; MS (ESI) m/z calcd for [C31H43N4O9S]+: 647.27 [M+H]+; found: 647.4 
 
Boc-DKP-f4-COOH (DKP-f4) 
Boc-DKP-f6-COOH (DKP-f6) 
 
 
 
A solution of compound 45 (320 mg, 0.5 mmol, 1 equiv) in THF (20 mL) was cooled to 0 
°C and treated dropwise with a solution of LiOH·H2O (52 mg, 1.24 mmol, 2.5 equiv) in 
H2O (10 mL). The resulting solution was stirred for 1 h at 0 °C, then acidified with a 1M 
KHSO4 solution to pH 1-2. The mixture was extracted with CH2Cl2 (4x), and the 
collected organic extracts were dried over Na2SO4 and evaporated under reduced 
pressure, to afford DKP-f4 or DKP-f6 as a white foam (310 mg, 100% yield), which was 
used without further purification. 
 
3.1.2.3 DKP-5, DKP-7 
N3-DKP-5-CO2Me (46a);  
N3-DKP-7-CO2Me (46b) 
 
 
 
A flame-dried flask under N2 was charged with a solution of 39 (640 mg, 1.93 mmol, 1 
eq.) in dry THF (32 ml). The temperature was lowered to -78°C and KHMDS (4.25 ml of 
a 0.5 M solution in toluene, 2.12 mmol, 1.1 eq.) was added dropwise. After 30 min 
benzyl bromide (1.18 ml, 9.65 mmol, 5 eq.) was added, and a final solvent ratio 
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THF/DMF 7:3 was reached by adding DMF (13.6 ml). The mixture was allowed to reach 
-40°C and stirred for 3 h. Then aqueous NH4Cl was slowly added and the mixture was 
extracted with EtOAc (3x). Organic phases were washed with brine and dried over 
Na2SO4. Volatiles were removed under reduced pressure and the residue was purified 
by flash chromatography on silica gel (Hex/EtOAc, 7:3) to afford the desired product as 
a viscous transparent oil (761 mg, 86%). 
Rf=0.20 (Hexane/EtOAc 6:4);  20Dα =+14.8 (46b, c=1  in CHCl3); 1H NMR (400 MHz, 
CD2Cl2) δ 7.46 – 7.27 (m, 10H), 5.42 – 5.34 (m, 1H, overlapping with solvent signal), 5.29 
(d, 1H, J = 15.5 Hz), 4.31 – 4.25 (m, 1H), 4.23 – 4.14 (m, 3H), 4.11 (dd, 1H, J = 12.9, 2.0 Hz), 
3.82 (dd, 1H, J = 12.8, 3.2 Hz), 3.61 (s, 3H), 3.26 (dd, 1H, J = 17.5, 2.9 Hz), 2.93 (dd, 1H, J = 
17.5, 5.1 Hz); 13C NMR (101 MHz, CD2Cl2) δ  170.9, 166.7, 165.6, 136.0, 129.5, 128.8, 128.4, 
127.3, 104.3, 59.0, 55.7, 52.5, 52.1, 47.8, 47.6, 35.4; IR (neat): νmax 2117, 1735, 1660, 1449, 
1439, 1362, 1329, 1267, 1216, 1174; MS (ESI) m/z calcd for [C22H24N5O4]+: 422.18 [M+H]+; 
found: 422.3. 
 
NHBoc-DKP-5-CO2Me (47a);  
NHBoc-DKP-7-CO2Me (47b) 
 
 
 
To a solution of azide 46 (751 mg, 1.78 mmol, 1 eq.) in THF (48 ml), under a nitrogen 
atmosphere and at -20 ºC, 2-(t-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 
964 mg, 3.92 mmol, 2.2 eq.) and Me3P (3.57 ml of 1 M solution in toluene, 3.56 mmol, 2 
equiv) were added successively. After stirring for 6 h at r.t., the solution was diluted 
with CH2Cl2 and washed with H2O (3x) and brine. The organic phase was dried over 
Na2SO4 and volatiles were removed under reduced pressure. The residue was purified 
by flash chromatography on silica gel (CH2Cl2/EtOAc, 8:2) to afford the desired product 
as a white foam (716 mg, 87%). 
Rf = 0.39 (CH2Cl2/EtOAc, 9:1);  20Dα =-103.6 (47b, c=1.5 in CHCl3); 1H NMR (400 MHz, 
CD2Cl2) δ 7.48 – 7.24 (m, 10H), 5.56 (d, 1H, J = 15.3 Hz), 5.12 (d, 1H, J = 15.1 Hz), 4.98 (br 
s, 1H), 4.36 – 4.18 (m, 3H), 4.05 (s, 1H), 3.87 – 3.63 (m, 2H), 3.57 (s, 3H), 3.23 (dd, 1H, J = 
17.3, 2.7 Hz), 2.92 (dd, 1H, J = 17.3, 4.9 Hz), 1.47 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 
170.8, 166.7, 166.4, 156.5, 136.5, 136.3, 129.6, 129.4, 129.2, 128.5, 128.4, 80.3, 59.4, 56.0, 
52.5, 48.0, 47.1, 41.5, 35.7, 28.8; IR (neat): νmax 3323, 2978, 1738, 1714, 1658, 1497, 1450, 
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1366, 1330, 1252, 1202, 1168; MS (ESI) m/z calcd for [C27H34N3O6]+: 496.24 [M+H]+; found: 
496.3. 
 
NHBoc-DKP-5-CO2H (DKP-5);  
NHBoc-DKP-7-CO2H (DKP-7) 
 
 
 
Compound 47 (370 mg, 0.75 mmol, 1 eq.) was dissolved in THF (30 ml) and the mixture 
was cooled to 0 °C. A solution of LiOH·H2O (78.3 mg, 1.86 mmol, 2.5 eq.) in H2O (15 ml) 
was added dropwise. The resulting solution was let reacting for 1 h at 0 °C. Then, 
maintaining the temperature at 0 °C, the mixture was acidified with HCl 1M to pH = 1-
2, and extracted with CH2Cl2 (4x). The collected organic phases were dried over Na2SO4 
and volatiles removed under reduced pressure. Either DKP-5 or DKP-7 were afforded 
as a white foam (361 mg, 100%), which was used in subsequent steps without further 
purification. 
 
3.1.2.4 DKP-8 
 (R)-N-(tert-butoxycarbonyl)glutamic acid -methyl ester (48) 8 
 
 
 
To a flask containing MeOH (4,6 ml) and cooled to -14 °C was slowly added Acetyl 
chloride (1.3ml, 18.4 mmol, 2.7 eq) followed by D-glutamic acid (1g, 6.8 mmol, 1eq). 
Cooling bath was removed, and the solution was stirred for 30 min at r.t. and then 
poured into Et2O (330 ml). The precipitate was filtered off and washed well with Et2O 
(50 ml) to give (R)- glutamic acid -methyl ester hydrochloride (1.25 g, 93%) as a white 
solid, which was used without further purification. 
In a round bottom flask was solved 1 g (5.06 mmol, 1 eq) of (R)- glutamic acid -methyl 
ester hydrochloride in 20 ml of THF/water 1:1 solution. The reaction flask was lowered 
into an ice bath, and triethylamine  (2.12 ml, 15.2 mmol, 3 eq.) and Boc2O (1.21 g, 5.56 
mmol, 1.1 eq)  were added. After stirring at r.t. for 24 h. The reaction mixture was 
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diluted with 60 ml of EtOAc and washed with aqueous KHSO4 1M until pH = 3 and 
brine. The organic phase was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The product was then dried under high vacuum for a few hours 
affording 1.3 g (98%) of the pure expected product as viscous transparent oil. 
 
(R)-1-((S)-2-(benzylamino)-3-methoxy-3-oxopropyl)5-methyl2-(tert-
butoxycarbonylamino)pentanedioate (49) 
 
 
 
(R)-N-(tert-butoxycarbonyl)glutamic acid -methyl ester 48 (1.0 g, 3.8 mmol, 1.3 eq.) was 
coupled with (S)-N-benzylserine methyl ester 47 (607 mg, 2.9 mmol, 1 eq.) according to 
general procedure GP2. The crude product was purified by flash chromatography on 
silica gel (Hexane/EtOAc, 7:3) to afford the desired product as a transparent oil (774 mg, 
59%). 
Rf = 0.35 (Hexane/EtOAc 7:3);  20Dα =-4 (c=1.00 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 
7.31 (m, 5H), 5.12 (m, 1H), 4.47 (dd, J = 11.0, 4.9 Hz, 1H), 4.40 (m, 1H); 4.30 (dd, J = 11.0, 
4.9 Hz, 1H), 3.90 (d, J = 13.1 Hz, 1H), 3.79  (s, 3H), 3.71 (d, J = 10.3 Hz, 1H), 3.68 (s, 3H), 
3.56 (t, J = 4.9 Hz, 1H), 2.49 – 2.34 (m, 2H), 2.17 (dt, J = 13.3, 7.4 Hz, 1H), 1.95 (dt, J = 14.8, 
7.9 Hz, 1H), 1.45 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 173.7, 173.1, 172.5, 155.8, 140.3, 
129.0, 128.8, 127.7, 80.3, 66.2, 59.8, 53.5, 52.7, 52.4, 52.2, 30.5, 28.6, 28.2; IR (neat): νmax 
3368, 2976, 2953, 1739, 1716, 1509, 1454, 1367, 1249, 1201, 1166, 1051; MS (ESI) m/z calcd 
for [C22H33N2O8]+: 453,22 [M+H]+; found: 453.6. 
 
HO-DKP-8-CO2Me (50) 
 
 
 
Isopeptide 49 (440 mg, 0.97 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt  was dissolved in iPrOH (12 ml) 
and iPr2EtN (0.7 ml, 3.9 mmol, 4 eq.) was added at r.t. The reaction was stirred for 18 h 
at r.t., monitoring the formation of DKP by TLC (EtOAc). The solution was then 
concentrated under reduced pressure and the residue was purified by flash 
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chromatography on silica gel (EtOAc) to afford the desired product as a white foam 
(289 mg, 93%).  
Rf = 0.12 (EtOAc);  20Dα =+29.5 (c=1.00 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.25 
(m, 5H), 5.32 (d, J = 15.1 Hz, 1H), 4.43 (t, J = 4.4 Hz, 1H), 4.13 (d, J = 15.1 Hz, 1H), 3.95 
(dd, J = 11.7, 2.4 Hz, 2H), 3.80 (t, J = 2.1 Hz, 1H), 3.67 (s, 3H), 2.53 – 2.26 (m, 3H), 2.23 – 
2.10 (m, 1H); 13C NMR (101 MHz, CD3OD) δ 174.35, 169.95, 168.69, 136.75, 129.19, 128.77, 
128.25, 128.17, 62.82, 61.46, 53.77, 51.51, 47.41, 29.05, 27.25; IR (neat): νmax 3420, 2952, 
1732, 1682, 1653, 1496, 1449, 1328, 1259, 1175, 1122, 1070; MS (ESI) m/z calcd for 
[C16H21N2O5]+: 321,14 [M+H]+; found: 321.4. 
 
N3-DKP-8-CO2Me (51) 
 
 
 
To a solution of diketopiperazine 50 (104 mg, 0.32 mmol, 1 eq.) in CH2Cl2/toluene/DMF 
(3 ml/2.5 ml/1 ml), under nitrogen atmosphere and at -20 ºC, PPh3 (128 mg, 0.49 mmol, 
1.5 eq.) was added and the mixture was stirred until a solution was obtained. Hydrazoic 
acid (1.9 M in toluene, 0.51 ml, 0.97 mmol, 3 eq.) was added followed by dropwise 
addition of DIAD (0.096 ml, 0.49 mmol, 1.5 eq.) and the reaction was stirred at -20ºC 
overnight. The reaction mixture was loaded onto a silica gel column (EtOAc/Hexane 
8:2) to afford the desired product as a white foam (72 mg, 65%). 
Rf = 0.52 (EtOAc);  20Dα =+57.9 (c=1.00 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.30 
(m, 3H), 7.30 – 7.23 (m, 2H), 5.15 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 4.7 Hz, 1H), 4.25 (d, J = 
15.0 Hz, 1H), 3.94 (d, J = 2.7 Hz, 1H), 3.88 (dd, J = 12.8, 2.4 Hz, 1H), 3.71 (s, 3H), 3.64 (dd, 
J = 12.7, 3.4 Hz, 1H), 2.61 – 2.46 (m, 2H), 2.34 (dd, J = 9.1, 3.7 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 174.58, 167.72, 167.37, 136.06, 129.82, 128.97, 128.71, 78.02, 77.70, 59.99, 
54.39, 52.71, 52.42, 48.51, 30.24, 27.73; IR (neat): νmax 2116, 1733, 1686, 1654, 1437, 1327, 
1289, 1258, 1174; MS (ESI) m/z calcd for [C16H20N5O4]+: 346,15 [M+H]+; found: 346.3. 
 
NHBoc-DKP-8-CO2Me (53) 
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Azide 51 (192 mg, 0.55 mmol, 1 eq.) was dissolved in 12 ml of THF. After addition of 59 
mg of Pd/C 10% (0.05 mmol, 0.1 eq.), the mixture was hydrogenated under vigorous 
stirring over 3 h. Pd/C was then filtered off on a celite pad, which was thoroughly 
washed with THF. The filtrate was concentrated to dryness, obtaining amine 52 as a 
white solid, which was, without further purification, dissolved in THF. The mixture 
was cooled to 0 °C before adding Boc anhydride (132 mg, 0.6 mmol, 1.1 eq.) and iPr2EtN 
(0.19 ml, 1.1 mmol, 2 eq.). The mixture was afterwards let to reach r.t. and stirred for 18 
h. Volatiles were then removed under reduced pressure, and the residue was purified 
by flash chromatography on silica gel (EtOAc/Hexane, 1:1) to afford the desired product 
as a white foam (201 mg, 87%). 
Rf = 0.34 (EtOAc); [a]D20=-4.4 (c=1.00 in CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 
9.9 Hz, 1H), 7.39 – 7.14 (m, 5H), 5.48 (d, J = 15.1 Hz, 1H), 5.29 (s, 1H), 4.25 (t, J = 4.4 Hz, 
1H), 4.06 (d, J = 15.0 Hz, 1H), 3.80 (s, 1H), 3.77 – 3.57 (m, 4H), 3.57 – 3.43 (m, 1H), 2.60 – 
2.42 (m, 2H), 2.38 – 2.19 (m, J = 6.1 Hz, 2H), 1.43 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
174.56, 168.93, 166.59, 156.62, 136.35, 129.64, 128.92, 128.66, 80.80, 60.21, 53.98, 52.59, 
47.78, 41.22, 29.96, 28.96, 28.28; IR (neat): νmax 3298, 2978, 2952, 1689, 1523, 1448, 1393, 
1366, 1329, 1253, 1169, 1059; MS (ESI) m/z calcd for [C21H30N3O6]+: 420.21 [M+H]+; found: 
420.3. 
 
NHBoc-DKP-8-CO2H (DKP-8) 
 
 
 
Compound 53 (117 mg, 0.28 mmol, 1 eq.) was dissolved in THF (7 ml). The mixture was 
cooled to 0°C and a 2.7 M solution of LiOOH in H2O2 (453 mg of LiOH in 7 ml of H2O2 
35%) was added  dropwise. The mixture was stirred for additional 30 min at 0°C, then 
warmed up to r.t. and stirred for 7h. After the addition of Na2SO3 (30.6 mg, 0.24 mmol, 6 
eq.) the reaction mixture was diluted with 8 ml of THF/H2O 1:1. KHSO4 1M was added 
to reach pH = 1-2, and the mixture was extracted with DCM (4x). The collected organic 
phases were dried over Na2SO4 and volatiles removed under reduced pressure, to 
afford crude DKP-8 as a yellowish solid. Crude product was dissolved in EtOAc and 
extracted with NaHCO3 sat.; collected aqueous layers were acidified with KHSO4 1M to 
reach pH 1-2, and extracted with DCM (4x). Collected organic phases were dried over 
Na2SO4 and volatiles removed under reduced pressure, to afford DKP-8 as a white 
foam (100 mg, 90%), which was used without further purification. 
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3.1.3 -  Synthesis of c[DKP-RGD] integrin ligands 
 
Boc-Arg(Mtr)-Gly-OBn (54) 
 
 
 
N-Boc glycine benzylester9 (1.6 mg, 6 mmol, 1.2 eq.) was deprotected according to 
general procedure GP1. The corresponding trifluoroacetate salt was then coupled with 
Boc-Arg(Mtr)-OH (Sigma-Aldrich) (2.5g, 5.14 mmol, 1 eq.) according to general 
procedure GP2. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH; 97:3) to afford the desired product as white foam (2.9 g, 90%). 
Rf = 0.21 (CH2Cl2/MeOH 97:3);  20Dα =-6.0 (c=0.5 in CHCl3); 1H NMR (400 MHz, CD2Cl2) δ 
7.40 - 7.31 (m, 5H), 7.27 (br, 1H), 6.58 (s, 1H), 6.19 (s, 2H), 6.00 (br, 1H), 5.50 (d, 1H, J = 
6.6), 5.15 (s, 2H), 4.24 (m, 1H), 4.09 (dd, 1H, J = 17.5, 6.4), 3.99 (dd, 1H, J = 17.9, 5.7), 3.84 
(s, 3H), 3.25 (m, 2H), 2.67 (s, 3H), 2.60 (s, 3H), 2.14 (s, 3H), 1.84 (m, 2H), 1.61 (m, 2H), 
1.43 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 172.9, 170.0, 158.5, 156.5, 156.0, 138.4, 136.5, 
135.4, 133.4, 128.5, 128.4, 128.2, 124.8, 111.7, 80.1, 67.1, 55.4, 50.5, 41.2, 40.4, 30.0, 28.0, 
25.1, 23.8, 18.1, 11.6; IR (neat): νmax 3343, 2937, 1669, 1621, 1555, 1455, 1366, 1307, 1251, 
1171, 1120; MS (ESI) m/z calcd for [C30H44N5O8S]+: 634.29 [M+H]+; found: 634.3. 
 
N-Boc-DKP-Arg(Mtr)-Gly-OBn (55) 
 
 
 
 
a) N-Boc-DKP-4-Arg(Mtr)-Gly-OBn (55a) 
 Compound 54 (973.5 mg, 1.54 mmol, 1.2 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with DKP-
4 (500 mg, 1.28 mmol, 1 eq.) according to general procedure GP2. The residue was 
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purified by flash chromatography on silica gel (CH2Cl2/MeOH, 93:7) to afford the 
desired product as white foam (811 mg, 70%). 
 Rf = 0.36 (CH2Cl2/MeOH 9:1);  20Dα =+21.7 (c=1 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 7.85 (t, 1H, J = 5.8 Hz), 7.61 (d, 1H, J = 7.7 Hz), 7.44 – 7.23 (m, 10H), 6.69 (s, 1H), 
6.54 (br s, 2H), 6.19 (br s, 1H), 5.24 (d, 1H, J = 15.2 Hz), 5.17 (s, 2H), 4.56 – 4.47 (m, 1H, 
J = 8.1 Hz), 4.35 (t, 1H, J = 4.8 Hz), 4.17 (d, 1H, J = 15.2 Hz), 4.10 (t, 1H, J = 5.4 Hz,), 4.00 
(d, 2H, J = 5.9 Hz), 3.85 (s, 3H), 3.77 – 3.68 (m, 1H), 3.62 – 3.50 (m, 1H), 3.34 – 3.11 (m, 
2H), 2.92 (d, 2H, J = 5.4 Hz), 2.69 (s, 3H), 2.64 (s, 3H), 2.12 (s, 3H), 1.97 – 1.79 (m, 1H), 
1.69 – 1.49 (m, 3H), 1.43 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 138.9, 137.4, 136.9, 
135.6, 129.3, 129.1, 128.7, 128.5, 128.2, 124.6, 112.3, 79.3, 66.8, 57.6, 55.9, 55.6, 53.1, 47.4, 
42.9, 41.5, 40.8, 37.3, 28.4, 26.1, 24.0, 18.5, 11.9; IR (neat): νmax 3331, 2936, 1681, 1555, 
1454, 1392, 1366, 1333, 1306, 1249, 1172, 1120; MS (ESI) m/z calcd for [C44H59N8O11S]+: 
907.40 [M+H]+; found: 907.5. 
 
b) N-Boc-DKP-5-Arg(Mtr)-Gly-OBn (55b) 
 Compound 54 (410 mg, 0.65 mmol, 1.2 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with DKP-
5 (260 mg, 0.54 mmol, 1 eq.) according to general procedure GP2. The residue was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 97:3) to afford the 
desired product as white foam (323 mg, 60% yield). 
 Rf=0.44 (CH2Cl2/MeOH, 9:1);  20Dα =-51.2 (c=0.6 in CHCl3); 1H NMR (400 MHz, CD2Cl2) 
δ 7.69 (br s, 1H), 7.41 (br s, 1H), 7.38 – 7.22 (m, 15H), 6.57 (s, 1H), 6.26 (br s, 2H), 5.33 
(d, 1H, J = 15.6 Hz), 5.24 (d, 1H, J = 15.3 Hz), 5.12 (s, 2H), 4.77 (br s, 1H), 4.51 – 4.41 
(m, 1H), 4.36 (br s, 1H), 4.28 (d, 1H, J = 15.5 Hz), 4.17 (d, 1H, J = 15.4 Hz), 4.08 – 3.95 
(m, 3H), 3.84 (s, 3H), 3.76 – 3.65 (m, 1H), 3.64 – 3.53 (m, 1H), 3.34 – 3.13 (m, 2H), 3.07 
(d, 1H, J = 13.3 Hz), 2.93 (dd, 1H, J = 15.8, 6.6 Hz), 2.66 (s, 3H), 2.58 (s, 3H), 2.11 (s, 
3H), 2.01 – 1.88 (m, 1H), 1.75 – 1.48 (m, 3H), 1.42 (s, 9H); 13C NMR (101 MHz, CD2Cl2) 
δ 172.9, 170.6, 170.3, 167.8, 166.7, 159.1, 157.1, 139.1, 137.1, 136.5, 136.1, 134.0, 129.6, 
129.5, 129.2, 128.9, 128.9, 128.6, 128.5, 128.4, 125.4, 112.4, 67.7, 59.8, 56.3, 56.1, 47.6, 
41.9, 41.6, 41.1, 37.2, 30.3, 29.5, 28.7, 26.2, 24.5, 18.8, 12.3; IR (neat): νmax 3329, 2938, 
2357, 2341, 1750, 1719, 1660, 1652, 1557, 1455, 1369, 1301, 1257, 1176, 1121; MS (ESI) 
m/z calcd for [C51H65N8O11S]+: 997.45 [M+H]+; found: 997.5. 
 
c) N-Boc-DKP-6-Arg(Mtr)-Gly-OBn (55c) 
 Compound 54 (973 mg, 1.54 mmol, 1.2 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with DKP-
6 (500 mg, 1.28 mmol, 1 eq.) according to general procedure GP2. The residue was 
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purified by flash chromatography on silica gel (CH2Cl2/MeOH, 93:7) to afford the 
desired product as white foam (811 mg, 70%). 
 Rf=0.38 (CH2Cl2/MeOH 9:1);  20Dα =+23.4 (c=1 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 7.93 (t, 1H, J = 5.8 Hz), 7.73 (d, 1H, J = 8.1 Hz,), 7.45 – 7.24 (m, 10H), 6.69 (s, 1H), 
6.59 (br s, 2H), 6.24 (br s, 1H), 5.34 (d, 1H, J = 15.2 Hz,), 5.16 (s, 2H), 4.68 – 4.58 (m, 
1H), 4.34 (t, 1H, J = 4.6 Hz), 4.17 (d, 1H, J = 15.1 Hz), 4.11 – 3.93 (m, 3H), 3.85 (s, 3H), 
3.75 – 3.65 (m, 1H), 3.65 – 3.54 (m, 1H), 3.32 – 3.11 (m, 2H), 3.07 (dd, 1H, J = 15.2, 5.8 
Hz), 2.97 – 2.85 (m, 1H, overlapping with water signal), 2.70 (s, 3H), 2.65 (s, 3H), 2.11 
(s, 3H), 1.92 – 1.80 (m, 1H), 1.67 – 1.47 (m, 3H), 1.42 (s, 9H); 13C NMR (101 MHz, 
Acetone-d6) δ 172.5, 170.2, 169.7, 168.7, 167.2, 158.7, 157.4, 157.3, 138.9, 137.1, 136.9, 
136.8, 135.6, 129.4, 129.1, 128.8, 128.6, 128.2, 124.6, 112.3, 79.3, 66.9, 57.3, 56.1, 55.7, 
52.7, 47.0, 43.1, 41.5, 40.8, 37.1, 30.5, 28.4, 25.7, 24.1, 18.5, 11.9; ; IR (neat): νmax 3329, 
2932, 1687, 1560, 1451, 1387, 1361, 1338, 1310, 1243, 1177, 1121; MS (ESI) m/z calcd for 
[C44H59N8O11S]+: 907.40 [M+H]+; found: 907.5. 
 
d) N-Boc-DKP-7-Arg(Mtr)-Gly-OBn (55d) 
 Compound 54 (327 mg, 0.52 mmol, 1.1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with DKP-
7 (227 mg, 0.47 mmol, 1 eq.) according to general procedure GP2. The residue was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the 
desired product as white foam (286 mg, 61%). 
 Rf=0.45 (CH2Cl2/MeOH 9:1);  20Dα =-55.6 (c=0.7 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 7.85 (t, 1H, J = 5.7 Hz), 7.55 (d, 1H, J = 8.2 Hz), 7.51 – 7.22 (m, 15H), 6.68 (s, 1H), 
6.54 (br s, 2H), 6.26 (br s, 1H), 5.92 (br s, 1H), 5.50 (d, 1H, J = 15.6 Hz), 5.29 (d, 1H, J = 
15.3 Hz), 5.16 (s, 2H), 4.68 – 4.56 (m, 1H), 4.32 (d, 2H, J = 15.2 Hz), 4.26 – 4.20 (m, 1H), 
4.06 (t, 1H, J = 3.3 Hz), 4.03 – 3.92 (m, 2H), 3.84 (s, 3H), 3.79 – 3.65 (m, 2H), 3.40 – 3.22 
(m, 1H), 3.22 – 2.99 (m, 3H), 2.69 (s, 3H), 2.64 (s, 3H), 2.10 (s, 3H), 1.96 – 1.79 (m, 1H), 
1.68 – 1.48 (m, 3H), 1.43 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 171.7, 169.4, 169.1, 
166.8, 166.4, 158.0, 156.7, 155.9, 138.3, 136.3, 128.7, 128.5, 128.3, 128.1, 127.6, 127.3, 
123.9, 111.6, 78.5, 66.1, 58.9, 55.5, 54.9, 51.8, 46.5, 46.2, 40.8, 40.5, 39.9, 36.1, 27.7, 25.1, 
23.4, 17.8, 11.2; IR (neat): νmax 3326, 2936, 2361, 2343, 1748, 1714, 1659, 1650, 1555, 1453, 
1366, 1306, 1253, 1172, 1120; MS (ESI) m/z calcd for [C51H65N8O11S]+: 997.45 [M+H]+; 
found: 997.6. 
 
e) N-Boc-DKP-8-Arg(Mtr)-Gly-OBn (55e) 
 Compound 54 (200 mg, 0.31 mmol, 1.1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with DKP-
8 (116 mg, 0.29 mmol, 1 eq.) according to general procedure GP2. The residue was 
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purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the 
desired product as white foam (163 mg, 61%). 
 Rf=0.4 (CH2Cl2/MeOH 9:1);  20Dα =-2.0 (c=0.2 in CHCl3); 1H NMR (400 MHz, CD3OD) δ 
7.42 – 7.26 (m, 10H), 6.67 (s, 1H), 5.39 (d, 1H, J = 15.3 Hz), 5.16 (s, 2H), 4.43 – 4.36 (m, 
1H), 4.30 (t, 1H, J = 3.7 Hz), 4.09 – 4.00 (m, 2H), 3.93 (d, 1H, J = 17.6 Hz), 3.84 (s, 3H), 
3.82 – 3.73 (m, 2H), 3.45 (d, 1H, J = 13.2 Hz), 3.25 – 3.09 (m, 2H), 2.69 (s, 3H), 2.63 (s, 
3H), 2.46 – 2.22 (m, 3H), 2.22 – 2.16 (m, 1H), 2.14 (s, 3H), 1.87 – 1.76 (m, 1H), 1.68 – 
1.52 (m, 3H), 1.44 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ   173.7, 173.1, 170.3, 168.8, 
167.0, 158.8, 157.0, 156.5, 138.8, 136.8, 136.5, 135.8, 133.9, 129.2, 128.9, 128.7, 128.5, 
128.3, 125.1, 112.1, 80.0, 67.4, 60.6, 55.8, 53.9, 53.0, 48.0, 41.6, 41.1, 40.8, 31.6, 30.3, 28.4, 
28.0, 25.6, 24.2, 18.5, 12.1; IR (neat): νmax 3328, 3066, 3007, 2974, 2937, 1747, 1660, 1550, 
1455, 1392, 1366, 1306, 1254, 1173, 1120; MS (ESI) m/z calcd for [C45H61N8O11S]+: 921.42 
[M+H]+; found: 921.7. 
 
Cbz-Asp(OtBu)-DKP-Arg(Mtr)-Gly-OBn (56) 
 
 
 
a) Cbz-Asp(OtBu)-DKP4-Arg(Mtr)-Gly-OBn (56a) 
 Compound 55a (290 mg, 0.32 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-
L-Asp(OtBu)-OH (124 mg, 0.38 mmol, 1.2 eq.)  according to general procedure GP2. 
The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 9:1) 
to afford the desired product as white foam (327 mg, 92%).  
 Rf=0.45 (CH2Cl2/MeOH 9:1);  20Dα =+22.1 (c=1 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 7.84 (t, 1H, J = 5.8 Hz), 7.77 (t, 1H, J = 5.9 Hz), 7.60 (d, 1H, J = 8.0 Hz), 7.46 – 7.21 
(m, 16H), 6.77 (d, 1H, J = 8.2 Hz), 6.69 (s, 1H), 6.54 (br s, 2H), 6.43 – 6.17 (br, 1H), 5.23 
(d, 1H, J = 15.2 Hz), 5.19 – 5.10 (m, 3H), 5.06 (d, 1H, J = 12.5 Hz), 4.58 (td, 1H, J = 7.8, 
5.6 Hz), 4.53 – 4.46 (m, 1H), 4.43 (t, 1H, J = 5.3 Hz), 4.18 (d, 1H, J = 15.2 Hz), 4.12 (t, 
1H, J = 5.3 Hz), 4.06 – 3.93 (m, 2H), 3.93 – 3.81 (m, 4H), 3.70 – 3.59 (m, 1H), 3.31 – 3.11 
(m, 2H), 2.97 – 2.89 (m, 2H), 2.87 – 2.77 (m, 1H, overlapping with water signal), 2.76 – 
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2.58 (m, 7H), 2.12 (s, 3H), 1.97 – 1.77 (m, 1H), 1.70 – 1.48 (m, 3H), 1.42 (s, 9H).; 13C 
NMR (101 MHz, Acetone-d6) δ 172.3, 172.0, 170.2, 169.8, 169.4, 168.5, 166.4, 158.4, 
157.1, 156.5, 138.7, 137.4, 137.1, 136.6, 135.4, 129.1, 128.8, 128.7, 128.4, 128.2, 127.9, 
124.3, 112.0, 80.9, 66.7, 66.6, 57.4, 55.4, 54.7, 47.1, 41.7, 41.3, 40.6, 37.9, 36.9, 29.9, 29.7, 
29.6, 29.4, 29.2, 29.0, 28.8, 27.7, 25.8, 23.8, 18.2, 11.6; IR (neat): νmax 3317, 2937, 1726, 
1667, 1548, 1454, 1367, 1306, 1254, 1190, 1156, 1120; MS (ESI) m/z calcd for 
[C55H70N9O14S]+: 1112.48 [M+H]+; found: 1112.5. 
 
b) Cbz-Asp(OtBu)-DKP5-Arg(Mtr)-Gly-OBn (56b) 
 Compound 55b (147 mg, 0.15 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-
L-Asp(OtBu)-OH (58 mg, 0.18 mmol, 1.2 eq.) according to general procedure GP2. 
The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) 
to afford the desired product as white foam (172 mg, 96%). 
 Rf=0.43 (CH2Cl2/MeOH 95:5);  20Dα =-23.6 (c=0.7 in CHCl3); 1H NMR (400 MHz, 
Acetone-d6) δ 7.89 (t, 1H, J = 5.9 Hz), 7.51 – 7.19 (m, 20H), 6.75 – 6.65 (m, 2H), 6.55 (br 
s, 2H), 6.33 (br s, 1H), 5.39 (d, 1H, J = 15.4 Hz), 5.16 (s, 2H), 5.10 (d, 1H, J = 13.8 Hz), 
5.04 (d, 1H, J = 15.5 Hz), 4.59 – 4.49 (m, 3H), 4.46 (d, 1H, J = 15.6 Hz), 4.28 (d, 1H, J = 
15.5 Hz), 4.20 – 4.15 (m, 1H), 4.08 – 3.91 (m, 3H), 3.84 (s, 3H), 3.81 – 3.73 (m, 1H), 3.39 
– 3.24 (m, 1H), 3.22 – 3.11 (m, 1H), 3.08 (dd, 1H, J = 15.9, 3.5 Hz), 2.92 (dd, 1H, J = 15.9, 
6.4 Hz), 2.87 – 2.77 (m, 4H), 2.73 – 2.60 (m, 4H), 2.08 (s, 3H, overlapping with solvent 
signal), 1.95 – 1.81 (m, 1H), 1.69 – 1.50 (m, 3H), 1.42 (s, 9H); 13C NMR (101 MHz, 
Acetone-d6) δ 171.7, 171.2, 169.8, 169.4, 166.1, 162.8, 158.0, 156.7, 147.4, 136.9, 136.5, 
128.7, 128.6, 128.3, 128.1, 128.0, 127.8, 127.6, 127.3, 111.6, 80.4, 66.3, 66.1, 58.5, 55.9, 
54.9, 52.2, 52.0, 46.8, 46.6, 40.9, 40.1, 39.3, 37.2, 35.9, 27.3, 25.6, 23.4, 17.8, 11.2; IR 
(neat): νmax 3324, 2938, 1731, 1660, 1654, 1546, 1451, 1368, 1310, 1253, 1160, 1122; MS 
(ESI) m/z calcd for [C62H76N9O14S]+: 1202.52 [M+H]+; found: 1202.5. 
 
c) Cbz-Asp(OtBu)-DKP6-Arg(Mtr)-Gly-OBn (56c) 
 Compound 55c (400 mg, 0.44 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-
L-Asp(OtBu)-OH (171 mg, 0.52 mmol, 1.2 eq.) according to general procedure GP2. 
The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 9:1) 
to afford the desired product as white foam (451 mg, 92%). 
 Rf=0.46 (CH2Cl2/MeOH 9:1);  20Dα =+25.1 (c=1 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 7.92 (br s, 1H), 7.82 (br s, 1H), 7.70 (br s, 1H), 7.43 – 7.22 (m, 15H), 6.81 (d, 1H, J = 
8.1 Hz), 6.68 (s, 1H), 6.58 (br s, 2H), 5.31 (d, 1H, J = 15.1 Hz), 5.19 – 5.10 (m, 3H), 5.05 
(d, 1H, J = 12.6 Hz), 4.60 (m, 2H), 4.41 (t, 1H, J = 5.1 Hz), 4.17 (d, 1H, J = 15.1 Hz), 4.10 
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– 3.91 (m, 3H), 3.89 – 3.80 (m, 4H), 3.80 – 3.68 (m, 1H), 3.31 – 3.11 (m, 2H), 3.04 (dd, 
1H, J = 15.3, 5.7 Hz), 2.98 – 2.86 (m, 1H, overlapping with water signal), 2.82 (dd, 1H, 
J = 16.2, 5.4 Hz), 2.70 (s, 3H), 2.65 (s, 3H), 2.11 (s, 3H), 1.92 – 1.79 (m, 1H), 1.70 – 1.46 
(m, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 172.7, 172.5, 170.4, 170.2, 
169.7, 168.7, 167.0, 158.7, 157.4, 156.9, 138.9, 137.7, 137.1, 136.9, 136.8, 135.6, 129.4, 
129.3, 129.1, 129.0, 128.8, 128.7, 128.5, 128.2, 124.6, 112.3, 81.1, 66.9, 57.3, 55.7, 55.3, 
52.8, 52.7, 47.1, 44.0, 43.7, 41.9, 41.5, 40.8, 38.6, 38.3, 37.0, 30.5, 28.0, 25.8, 24.1, 18.5, 
11.9; IR (neat): νmax 3312, 2943, 1729, 1672, 1553, 1453, 1369, 1309, 1259, 1186, 1161, 
1124; MS (ESI) m/z calcd for [C55H70N9O14S]+: 1112.48 [M+H]+; found: 1112.5. 
 
d) Cbz-Asp(OtBu)-DKP7-Arg(Mtr)-Gly-OBn (56d) 
 Compound 55d (210 mg, 0.21 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-
L-Asp(OtBu)-OH (82 mg, 0.25 mmol, 1.2 eq.) according to general procedure GP2. 
The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 97:3) 
to afford the desired product as white foam (226 mg, 90%). 
 Rf=0.45 (CH2Cl2/MeOH 95:5);  20Dα =-28.9 (c=0.8 in CHCl3); 1H NMR (400 MHz, 
Acetone-d6) δ 7.85 (t, 1H, J = 5.8 Hz), 7.53 (d, 1H, J = 8.1 Hz), 7.50 – 7.21 (m, 21H), 6.71 
(d, 1H, J = 8.3 Hz), 6.67 (s, 1H), 6.53 (br s, 2H), 6.24 (br s, 1H), 5.44 (d, 1H, J = 15.5 Hz), 
5.24 (d, 1H, J = 15.2 Hz), 5.18 – 5.10 (m, 3H), 5.07 (d, 1H, J = 12.6 Hz), 4.64 – 4.50 (m, 
2H), 4.39 – 4.30 (m, 2H), 4.27 (s, 1H), 4.14 (t, 1H, J = 3.5 Hz), 4.06 – 3.94 (m, 2H), 3.94 – 
3.77 (m, 5H), 3.38 – 3.22 (m, 1H), 3.20 – 3.01 (m, 3H), 2.84 – 2.78 (m, 1H, overlapping 
with water signal), 2.69 (s, 3H), 2.66 – 2.56 (m, 4H), 2.09 (s, 3H), 1.94 – 1.78 (m, 1H), 
1.66 – 1.45 (m, 3H), 1.41 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 172.1, 171.5, 170.0, 
169.8, 169.5, 167.5, 166.7, 158.4, 157.1, 138.6, 136.7, 136.6, 129.2, 128.9, 128.8, 128.7, 
128.6, 128.5, 128.4, 128.2, 127.9, 127.6, 124.3, 111.9, 80.7, 66.6, 66.5, 58.7, 55.9, 55.4, 52.3, 
52.2, 47.0, 46.6, 41.2, 40.3, 39.5, 37.7, 36.4, 30.2, 27.7, 25.6, 23.8, 18.2, 11.6; IR (neat): νmax 
3322, 2936, 1729, 1659, 1651, 1549, 1454, 1367, 1306, 1256, 1161, 1120; MS (ESI) m/z 
calcd for [C62H76N9O14S]+: 1202.52 [M+H]+; found: 1202.5. 
 
e) Cbz-Asp(OtBu)-DKP8-Arg(Mtr)-Gly-OBn (56e) 
 Compound 55e (143 mg, 0.16 mmol, 1 eq.) was deprotected according to general 
procedure GP1. The corresponding trifluoroacetate salt was then coupled with Cbz-
L-Asp(OtBu)-OH (62 mg, 0.19 mmol, 1.2 eq.) according to general procedure GP2. 
The residue was purified by flash chromatography on silica gel (CH2Cl2/EtOH, 95:5) 
to afford the desired product as white foam (155 mg, 86%). 
 Rf=0.5 (CH2Cl2/MeOH 9:1);  20Dα =-3.0 (c=0.35 in CHCl3); 1H NMR (400 MHz, Acetone-
d6) δ 8.02 (s, 1H), 7.97 – 7.89 (m, 2H), 7.58 (d, 1H, J = 7.9 Hz), 7.39 – 7.21 (m, 15H), 6.87 
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(d, 1H, J = 8.6 Hz), 6.66 (s, 1H), 6.54 (br s, 2H), 5.31 (d, 1H, J = 15.2 Hz), 5.16 – 5.09 (m, 
3H), 5.01 (d, 1H, J = 12.5 Hz), 4.61 – 4.52 (m, 2H), 4.41 (br s, 1H), 4.14 (d, 1H, J = 15.2 
Hz), 4.04 (dd, 1H, J = 17.6, 6.0 Hz), 3.95 (dd, 1H, J = 17.6, 5.8 Hz), 3.90 – 3.86 (m, 1H), 
3.85 – 3.76 (m, 4H), 3.76 – 3.66 (m, 1H), 3.28 – 3.10 (m, 2H), 2.81 (dd, 1H, J = 16.3, 5.3 
Hz), 2.70 – 2.59 (m, 7H), 2.56 – 2.40 (m, 2H), 2.36 – 2.24 (m, 1H), 2.23 – 2.11 (m, 1H), 
2.08 (s, 3H), 1.89 – 1.78 (m, 1H), 1.70 – 1.49 (m, 3H), 1.38 (s, 9H); 13C NMR (101 MHz, 
Acetone-d6) δ 174.0, 173.2, 172.7, 170.7, 170.5, 168.5, 167.6, 158.9, 157.6, 157.2, 139.1, 
137.8, 137.1, 137.0, 135.8, 129.6, 129.3, 129.2, 129.0, 128.8, 128.7, 128.4, 124.9, 112.5, 81.3, 
67.3, 67.2, 60.6, 55.9, 54.2, 53.3, 53.0, 48.0, 41.8, 41.1, 40.4, 38.3, 31.9, 30.5, 28.2, 28.0, 
26.3, 24.3, 18.7, 12.1; IR (neat): νmax 3309, 2932, 2359, 1731, 1652, 1541, 1455, 1258, 1120; 
MS (ESI) m/z calcd for [C56H72N9O14S]+: 1126.49 [M+H]+; found: 1126.7. 
 
H-Asp(OtBu)-DKP-Arg(Mtr)-Gly-OH (57) 
 
 
 
 
 
a) H-Asp(OtBu)-DKP4-Arg(Mtr)-Gly-OH (57a) 
 Compound 56a (307 mg, 0.28 mmol, 1 eq.) was treated with Pd/C 10%  (29.3 mg, 0.03 
mmol, 0.1 eq.) in the conditions described in general procedure GP3. The crude 
product was obtaine as white solid (248 mg, 100%) that was used without further 
purification. 
 
b) H-Asp(OtBu)-DKP5-Arg(Mtr)-Gly-OH (57b) 
 Compound 56b (170 mg, 0.14 mmol, 1 eq.) was treated with Pd/C 10%  (14.9 mg, 
0.014 mmol, 0.1 eq.) in the conditions described in general procedure GP3. The crude 
product was obtained as white solid (137 mg, 100%) that was used without further 
purification. 
 
c) H-Asp(OtBu)-DKP6-Arg(Mtr)-Gly-OH (57c) 
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 Compound 56c (400 mg, 0.36 mmol, 1 eq.) was treated with Pd/C 10%  (38.1 mg, 0.04 
mmol, 0.1 eq.) in the conditions described in general procedure GP3. The crude 
product was obtained as white solid (322 mg, 100%) that was used without further 
purification. 
 
d) H-Asp(OtBu)-DKP7-Arg(Mtr)-Gly-OH (57d) 
 Compound 56d (218 mg, 0.18 mmol, 1 eq.) was treated with Pd/C 10%  (19.3 mg, 
0.018 mmol, 0.1 eq.) in the conditions described in general procedure GP3. The crude 
product was obtained as white solid (176 mg, 100%) that was used without further 
purification. 
 
e) H-Asp(OtBu)-DKP8-Arg(Mtr)-Gly-OH (57e) 
 Compound 56e (148 mg, 0.13 mmol, 1 eq.) was treated with Pd/C 10%  (13.8 mg, 
0.013 mmol, 0.1 eq.) in the conditions described in general procedure GP3. The crude 
product was obtained as white solid (124 mg, 100%) that was used without further 
purification. 
 
Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP] (58) 
 
 
 
a) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP4] (58a) 
 Compound 57a (224 mg, 0.25 mmol, 1 eq.) was cyclized in the conditions described in 
general procedure GP4, in presence of HATU (380.2 mg, 1 mmol, 4 eq.), HOAt (136.1 
mg, 1 mmol, 4 eq.) and DIPEA (0.26 ml, 1.5 mmol, 6 eq). The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford 
yellowish solid that was further purified by Biotage (gradient: 95% H2O / 5% 
acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product as white foam (133 
mg, 61%). 
 Rf=0.45 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, CD3OD) δ 7.41 – 7.21 (m, 5H), 6.68 (s, 
1H), 5.36 (br s, 1H), 4.53 – 4.41 (m, 1H), 4.39 – 4.28 (m, 1H), 4.24 – 3.89 (m, 3H), 3.85 (s, 
1H), 3.78 (d, 1H, J = 10.6 Hz,), 3.68 – 3.48 (m, 1H), 3.31 – 3.26 (m, 1H) 3.20 (t, 2H, J = 5.7 
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Hz), 2.98 – 2.86 (m, 1H), 2.83 – 2.72 (m, 2H), 2.72 – 2.56 (m, 7H), 2.14 (s, 3H), 1.89 – 
1.75 (m, 1H), 1.74 – 1.52 (m, 3H), 1.49 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 172.3, 
172.1, 169.9, 169.4, 168.4, 166.9, 158.5, 138.1, 136.5, 128.6, 127.5, 124.3, 111.4, 81.3, 56.8, 
54.6, 53.2, 41.9, 40.7, 40.1, 35.8, 30.7, 27.8, 26.9, 22.8, 17.3, 10.7; MS (ESI) m/z calcd for 
[C40H56N9O11S]+: 870.38 [M+H]+; found: 870.4. 
 
b) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP5] (58b) 
 Compound 57b (224 mg, 0.25 mmol, 1 eq.) was cyclized in the conditions described 
in general procedure GP4, in presence of HATU (103.4 mg, 0.27 mmol, 4 eq.), HOAt 
(37.3 mg, 0.27 mmol, 4 eq.) and DIPEA (54 μl, 0.41 mmol, 6 eq). The crude product 
was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford 
yellowish solid that was further purified by Biotage (gradient: 95% H2O / 5% 
acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product as white foam (20 
mg, 31%). 
 Rf=0.33 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, Acetone-d6) δ 8.00 (d, 1H, J = 6.9 Hz), 
7.84 (d, 1H, J = 6.7 Hz), 7.79 – 7.70 (m, 1H), 7.58 (d, 1H, J = 7.7 Hz), 7.48 – 7.17 (m, 
10H), 6.69 – 6.62 (m, 2H), 6.52 (br s, 2H), 6.38 (br s, 2H), 5.30 (d, 1H, J = 15.4 Hz), 5.24 
(d, 1H, J = 16.0 Hz), 5.02 (d, 1H, J = 8.2 Hz), 4.65 – 4.38 (m, 2H), 4.38 – 3.89 (m, 5H), 
3.82 (s, 3H), 3.52 (dd, 1H, J = 15.6, 2.3 Hz), 3.42 (dd, 1H, J = 13.9, 4.4 Hz), 3.28 – 3.13 
(m, 2H), 2.87 (dd, 1H, J = 16.2, 8.2 Hz), 2.72 – 2.54 (m, 9H), 2.08 (s, 3H), 1.91 – 1.78 (m, 
1H), 1.73 – 1.48 (m, 3H), 1.40 (s, 9H); 13C NMR (101 MHz, Acetone-d6) δ 172.1, 171.7, 
171.6, 169.4, 169.1, 166.9, 158.0, 156.6, 138.5, 138.2, 136.3, 136.1, 128.9, 128.5, 127.9, 
127.7, 127.0, 123.9, 111.6, 80.4, 58.9, 58.7, 54.9, 50.8, 49.3, 46.7, 41.9, 40.3, 39.4, 39.2, 36.8, 
27.7, 27.3, 26.2, 23.3, 17.7, 11.2; MS (ESI) m/z calcd for [C47H62N9O11S]+: 960.43 [M+H]+; 
found: 960.7. 
 
c) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP6] (58c) 
 Compound 57c (322 mg, 0.36 mmol, 1 eq.) was cyclized in the conditions described in 
general procedure GP4, in presence of HATU (547.2 mg, 1.44 mmol, 4 eq.), HOAt 
(195.8 mg, 1.44 mmol, 4 eq.) and DIPEA (0.37 ml, 2.2 mmol, 6 eq). The crude product 
was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford 
yellowish solid that was further purified by Biotage (gradient: 95% H2O / 5% 
acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product as white foam (180 
mg, 58%). 
 Rf=0.47 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, DMSO-d6) δ 9.08 – 8.95 (m, 1H), 8.37 
(d, 1H, J = 8.2 Hz), 7.95 (br s, 1H), 7.71 – 7.61 (m, 1H), 7.46 (br s, 1H, J = 7.6 Hz), 7.39 – 
7.22 (m, 5H), 6.88 – 6.64 (m, 2H), 6.55 – 6.25 (m, 1H), 5.14 (d, 1H, J = 14.9 Hz), 4.21 (br 
s, 2H), 4.05 (d, 1H, J = 16.0 Hz), 3.99 – 3.92 (m, 1H), 3.90 – 3.75 (m, 5H), 3.63 – 3.43 (m, 
3 | Experimental Section 
 
174 
3H), 3.01 (m, 2H), 2.88 (dd, 1H, J = 16.2, 7.4 Hz), 2.78 – 2.48 (m, 8H, overlapping with 
solvent signal), 2.44 (dd, 1H, J = 16.3, 7.0 Hz), 2.06 (s, 3H), 1.74 – 1.58 (m, 1H), 1.56 – 
1.26 (m, 12H); 13C NMR (101 MHz, DMSO-d6) δ 172.3, 171.6, 170.9, 169.8, 167.4, 166.7, 
158.6, 157.2, 138.8, 137.8, 136.7, 135.7, 129.8, 128.8, 128.5, 124.7, 112.9, 81.2, 58.5, 56.6, 
55.6, 53.4, 51.5, 47.2, 43.6, 42.1, 36.6, 35.5, 32.4, 29.9, 28.8, 26.8, 24.7, 19.1, 12.9; MS (ESI) 
m/z calcd for [C40H56N9O11S]+: 870.38 [M+H]+; found: 870.4. 
 
d) Cyclo[Arg(Mtr)-Gly-Asp(OtBu)-DKP7] (58d) 
 Compound 57d (167 mg, 0.17 mmol, 1 eq.) was cyclized in the conditions described 
in general procedure GP4, in presence of HATU (259.7 mg, 0.68 mmol, 4 eq.), HOAt 
(93 mg, 0.68 mmol, 4 eq.) and DIPEA (0.17 ml, 1.02 mmol, 6 eq). The crude product 
was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford 
yellowish solid that was further purified by Biotage (gradient: 95% H2O / 5% 
acetonitrile to 5% H2O / 95% acetonitrile), to obtain the product (75 mg, 46%) as a 2:1 
mixture of two inseparable diastereomers. 
 Rf=0.32 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, CD3OD) δ (two diastereomers A and 
B; A/B = 2:1) 7.47 – 7.19 (m, 10HA+ 10HB), 6.70 – 6.65 (m, 1HA + 1HB), 5.40 (d, 1HB, J = 
15.2 Hz), 5.35 (d, 1HB, J = 16.6 Hz), 5.19 (d, 1HA, J = 14.9 Hz), 5.05 – 4.94 (m, 2HA), 4.78 
(dd, 1HA, J = 11.5, 2.1 Hz), 4.57 (t, 1HB, J = 6.7 Hz), 4.52 (d, 1HB, J = 16.7 Hz), 4.46 (d, 
1HA, J = 17.4 Hz), 4.43 – 4.39 (m, 1HB), 4.34 (d, 1HB, J = 16.5 Hz), 4.29 – 4.19 (m, 1HA + 
2HB), 4.13 (d, 1HA, J = 15.1 Hz), 4.08 – 3.96 (m, 2HA), 3.91 (d, 1HB, J = 15.3 Hz), 3.88 – 
3.78 (m, 3HA + 4HB), 3.70 (dd, 1HA, J = 10.4, 4.1 Hz), 3.66 – 3.56 (m, 1HA + 1HB), 3.53 – 
3.42 (m, 1HA + 1HB), 3.28 – 3.09 (m, 2HA + 2HB), 3.03 – 2.80 (m, 2HA + 1HB), 2.78 – 2.65 
(m, 4HA + 4HB), 2.63 (s, 3HB), 2.60 (s, 3HA), 2.58 – 2.43 (m, 1HA + 2HB), 2.15 (s, 3HB), 
2.13 (s, 3HA), 2.11 – 2.00 (m, 1HA), 1.94 – 1.81 (m, 1HA + 1HB), 1.80 – 1.70 (m, 1HB), 1.66 
– 1.52 (m, 2HA + 2HB), 1.49 – 1.44 (m, 9HA + 9HB); 13C NMR (101 MHz, CD3OD) δ (two 
rotamers) 173.2, 172.2, 171.7, 171.1, 170.7, 170.4, 169.8, 168.5, 167.5, 158.5, 156.7, 138.1, 
136.9, 136.5, 135.8, 135.5, 133.5, 128.7, 128.6, 128.5, 128.3, 127.9, 127.8, 127.0, 126.9, 
126.1, 124.3, 111.4, 80.9, 59.7, 58.4, 56.9, 56.8, 54.6, 53.8, 50.2, 48.7, 43.2, 42.2, 39.7, 38.2, 
35.9, 35.6, 35.1, 28.3, 26.9, 26.0, 25.5, 22.9, 17.4, 13.0, 10.7; MS (ESI) m/z calcd for 
[C47H62N9O11S]+: 960.43 [M+H]+; found: 960.5. 
 
e) Cyclo[DKP-8-Arg(Mtr)-Gly-Asp(OtBu)] (58e) 
 Compound 57e (124 mg, 0.13 mmol, 1 eq.) was cyclized in the conditions described in 
general procedure GP4, in presence of HATU (197 mg, 0.52 mmol, 4 eq.), HOAt (70 
mg, 0.52 mmol, 4 eq.), and DIPEA (137 μl, 0.8 mmol, 6 eq.). The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 93:7) to afford the 
desired product as white foam (85 mg, 74%). 
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 Rf=0.4 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, CD3OD) δ 7.41 – 7.22 (m, 5H), 6.66 (s, 
1H), 5.31 (d, 1H, J = 15.3 Hz), 4.47 (dd, 1H, J = 8.4, 4.9 Hz), 4.27 (dd, 1H, J = 8.7, 5.8 
Hz), 4.18 – 4.08 (m, 2H), 4.05 (d, 1H, J = 15.3 Hz), 3.97 (d, 1H, J = 16.8 Hz), 3.88 – 3.79 
(m, 4H), 3.67 (d, 1H, J = 16.8 Hz), 3.55 (d, 1H, J = 13.7 Hz), 3.26 – 3.14 (m, 2H), 2.91 
(dd, 1H, J = 16.6, 4.9 Hz), 2.76 (dd, 1H, J = 16.6, 8.4 Hz), 2.71 – 2.56 (m, 7H), 2.56 – 2.42 
(m, 2H), 2.12 (s, 3H), 1.86 – 1.52 (m, 5H), 1.44 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 
176.4, 175.9, 175.0, 173.9, 171.6, 171.6, 169.6, 169.5, 159.9, 158.2, 139.5, 138.0, 137.4, 
134.8, 130.0, 129.0, 125.7, 112.8, 82.4, 60.4, 56.0, 54.9, 53.0, 52.4, 48.2, 44.0, 41.1, 40.2, 
37.5, 31.8, 30.7, 29.0, 28.3, 27.4, 24.4, 18.9, 12.1; MS (ESI) m/z calcd for [C41H58N9O11S]+: 
884.40 [M+H]+; found: 884.46. 
 
Cyclo[Arg-Gly-Asp-DKP] – c[DKP-RGD] 
 
 
 
Cyclo[Arg-Gly-Asp-DKP4] - c[DKP-4-RGD] 
 Compound 58a (93.7 mg, 0.11 mmol) was fully deprotected in the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
(Water's Atlantis 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 
70% H2O / 30% acetonitrile) to give the desired compound as white solid (62 mg, 
80%). 
 1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ  8.88 (br s, 1H, Asp-NH), 8.37 – 8.23 
(m, 2H, Arg-NH + Gly-NH), 8.20 (m, 1H, DKP-NH4), 7.59 (m, 1H, DKP-NH10), 7.35 
– 7.19 (m, 5H, H-Ar), 7.11 (t, 1H, J = 6.1 Hz, NH-guan), 5.08 (m, 1H, CH2-Ph), 4.35 
(m, 1H, αH-Asp), 4.29 – 4.14 (m, 2H, αH-Arg + DKP-H6), 4.01 – 3.82 (m, 2H, αH-Gly 
+ DKP-H3), 3.77 – 3.58 (m, 2H, αH-Gly + DKP-H9), 3.34 (m, 1H, DKP-H9), 3.12 (m, 
2H, δH-Arg), 3.01 – 2.67 (m, 4H, DKP-H7 + βH-Asp), 1.85 – 1.43 (m, 4H, βH-Arg + 
γH-Arg); 13C NMR (101 MHz, D2O, T= 298K) δ 173.8, 172.8, 170.8, 168.5, 156.8, 135.3, 
128.7, 127.6, 57.5, 53.5, 53.3, 52.0, 47.3, 42.3, 40.7, 40.6, 35.7, 34.3, 28.0, 24.4; HRMS 
(ESI) m/z calcd for [C26H35N9O8Na]+: 624.25008 [M+Na]+; found: 624.24942. 
 
Cyclo[Arg-Gly-Asp-DKP5] - c[DKP-5-RGD] 
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 Compound 58b (20 mg, 0.02 mmol) was fully deprotected in the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
(Water's Atlantis 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 
30% H2O / 70% acetonitrile) to give the desired compound (as trifluoroacetate salt) 
as white solid (9.5 mg, 60%). 
 1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.61 – 8.53 (m, 1H, DKP-NH10), 8.48 
(d, 1H, J = 6.6 Hz, Arg-NH), 8.42 (d, 1H, J = 8.3 Hz, Asp-NH), 8.23 (d, 1H, J = 9.6 Hz, 
Gly-NH), 7.44 – 7.19 (m, 10H, H-Ar), 7.11 – 7.03 (m, 1H, NH-guan), 5.10 (m, 1H, 
CH2-Ph), 5.00 (m, 1H, CH2-Ph), 4.62 (m, 1H, αH-Asp), 4.41 (m, 1H, DKP-H6), 4.37 
(m, 1H, CH2-Ph), 4.33 (m, 1H, DKP-H3), 4.32 (m, 1H, DKP-H9), 4.23 (m, 1H, αH-
Gly), 4.15 (d, 1H, J = 15.4 Hz, CH2-Ph), 4.11 (m, 1H, αH-Arg), 3.42 (d, 1H, J = 17.3 Hz, 
αH-Gly), 3.34 (m, 1H, DKP-H9), 3.10 (dd, 2H, J = 12.6, 6.6 Hz, δH-Arg), 2.86 (dd, 1H, 
J = 16.8, 7.8 Hz, βH-Asp), 2.70 (dd, 1H, J = 17.0, 7.2 Hz, βH-Asp), 2.55 (m, 2H, DKP-
H7), 1.82 – 1.50 (m, 4H, βH-Arg + γH-Arg); 13C NMR (101 MHz, D2O, T= 298K) δ 
175.0, 174.8, 174.4, 173.7, 173.3, 169.7, 167.8, 136.5, 135.5, 129.1, 129.0,  128.7, 128.5, 
127.6, 126.2, 59.5, 55.1, 51.5, 50.1, 48.3, 48.1, 41.9, 40.3, 39.7, 39.4, 38.6, 26.8, 24.3; 
HRMS (ESI) m/z calcd for [C33H41N9O8Na]+: 714.29703 [M+Na]+; found: 714.29588. 
 
Cyclo[Arg-Gly-Asp-DKP6] - c[DKP-6-RGD] 
 Compound 58c (80.2 mg, 0.09 mmol) was fully deprotected in the conditions 
described in  general procedure GP5. The crude product was purified by (Water's 
Atlantis 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 70% H2O / 
30% acetonitrile) to give the desired compound (as trifluoroacetate salt) as white 
solid (54 mg, 82%). 
 1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.80 (d, 1H, J = 6.4 Hz, Asp-NH), 8.40 – 
8.26 (m, 2H, Gly-NH + Arg-NH), 8.07 (s, 1H, DKP-NH4), 7.89 (t, 1H, J = 6.1 Hz, 
DKP-NH10), 7.40 – 7.22 (m, 5H, H-Ar), 7.10 (t, 1H, J = 5.7 Hz, NH-guan), 5.06 (d, 1H, 
J = 17.9 Hz, CH2-Ph), 4.35 (m, 1H, αH-Asp), 4.29 (m, 1H, αH-Arg), 4.26 – 4.19 (m, 
2H, DKP-H6 + CH2-Ph), 3.96 – 3.89 (m, 1H, DKP-H3), 3.90 – 3.75 (m, 2H, αH-Gly + 
DKP-H9), 3.67 (dd, 1H, J = 15.6, 6.1 Hz, αH-Gly), 3.58 – 3.43 (m, 1H, DKP-H9), 3.13 
(dd, 2H, J = 12.9, 6.9 Hz, δH-Arg), 2.81 – 2.67 (m, 3H, DKP-H7 + βH-Asp), 2.56 (dd, 
1H, J = 16.1, 8.3 Hz, βH-Asp), 1.84 – 1.48 (m, 4H, βH-Arg + γH-Arg); 13C NMR (101 
MHz, D2O, T= 298K) δ 174.6, 173.3, 172.7, 171.9, 171.0, 168.3, 166.7, 135.3, 129.1, 
128.6, 127.6, 57.6, 54.9, 53.1, 51.3, 47.7, 47.1, 42.8, 40.4, 35.4, 35.0, 27.8, 24.2; HRMS 
(ESI) m/z calcd for [C26H35N9O8Na]+: 624.25008 [M+Na]+; found: 624.24929. 
 
Cyclo[Arg-Gly-Asp-DKP7] - c[DKP-7-RGD] 
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 Compound 58d (65 mg, 0.068 mmol) was fully deprotected in the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
(Water's Atlantis 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 
40% H2O / 60% acetonitrile) to give c[DKP-7-RGD]-A (as trifluoroacetate salt) (21.3 
mg) and c[DKP-7-RGD]-B (as trifluoroacetate salt) (10.6 mg) as white solids (60% 
overall). 
 A: 1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.66 (d, 1H, J = 7.7 Hz, Arg-NH), 
8.04 (t, 1H, J = 6.6 Hz, DKP-NH10), 7.95 – 7.89 (m, 1H, Gly-NH), 7.77 – 7.70 (m, 1H, 
Asp-NH), 7.44 – 7.16 (m, 10H, H-Ar), 7.10 – 7.04 (m, 1H, NH-guan), 5.06 – 4.99 (m, 
1H, CH2-Ph), 4.89 (m, 1H, αH-Asp), 4.80 (m, 1H, CH2-Ph), 4.69 (m, 1H, DKP-H6), 
4.57 (m, 1H, CH2-Ph), 4.39 – 4.33 (m, 2H, αH-Gly, DKP-H3), 4.14 – 4.07 (m, 1H, αH-
Arg), 4.04 (d, 1H, J = 14.8 Hz, CH2-Ph), 3.91 (dd, 1H, J = 15.4, 7.1 Hz, DKP-H9), 3.71 – 
3.61 (m, 1H, DKP-H9), 3.60 – 3.52 (m, 1H, αH-Gly), 3.10 (dd, 2H, J = 12.9, 6.9 Hz, δH-
Arg), 2.90 – 2.76 (m, 2H, DKP-H7, βH-Asp), 2.62 (dd, 1H, J = 17.1, 6.3 Hz, βH-Asp), 
2.58 – 2.49 (m, 1H, DKP-H7), 2.01 – 1.87 (m, 1H, βH-Arg), 1.73 – 1.58 (m, 1H, βH-
Arg), 1.55 – 1.42 (m, 2H, γH-Arg); 13C NMR (101 MHz, D2O, T= 298K) δ 174.3, 173.4, 
173.0, 172.4, 171.2, 170.6, 169.4, 156.8, 129.3, 129.1, 128.5, 127.8, 126.5, 58.7, 56.9, 53.7, 
48.9, 48.3, 47.6,  43.2, 40.9, 39.7, 37.7, 36.9, 25.4, 24.4; HRMS (ESI) m/z calcd for 
[C33H41N9O8Na]+: 714.29703 [M+Na]+; found: 714.29618. 
 
 B: 1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.55 (d, 1H, J = 8.1 Hz, Asp-NH), 
8.45 (t, 1H, J = 5.8 Hz, Gly-NH), 8.34 (d, 1H, J = 5.9 Hz, Arg-NH), 7.73 (d, 1H, J = 8.4 
Hz, DKP-NH10), 7.46 – 7.16 (m, 10H, H-Ar), 7.16 – 7.10 (m, 1H, NH-guan), 5.27 – 
5.15 (m, 2H, CH2-Ph), 4.52 (m, 1H, αH-Asp), 4.44 (m, 1H, DKP-H6), 4.36 – 4.29 (m, 
1H, CH2-Ph), 4.20 (d, 1H, J = 14.8 Hz, CH2-Ph), 4.16 – 4.07 (m, 2H, αH-Arg, DKP-
H3), 3.80 (dd, 1H, J = 15.2, 4.1 Hz, αH-Gly), 3.76 – 3.63 (m, 2H, αH-Gly, DKP-H9), 
3.38 – 3.28 (m, 1H, DKP-H9), 3.16 (dd, 2H, J = 13.6, 7.1 Hz, δH-Arg), 2.94 (dd, 1H, J = 
14.9, 6.1 Hz, DKP-H7), 2.87 – 2.72 (m, 2H, DKP-H7, βH-Asp), 2.60 (dd, 1H, J = 16.6, 
7.2 Hz, βH-Asp), 1.77 (dd, 2H, J = 15.6, 8.3 Hz, βH-Arg), 1.69 – 1.52 (m, 2H, γH-
Arg);13C NMR (101 MHz, D2O, T= 298K) δ 174.5, 174.1, 171.9, 171.6, 170.8, 169.0, 
168.3, 136.8, 135.4, 129.2, 129.0, 128.3, 127.8, 127.6, 125.9, 60.7, 56.8, 53.6, 51.4, 49.6, 
47.5, 43.5, 40.6, 39.3, 36.7, 35.6, 27.8, 24.7; HRMS (ESI) m/z calcd for [C33H41N9O8Na]+: 
714.29703 [M+Na]+; found: 714.29676. 
 
Cyclo[Arg-Gly-Asp-DKP8] - c[DKP-8-RGD] 
 Compound 58e (50 mg, 0.06 mmol) was fully deprotected in the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
HPLC (Water's Atlantis 21 mm x 10 cm column, gradient: 95% H2O / 5% acetonitrile 
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to 80% H2O / 20% acetonitrile) to give the desired compound (as trifluoroacetate 
salt) as white solid (34 mg, 80%). 
 1H NMR (600 MHz, H2O/D2O 9:1, T= 298K) δ 8.42 (d, 1H, J = 7.3 Hz, Arg-NH), 8.27 
(t, 1H, J = 6.6 Hz, Gly-NH), 8.16 – 8.14 (m, 2H, Asp-NH, DKP-NH10), 7.75 (s, 1H, 
DKP-NH1), 7.26 – 7.14 (m, 5H, H-Ar), 7.05 (t, 1H, J = 5.9 Hz, NH-guan), 5.03 (d, 1H, 
J = 17.6 Hz, CH2-Ph), 4.42 (m, 1H, αH-Asp), 4.16 (q, 1H, J = 7.8 Hz, αH-Arg), 4.02 (d, 
1H, J = 15.9, CH2-Ph), 4.05 – 3.96 (m, 2H, DKP-H3, DKP-H6), 3.90 – 3.75 (m, 3H, αH-
Gly, DKP-H9), 3.65 (dd, 1H, J = 15.0, 6.2 Hz, DKP-H9), 3.10 (q, 2H, J = 7.1 Hz, δH-
Arg), 2.76 – 2.71 (m, 2H, βH-Asp), 2.50 – 2.30 (m, 3H, DKP-H7, DKP-H8), 1.75 – 1.45 
(m, 5H, DKP-H8, βH-Arg, γH-Arg); 13C NMR (151 MHz, D2O, T= 298K) δ 174.9, 
174.5, 174.3, 173.8, 171.1, 168.6, 168.2, 157.1, 135.4, 129.1, 128.1, 127.6, 59.3, 53.6, 51.9, 
50.9, 47.6, 42.3, 40.6, 39.4, 35.3, 30.3, 29.6, 27.1, 24.5; HRMS (ESI) m/z calcd for 
[C27H37N9O8Na]+: 638.26573 [M+Na]+; found: 638.26512.  
 
3.1.4 - Synthesis of c[DKP-f-RGD] integrin ligands  
N-Boc-DKP-f-Arg(Mtr)-Gly-OBn (59) 
 
 
 
a) Boc-DKP-f4-Arg(Mtr)-Gly-OBn (59a) 
Dipeptide Boc-Arg(Mtr)-Gly-OBn 54 (280 mg, 0.44 mmol, 1.2 equiv) was deprotected 
according to general procedure GP1. The corresponding trifluoroacetate salt was then 
coupled with DKP-f4 (230 mg, 0.37 mmol, 1 equiv), according to general procedure 
GP2. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 
93:7) to afford the desired product as a white foam (350 mg, 83%). 
Rf=0.36 (CH2Cl2/MeOH 9:1);  20Dα =+29.7 (c=1.0 in CH2Cl2); 1H NMR (400 MHz, acetone-d6) 
δ 7.84 (t, 1H, J = 5.9 Hz), 7.49 (d, 1H, J = 7.3 Hz), 7.40-7.32 (m, 5H), 7.19-7.15 (A2 system, 
4H), 6.76 (s, 1H), 6.71-6.67 (m, 2H), 6.51 (br s, 2H), 6.16 (t, 1H, J = 4.7 Hz), 5.15 (s, 2H), 
5.06 (d, 1H, J = 15.2 Hz), 4.52-4.47 (m, 1H), 4.33 (t, 1H, J = 4.9 Hz), 4.20 (d, 1H, J = 15.2 
Hz), 4.07-4.02 (m, 3H), 4.00 (d, 2H, J = 6.8 Hz), 3.88 (s, 3H), 3.84 (s, 3H), 3.70 (ddd, 1H, J = 
14.0, 5.9, 4.6 Hz), 3.57-3.51 (m, 1H), 3.27-3.11 (m, 2H), 2.92-2.82 (m overlapped with 
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water signal, 2H), 2.67 (s, 3H), 2.63 (s, 3H), 2.62 (s 3H), 2.57 (s, 3H), 2.10 (s, 6H), 1.87-1.82 
(m, 1H), 1.63-1.52 (m, 4H), 1.41 (s, 9H); 13C NMR (101 MHz, acetone-d6) δ 172.6, 170.3, 
169.9, 169.1, 167.0, 160.0, 159.0, 157.57, 157.53, 139.51, 139.32, 139.17, 138.2, 137.12, 
137.08, 136.7, 135.8, 131.2, 129.3, 129.12, 128.99, 128.97, 128.6, 125.5, 124.9, 113.0, 112.5, 
79.6, 67.1, 58.0, 56.14, 56.10, 55.91, 53.3, 47.6, 46.8, 43.2, 41.8, 41.1, 37.5, 30.2, 28.6, 26.3, 
24.42, 24.28, 18.7, 18.2, 12.1; IR (film) 3343, 2972, 2939, 1741, 1680, 1656, 1586, 1557, 1455, 
1306, 1140 cm-1; MS (ESI) m/z calcd for [C55H74N9O14S2]+: 1148.48 [M+H]+; found: 1148.6. 
 
a) Boc-DKP-f6-Arg(Mtr)-Gly-OBn (59b) 
Dipeptide Boc-Arg(Mtr)-Gly-OBn 54 (460 mg, 0.73 mmol, 1.1 equiv) was deprotected 
according to general procedure GP1. The corresponding trifluoroacetate salt was then 
coupled with DKP-f6 (420 mg, 0.66 mmol, 1 equiv), according to general procedure 
GP2. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 
93:7) to afford the desired product as a white foam (630 mg, 83%). 
Rf=0.47 (DCM/MeOH 9:1);  20Dα =-34.8 (c=1.0 in CH2Cl2); 1H NMR (400 MHz, acetone-d6) δ 
7.97 (br s, 1H , J = 5.3 Hz), 7.73 (d, 1H, J = 7.4 Hz), 7.49 (s, 1H), 7.40 – 7.27 (m, 5H), 7.23 – 
7.13 (m, 4H), 6.80 – 6.73 (m, 2H), 6.67 (s, 1H), 6.58 (br s, 2H), 6.25 (t, 1H, J = 5.0 Hz), 5.25 
(d, 1H, J = 15.1 Hz), 5.13 (s, 2H), 4.68 – 4.58 (m, 1H, J = 4.4 Hz), 4.31 (br s, 1H, J = 3.8 Hz), 
4.14 – 3.91 (m, 6H), 3.87 (s, 3H), 3.82 (s, 3H), 3.74 – 3.63 (m, 1H), 3.62 – 3.52 (m, 1H), 3.15 
(m, 2H), 3.02 (dd, 2H), 2.89 (d, 1H, J = 12.7 Hz), 2.68 (s, 3H), 2.66 – 2.60 (m, 6H), 2.55 (s, 
3H), 2.09 (s, 6H), 1.89 – 1.77 (m, 1H), 1.66 – 1.46 (m, 3H), 1.40 (s, 9H); 13C NMR (101 
MHz, acetone-d6) δ 172.9, 170.4, 170.0, 169.0, 167.3, 159.9, 158.9, 157.6, 157.4, 139.4, 139.3, 
139.2, 138.3, 137.1, 136.9, 136.1, 135.6, 131.0, 129.3, 129.1, 129.0, 128.8, 125.4, 124.9, 113.0, 
112.5, 79.6, 67.2, 57.4, 56.2, 56.1, 55.9, 52.9, 46.9, 46.6, 43.3, 41.7, 40.9, 37.3, 30.7, 28.6, 25.9, 
24.4, 24.3, 18.7, 18.2, 12.1; IR (film) 3340, 2971, 2937, 1740, 1684, 1660, 1584, 1558, 1456, 
1307, 1141 cm-1; MS (ESI) m/z calcd for [C55H74N9O14S2]+: 1148.48 [M+H]+; found: 1148.7 
 
Cbz-Asp(OtBu)-DKP-f-Arg(Mtr)-Gly-OBn (60) 
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a) Cbz-Asp(OtBu)-DKP-f4-Arg(Mtr)-Gly-OBn (60a) 
Boc-DKP-f4-Arg(Mtr)-Gly-OBn 59a (270 mg, 0.235 mmol, 1 equiv) was deprotected 
according to general procedure GP1. The corresponding trifluoroacetate salt was then 
coupled with Cbz-L-Asp(OtBu)-OH (91 mg, 0.28 mmol, 1.2 equiv),  according to general 
procedure GP2. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 9:1) to afford the desired product as a white foam (280 mg, 88%). 
Rf=0.45 (CH2Cl2/MeOH 9:1);  20Dα =+22.1 (c=1.0 in CH2Cl2); 1H NMR (400 MHz, acetone-d6) 
δ 7.85 (t, 1H, J = 5.5 Hz), 7.74 (t, 1H, J = 5.8 Hz), 7.47 (d, 1H, J = 7.9 Hz), 7.40-7.28 (m, 
10H), 7.17 (A2 system, 4H), 6.76 (m, 2H), 6.68 (m, 2H), 6.51 (br s, 2H), 5.14-5.01 (m, 5H), 
4.54 (td, 1H, J = 7.8, 6.0 Hz), 4.47 (m, 1H), 4.41 (t, 1H, J = 5.4 Hz), 4.22 (d, 1H, J = 15.1 Hz), 
4.06 (t, 1H, J = 5.3 Hz), 4.02 (d, 2H, J = 6.3), 3.99 (d, 2H, J = 6.6), 3.90-3.84 (m, 4H), 3.83 (s, 
3H), 3.61 (dt, J = 14.0, 6.6 Hz, 1H), 3.25-3.12 (m, 2H), 2.91-2.85 (m, 2H), 2.81-2.79 (m 
overlapped with water signal, 1H), 2.69-2.65 (m, 4H), 2.64 (s, 3H), 2.62 (s, 3H), 2.55 (s, 
3H), 2.10 (s, 6H), 1.87-1.81 (m, 1H), 1.62-1.51 (m, 3H), 1.40 (s, 9H); 13C NMR (101 MHz, 
acetone-d6) δ 172.8, 172.5, 170.7, 170.3, 169.8, 169.0, 166.9, 160.0, 158.9, 157.5, 157.0, 
139.51, 139.34, 139.17, 138.07, 137.88, 137.12, 137.08, 136.8, 135.8, 129.32, 129.23, 129.14, 
129.09, 128.99, 128.95, 128.7, 125.5, 124.8, 113.0, 112.5, 81.4, 67.21, 67.11, 58.1, 56.08, 55.88, 
55.2, 53.3, 52.9, 47.6, 46.8, 42.3, 41.8, 38.4, 37.5, 30.3, 28.2, 26.2, 24.43, 24.29, 18.7, 18.2, 
12.1; IR (film) 3343, 3291, 2927, 1718, 1685, 1655, 1554, 1456, 1308, 1141 cm-1; MS (ESI) m/z 
calcd for [C66H85N10O17S2]+: 1353.56 [M+H]+; found: 1353.6. 
 
b) Cbz-Asp(OtBu)-DKP-f4-Arg(Mtr)-Gly-OBn (60b) 
Boc-DKP-f6-Arg(Mtr)-Gly-OBn 59b (420 mg, 0.37 mmol, 1 equiv) was deprotected 
according to general procedure GP1. The corresponding trifluoroacetate salt was then 
coupled with Cbz-L-Asp(OtBu)-OH (141.6 mg, 0.44 mmol, 1.2 equiv), according to 
general procedure GP2. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 9:1) to afford the desired product as a white foam (428 mg, 86%). 
Rf=0.49 (DCM/MeOH 9:1);  20Dα =-27.6 (c=0.5 in MeOH); 1H NMR (400 MHz, acetone-d6) δ 
7.97 (t, 1H, J = 5.5 Hz), 7.83 (br s, 1H), 7.70 (d, 1H, J = 6.8 Hz), 7.48 (s, 1H), 7.40 – 7.24 (m, 
10H), 7.24 – 7.14 (m, 4H), 6.84 (d, 1H, J = 8.2 Hz), 6.79 – 6.71 (m, 2H), 6.66 (s, 1H), 6.58 (br 
s, 2H), 5.21 (d, 1H, J = 15.0 Hz), 5.16 – 5.06 (m, 3H), 5.00 (d, 1H, J = 12.5 Hz), 4.65 – 4.55 
(m, 2H), 4.38 (t, 1H, J = 4.8 Hz), 4.17 – 3.92 (m, 6H), 3.90 – 3.77 (m, 7H), 3.75 – 3.65 (m, 
1H), 3.28 – 3.09 (m, 2H), 3.04 – 2.95 (m, 1H), 2.94 – 2.86 (m, 1H), 2.85 – 2.76 (m, 1H), 2.75 
– 2.59 (m, 10H), 2.55 (s, 3H), 2.17 – 2.05 (m, 6H), 1.88 – 1.76 (m, 1H), 1.66 – 1.46 (m, 3H), 
1.38 (s, 9H); 13C NMR (101 MHz, acetone-d6) δ 172.9, 170.7, 170.4, 170.0, 168.9, 167.1, 
159.9, 158.9, 157.6, 157.1, 139.3, 139.2, 138.2, 137.8, 137.1, 136.9, 136.2, 135.7, 131.0, 129.2, 
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129.0, 128.7, 125.4, 124.9, 113.0, 112.5, 81.4, 67.2, 57.5, 56.1, 55.9, 55.4, 53.0, 52.9, 47.1, 46.7, 
42.3, 41.8, 41.0, 38.4, 37.3, 30.7, 28.2, 26.1, 24.4, 18.7, 18.2, 12.1; IR (film) 3342, 3299, 2927, 
1718, 1683, 1658, 1557, 1453, 1307, 1141 cm-1; MS (ESI) m/z calcd for [C66H85N10O17S2]+: 
1353.55 [M+H]+; found: 1353.8. 
 
H-Asp(OtBu)-DKP-f-Arg(Mtr)-Gly-OH (61) 
 
 
 
a) H-Asp(OtBu)-DKP-f4-Arg(Mtr)-Gly-OH (61a) 
A solution of Cbz-Asp(OtBu)-DKP-f4-Arg(Mtr)-Gly-OBn 60a (200 mg, 0.148 mmol, 1 
equiv) in THF/H2O 1:1 (50 mL) was treated with 10% Pd/C (16 mg, 0.015 mmol, 0.1 
equiv), and the flask was purged three times with vacuum/H2. The mixture was stirred 
at rt overnight under H2 atmosphere, then filtered through a pad of Celite and the Celite 
cake was washed thoroughly with THF/H2O 1:1. The solvents were removed under 
vacuum to give the crude product as a white solid (166 mg, 100%), which was used 
without further purification.  
 
b) H-Asp(OtBu)-DKP-f6-Arg(Mtr)-Gly-OH (61b) 
A solution of Cbz-Asp(OtBu)-DKP-f6-Arg(Mtr)-Gly-OBn 60b (317 mg, 0.23 mmol, 1 
equiv) in THF/H2O 1:1 (80 mL) was treated with 10% Pd/C (25 mg, 0.023 mmol, 0.1 
equiv), and the flask was purged three times with vacuum/H2. The mixture was stirred 
at rt overnight under H2 atmosphere, then filtered through a pad of Celite and the Celite 
cake was washed thoroughly with THF/H2O 1:1. The solvents were removed under 
vacuum to give the crude product 138 as a white solid (260 mg, 100%), which was used 
without further purification.  
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Cyclo[DKP-f-Arg(Mtr)-Gly-Asp(OtBu)] (62) 
 
 
 
a) Cyclo[DKP-f4-Arg(Mtr)-Gly-Asp(OtBu)] (62a) 
To a solution of H-Asp(OtBu)-DKP-f4-Arg(Mtr)-Gly-OH 61a (166 mg, 0.148 mmol, 1 
equiv) in DMF (110 mL), under nitrogen atmosphere and at 0 ºC, HATU (224 mg, 0.593 
mmol, 4 equiv), HOAt (81 mg, 0.592 mmol, 4 equiv) and i-Pr2NEt (0.160 mL, 0.89 mmol, 
6 equiv) were added. The reaction was warmed up to rt and stirred overnight. DMF 
was then removed under reduced pressure to afford a yellowish solid. The solid was 
dissolved in AcOEt (150 mL) and the resulting solution was washed with 1 M aqueous 
KHSO4 (2×20 mL), saturated aqueous NaHCO3 (2×20 mL) and brine (2×32 mL), dried 
over Na2SO4 and the solvent evaporated under reduced pressure to afford the crude 
product. The crude was purified by flash-chromatography on silica gel (CH2Cl2/MeOH, 
9:1) to afford the desired product as a fluffy solid (110 mg, 67%). 
Rf=0.4 (CH2Cl2/MeOH 9:1);  20Dα =-42.0 (c=1.0 in DMSO); 1H NMR (400 MHz, DMSO-d6) δ 
8.88 (br s, 1H), 8.25 (m, 2H), 8.03 (br s, 1H), 7.85 (t, 1H, J = 6.2 Hz), 7.41 (br s, 1H), 7.12 
(AB system, 4H), 6.75 (s, 1H), 6.68 (s, 1H), 6.41 (br s, 1H), 5.18 (d, 1H, J = 14.1 Hz), 4.26-
4.18 (m, 2H), 4.02-3.97 (m, 1H), 3.92-3.87 (m, 3H), 3.82 (s, 3H), 3.80-3.74 (m, 4H), 3.70-
3.56 (m, 2H), 3.34 (m overlapped with water signal, 1H), 3.08-2.95 (m, 3H), 2.93-2.83 (m, 
1H), 2.64-2.60 (m, 4H), 2.54 (m, 7H), 2.50 (m overlapped with solvent signal, 1H), 2.44 (s, 
3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.73-1.61 (m, 1H), 1.55-1.40 (m, 12H); 13C NMR (101 MHz, 
DMSO-d6) δ 171.2, 170.3, 169.8, 169.1, 168.4, 167.6, 158.5, 157.5, 156.1, 138.2, 137.79, 
137.65, 137.3, 135.6, 135.0, 130.0, 128.0, 127.5, 124.0, 123.5, 112.2, 111.7, 80.5, 55.67, 55.50, 
52.19, 52.05, 51.98, 45.10, 45.00, 42.1, 39.9, 39.7, 36.1, 35.6, 28.1, 27.7, 25.8, 23.81, 23.64, 
18.0, 17.7, 11.8; IR (film) 3436, 3309, 3055, 2927, 2857, 1720, 1674, 1656, 1584, 1557, 1458, 
1306 cm-1; MS (ESI) m/z calcd for [C51H71N10O14S2]+: 1111.46 [M+H]+; found: 1111.7. 
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b) Cyclo[DKP-f6-Arg(Mtr)-Gly-Asp(OtBu)] (62b) 
To a solution of H-Asp(OtBu)-DKP-f6-Arg(Mtr)-Gly-OH 61b (260 mg, 0.23 mmol, 1 
equiv) in DMF (165 mL), under nitrogen atmosphere and at 0 ºC, HATU (350 mg, 0.92 
mmol, 4 equiv), HOAt (125 mg, 0. 92 mmol, 4 equiv) and i-Pr2NEt (0.236 mL, 1.38 mmol, 
6 equiv) were added. The reaction was warmed up to rt and stirred overnight. DMF 
was then removed under reduced pressure to afford a yellowish solid. The solid was 
dissolved in AcOEt (200 mL) and the resulting solution was washed with 1 M aqueous 
KHSO4 (2×20 mL), saturated aqueous NaHCO3 (2×20 mL) and brine (2×32 mL), dried 
over Na2SO4 and the solvent evaporated under reduced pressure to afford the crude 
product. The crude was purified by flash-chromatography on silica gel (CH2Cl2/MeOH, 
9:1) to afford the desired product as a fluffy solid (170 mg, 68%). 
Rf=0.35 (DCM/MeOH 9:1);  20Dα =-38.0 (c=0.5 in DMSO); 1H NMR (400 MHz, CD3OD) δ 
7.19 – 7.06 (m, 4H), 6.67 (s, 1H), 6.65 (s, 1H), 5.18 (d, 1H, J = 14.7 Hz), 4.50 – 4.39 (m, 2H), 
4.12 – 3.95 (m, 5H), 3.92 – 3.81 (m, 7H), 3.78 – 3.65 (m, 2H), 3.61 (dd, 1H, J = 13.7, 3.6 Hz), 
3.29 – 3.08 (m, 2H), 2.99 (dd, 1H, J = 16.6, 7.0 Hz), 2.75 – 2.69 (m, 2H), 2.66 (s, 3H), 2.64 – 
2.56 (m, 7H), 2.47 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 1.83 – 1.71 (m, 1H), 1.69 – 1.49 (m, 
3H), 1.45 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 174.2, 174.0, 173.1, 172.3, 171.8, 171.3, 
160.7, 159.9, 158.2, 139.9, 139.5, 138.6, 137.9, 136.3, 134.7, 131.0, 129.5, 129.0, 126.1, 125.7, 
113.2, 112.8, 82.3, 56.2, 56.0, 54.5, 52.2, 47.8, 46.9, 44.0, 42.5, 36.6, 36.1, 28.3, 24.5, 24.4, 
18.9, 18.2, 12.1; IR (film) 3304, 3060, 2927, 2855, 1719, 1674, 1654, 1584, 1559, 1456, 1307 
cm-1; MS (ESI) m/z calcd for [C51H71N10O14S2]+: 1111.46 [M+H]+; found: 1111.6 
 
Cyclo[DKP-f-Arg-Gly-Asp]  - c[DKP-f-RGD] 
 
 
 
a) Cyclo[DKP-f4-Arg-Gly-Asp]  - c[DKP-f4-RGD] 
Cyclo[DKP-f4-Arg(Mtr)-Gly-Asp(OtBu)] 62a (90 mg, 0.081 mmol) was treated with TFA 
(10 mL), in the presence of ion scavengers thioanisole (1.5 mL), ethanedithiol (0.75 mL) 
and phenol (150 mg). The mixture was cooled to 0 °C and flushed with N2. 
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Trimethylsilylbromide (2 mL) was then added, the flask was open and the mixture 
warmed up to rt and stirred for 2 h. All volatiles were then evaporated and the crude 
was dissolved in a mixture of water and diisopropyl ether 1:1 (30 mL). The aqueous 
phase was washed several time with diisopropyl ether and then concentrated under 
reduced pressure to give the crude compound, which was purified by semipreparative-
HPLC (Water's Atlantis 21 mm x 10 cm column, gradient: 95% H2O / 5% acetonitrile to 
80% H2O / 20% acetonitrile) to give the desired compound (as trifluoroacetate salt) as a 
white solid (49 mg, 70% yield).  
1H NMR (400 MHz, D2O) δ 7.40 (AB system, 4H), 5.35-5.18 (m, 1H), 4.44 (br s, 1H), 4.35 
(dd, 1H, J = 9.1, 5.0 Hz), 4.28 (br s, 1H), 4.22-4.12 (m, 3H), 4.08-3.94 (m, 2H), 3.78-3.63 (m, 
2H), 3.43 (br s, 1H), 3.22 (t, 2H, J = 6.6 Hz), 3.10-3.00 (m, 1H), 2.96-2.83 (m, 3H), 1.93-1.76 
(m, 2H), 1.73-1.61 (m, 2H); 13C NMR (101 MHz, D2O,) δ 174.5, 173.9, 173.4, 171.3, 169.1, 
157.4, 136.7, 132.9, 130.0, 128.6, 58.2, 54.2, 53.6, 53.0, 47.3, 43.3, 43.1, 41.05, 41.02, 36.9, 
35.2, 28.3, 25.2; IR (film) 3258, 3063, 2942, 1671, 1545, 1425, 1202, 1133 cm-1 MS (ESI) m/z 
calcd for [C27H39N10O8]+: 631.30 [M+H]+; found: 631.4 
 
b) Cyclo[DKP-f6-Arg-Gly-Asp]  - c[DKP-f6-RGD] 
Cyclo[DKP-f6-Arg(Mtr)-Gly-Asp(OtBu)] 62b (90 mg, 0.081 mmol) was treated with TFA 
(10 mL), in the presence of ion scavengers thioanisole (1.5 mL), ethanedithiol (0.75 mL) 
and phenol (150 mg). The mixture was cooled to 0 °C and flushed with N2. 
Trimethylsilylbromide (2 mL) was then added, the flask was open and the mixture 
warmed up to rt and stirred for 2 h. All volatiles were then evaporated and the crude 
was dissolved in a mixture of water and diisopropyl ether 1:1 (30 mL). The aqueous 
phase was washed several time with diisopropyl ether and then concentrated under 
reduced pressure to give the crude compound, which was purified by semipreparative-
HPLC (Water's Atlantis 21 mm x 10 cm column, gradient: 95% H2O / 5% acetonitrile to 
80% H2O / 20% acetonitrile) to give the desired compound (as trifluoroacetate salt) as a 
white solid (50 mg, 71% yield).  
1H NMR (400 MHz, D2O) δ 8.06 (t, 1H, J = 6.1 Hz), 7.43 (AB system, 4H), 5.16 (d, 1H, J = 
15.7 Hz), 4.53 (t, 1H, J = 7.1 Hz), 4.39 (dd, 1H, J = 9.3, 5.7 Hz), 4.36 – 4.29 (m, 2H), 4.20 (s, 
2H), 4.05 (t, 1H, J = 6.2 Hz), 3.89 (d, 1H, J = 15.4 Hz), 3.82 (d, 1H, J = 15.4 Hz), 3.77 – 3.71 
(m, 2H), 3.21 (t, 2H, J = 6.8 Hz), 3.11 (dd, 1H, J = 17.0, 6.8 Hz), 2.92 – 2.76 (m, 3H), 1.92 – 
1.54 (m, 4H); 13C NMR (101 MHz, D2O) δ 175.2, 173.9, 173.3, 172.5, 171.6, 168.8, 167.4, 
157.4, 136.9, 132.9, 130.0, 128.8, 58.9, 55.4, 54.2, 51.6, 48.3, 43.4, 43.4, 41.7, 41.0, 35.9, 34.4, 
28.4, 25.1; IR (film) 3254, 3062, 2942, 1671, 1545, 1423, 1202, 1134 cm-1; MS (ESI) m/z calcd 
for [C27H39N10O8]+: 631.29 [M+H]+; found: 631.5 
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3.1.5 - Synthesis of c[DKP-isoDGR] integrin ligands 
N3-(3R,6S)-DKP-COOH (63a) 
N3-(3S,6R)-DKP-COOH (63b) 
 
 
 
N3-(3R,6S)-DKP-COOAllyl11 or N3-(3S,6R)-DKP-COOAllyl11 (300 mg, 0.84 mmol, 1 eq.) 
was dissolved in CH2Cl2 (8.0 ml) under a nitrogen atmosphere, and the mixture was 
cooled to 0°C. [Pd(PPh3)4] (290 mg, 0.25 mmol, 0.3 eq.) and freshly distilled N-methyl 
aniline (109μl, 1.0 mmol, 1.2 eq.) were added successively. The mixture was then 
allowed to reach room temperature. After 1 h of stirring, the mixture was diluted with 
EtOAc (40 ml) and extracted with aqueous NaHCO3 (4 x 20 ml). The combined aqueous 
phases were acidified to pH 2 by adding KHSO4 (1M solution) and then extracted with 
CH2Cl2 (4 x 20 ml). The resulting organic phase was dried over Na2SO4 and the solvent 
was evaporated to afford the desired product as a slightly yellow solid (241 mg, 90%) 
which was used without further purification.  
Rf=0.40 (CH2Cl2/MeOH 8:2); 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H, COOH), 7.42 – 
7.31 (m, 3H), 7.31 – 7.23 (m, J = 7.9 Hz, 2H), 5.18 (d, J = 15.1 Hz, 1H), 4.66 (dd, J = 9.8, 2.9 
Hz, 1H), 4.27 (d, J = 15.1 Hz, 1H), 3.96 (t, J = 2.4 Hz, 1H), 3.89 (dd, J = 12.8, 2.2 Hz, 1H), 
3.69 (dd, J = 12.8, 3.4 Hz, 1H), 3.38 (dd, J = 17.9, 3.2 Hz, 1H), 2.80 (dd, J = 17.9, 9.9 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 173.8, 167.5, 166.3, 129.2, 128.4, 128.2, 77.5, 77.2, 76.8, 
59.2, 51.8, 51.1, 48.1, 37.2. 
 
The syntheses of compounds c[DKP-2-isoDGR] and c[DKP-3-isoDGR]  were carried 
out by manual coupling using Fmoc/tBu strategy on SASRINTM resin (200-400 mesh, 
1.02 mmol/g) on a 0.1 mmol scale. Swelling of the resin was achieved suspending it in 
either DCM or DMF for 15 min. 
SASRINTM RESIN LOADING: The first Fmoc protected amino acid (Fmoc-Gly-OH, 119 
mg, 0.4 mmol, 4 eq.) residue was dissolved in the minimum amount of DMF, and the 
solution was cooled to 0° C. DIC (62 l, 0.4 mmol, 4 eq.) was added dropwise. The 
mixture was stirred for 20 min at the same temperature before adding it to the resin (98 
mg, 0.1 mmol, 1 eq.). DMAP (1.2 mg, 0.01 mmol, 0.1 eq.) was then added in one portion. 
The reaction vessel was gently shaken for 1 h at r.t.. Resin was thoroughly washed  in 
the order with DMF (4x), DCM (4x), iPrOH (3x). Capping was performed (see general 
procedure GP6). 
COUPLING REACTIONS: A sample vial equipped with a magnetic stirrer was charged 
with the appropriate N-protected-amino acid (2.5 - 4 eq.), which was dissolved in a 1:1 
mixture of DCM/DMF. After cooling the mixture to 0 °C, DIC (2.5 – 4 eq.) and HOAt 
(2.5 – 4 eq.) were added successively. The mixture was stirred for 20 min at the same 
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temperature. The solution was then added to the swelled peptidylresin (0.1 mmol, 1 
eq.). The resin was gently agitated for 2-18 h and, after sucking off the solution, it was 
washed in the order with DMF (4x), DCM (4x), iPrOH (3x) and/or Et2O (2x). If a Fmoc-
amino acid was coupled, Kaiser test was performed (see general procedure GP7). If 
resin gives a positive color test, coupling procedure was repeated with fresh reagents. 
After a maximum of 3 coupling cycles, capping was performed (see general procedure 
GP6). 
Fmoc DEPROTECTION: After successful coupling, washing and  Fmoc deprotecting 
steps were carried out as described in general procedure GP8. This 
deprotection/coupling strategy was applied for each synthetic step involving N-Fmoc 
protected -amino acids. 
AZIDE REDUCTION: After successful coupling of DKP building blocks (63a and 63b), 
washing and  azide reduction steps were carried out as described in general procedure 
GP9. 
 
Exact amounts of the amino acids and coupling reagents used for SPPS are reported in 
Table 3.1.1. 
Table 3.1.1 
REAGENTS eq. mmol amounts 
Fmoc-L-Asp(OH)-OtBu 3 0.3 123 mg 
DIC 3 0.3 47 l 
HOAt 3 0.3 41 mg 
63a or 63b 2.5 0.25 79 mg 
DIC 2.5 0.25 38 l 
HOAt 2.5 0.25 34 mg 
Cbz-L-Arg(Mtr)-OH · CHA 4 0.4 248 mg 
DIC 4 0.4 62 l 
HOAt 4 0.4 27 mg 
 
 
Cbz-Arg(Mtr)-DKP-isoAsp(OtBu)-Gly-OH (64) 
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CLEAVAGE FROM SASRINTM RESIN: The resin was thoroughly washed with DCM (10 
times) and then treated with 1% TFA in DCM (2 ml) for 2-5 min. The mixture was 
filtered off with a N2 pressure into a vial containing 0.2 ml of 12% of pyridine in MeOH. 
The filtrate was checked for the presence of peptide by TLC (DCM/MeOH 9:1). 
Treatment with 1% TFA in DCM was repeated as long as the peptide was being cleaved 
from the resin (5-8 times). Peptide containing fractions were combined and half of the 
DCM volume was removed at reduced pressure. The mixture was then diluted with 
abundant EtOAc and washed with 1M KHSO4 (4x) to remove pyridinium 
trifluoroacetate and to free the carboxylic acid. The organic layer was dried over 
Na2SO4, filtered and evaporated to afford a white solid which was purified by flash 
chromatography (DCM/MeOH 8:2) (64a: 89 mg, 88%; 64b: 90 mg, 88%). 
 
64a 
Rf=0.55 (CH2Cl2/MeOH 8:2);  1H NMR (400 MHz, CD3OD) δ 8.33 (m, 1H), 8.26 – 8.15 (m, 
1H), 7.40 – 7.21 (m, 9H), 7.17 (d, J = 7.6 Hz, 1H), 6.63 (s, 1H), 5.36 (d, J = 15.4 Hz, 1H), 
5.07 (q, J = 12.4 Hz, 2H), 4.72 – 4.58 (m, 2H), 4.19 – 4.04 (m, 2H), 3.98 – 3.82 (m, 4H), 3.80 
(s, 3H), 3.65 – 3.53 (m, 1H), 3.25 – 3.07 (m, 2H), 3.03 (dd, J = 16.3, 4.0 Hz, 1H), 2.81 (dd, J = 
16.4, 6.8 Hz, 1H), 2.75 (d, J = 6.2 Hz, 2H), 2.66 (s, 3H), 2.60 (s, 3H), 2.10 (s, 3H), 1.79 – 1.64 
(m, 1H), 1.64 – 1.46 (m, 3H), 1.43 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 175.7, 173.3, 
172.6, 171.6, 171.5, 169.0, 168.4, 159.8, 158.4, 158.2, 139.5, 138.1, 137.9, 137.2, 134.8, 129.9, 
129.5, 129.2, 129.0, 128.9, 125.7, 112.8, 83.3, 67.9, 60.6, 56.2, 56.0, 52.2, 51.4, 49.6, 41.9, 40.2, 
38.2, 30.2, 28.2, 27.0, 24.4, 18.9, 12.1; MS (ESI) m/z calcd for [C48H64N9O14S]+: 1022.43 
[M+H]+; found: 1022.8. 
 
64b: 
Rf=0.53 (CH2Cl2/MeOH 8:2);  1H NMR (400 MHz, CD3OD) δ  7.40 – 7.20 (m, 9H), 6.65 (s, 
1H), 5.36 (d, J = 15.3 Hz, 1H), 5.15 – 5.02 (m, 2H), 4.69 (t, J = 5.9 Hz, 1H), 4.60 (t, J = 5.5 
Hz, 1H), 4.15 – 4.06 (m, 2H), 3.98 – 3.83 (m, 4H), 3.81 (s, 3H), 3.65 – 3.55 (m, 1H), 3.28 – 
3.07 (m, 2H), 2.95 (dd, J = 15.8, 5.4 Hz, 1H), 2.81 (dd, J = 16.4, 6.4 Hz, 1H), 2.75 (d, J = 5.9 
Hz, 2H), 2.67 (s, 3H), 2.60 (s, 3H), 2.11 (s, 3H), 1.80 – 1.69 (m, 1H), 1.64 – 1.48 (m, 3H), 
1.45 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 175.7, 173.2, 172.5, 171.6, 168.9, 168.4, 159.9, 
158.5, 158.1, 139.6, 138.1, 138.0, 137.1, 130.0, 129.5, 129.2, 129.1, 128.9, 125.8, 112.8, 83.5, 
67.8, 60.5, 56.1, 56.0, 52.4, 51.4, 48.2, 41.8, 40.2, 38.8, 38.3, 30.3, 28.2, 24.4, 18.8, 14.4, 12.1; 
MS (ESI) m/z calcd for [C48H64N9O14S]+: 1022.43 [M+H]+; found: 1022.9. 
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H-Arg-DKP-isoAsp(OtBu)-Gly-OH (65) 
 
 
 
Compound 65a: 
Compound 64a (89 mg, 0.09 mmol, 1 eq.) was treated with 10%  Pd/C (9.2 mg, 0.009 
mmol, 0.1 eq.) under the conditions described in general procedure GP3. The crude 
product was obtained  as a white solid (77 mg, 100%) and was used without further 
purification. 
 
Compound 65b: 
Compound 64b (90 mg, 0.09 mmol, 1 eq.) was treated with 10%  Pd/C (9.3 mg, 0.009 
mmol, 0.1 eq.) under the conditions described in general procedure GP3. The crude 
product was obtained  as a white solid (78 mg, 100%) and was used without further 
purification. 
 
Cyclo[isoAsp(OtBu)-Gly-Arg(Mtr)-DKP] (66) 
 
 
 
66a: 
Compound 65a (77 mg, 0.09 mmol, 1 eq.) was cyclized in presence of HATU (136 mg, 
0.36 mmol, 4 eq.), HOAt (49 mg, 0.36 mmol, 4 eq.) and DIPEA (93 l, 0.54 mmol, 6 eq) 
under the conditions described in general procedure GP2. The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the 
desired product as a white foam (41 mg, 55%). 
Rf=0.83 (CH2Cl2/MeOH 8:2); 1H NMR (400 MHz, CD3OD) δ 7.40 – 7.24 (m, 5H), 6.66 (s, 
1H), 5.35 (d, J = 15.3 Hz, 1H), 5.01 (t, J = 6.9 Hz, 1H), 4.74 – 4.68 (m, 1H), 4.24 – 4.04 (m, 
4H), 3.87 – 3.76 (m, 5H), 3.40 – 3.33 (m, 1H), 3.17 (t, J = 6.0 Hz, 2H), 2.96 – 2.85 (m, 1H), 
2.77 (dd, J = 14.0, 4.5 Hz, 1H), 2.73 – 2.68 (m, 2H), 2.67 (s, 3H), 2.60 (s, 3H), 2.12 (s, 3H), 
1.79 – 1.53 (m, 4H), 1.49 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 175.6, 172.9, 172.1, 171.5, 
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171.1, 168.5, 168.1, 159.9, 158.2, 139.5, 137.9, 137.0, 130.1, 129.2, 129.1, 112.8, 83.4, 60.5, 
56.0, 55.3, 52.2, 47.8, 42.8, 42.8, 41.4, 39.7, 38.7, 29.0, 28.3, 27.0, 24.3, 18.8, 12.1; MS (ESI) 
m/z calcd for [C40H56N9O11S]+: 870.38 [M+H]+; found: 870.8. 
 
66b: 
Compound 65b (78 mg, 0.09 mmol, 1 eq.) was cyclized in presence of HATU (137 mg, 
0.36 mmol, 4 eq.), HOAt (49 mg, 0.36 mmol, 4 eq.) and DIPEA (93 l, 0.54 mmol, 6 eq) 
under the conditions described in general procedure GP2. The crude product was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH, 95:5) to afford the 
desired product as a white foam (31 mg, 35%). 
Rf=0.64 (CH2Cl2/MeOH 8:2); 1H NMR (400 MHz, CD3OD) δ 7.40 – 7.21 (m, 5H), 6.66 (s, 
1H), 5.42 (d, J = 15.3 Hz, 1H), 5.04 (dd, J = 11.8, 3.2 Hz, 1H), 4.59 (d, J = 10.1 Hz, 1H), 4.31 
– 4.19 (m, 2H), 4.05 (d, J = 15.3 Hz, 1H), 3.88 – 3.79 (m, 4H), 3.78 – 3.61 (m, 2H), 3.28 – 
3.09 (m, 3H), 2.89 (dd, J = 14.7, 3.3 Hz, 1H), 2.73 – 2.57 (m, 7H), 2.31 – 2.21 (m, 1H), 2.12 
(s, 3H), 1.86 – 1.73 (m, 1H), 1.72 – 1.52 (m, 3H), 1.48 (s, 9H); 13C NMR (101 MHz, CD3OD) 
δ 176.5, 173.3, 172.5, 171.7, 171.2, 169.1, 167.8, 159.9, 158.3, 139.5, 137.9, 137.1, 134.8, 
130.0, 129.1, 125.7, 112.8, 83.6, 60.4, 56.0, 55.1, 52.0, 50.9, 47.9, 42.7, 40.9, 40.0, 39.2, 38.5, 
29.8, 28.2, 27.2, 24.3, 18.9, 12.1; MS (ESI) m/z calcd for [C40H56N9O11S]+: 870.38 [M+H]+; 
found: 870.8. 
 
Cyclo[isoAsp-Gly-Arg-DKP] – c[DKP-isoDGR] 
 
 
 
c[DKP-2-isoDGR]: 
Compound 66a (41 mg, 0.05 mmol) was fully deprotected under the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
(Water's AtlantisTM 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 40% 
H2O / 60% acetonitrile) to give the desired compound (as trifluoroacetate salt) as a white 
solid (7 mg, 24%). 
1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.44 (t, J = 6.5 Hz, 1H, DKP-NH10), 8.35 (s, 
1H, DKP-NH1), 8.30 – 8.21 (m, 2H, Asp-NH, Arg-NH), 7.89 (t, J = 6.2 Hz, 1H, Gly-NH), 
7.40 – 7.21 (m, 5H, H-Ar), 7.11 (t, J = 5.7 Hz, 1H, NH-guan), 5.09 (d, J = 15.8 Hz, 1H, CH2-
Bn), 4.20 – 4.09 (m, 2H, αH-Arg, CH2-Bn), 4.08 – 3.88 (m, 3H, αH-Gly, DKP-H9, DKP-
H3), 3.83 (dd, J = 17.1, 5.7 Hz, 1H, αH-Gly), 3.53 – 3.41 (m, 1H, DKP-H9), 3.13 (q, J = 6.7 
Hz, 2H, H-Arg), 2.83 – 2.71 (m, 3H, βH-Asp, DKP-H7), 2.59 (dd, J = 14.8, 10.4 Hz, 1H, 
DKP-H7), 1.79 – 1.42 (m, 4H, βH-Arg, γH-Arg); 13C NMR (101 MHz, D2O, T= 298K) δ 
175.4, 174.6, 172.6, 171.7, 170.7, 167.5, 167.0, 135.2, 129.2, 128.3,127.9, 59.5, 54.3, 51.3, 47.3, 
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41.8, 41.3, 40.5, 39.1, 37.6, 27.4, 24.5; MS (ESI) m/z calcd for [C26H36N9O8]+: 602.27 [M+H]+; 
found: 602.3. 
 
c[DKP-3-isoDGR]: 
Compound 66b (31 mg, 0.035 mmol) was fully deprotected under the conditions 
described in  general procedure GP5. The crude product was purified by HPLC 
(Water's AtlantisTM 21 mm x 10 cm column, gradient: 90% H2O / 10% acetonitrile to 60% 
H2O / 40% acetonitrile) to give the desired compound (as trifluoroacetate salt) as a white 
solid (6 mg, 29%). 
1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) δ 8.62 (d, J = 8.2 Hz, 1H, Asp-NH), 8.45 (t, J = 
6.7 Hz, 1H, DKP-H10), 8.26 (d, J = 6.5 Hz, 1H, Arg-NH), 8.15 (t, J = 6.1 Hz, 1H, Gly-NH), 
7.60 (s, 1H, DKP-NH1), 7.41 – 7.19 (m, 5H, H-Ar), 7.17 – 7.05 (m, 1H, NH-guan), 5.15 (d, 
J = 15.6 Hz, 1H, CH2-Bn), 4.34 (d, J = 11.4 Hz, 1H, DKP-H6), 4.23 – 4.07 (m, 3H, αH-Gly, 
αH-Arg, CH2-Bn), 4.06 – 4.00 (m, 1H, DKP-H3), 3.88 (dd, J = 13.6, 6.6 Hz, 1H, DKP-H9), 
3.71 (dd, J = 17.5, 5.0 Hz, 1H, αH-Gly), 3.59 (dd, J = 15.5, 6.8 Hz, 1H, DKP-H9), 3.17 – 3.02 
(m, 3H, H-Arg, DKP-H7), 2.94 (dd, J = 15.3, 3.8 Hz, 1H, βH-Asp), 2.62 (dd, J = 15.4, 11.8 
Hz, 1H, βH-Asp), 2.30 (dd, J = 14.1, 11.9 Hz, 1H, DKP-H7), 1.82 – 1.43 (m, 4H, βH-Arg, 
γH-Arg); 13C NMR (101 MHz, D2O, T= 298K) δ 176.0, 174.5, 172.3, 171.3, 168.0, 167.0, 
135.2, 129.2, 128.2, 127.7, 59.5, 54.2, 51.3, 47.8, 41.6, 40.5, 39.3, 38.3, 37.7, 28.1, 24.6; MS 
(ESI) m/z calcd for [C26H36N9O8]+: 602.27 [M+H]+; found: 602.2. 
 
3.1.6 -  Synthesis of SMAC-RGD conjugates 
 
4-(hydroxymethyl)benzaldehyde (86) 
 
 
 
Terephthalaldehyde (benzene-1,4-dicarboxaldehyde) (1.0 g, 7.45 mmol, 1 eq.) was 
dissolved in 12.5 ml of EtOH/H2O (95:5) and then 17.5 ml of THF were added. To the 
resulting stirred solution, NaBH4 (70 mg, 1.86 mmol, 0.25 eq.) was added at -5 °C in 
small portions over 30 min. The mixture was stirred for 6 h, while the temperature was 
maintained at 0 °C. The reaction mixture was then adjusted to pH = 5 with 2 M HCl. The 
solvent was evaporated, then H2O (20 ml) was added and the solution was extracted 
three times with AcOEt. The resulting organic phase was dried over Na2SO4 and the 
solvent was evaporated. The crude product was purified by flash chromatography on 
silica gel (Hex/AcOEt, 1:1) to afford the desired product as a white solid (840 mg, 83%). 
Rf = 0.5 (Hex/AcOEt, 4:6); 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 7.71 (d, J = 7.8 Hz, 
2H), 7.39 (d, J = 7.9 Hz, 2H), 4.65 (s, 2H), 2.07 (s, 1H); 13C NMR (101 MHz, CD2Cl2) δ 
192.6, 148.8, 135.9, 130.2, 127.3, 64.5. 
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Benzyl 4-formylbenzylcarbamate (87) 
 
 
 
(4-(aminomethyl)phenyl)methanol (800 mg, 5.83 mmol, 1 eq.) was dissolved in 60 ml of 
THF, under N2 atmosphere. The mixture was cooled to 0 °C and DIPEA (2 ml, 11.66 
mmol, 2 eq.) was added dropwise. The resulting mixture was left stirring for 5 min. at 0 
°C, then benzyl chloroformate (1.66 ml, 11.66 mmol, 2 eq.) was added dropwise. The 
reaction was left stirring at 0 °C for 45 min, then it was allowed to reach room 
temperature. The mixture was left stirring overnight. DIPEA·HCl salts was then 
removed over celite and the filter was washed with AcOEt. The solution was 
concentrated, the residue was dissolved in AcOEt and washed with KHSO4 1M solution. 
The resulting organic phase was dried over Na2SO4 and the solvent was evaporated. 
The crude product was recrystallized from cold CH2Cl2, the desired product (benzyl 4-
(hydroxymethyl)benzylcarbamate) was filtered over buckner and washed with cold 
CH2Cl2, affording a white solid that was used without further purification (1.13 g, 71%). 
Rf = 0.5 (Hex/AcOEt, 3:7); 1H NMR (400 MHz, CD3OD) δ 7.46 – 7.18 (m, 9H), 5.11 (s, 2H), 
4.59 (s, 2H), 4.30 (s, 2H). 
 
Benzyl 4-(hydroxymethyl)benzylcarbamate (500 mg, 1.84 mmol, 1 eq.) was dissolved in 
45 ml of THF, under N2 atmosphere. MnO2 (1.76 g, 20.27 mmol, 11 eq.) was added at 
room temperature and the reaction was left stirring overnight. MnO2 was then filtered 
over celite, washing the filter with  THF. The solvent was then evaporated affording 87 
as a white solid that was used without further purification (480 mg, 97%). 
Rf = 0.55 (Hex/AcOEt, 1:1); 1H NMR (400 MHz, CDCl3) δ 9.98 (s, 1H), 7.83 (d, J = 7.8 Hz, 
2H), 7.44 (d, J = 7.6 Hz, 2H), 7.36 (m, 5H), 5.30 (br, 1H), 5.14 (s, 2H), 4.46 (d, J = 6.0 Hz, 
2H); 13C NMR (101 MHz, CD2Cl2) δ 192.2, 157.0, 146.3, 137.1, 136.0, 130.2, 128.9, 128.5, 
128.3, 128.0, 67.2, 45.0. 
 
tert-butyl ((S)-1-(((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-7-(2-((4 
(hydroxymethyl)benzyl)amino)ethyl)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-6-yl)amino)-1-
oxobutan-2-yl)(methyl)carbamate (89) 
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A solution of 8112 (50 mg, 0.074 mmol, 1.05 eq.), DIPEA (18 µl, 0.105 mmol, 1.5 eq.) in 
dry MeOH (0.5 ml) was added into a flask containing 4-(hydroxymethyl)benzaldehyde 
86 (9.5 mg, 0.074 mmol, 1 eq.) under nitrogen atmosphere. The mixture was let stirring 
at room temperature for 5 h. NaBH4 (5.3 mg, 0.14 mmol, 2 eq.) was then added stepwise 
(5 additions within 3 min) and the mixture was let react at room temperature under 
nitrogen for 30 min. The mixture was then concentrated under vacuum. 5 ml of a 
saturated solution of NaHCO3 were added, then the mixture was extracted with AcOEt 
(7 ml, three times). The organic phase was dried over Na2SO4 and the solvent was 
evaporated. The crude product was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH, 9:1) to afford the desired product as a white foam (41 mg, 80% yield). 
Rf = 0.3 (CH2Cl2/MeOH, 9:1);  1H NMR (400 MHz, THF-d8) δ 8.27 (bs, 1H), 7.54 (bs, 1H), 
7.40 – 7.00 (m, 14H), 6.21 (d, J = 8.81 Hz, 1H) 4.62 (d, J = 6.53 Hz, 1H), 4.60 – 4.35 (m, 4H), 
4.00 – 3.70 (m, 4H), 2.84 (bs, 3H), 2.66 (bs, 1H), 2.52 (bs, 1H), 2.15 (m, 4H), 1.91 (m, 2H), 
1.85 – 2.57 (m, 4H), 1.46 (s, 9H), 1.47 – 1.31 (m, 4H), 0.87 (t, J = 7.32 Hz, 3H); 13C NMR 
(400 MHz, THF-d8) δ172.3, 171.5, 170.6, 157.0, 143.5, 143.3, 142.7, 129.2, 129.0, 128.9, 
128.2, 128.1, 127.6, 127.5, 127.0., 80.2, 80.1, 79.7, 67.9, 67.7, 67.4, 67.2, 66.9, 66.7, 66.6, 64.6, 
64.4, 53.4, 53.1, 49.3, 48.4, 47.1, 35.0, 34.9, 34.6, 34.4, 34.3, 33.9, 33.7, 33.5, 31.8, 27.7, 27.4, 
27.1, 25.5, 25.3, 25.1, 24.9, 24.7, 22.4, 22.2, 22.2; MS (ESI) m/z calcd for [C43H58N5O6]+: 
740.44 [M+H]+; found: 739.75. 
 
tert-butyl ((S)-1-(((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-7-(2-((tert-butoxycarbonyl)(4-
(hydroxymethyl)benzyl)amino)ethyl)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-6-yl)amino)-1-
oxobutan-2-yl)(methyl)carbamate (90) 
 
 
 
A solution of compound 89 (41 mg, 0.056 mmol, 1 eq.) and DIPEA (19 µl, 0.112 mmol, 2 
eq.) in dry CH2Cl2 (0.6 ml) was put in an ice bath under nitrogen atmosphere. A solution 
of Boc2O (17 mg, 0.079 mmol, 1.4 eq.) in dry CH2Cl2 (0.2 ml) was added. The mixture 
was let react at 0°C for 1h under nitrogen atmosphere, then it was let stirring overnight 
at room temperature. As the starting material was still present, more Boc2O (6.7 mg, 
0.030 mmol, 0.5 eq.) was dissolved in CH2Cl2 (0.2 ml) and added to the mixture, which 
was let react for 4 h. Then the solvent was removed under reduced pressure. The crude 
product was passed through a plug of silica gel (CH2Cl2/MeOH, 95:5) to afford the 
desired product as a white foam (41 mg, 87% yield). 
Rf = 0.7 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, acetone-d6) δ 8.18 (d, J = 8.70 Hz, 1H), 
7.40 – 7.08 (m, 14H), 6.19 (d, J = 8.66 Hz, 1H), 4.69 (d, J = 7.92 Hz, 1H), 4.61 (d, J = 5.76 
Hz, 2H), 4.58 – 4.30 (m, 4H), 4.13 (t, J = 5.76 Hz,  1H), 3.99 (m, 1H), 3.25 (m, 1H), 2.25 (m, 
  3 | Experimental Section 
 
 
193 
1H), 2.17 (bs, 1H), 2.00 – 1.58 (m, 7H), 1.50 (s, 18H), 1.46 (m, 4H), 1.32 (m, 2H), 0.90 (t, J = 
7.38 Hz, 3H); MS (ESI) m/z calcd for [C48H66N5O8]+: 840.49 [M+H]+; found: 840.45. 
 
4-((4-(((2-((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-6-((S)-2-((tert-
butoxycarbonyl)(methyl)amino)butanamido)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-7-
yl)ethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)oxy)-4-oxobutanoic acid (91) 
 
 
 
Compound 90 (17 mg, 0.020 mmol, 1 eq.) was dissolved in dry CH2Cl2 (0.12 ml). Then 
DIPEA (4.1 µl, 0.024 mmol, 1.2 eq.) was addes and the mixture was put in an ice bath. 
DMAP (1.46 mg, 0.012 mmol, 0.6 eq.) and succinic anhydride (3.6 mg, 0.036 mmol, 1.8 
eq.) were added. The reaction was let stirring at room temperature under nitrogen 
atmosphere for 2h. CH2Cl2 (15 ml) was then added and the solution was washed with a 
solution of KHSO4 1M (7 ml, twice). The aqueous phase was extracted with CH2Cl2 (7 
ml, once), then the collected organic phases were dried over Na2SO4 and the solvent 
was evaporated, to afford a white foam that was used without further purification (17 
mg, 90% yield). 
Rf = 0.6 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, acetone-d6) δ 10.72 (bs, 1H), 8.19 (d, J = 
8.4 Hz, 1H), 7.48 – 6.98 (m, 15H), 6.19 (d, J = 8.4 Hz, 1H), 5.12 (s, 2H), 4.69 (d, J = 7.1 Hz, 
1H), 4.63 – 4.26 (m, 3H), 3.99 (d, J = 7.1 Hz, 1H), 3.27 (s, 1H), 3.03 – 2.93 (m, 2H), 2.80 (s, 
3H), 2.70 – 2.54 (m, 2H), 2.36 – 2.21 (m, 1H), 2.16 (s, 1H), 2.02 – 1.57 (m, 6H), 1.49 (s, 
18H), 1.45 – 1.35 (m, 6H), 0.88 (t, J = 7.4 Hz, 3H).13C NMR (400 MHz, acetone-d6) δ 173.6, 
172.7, 170.8, 143.6, 143.3, 139.7, 136.3, 129.4, 129.3, 129.1, 128.1, 128., 127.9, 79.8, 66.3, 
62.1, 60.7, 59.2, 57.3, 55.8, 49.6, 45.4, 34.6, 34.0, 33.6, 30.1 (overlapping with solvent 
signal), 29.8 (overlapping with solvent signal), 29.2, 28.6, 27.3, 22.2, 11.0; MS (ESI) m/z 
calcd for [C52H70N5O11]+: 940.51 [M+H]+; found: 940.33. 
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2-((1S,5S,11S,15R)-18-(4-((4-((4-(((2-((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-6-((S)-2-((tert-
butoxycarbonyl)(methyl)amino)butanamido)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-7-
yl)ethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)oxy)-4-oxobutanamido)methyl)benzyl)-
11-(3-guanidinopropyl)-4,7,10,13,17,19-hexaoxo-3,6,9,12,16,18-
hexaazabicyclo[13.2.2]nonadecan-5-yl)acetic acid (92) 
 
 
 
Compound 91 (17 mg, 0.018 mmol, 1 eq.) was dissolved under nitrogen atmosphere in a 
flame dried Schlenk tube with 1 ml of DMF. Then were added, at room temperature 
and in a single portion, N-hydroxysulfosuccinimide (5 mg, 0.023 mmol, 1.24 eq.) and 
N,N'-diisopropylcarbodiimide (4.18 l, 0.027 mmol, 1.52 eq.). The solution was stirred 
overnight, then DMF was removed under vacuum in the Schlenk tube. The resulting 
residue was then dissolved, in the same Schlenk tube, with 1.2 ml of CH3CN. To this 
solution was added a previously prepared solution of c[DKP-f3-RGD]10 (12.4 mg, 
0.0144 mmol, 0.8 eq.) dissolved in 1 ml of phosphate buffer solution (the pH was 
adjusted to 7.5 with 0.2 M NaOH). The resulting mixture was set to 0 °C and pH was 
adjusted to 7.5 with 0.2M NaOH. The solution was then stirred overnight. The reaction 
was then concentrated and purified by HPLC (gradient: 90% H2O + 0.2% HCOOH / 10% 
acetonitrile + 0.2% HCOOH to 30% H2O + 0.2% HCOOH / 70% acetonitrile + 0.2% 
HCOOH in 15 min). The purified product was then freeze dried to give the desired 
compound 92 as a white foam (9 mg, 40% yield). 
tR = 12.7 min; 1H NMR (400 MHz, CD3OD) δ 8.80 (d, J = 8.3 Hz, 1H), 8.40 (t, J = 5.5 Hz, 
1H), 8.34 – 8.15 (br m, 1H), 7.39 – 7.12 (m, 18H), 6.12 (d, J = 8.3 Hz, 1H), 5.21 – 5.03 (m, 
3H), 4.84 – 4.73 (m, 2H), 4.61 (t, J = 5.8 Hz, 1H), 4.58 – 4.27 (m, 7H), 4.24 – 4.15 (m, 1H), 
4.07 – 3.91 (m, 3H), 3.88 (d, J = 6.3 Hz, 1H), 3.52 (d, J = 17.2 Hz, 1H), 3.45 (dd, J = 14.7, 6.8 
Hz, 1H), 3.29 – 3.14 (m, 3H), 3.14 – 2.89 (m, 1H), 2.80 (s, 3H), 2.74 – 2.57 (m, 6H), 2.54 (t, J 
= 6.7 Hz, 2H), 2.30 – 2.16 (m, 1H), 2.15 – 1.33 (m, 33H), 0.92 (t, J = 7.2 Hz, 3H).; 13C NMR 
(101 MHz, CD3OD) δ 174.2, 174.0, 173.7, 173.6, 173.0, 172.9, 172.3, 172.2, 172.2, 171.3, 
171.2, 171.1, 158.6, 143.1, 140.2, 136.7, 135.9, 135.9, 129.7, 129.5, 129.3, 128.7, 128.6, 128.5, 
128.3, 81.4, 67.1, 62.8, 62.2, 60.6, 59.7, 58.3, 56.9, 54.3, 53.2, 51.3, 50.6, 48.1, 46.0, 43.9, 43.8, 
42.2, 40.1, 40.1, 39.9, 37.8, 34.0, 33.6, 31.4, 31.1, 31.0, 30.8, 30.4, 28.9, 28.8, 27.7, 26.5, 23.0, 
11.1; MS (ESI) m/z calcd for [C79H106N15O18]+: 1552.78 [M+H]+; found: 1552.85. 
 
 
 
  3 | Experimental Section 
 
 
195 
c[DKP-RGD]-O-SMAC 
 
 
 
Compound 92 (9 mg, 0.0058 mmol, 1 eq.) was dissolved in CH2Cl2 (100 l) and then was 
added, at room temperature, TFA (66 l, 0.87 mmol, 150 eq.). The reaction was stirred at 
room temperature for 50 min, then the volatiles were removed and the crude product 
was purified by HPLC (gradient: 90% H2O + 0.1% CF3COOH / 10% acetonitrile + 0.1% 
CF3COOH to 30% H2O + 0.1% CF3COOH / 70% acetonitrile + 0.1% CF3COOH in 14 min). 
The purified product was then freeze dried to give the desired compound (as tris-
trifluoroacetate salt) as a white foam (9.7 mg, 99% yield). 
tR = 8.7 min;
1
H NMR (400 MHz, CD3CN) δ 7.97 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.4, 3.6 Hz, 
1H), 7.44 – 7.13 (m, 18H), 6.05 (d, J = 8.1 Hz, 1H), 5.08 (s, 2H), 4.99 (d, J = 15.2 Hz, 1H), 4.75 
(t, J = 6.8 Hz, 1H), 4.54 (d, J = 9.4 Hz, 1H), 4.50 (dd, J = 7.9, 4.2 Hz, 1H), 4.45 (dd, J = 9.0, 4.3 
Hz, 1H), 4.31 – 4.23 (m, 3H), 4.10 (s, 2H), 4.04 – 3.89 (m, 3H), 3.89 – 3.78 (m, 3H), 3.46 (d, J = 
17.1 Hz, 1H), 3.34 (dd, J = 15.0, 6.5 Hz, 1H), 3.12 (t, J = 6.5 Hz, 2H), 3.07 – 2.98 (m, 1H), 2.82 
– 2.66 (m, 2H), 2.65 – 2.54 (m, 6H), 2.55 – 2.43 (m, 3H), 2.26 – 2.14 (m, 1H), 2.13 – 1.42 (m, 
15H, overlapping with solvent signal), 0.92 (t, J = 7.5 Hz, 3H); 
13
C NMR (101 MHz, CD3CN) δ 
173.9, 173.2, 173.1, 173.0, 172.2, 171.2, 170.8, 170.6, 170.6, 170.0, 168.6, 168.5, 157.9, 143.1, 
142.9, 140.1, 138.7, 135.4, 131.8, 131.2, 129.7, 129.3, 129.1, 128.8, 128.4, 128.3, 128.0, 66.4, 
63.2, 62.4, 60.3, 59.2, 58.0, 56.5, 54.9, 52.8, 51.7, 50.0, 48.2, 46.4, 43.4, 43.2, 41.8, 39.8, 38.9, 
37.3, 35.5, 33.6, 32.9, 32.5, 32.3, 31.1, 30.2, 29.0, 28.6, 26.9, 26.0, 23.9, 9.1; MS (ESI) m/z calcd 
for [C69H90N15O14]
+
: 1352.68 [M+H]
+
; found: 1353.41; HRMS (ESI) m/z calcd for 
[C69H90N15O14]
+
: 1352.67862 [M+H]
+
; found: 1352.68112. 
 
tert-butyl ((S)-1-(((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-7-(2-((4-
((((benzyloxy)carbonyl)amino)methyl)benzyl)amino)ethyl)-5-oxooctahydro-1H-pyrrolo[1,2-
a]azepin-6-yl)amino)-1-oxobutan-2-yl)(methyl)carbamate (93) 
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A solution of 8112 (20.6 mg, 0.030 mmol, 1.05 eq.), DIPEA (7.42 µl, 0.043 mmol, 1.5 eq.) in 
dry MeOH (0.2 ml) was put into a flask containing benzyl 4-formylbenzylcarbamate (7.8 
mg, 0.029 mmol, 1 eq.) under nitrogen atmosphere. The mixture was let stirring at room 
temperature for 5 h. NaBH4 (2.2 mg, 0.058 mmol, 2 eq.) was then added stepwise (5 
additions within 3 min) and the mixture was let react at room temperature under 
nitrogen for 30 min. The mixture was then concentrated under vacuum and 5 ml of a 
saturated solution of NaHCO3 were added, then the mixture was extracted with AcOEt 
(7 ml, three times). The organic phase was dried over Na2SO4 and the solvent was 
evaporated. The crude product was purified by flash chromatography on silica gel 
(DCM/MeOH, 9:1) to afford the desired product as a white foam (21 mg, 83%yiled). 
Rf = 0.53 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, CD2Cl2) δ 7.99 (br s, 1H), 7.45 – 7.10 
(m, 19H), 7.10 – 6.93 (m, 1H), 6.14 (d, J = 8.4 Hz, 1H), 5.41 (s, 1H), 5.10 (s, 2H), 4.68 (d, J = 
6.8 Hz, 1H), 4.52 (t, J = 8.2 Hz, 1H), 4.43 (dd, J = 9.6, 5.8 Hz, 1H), 4.32 (d, J = 6.0 Hz, 2H), 
3.86 (m, 1H), 3.78 (s, 2H), 2.78 (br s, 3H), 2.67 (br s, 1H), 2.48 (s, 1H), 2.35 (s, 1H), 2.28 – 
2.14 (m, 1H), 1.99 – 1.57 (m, 7H), 1.56 – 1.30 (m, 12H), 1.14 (s, 1H), 0.88 (t, J = 7.4 Hz, 3H); 
13C NMR (101 MHz, CD2Cl2) δ 172.9, 171.4, 171.0, 170.2, 156.7, 142.7, 142.0, 138.3, 137.9, 
137.3, 129.0, 128.9, 128.8, 128.3, 128.3, 127.8, 127.7, 127.6, 127.5, 127.4, 80.5, 66.9, 61.5, 
61.1, 60.6, 59.0, 57.2, 55.2, 53.6, 47.3, 45.0, 38.4, 35.0, 34.0, 33.8, 31.9, 30.9, 28.5, 26.1, 21.7, 
10.7; MS (ESI) m/z calcd for [C51H65N6O7]+: 873.49 [M+H]+; found: 873.39. 
 
tert-butyl ((S)-1-(((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-7-(2-((4-
((((benzyloxy)carbonyl)amino)methyl)benzyl)(tert-butoxycarbonyl)amino)ethyl)-5-
oxooctahydro-1H-pyrrolo[1,2-a]azepin-6-yl)amino)-1-oxobutan-2-yl)(methyl)carbamate (94) 
 
 
 
A solution of compound 93 (21 mg, 0.024 mmol, 1 eq.) and DIPEA (8.2 µl, 0.048 mmol, 2 
eq.) in dry CH2Cl2 (0.15 ml) was put in an ice bath under nitrogen atmosphere. A 
solution of Boc2O (7.9 mg, 0.036 mmol, 1.5 eq.) in dry CH2Cl2 (0.1 ml) was added. The 
mixture was let react at 0°C for 1h under nitrogen atmosphere, then it was let stirring 
overnight at room temperature. As the starting material was still present, more Boc2O 
(2.1 mg, 0.01 mmol, 0.4 eq.) was dissolved in CH2Cl2 (80 µl) and added to the mixture, 
which was let react for 4 h. Then the solvent was removed under reduced pressure. The 
crude product was passed through a plug of silica gel (CH2Cl2/MeOH 95:5) to afford the 
desired product as a white foam (23.2 mg, 100% yield). 
Rf = 0.62 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, acetone-d6) δ 8.18 (d, J = 8.4 Hz, 1H), 
7.41 – 7.05 (m, 20H), 6.83 (t, J = 5.6 Hz, 1H), 6.19 (d, J = 8.7 Hz, 1H), 5.08 (s, 2H), 4.69 (d, J 
= 7.4 Hz, 1H), 4.63 – 4.24 (m, 6H), 4.05 – 3.92 (m, 1H), 3.33 – 3.18 (m, 1H), 3.17 – 2.88 (m, 
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1H), 2.78 (s, 3H), 2.33 – 2.10 (m, 2H), 2.02 – 1.57 (m, 7H), 1.56 – 1.21 (m, 22H), 0.87 (t, J = 
7.4 Hz, 3H); MS (ESI) m/z calcd for [C56H73N6O9]+: 973.54 [M+H]+; found: 973.33. 
 
tert-butyl ((S)-1-(((3S,6S,7R,9aS)-7-(2-((4-(aminomethyl)benzyl)(tert-
butoxycarbonyl)amino)ethyl)-3-(benzhydrylcarbamoyl)-5-oxooctahydro-1H-pyrrolo[1,2-
a]azepin-6-yl)amino)-1-oxobutan-2-yl)(methyl)carbamate (95) 
 
 
 
Compound 94 (18.4 mg, 0.019 mmol, 1 eq.) was dissolved in a mixture of THF/H2O 1:1 
(6.4 ml) and Pd/C 10% (2.01 mg, 0.002 mmol, 0.1 eq.) was added. The reaction mixtures 
were subjected to three vacuum/hydrogen cycles and then left stirring overnight at 
room temperature under 1 bar of hydrogen. The mixture was filtered through Celite, 
and the cake thus obtained was washed thoroughly with THF/H2O 1:1. The filtrate was 
concentrated and dried to give the crude product as white foam (17 mg, 100% yield) 
that was used without further purification. 
Rf = 0.23 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, acetone-d6) δ 8.20 (d, J = 8.4 Hz, 1H), 
7.41 – 7.04 (m, 14H), 6.19 (d, J = 8.7 Hz, 1H), 4.69 (d, J = 7.0 Hz, 1H), 4.64 – 4.25 (m, 5H), 
4.06 – 3.93 (m, 1H), 3.78 (s, 1H), 3.29 – 3.19 (m, 1H), 3.19 – 2.91 (m, 2H), 2.79 (s, 3H), 2.28 
– 2.20 (m, 1H), 2.21 – 2.11 (m, 1H), 2.02 – 1.31 (m, 29H), 0.88 (t, J = 7.4 Hz, 3H); MS (ESI) 
m/z calcd for [C48H67N6O7]+: 839.51 [M+H]+; found: 839.12. 
 
4-((4-(((2-((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-6-((S)-2-((tert-
butoxycarbonyl)(methyl)amino)butanamido)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-7-
yl)ethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)amino)-4-oxobutanoic acid (96) 
 
 
 
Compound 95 (17 mg, 0.020 mmol, 1 eq.) was dissolved in dry CH2Cl2 (0.15 ml). Then 
DIPEA (3.4 µl, 0.020 mmol, 1 eq.) was added and the mixture was put in an ice bath. 
DMAP (1.22 mg, 0.010 mmol, 0.5 eq.) and succinic anhydride (3.04 mg, 0.030 mmol, 1.5 
eq.) were added. The reaction was let stirring at room temperature under nitrogen 
atmosphere for 2h. CH2Cl2 (15 ml) was then added and the solution was washed with a 
solution of KHSO4 1M (7 ml, 2x). The aqueous phase was extracted with CH2Cl2 (7 ml, 
1x), then the collected organic phases were dried over Na2SO4 and the solvent was 
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evaporated, to afford the crude product. The crude product was purified by HPLC 
(gradient: 70% H2O + 0.2% HCOOH / 30% acetonitrile + 0.2% HCOOH to 100% 
acetonitrile + 0.2% HCOOH in 10 min) to give the desired compound as a white foam 
(17.6 mg, 99% yield). 
tR = 8.7 min; 1H NMR (400 MHz, acetone-d6) δ 8.22 (d, J = 7.6 Hz, 1H), 7.65 (s, 1H), 7.39 – 
7.01 (m, 15H), 6.19 (d, J = 8.6 Hz, 1H), 4.69 (d, J = 7.1 Hz, 1H), 4.64 – 4.23 (m, 6H), 4.07 – 
3.90 (m, 1H), 3.32 – 2.89 (m, 2H), 2.80 (s, 3H), 2.60 (dd, J = 10.3, 4.1 Hz, 2H), 2.51 (dd, J = 
10.2, 3.9 Hz, 2H), 2.31 – 2.19 (m, 1H), 2.19 – 2.09 (m, 1H), 2.07 – 1.55 (m, 9H), 1.56 – 1.36 
(m, 20H), 0.87 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, acetone-d6) δ 174.2, 172.2, 170.9, 
170.8, 156.3, 155.7, 143.5, 143.3, 139.2, 138.6, 129.4, 129.3, 128.6, 128.1, 128.0, 128.0, 79.7, 
62.1, 60.6, 59.3, 57.3, 55.8, 50.7, 49.7, 43.4, 38.5, 34.6, 33.9, 33.6, 33.5, 31.1, 28.6, 27.4, 22.2, 
11.0; MS (ESI) m/z calcd for [C52H71N6O10]+: 939.52 [M+H]+; found: 939.45. 
 
2-((1S,5S,11S,15R)-18-(4-((4-((4-(((2-((3S,6S,7R,9aS)-3-(benzhydrylcarbamoyl)-6-((S)-2-((tert-
butoxycarbonyl)(methyl)amino)butanamido)-5-oxooctahydro-1H-pyrrolo[1,2-a]azepin-7-
yl)ethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)amino)-4-
oxobutanamido)methyl)benzyl)-11-(3-guanidinopropyl)-4,7,10,13,17,19-hexaoxo-3,6,9,12,16,18-
hexaazabicyclo[13.2.2]nonadecan-5-yl)acetic acid (97) 
 
 
 
Compound 96 (20 mg, 0.021 mmol, 1 eq.) was dissolved under nitrogen atmosphere in a 
flame dried Schlenk tube with 2 ml of DMF. Then were added, at room temperature 
and in a single portion, N-hydroxysulfosuccinimide (5.7 mg, 0.026 mmol, 1.24 eq.) and 
N,N'-diisopropylcarbodiimide (4.94 l, 0.032 mmol, 1.52 eq.). The solution was stirred 
overnight, then DMF was removed under vacuum in the Schlenk tube. The resulting 
residue was then dissolved, in the same Schlenk tube, with 2 ml of CH3CN. To this 
solution was added a previously prepared solution of c[DKP-f3-RGD]10 (11.0 mg, 
0.0128 mmol, 0.67 eq.) dissolved in 1 ml of phosphate buffer solution (the pH was 
adjusted to 7.5 with 0.2M NaOH). The resulting mixture was set to 0 °C and pH was 
adjusted to 7.5 with 0.2M NaOH. The solution was then stirred overnight. The reaction 
was then concentrated and purified by HPLC (gradient: 90% H2O + 0.2% HCOOH / 10% 
acetonitrile + 0.2% HCOOH to 30% H2O + 0.2% HCOOH / 70% acetonitrile + 0.2% 
HCOOH in 15 min). The purified product was then freeze dried to give the desired 
compound as a white foam (9.7 mg, 49% yield). 
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tR = 12.1 min; 1H NMR (400 MHz, CD3OD) δ 8.44 (s, 1H), 7.38 – 7.12 (m, 18H), 6.13 (s, 
1H), 5.15 (d, J = 14.9 Hz, 1H), 5.05 (dd, J = 10.2, 2.1 Hz, 1H), 4.69 – 4.59 (m, 2H), 4.58 – 
4.23 (m, 10H), 4.11 – 4.01 (m, 2H), 3.97 (dd, J = 14.6, 7.3 Hz, 1H), 3.85 (d, J = 5.7 Hz, 1H), 
3.52 (d, J = 17.1 Hz, 1H), 3.42 (dd, J = 14.3, 5.7 Hz, 1H), 3.28 – 2.92 (m, 4H), 2.88 – 2.72 (m, 
5H), 2.60 – 2.51 (m, 4H), 2.45 (dd, J = 16.7, 5.5 Hz, 1H), 2.29 – 2.17 (m, 1H), 2.11 – 1.52 (m, 
14H), 1.52 – 1.24 (m, 19H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 178.0, 
174.5, 174.4, 173.8, 173.6, 173.5, 173.0, 172.6, 172.2, 171.5, 171.2, 170.6, 158.7, 143.1, 140.2, 
140.0, 139.1, 138.7, 135.9, 129.7, 129.5, 129.3, 128.9, 128.7, 128.6, 128.5, 128.3, 81.7, 81.4, 
62.8, 62.0, 60.8, 59.7, 58.3, 56.8, 53.4, 53.2, 51.4, 50.8, 48.1, 46.0, 43.9, 43.8, 42.2, 40.9, 40.1, 
37.8, 37.2, 34.1, 33.7, 33.4, 32.3, 31.1, 30.9, 28.8, 27.8, 26.2, 23.0, 11.1; MS (ESI) m/z calcd for 
[C79H107N16O17]+: 1551.80 [M+H]+; found: 1552.30. 
 
c[DKP-RGD]-N-SMAC 
 
 
 
Compound 97 (9 mg, 0.0058 mmol, 1 eq.) was dissolved in CH2Cl2 (100 l) and then was 
added, at room temperature, TFA (66 l, 0.87 mmol, 150 eq.). The reaction was stirred at 
room temperature for 50 min, then the volatiles were removed and the crude product 
was purified by HPLC (gradient: 90% H2O + 0.1% CF3COOH / 10% acetonitrile + 0.1% 
CF3COOH to 30% H2O + 0.1% CF3COOH / 70% acetonitrile + 0.1% CF3COOH in 14 min). 
The purified product was then freeze dried to give the desired compound (as tris-
trifluoroacetate salt) as a white foam (9.8 mg, 100% yield). 
tR = 8.3 min;
1
H NMR (400 MHz, CD3CN) δ 7.95 (d, J = 8.1 Hz, 1H), 7.85 (dd, J = 8.2, 3.3 Hz, 
1H), 7.40 – 7.14 (m, 18H), 6.05 (d, J = 8.1 Hz, 1H), 4.96 (d, J = 15.2 Hz, 1H), 4.73 (t, J = 6.7 
Hz, 1H), 4.58 – 4.42 (m, 3H), 4.36 – 4.20 (m, 5H), 4.14 – 3.80 (m, 7H), 3.45 (d, J = 16.9 Hz, 
1H), 3.33 (dd, J = 14.8, 6.3 Hz, 1H), 3.19 – 3.06 (m, 2H), 3.06 – 2.94 (m, 1H), 2.95 – 2.80 (m, 
1H, overlapping with solvent signal), 2.80 – 2.64 (m, 2H), 2.63 – 2.43 (m, 9H), 2.25 – 2.13 (m, 
1H), 2.10 – 1.40 (m, 15H), 0.92 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CD3CN) δ 174.0, 
173.9, 173.2, 173.1, 172.2, 171.2, 170.8, 170.6, 170.0, 168.6, 158.0, 143.1, 142.9, 141.5, 140.0, 
135.5, 131.2, 130.7, 129.7, 129.7, 129.1, 128.8, 128.8, 128.4, 128.3, 128.1, 63.2, 62.5, 60.5, 
59.2, 58.0, 56.5, 54.9, 52.9, 51.8, 50.1, 48.3, 46.3, 43.4, 43.3, 41.8, 39.9, 39.0, 37.3, 35.7, 33.7, 
32.9, 32.5, 32.3, 32.0, 29.1, 28.6, 27.0, 26.0, 23.9, 9.2; MS (ESI) m/z calcd for [C69H91N16O13]
+
: 
1351.69 [M+H]
+
; found: 1352.40; HRMS (ESI) m/z calcd for [C69H90N16O13Na]
+
: 1373.67655 
[M+Na]
+
; found: 1373.67702. 
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3.1.7 -  Synthesis of V3 / VEGFR dual action ligands 
 
MA peptide 
 
 
 
The semi-automatic SPPS was accomplished as described in 3.1.1 on 0.100 mmol of 
resin (200 mg). 
Exact amounts of the amino acids used for SPPS are reported in Table 3.1.2. 
 
Table 3.1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The on bead-peptide 106 (66 mg of resin, 0.033 mmol) cleavage, RP-HPLC purification 
and freeze-drying were performed as described in 3.1.1.  
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 20% 
H2O + 0.1% CF3COOH / 80% CH3CN + 0.1% CF3COOH in 30 min, then 20% H2O / 80% 
CH3CN to 100% CH3CN in 1 min; flow: 5 mL/min. 
The desired compound was obtained (as acetate salt) as a white solid (8 mg, 12%). 
tR = 15.2 min; MS (MALDI-TOF) m/z calcd for [C91H141N20O22S]+: 1899.03 amu [M+H]+; 
found: 1899.1 amu (HCCA matrix). 
Fmoc-AA-OH 
M.W. 
(g/mol) 
Mass (mg) 
Fmoc-Ile-OH 353.41 141.4 
Fmoc-Gly-OH 297.31 118.9 
Fmoc-Lys(Boc)-OH 468.54 187.4 
Fmoc-Tyr(t-Bu)-OH 459.53 183.8 
Fmoc-Ala-OH 311.33 124.5 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Gln(Trt)-OH 610.70 244.3 
Fmoc-Tyr(t-Bu)-OH 459.53 183.8 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Glu(Ot-Bu)-OH 425.47 170.2 
Fmoc-Met-OH 371.45 148.6 
Fmoc-Trp(Boc)-OH 526.58 210.6 
Fmoc-Thr(t-Bu)-OH 397.46 159.0 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Lys(Mtt)-OH 624.79 249.9 
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Ac-MA peptide 
 
 
 
The semi-automatic SPPS was accomplished as described in 3.1.1 on 0.100 mmol of 
resin (200 mg). 
Exact amounts of the amino acids used for SPPS are reported in Table 3.1.3. 
 
Table 3.1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The on bead-peptide 107 (66 mg of resin, 0.033 mmol) cleavage, RP-HPLC purification 
and freeze-drying were performed as described in 3.1.1.  
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 20% 
H2O + 0.1% CF3COOH / 80% CH3CN+ 0.1% CF3COOH in 30 min, then 20% H2O + 0.1% 
CF3COOH / 80% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; 
flow: 5 mL/min. 
The desired compound was obtained (as acetate salt) as a white solid (3.6 mg, 5%). 
tR = 16.0 min; MS (MALDI-TOF) m/z calcd for [C93H143N20O23S]+: 1941.04 amu [M+H]+; 
found: 1941.0 amu (SIN matrix). 
 
Fmoc-AA-OH 
M.W. 
(g/mol) 
Mass (mg) 
Fmoc-Ile-OH 353.41 141.4 
Fmoc-Gly-OH 297.31 118.9 
Fmoc-Lys(Ac)-OH 410.50 164.2 
Fmoc-Tyr(t-Bu)-OH 459.53 183.8 
Fmoc-Ala-OH 311.33 124.5 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Gln(Trt)-OH 610.70 244.3 
Fmoc-Tyr(t-Bu)-OH 459.53 183.8 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Glu(Ot-Bu)-OH 425.47 170.2 
Fmoc-Met-OH 371.45 148.6 
Fmoc-Trp(Boc)-OH 526.58 210.6 
Fmoc-Thr(t-Bu)-OH 397.46 159.0 
Fmoc-Leu-OH 353.41 141.4 
Fmoc-Lys(Mtt)-OH 624.79 249.9 
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Selective removal of Mtt-protecting group (108, 109 and 110) 
 
 
108 and 109: 
The on bead-MA peptide 106 or 107 (100 mg of resin, 0.05 mmol) was swollen first with 
DMF, then with DCM (3 mL for each swelling). The Mtt-selective cleavage cocktail was 
prepared: DCM (33.84 mL, 94%), TIS (1.80 mL, 5%) and TFA (360 µL, 1%) were put in a 
round bottom flask under stirring and inert atmosphere. The beads were treated with 
the cleavage cocktail (3 mL per 12 times, 2 minutes each step, 36 mL of cleavage 
mixture). At the end of the cleavage steps, the the on bead-peptides 108 and 109 were 
washed twice with DCM, MeOH, DCM, 1% DIPEA in DMF, DMF (3 mL per 5 minutes 
for each wash).  
 
110: 
To a small amount of 108 was added a solution of Ac2O/DMF 1:3 (3 mL): the reaction 
was carried out at r.t. under inert atmosphere and mechanical stirring for 3 h. A Kaiser 
test was performed on a small amount of resin. The full cleavage of the peptide from 
the resin was effected as reported in 3.1.1. The crude product was purified with RP-
HPLC (gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 20% 
H2O + 0.1% CF3COOH / 80% CH3CN + 0.1% CF3COOH in 30 min, then 20% H2O + 0.1% 
CF3COOH / 80% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; 
flow: 5 mL/min) and freeze-dried from glacial acetic acid to give the product (as acetate 
salt) as a white solid (9 mg, 9%). 
tR = 15.9 min; MS (MALDI) m/z calcd for [C93H143N20O23S]+: 1941.04 amu [M+H]+; found: 
1940.2 amu (SIN matrix). 
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1-azido-28-oxo-3,6,9,12,15,18,21,24-octaoxa-27-azahentriacontan-31-oic acid (112) 
 
 
 
Azide 111 (30.0 mg, 0.07 mmol, 1.0 eq) was dissolved in a Schlenk tube with DCM (0.80 
mL, dry solvent) under inert atmosphere and stirring. Succinic anhydride (13.7 mg, 0.14 
mmol, 2.0 eq) and DIPEA (12 µL, 0.07 mmol, 1.0 eq) were added: the reaction was left at 
r.t. under stirring and inert atmosphere overnight. The reaction mixture was transferred 
in a round bottom flask with DCM and acidified with TFA (5 µL, 0.07 mmol). The 
reaction mixture was concentrated under vacuum and purified with RP-HPLC as 
described in 3.1.1  
RP-HPLC gradient: 100% H2O + 0.1% CF3COOH to 70% H2O + 0.1% CF3COOH / 30% 
CH3CN + 0.1% CF3COOH in 11 min, then 70% H2O + 0.1% CF3COOH / 30% CH3CN + 
0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 2 min; flow: 15 mL/min. 
The desired product was obtained as a colourless oil (35 mg, 96%). 
tR = 8.2 min; 1H NMR (400 MHz, Acetone) δ 7.31 (s, 1H), 3.74 – 3.68 (m, 2H), 3.67 – 3.56 
(m, 28H), 3.53 (t, J = 5.6 Hz, 2H), 3.45 – 3.32 (m, 4H), 2.59 (dd, J = 10.4, 4.2 Hz, 2H), 2.50 
(dd, J = 10.5, 4.0 Hz, 2H). 
2-((1S,5S,11S,15R)-18-(4-(33-azido-3,6-dioxo-10,13,16,19,22,25,28,31-octaoxa-2,7-
diazatritriacontyl)benzyl)-11-(3-guanidinopropyl)-4,7,10,13,17,19-hexaoxo-3,6,9,12,16,18-
hexaazabicyclo[13.2.2]nonadecan-5-yl)acetic acid (113) 
 
 
122 (35.0 mg, 0.065 mmol, 1.24 eq) was dissolved with DCM (2.8 mL) in a Schlenk tube; 
N-hydroxysuccinimide (9.5 mg, 0.081 mmol, 1.55 eq) and DIC (18 µL, 0.117 mmol, 2.23 
eq) were added: the reaction was left at r.t., under stirring and inert atmosphere. After 2 
h, the reaction mixture was concentrated under vacuum and the residue was dissolved 
with CH3CN (2.8 mL). The previously prepared solution of c[DKP-f3-RGD]10 (45.0 mg, 
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0.052 mmol, 1.0 eq) in phosphate-buffer solution (1.4 mL) was added at 0 °C: pH had to 
be controlled and maintained in the 7.3-7.6 range, correcting it with some drops of 
NaOH 0.2 M. pH was monitored for the first 2 h of the reaction, and then the reaction 
was left at r.t. overnight. The reaction mixture was concentrated, purified with RP-
HPLC as described in 3.1.1 
RP-HPLC gradient: 100% H2O + 0.1% CF3COOH to 55% H2O + 0.1% CF3COOH / 45% 
CH3CN + 0.1% CF3COOH in 11 min, then 55% H2O + 0.1% CF3COOH / 45% CH3CN + 
0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; flow: 15 mL/min. 
The desired compound was obtained (as trifluoroacetate salt) as a white solid (43.0 mg, 
65%). 
tR = 11.7 min; 1H NMR (400 MHz, CD3OD) δ 8.17 (dd, J = 8.6, 3.1 Hz, 1H), 7.27 (AB 
system , J = 17.3, 8.2 Hz, 4H), 5.16 (d, J = 15.0 Hz, 1H), 4.99 – 4.83 (m, 1H, overlap with 
the solvent signal), 4.59 (dd, J = 9.6, 3.8 Hz, 1H), 4.47 – 4.38 (m, 1H), 4.35 (s, 2H), 4.01 – 
3.87 (m, 4H), 3.70 – 3.57 (m, 31H), 3.53 (dd, J = 10.8, 5.4 Hz, 4H), 3.40 – 3.32 (m, 4H), 3.22 
(t, J = 7.0 Hz, 2H), 3.02 – 2.92 (m, 1H), 2.79 (dd, J = 13.4, 9.8 Hz, 1H), 2.61 – 2.45 (m, 6H), 
2.19 – 2.08 (m, 1H), 2.01 – 1.89 (m, 1H), 1.66 (dtt, J = 20.1, 13.3, 6.5 Hz, 2H); 13C NMR (101 
MHz, CD3OD) δ 174.70, 174.55, 173.86, 173.84, 173.54, 171.95, 171.59, 170.90, 158.60, 
140.20, 135.79, 129.39, 129.17, 71.52, 71.43, 71.23, 71.07, 70.54, 60.26, 55.96, 53.13, 51.75, 
50.28, 48.16, 43.72, 43.59, 42.15, 40.41, 39.68, 38.59, 35.60, 32.23, 32.16, 27.37, 27.05; MS 
(ESI) m/z calcd for [C49H78N14NaO18]+: 1173.55 amu [M+Na]+; found: 1173.9 amu. 
 
But-3-ynoic acid (114) 
 
 
 
In a round bottom flask 3-butyn-1-ol (0.50 g, 7.1 mmol, 1.0 eq) was dissolved in acetone 
(7.0 mL). In a second round bottom flask CrO3 (1.39 g, 13.9 mmol, 2.0 eq) was dissolved 
in H2O (36 mL) and 97% H2SO4  (9.6 mL) was added carefully (exothermic reaction). The 
solution of 3-butyn-1-ol was added, at 0 °C and dropwise over a period of 1 h, to the 
solution of CrO3. The solution was stirred at 0 °C for 3.5 h. The mixture was then 
extracted three times with Et2O and the combined organic phases were washed twice 
with brine, dried with Na2SO4 and concentrated. The solid product obtained was 
dissolved in DCM and extracted three times with sat. aq. NaHCO3: the combined 
aqueous phases were acidified (pH = 3) with KHSO4 and washed with Et2O. The final, 
combined organic phases were dried and concentrated, affording the desired product 
114 (156 mg, 26%). 
1H NMR (400 MHz, CDCl3) δ 10.97 (s, 1H), 3.37 (d, J = 2.7 Hz, 2H), 2.23 (t, J = 2.7 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 174.52, 74.86, 72.06, 25.70. 
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Alkyne-bearing peptide 115 
 
 
 
On bead-peptide 109 (100 mg of resin, 0.05 mmol, 1.0 eq) was swollen in DMF. But-3-
ynoic acid 114 (17 mg, 0.20 mmol, 4.0 eq) was dissolved in DMF (3 mL) and HATU (76 
mg, 0.20 mmol, 4.0 eq), HOAt (27 mg, 0.20 mmol, 4.0 eq) and DIPEA (51 µL, 0.30 mmol, 
6.0 eq) were added at 0 °C. The reaction was left at 0 °C under stirring for 20 min. The 
reaction mixture was then added to the on bead-peptide 109.  The reaction was left at 
r.t. under mechanical stirring and inert atmosphere. After 16 h, the beads were washed 
twice with DMF, MeOH, Et2O, MeOH, DMF (3 mL per 5 min for each wash). A Kaiser 
test was performed on some beads as described in 3.1.1. 
 
(3-azidopropyl)benzene (116) 
 
 
 
Cinnamyl alcohol (500 mg, 3.37 mmol, 1.0 eq) was dissolved in MeOH (37.3 mL) and 
Pd/C 10 % (39.7 mg, 0.37 mmol, 0.1 eq) was added: the reaction was left overnight at r.t. 
under stirring and 1 bar of H2 atmosphere. The reaction mixture was filtered on celite 
and concentrated affording to the 3-phenylpropan-1-ol as a clear yellow oil (485 mg, 
96%), that was directly used in the next step without further purification. 
Rf = 0.3 (Hexane/EtOAc, 6:4) 
 
3-phenylpropan-1-ol (485 mg, 3.23 mmol, 1.0 eq) was dissolved in a round bottom flask 
in DCM (36.4 mL, dry solvent). DIPEA (1.828 mL, 10.68 mmol, 3.3 eq) and MsCl (522 
µL, 5.34 mmol, 1.65 eq) were added dropwise under stirring and inert atmosphere at 0 
°C. The temperature was let to reach r.t. and the reaction progress was monitored by 
TLC. After 2 h, the reaction mixture was diluted with DCM and washed twice with 5% 
aqueous citric acid, once with NaHCO3 and brine. The combined organic phases were 
dried and concentrated, affording 736 mg (quantitative yield) of 3-phenylpropyl 
methanesulfonate as a yellow oil, that was directly used in the next step without further 
purification. 
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The 3-phenylpropyl methanesulfonate (736 mg, 3.23 mmol, 1.0 eq) was dissolved in a 
round bottom flask in DMF (16 mL) and NaN3 (1.05 g, 16.15 mmol, 5.0 eq) was added at 
0 °C: the reaction was let to reach r.t. and monitored via TLC. After 24 h, the reaction 
mixture was diluted with AcOEt, the organic phase was washed twice with brine, dried 
and concentrated. The crude product was purified by flash chromatography on silica 
gel (85:15 hexane/EtOAc) to afford the desired product as viscous colourless oil (451.7 
mg, 80%). 
Rf = 0.56 (Hexane/EtOAc, 85:15); 1H NMR (400 MHz, CDCl3) δ 7.30 (m, 2H), 7.24 – 7.16 
(m, 3H), 3.29 (t, J = 6.8 Hz, 2H), 2.76 – 2.68 (m, 2H), 1.92 (dt, J = 14.1, 6.9 Hz, 2H). 
CuAAC reaction adduct 117 
 
 
On-bead alkyne 115 (50 mg of resin, 0.025 mmol, 1.0 eq) was swollen in DMF (3 mL). 
Azide 116 (22 mg, 0.125 mmol, 5.0 eq) was dissolved in a DMF/piperidine 4:1 solution (2 
mL) and added to the resin. CuI (24 mg, 0.125 mmol, 5.0 eq) and sodium ascorbate (24 
mg, 0.125 mmol, 5.0 eq) were added to the mixture: the reaction was carried out at r.t. 
under mechanical stirring. After 42 h, the beads were washed two times with DMF, 
MeOH and DCM (3 mL per 5 min for each wash). The product was fully cleaved from 
the resin and purified with RP-HPLC as described in 3.1.1.  
RP-HPLC gradient: from 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 
20% H2O + 0.1% CF3COOH / 80% CH3CN + 0.1% CF3COOH in 30 min, then 20% H2O + 
0.1% CF3COOH / 80% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 
min; flow: 5 mL/min.  
None of the isolated peaks corresponded to the desired product 117. 
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Alkyne-bearing peptide 119 
 
 
 
On bead-peptide 109 (50 mg of resin, 0.025 mmol, 1.0 eq) was swollen in DMF. Pent-4-
ynoic acid 118 (Sigma-Aldrich) (31.8 mg, 0.100 mmol, 4.0 eq) was dissolved in a round 
bottom flask with DMF (2.00 mL). HATU (24.7 mg, 0.100 mmol, 4.0 eq), HOAt (8.9 mg, 
0.100 mmol, 4.0 eq) and DIPEA (39 µL, 0.150 mmol, 6.0 eq) were added under stirring at 
0 °C: the reaction was left at 0 °C under stirring and inert atmosphere. After 20 min, the 
reaction mixture was added to the beads: the reaction was left at r.t. under mechanical 
stirring. After 16 h, the beads were washed twice with DMF, MeOH, Et2O, MeOH, DMF 
(3 mL per 5 min for each wash). A Kaiser test was performed on some beads as 
described in 3.1.1. 
 
CuAAC reaction adduct 120 
 
 
 
On bead-alkyne 119 (50 mg of resin, 0.025 mmol, 1.0 eq) was swollen in DMF and then 
suspended in DMF (1 mL). Azide 116 (25 mg, 0.125 mmol, 5.0 eq) was dissolved in a 
round bottom flask in DMF (1 mL) and then added to the beads. CuI (9 mg, 0.125 mmol, 
5.0 eq), sodium ascorbate (32 mg, 0.125 mmol, 5.0 eq) and DIPEA (39 µL, 0.125 mmol, 
5.0 eq) were added to the solution: the reaction was left under mechanical stirring at r.t. 
for 72 h. The beads were washed twice with DMF, MeOH, Et2O, MeOH, DCM, 
DMF/EDTA (saturated aqueous solution) 1:1, DMF. The product was cleaved from resin 
and purified by RP-HPLC as described in 3.1. 
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 20% 
H2O + 0.1% CF3COOH / 80% CH3CN + 0.1% CF3COOH in 15 min, then 20% H2O + 0.1% 
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CF3COOH / 80% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; 
flow: 5 mL/min. 
The product was obtained as a white solid (3.4 mg, 6%). 
tR = 21.7 min; MS (ESI) m/z calcd for [C107H159N23O24S]2+: 1091.08 amu [M+2H]2+; found: 
1091.3 amu. 
 
Dual action ligand Ac-MA-RGD 
 
 
 
On-bead alkyne 119 (36 mg of resin, 0.0183 mmol, 1.0 eq) was swollen in DMF (3 mL). 
Azide 113 (35 mg, 0.0275 mmol, 1.5 eq) was dissolved in DMF (1.5 mL) under inert 
atmosphere and added to the resin. CuI (5 mg, 0.0275 mmol, 1.5 eq), sodium ascorbate 
(5 mg, 0.0275 mmol, 1.5 eq) and DIPEA (9.4 µL, 0.0550 mmol, 3.0 eq) were added to the 
mixture. The reaction was carried out at r.t. under mechanical stirring and inert 
atmosphere. After 72 h, the beads were washed two times with DMF, MeOH, DCM, a 
DMF/EDTA (saturated aqueous solution) 1:1 solution, a 1% TFA in DCM solution and 
DMF (3 mL per 5 min for each wash). The product was cleaved from the resin and 
purified by RP-HPLC as described in 3.1.1.  
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 55% 
H2O + 0.1% CF3COOH / 45% CH3CN + 0.1% CF3COOH in 17 min, then 55% H2O + 0.1% 
CF3COOH / 45% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; 
flow: 10 mL/min. 
The product was obtained (as acetate salt) as a white solid (3.5 mg, 6%). 
tR = 18.7 min; MS (MALDI-TOF) m/z calcd for [C147H225N34O42S]+: 3171.63 amu [M+H]+; 
found: 3172.5 amu (HCCA matrix). 
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Alkyne-bearing peptide 122 
 
 
Peptide 108 (32 mg of resin, 0.016 mmol, 1.0 eq) was swollen in DMF. Pent-4-ynoic acid 
118 (6.3 mg, 0.064 mmol, 4.0 eq) was dissolved in a round bottom flask in DMF (1.00 
mL) and HATU (24 mg, 0.064 mmol, 4.0 eq), HOAt (9 mg, 0.064 mmol, 4.0 eq) and 
DIPEA (16 µL, 0.096 mmol, 6.0 eq) were added under stirring at 0 °C: the reaction was 
left at 0 °C under inert atmosphere. After 20 min, the reaction mixture was added to the 
peptide 108: the reaction was left at r.t. under mechanical stirring. After 16 h, the beads 
were washed twice with DMF, MeOH, Et2O, MeOH, DMF (3 mL per 5 min for each 
wash). A Kaiser test was performed as described in 3.1.1. The product was fully cleaved 
and purified with RP-HPLC as described in 3.1.1. 
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 37% 
H2O + 0.1% CF3COOH / 63% CH3CN + 0.1% CF3COOH in 22 min, then 37% H2O + 0.1% 
CF3COOH / 63% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% CF3COOH in 1 min; 
flow: 5 mL/min. 
The product was obtained (as acetate salt) as a white solid (10.0 mg, 31%). 
tR = 21.7 min; MS (MALDI-TOF) m/z calcd for [C96H145N20O23S]+: 1979.05 amu [M+H]+; 
found: 1979.1 amu (SIN matrix). 
 
Dual action ligand MA-RGD 
 
 
3 | Experimental Section 
 
210 
Alkyne 122 (10.0 mg, 5.0 µmol, 1.05 eq) and azide 113 (6 mg, 4.7 µmol, 1.0 eq) were 
dissolved in a Schlenk tube in DMF (400 µL). CuSO4·5H2O (0.24 mg, 0.96 µmol, 0.2 eq), 
sodium ascorbate (0.30 mg, 1.5 µmol, 0.3 eq) and DIPEA (1.6 µL, 9.4 µmol, 2.0 eq) were 
added: the reaction was left at r.t. under stirring and inert atmosphere for 48 h. The 
reaction mixture was diluted with DMF and purified with RP-HPLC as described in 
3.1.1.  
RP-HPLC gradient: 80% H2O + 0.1% CF3COOH / 20% CH3CN + 0.1% CF3COOH to 40% 
H2O + 0.1% CF3COOH / + 0.1% CF3COOH 60% CH3CN + 0.1% CF3COOH in 12 min, 
then 40% H2O + 0.1% CF3COOH / 60% CH3CN + 0.1% CF3COOH to 100% CH3CN + 0.1% 
CF3COOH in 1 min; flow: 10 mL/min. 
The product was obtained (as acetate salt) as a white solid (3.8 mg, 25%). 
tR = 11.7 min; MS (MALDI-TOF) m/z calcd for [C145H223N34O41S]+: 3129.62 amu [M+H]+; 
found: 3130.5 amu (SIN matrix). 
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3.2 NM R , CD , COM PUTATIONAL AND B IOLOGICAL PROCEDURES 
 
3.2.1 NMR studies 
NMR experiments were performed at a temperature of 298 K on Bruker Avance 400 and 
600 MHz spectrometers. All proton and carbon chemical shifts were assigned 
unambiguously. The NMR experiments were carried out in a D2O/H2O 1:9 mixture in 
order to observe amide protons. Two-dimensional experiments (TOCSY, NOESY, and 
HSQC) were carried out on samples of cyclic RGD-peptidomimetics c[DKP-RGD] at a 
concentration in the range 3-6 mM. NOESY experiments were performed at 0.7 or 0.8 s. 
The water resonance was saturated with the excitation sculpting sequence from the 
Bruker library. The conformations of the cyclic pentapeptides were analyzed with 
respect to hydrogen bonding of amide protons (VT-NMR spectroscopy) and NOE 
contacts. 
 
3.2.2 Circular Dichroism studies  
The circular dichroism spectra were registered on a Jasco J-715 CD instrument with 
Hellma 0.1 cm quarts cell in milliQ H2O solvent (for the CD spectra recorded in water). 
The spectra were elaborated with Origin and Jasco instrument associated softwares. The 
values are reported as total molar ellipticity [θ]T (deg × cm2 × dmol-1). 
 
3.2.3 Computational procedures 
All calculations were run using the Schrödinger suite of programs 
(http://www.schrodinger.com) through the Maestro graphical interface. Conformational 
analysis. Conformational preferences of the RGD-peptidomimetics were investigated by 
Monte Carlo/stochastic dynamics (MC/SD) hybrid simulations using the NMR 
restraints derived from the experimental NOE contacts (for distance restraints used for 
each calculation, see the Supporting Information). All the NOE restraints have been set 
to a distance value of 2±0.5Å with a force constant of 100 kJ/mol·Å2. MC/SD simulations 
were performed at 300K within the framework of MacroModel version 9.5 employing 
the OPLS_2001 force field and the implicit water GB/SA solvation model RGD side-
chain dihedral angles were defined as internal coordinate degrees of freedom in the 
Monte Carlo part of the algorithm. A time step of 1 fs was used for the stochastic 
dynamics (SD) part of the algorithm for 10 ns of simulation time. Samples were taken at 
2 ps intervals during each simulation, yielding 5000 conformations for analysis. The 
3 | Experimental Section 
 
212 
percentages of H-bonds discussed in this thesis have been calculated as percentages of 
conformations sampled during the simulation in which donor H - acceptor O distance  
< 2.5 Å (-turn) or < 4 Å (-turn). 
 
3.2.3.1 Molecular docking 
The recently solved crystal structure of the extracellular domain of the integrin v3 
receptor in complex with Cilengitide and in the presence of the proadhesive ion Mn2+ 
(PDB entry code 1L5G) was used for docking studies. Docking was performed only on 
the globular head of the integrin because the headgroup of integrin has been identified 
in the X-ray structure as the ligand-binding region. The protein structure was setup for 
docking as follows; the protein was truncated to residue sequences 41-342 for chain  
and 114-347 for chain . Due to a lack of parameters, the Mn2+ ions in the experimental 
protein structure were modelled by replacing them with Ca2+ ions. The resulting 
structure was prepared using the Protein Preparation Wizard of the graphical user 
interface Maestro and the OPLSAA force field. The automated docking calculations 
were performed using Glide (Grid-based Ligand Docking with Energetics). The grid 
generation step started from the extracellular fragment of X-ray structure of v3 
complex with Cilengitide, as described in the protein setup section. The center of the 
grid enclosing box was defined by the center of the bound ligand, as described in the 
original PDB entry. The enclosing box dimensions, which are automatically deduced 
from the ligand size, fit the entire active site. For the docking step, the size of the 
bounding box for placing the ligand center was set to 12 Å. No further modifications 
were applied to the default settings. The GlideScore function was used to select 20 
poses for each ligand. The Glide program was initially tested for its ability to reproduce 
the crystallized binding geometry of cilengitide. The program was successful in 
reproducing the experimentally determined binding mode of this compound, as it 
corresponds to the best-scored pose. 
 
3.2.4 Solid-phase integrin receptor binding assay 
Purified v3 and v5 receptors (Millipore Corporation, Billerica, MA, USA) were 
diluted to 0.5 g/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM MnCl2, 2 mM CaCl2, and 1 mM MgCl2. An aliquot of diluted receptors (100 
L/well) was added to 96-well microtiter plates (NUNC MW 96F Maxisorp Straight) 
and incubated overnight at 4°C. The plates were then incubated with blocking solution 
(coating buffer plus 1% bovine serum albumin) for an additional 2 h at room 
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temperature to block nonspecific binding, followed by 3 h incubation at room 
temperature with various concentrations (10-5–10-12 M) of test compounds in the 
presence of biotinylated vitronectin (1 g/mL). Biotinylation was performed using an 
EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing, the 
plates were incubated for 1 hr at room temperature with biotinylated streptavidin–
peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min 
incubation with 100 L/well Substrate Reagent Solution (R&D Systems, Minneapolis, 
MN, USA) before stopping the reaction with the addition of 50 L/well 2N H2SO4. 
Absorbance at 415 nm was read in a SynergyTM HT Multi-Detection Microplate Reader 
(BioTek Instruments, Inc.). Each data point represents the average of triplicate wells; 
data analysis was carried out by nonlinear regression analysis with GraphPad Prism 
software. Each experiment was repeated in triplicate. 
Purified 51 receptor (R&D Systems, Minneapolis, MN) was diluted to 0.5 g/mL in 
coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 2 mM 
CaCl2, and 1 mM MgCl2. An aliquot of diluted receptor (100 L/well) was added to 96-
well microtiter plates (NUNC MW 96F Maxisorp Straight) and incubated overnight at 
4°C. The plates were then incubated with blocking solution (coating buffer plus 1% 
bovine serum albumin) for an additional 2 h at room temperature to block nonspecific 
binding, followed by 3 h incubation at room temperature with various concentrations 
(10-4–10-11 M) of test compounds in the presence of biotinylated fibronectin (1 g/mL). 
Fibronectin was purchased from Sigma. Biotinilation was performed using an EZ-Link 
Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL, USA). After washing, the plates were 
incubated for 1 h at room temperature with biotinylated streptavidin–peroxidase 
complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min incubation 
with 100 L/well Substrate Reagent Solution (R&D Systems, Minneapolis, MN) before 
stopping the reaction with the addition of 50 L/well 2N H2SO4. Absorbance at 415 nm 
was read in a SynergyTM HT Multi-Detection Microplate Reader (BioTek Instruments, 
Inc.). Each data point represents the average of triplicate wells; data analysis was 
carried out by nonlinear regression analysis with GraphPad Prism software. Each 
experiment was repeated in duplicate. 
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3.2.5 Fluorescence polarization-based BIR/IAP binding assay 
Recombinant XIAP (60 nM final concentration) and cIAP2 (25 nM) BIR3, or XIAP 
BIR23 (3 nM) domains were diluted in the assay buffer containing 100 mM 
potassium phosphate, pH 7.5, 100 μg/mL bovine γ-globulin and 0.02 % sodium 
azide. Serial dilutions of each tested compound (concentrations ranging from 2 
µM to 0.2 nM) were added to displace a fluorescent probe (FITC-SMAC for BIR3 
domains; SMAC-1F for BIR23)14 and fluorescence polarization was measured 
with the Ultra plate reader (Tecan), at excitation and emission wavelengths of 485 
nm and 530 nm, respectively. All experiments were performed in black, flat-
bottom 96 well plates (Greiner Bio-One). Three independent experiments were 
performed in duplicates. The analyses were performed using Graphpad Prism 
v.5.02. 
 
3.2.6 Measurement of cytotoxic activity 
Human breast MDA-MB231 and ovarian IGROV-1 carcinoma cell lines were 
cultured in vitro with RPMI plus 10% fetal calf serum. For cytotoxic experiments, 
104 cells were plated in 96 well plates and grown overnight before being treated 
with serial dilutions of the compounds (concentrations ranging from 25 µM to 10 
nM). Cell viability was determined after 72 hours using the CellTiter-Glo 
(Promega) assay for ATP. Three independent experiments were performed in 
triplicates. 
 
3.2.7 In vitro tube formation assay 
Matrigel Basement Membrane Matrix (10 mg/mL) was purchased from BD (Becton 
Dickinson Italy, Milan, Italy). Human umbilical vein endothelial cells (HUVEC) were 
obtained from PromoCell (PromoCell Gmbh, Germany). EndoGRO Basal Medium (BM) 
and rh-VEGF were purchased from Millipore (Millipore S.p.A., MI, Italy). HUVEC 
2.5x104 cells were seeded in a 24-well plate coated with 100 µL/well of BD-Matrigel 
previously polymerized for 1 h at 37 °C. Cells were treated with HUVEC+VEGF (10-8 M) 
and with HUVEC+VEGF (10-8 M) + tested compounds (MA, Ac-MA, c[DKP-3-RGD], 
Ac-MA-RGD) at three different concentrations (10-6 M, 10-9 M, 10-12 M) and incubated 
for 5 h at 37 °C in a moist atmosphere of 5% CO2. Tube‐like structure formation was 
evaluated by phase‐contrast microscopy using a fluorescence microscope (Axiovert 
40CFL, Carl Zeiss S.p.A. Milan, Italy). The total tube length (pixels) was quantified 
using Adobe Photoshop CS4 (Adobe). 
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30a:  
1H NMR (400 MHz, CD2Cl2) 
 
 
13C NMR (101 MHz, CD2Cl2) 
 
   Appendix 
 
 
219 
38a:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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39a:  
1H NMR (400 MHz, CD2Cl2) 
13C NMR (101 MHz, CD2Cl2) 
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40a:  
1H NMR (400 MHz, CD2Cl2) 
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41a:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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42a:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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43a:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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44a:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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45a:  
1H NMR (400 MHz, CD2Cl2) 
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46b:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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47b:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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49: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CD2Cl2) 
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50: 
 1H-NMR (400 MHz, CD2Cl2) 
 
13C-NMR (101 MHz, CD3OD) 
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51: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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53: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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54: 
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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55a:  
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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55b:  
1H NMR (400 MHz, CD2Cl2) 
 
13C NMR (101 MHz, CD2Cl2) 
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55c: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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55d: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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55e: 
1H-NMR (400 MHz, CD3OD) 
13C-NMR (101 MHz, CD2Cl2) 
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56a: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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56b: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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56c:  
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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56d:  
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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56e: 
1H-NMR (400 MHz, Acetone-d6) 
 
13C-NMR (101 MHz, Acetone-d6) 
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58a:  
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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58b: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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58c: 
1H NMR (400 MHz, DMSO-d6) 
 
b) 13C NMR (101 MHz, DMSO-d6) 
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58d: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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58e: 
1H-NMR (400 MHz, CD3OD) 
13C-NMR (101 MHz, CD3OD) 
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c[DKP-4-RGD]: 
1H NMR (400 MHz, H2O/D2O 9:1) 
13C NMR (101 MHz, D2O) 
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c[DKP-5-RGD]: 
1H NMR (400 MHz, H2O/D2O 9:1) 
 
13C NMR (101 MHz, D2O) 
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c[DKP-6-RGD]: 
1H NMR (400 MHz, H2O/D2O 9:1) 
13C NMR (101 MHz, D2O) 
 
Appendix 
 
252 
c[DKP-7-RGD]-A: 
1H NMR (400 MHz, H2O/D2O 9:1) 
 
13C NMR (101 MHz, D2O) 
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c[DKP-7-RGD]-B: 
1H NMR (400 MHz, H2O/D2O 9:1) 
 
13C NMR (101 MHz, D2O) 
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c[DKP-8-RGD]: 
1H-NMR (600 MHz, H2O/D2O 9:1) 
 
13C-NMR (151 MHz, D2O) 
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59a: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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59b: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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60a: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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60b: 
1H NMR (400 MHz, Acetone-d6) 
 
13C NMR (101 MHz, Acetone-d6) 
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62a: 
1H NMR (400 MHz, DMSO-d6) 
 
13C NMR (101 MHz, DMSO-d6) 
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62b: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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c[DKP-f4-RGD]: 
1H NMR (400 MHz, D2O) 
 
13C NMR (101 MHz, D2O) 
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c[DKP-f6-RGD]: 
1H NMR (400 MHz, D2O) 
 
13C NMR (101 MHz, D2O) 
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63a: 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (101 MHz, CDCl3) 
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64a: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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64b: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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66a: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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66b: 
1H NMR (400 MHz, CD3OD) 
13C NMR (101 MHz, CD3OD) 
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c[DKP-2-isoDGR]: 
1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) 
 
13C NMR (101 MHz, D2O, T= 298K) 
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c[DKP-3-isoDGR]: 
1H NMR (400 MHz, H2O/D2O 9:1, T= 298K) 
 
13C NMR (101 MHz, D2O, T= 298K) 
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86: 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (101 MHz, CD2Cl2) 
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87: 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (101 MHz, CD2Cl2) 
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89: 
1H NMR (400 MHz, THF-d8) 
13
C NMR (101 MHz, THF-d8) 
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90: 
1H NMR (400 MHz, acetone-d6) 
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91: 
1H NMR (400 MHz, acetone-d6) 
1
3C NMR (101 MHz, acetone-d6) 
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92: 
1H NMR (400 MHz, CD3OD) 
1
3C NMR (101 MHz, CD3OD) 
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c[DKP-RGD]-O-SMAC: 
1H NMR (400 MHz, CD3CN) 
1
3C NMR (101 MHz, CD3CN) 
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93: 
1H NMR (400 MHz, CD2Cl2) 
13C NMR (101 MHz, CD2Cl2) 
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94: 
1H NMR (400 MHz, acetone-d6) 
9
5: 
1H NMR (400 MHz, acetone-d6) 
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96: 
1H NMR (400 MHz, acetone-d6) 
1
3C NMR (101 MHz, acetone-d6) 
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97: 
1H NMR (400 MHz, CD3OD) 
13
C NMR (101 MHz, CD3OD) 
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c[DKP-RGD]-N-SMAC: 
1H NMR (400 MHz, CD3CN) 
1
3C NMR (101 MHz, CD3CN) 
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112: 
1H NMR (400 MHz, acetone-d6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Appendix 
 
 
283 
113: 
1H NMR (400 MHz, CD3OD) 
 
13C NMR (101 MHz, CD3OD) 
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MA: 
MS-MALDI-TOF (HCCA matrix) 
 
 
Ac-MA: 
MS-MALDI-TOF (SIN matrix) 
 
 
MA-RGD: 
MS-MALDI-TOF (SIN matrix) 
 
 
Ac-MA-RGD: 
MS-MALDI-TOF (HCCA matrix) 
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ABBREVIATIONS 
 
 
Amino acid  One-letter code Three-letter code 
Alanine A Ala 
Arginine R Arg 
Asparagine N Asn 
Aspartic D Asp 
Cysteine C Cys 
Glutamine Q Gln 
Glutamic acid E Glu 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Leucine L Leu 
Lysine K Lys 
Methionine M Met 
Phenylalanine F Phe 
Proline P Pro 
Serine S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine Y Tyr 
Valine V Val 
Unspecified amino acid X Xaa, Yaa 
 
 
D-amino acids are described by D-Xaa in the three-letter code and with the small letter in the 
one-letter code. 
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1D, 2D, 3D One / two / three- dimensional HBTU O-benzotriazole-N,N,N’,N’-
tetramethyl- 
uronium hexafluorophosphate 
Ac acetyl 
ACC  aminocyclopropanecarboxylic acid HMBC heteronuclear multiple bond 
correlation AcOH acetic acid 
ACPC  aminocyclopentanecarboxylic acid HOAt 1-Hydroxy-7-azabenzotriazole 
All allyl HOBt N-Hydroxybenzotriazole 
aq. aqueous solution HPLC high performance liquid 
chromatography Ar aryl 
Bn benzyl HSQC heteronuclear single quantum 
correlation Boc  tert-butyloxycarbonyl- 
Bu Butyl IC inhibitory capacity 
c- cyclo iPrOH propan-2-ol 
Cbz Benzyloxycarbonyl- IR Infrared Spectroscopy 
CD Circular Dichroism J Scalar coupling constants 
Conc.  Concentrated KHMDS potassium hexamethyldisilazane 
COSY Correlation Spectroscopy MALDI Matrix-assisted laser desorption 
 ionization DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide MC Monte Carlo 
DCM dichloromethane MD  molecular dynamics 
DIAD diisopropylazadicarboxylate Me methyl 
DIC diisopropylcarbodiimide MeOH methanol 
DIPEA diisopropylethylamine MIDAS Metal ion dependent site 
DKP diketopiperazine min. minutes 
DMAP dimethylaminopyridine MS Mass Spectroscopy 
DMF dimethylformamide MW  Molecular weight 
DMSO dimethylsulfoxyde NMR Nuclear Magnetic Resonance 
DPPA  diphenylphosphoric acid azide NOE Nuclear Overhauser Effect 
ECM Extracellular matix PG Protecting group 
EDC Ethyl-N,N-dimethyl-3-aminopropyl 
carbodiimide 
Ph Phenyl 
ppb Part per billion 
eq. equivalents ppm Part per million 
ESI  electrospray ionisation Py Pyridine 
Et Ethyl quant. quantitative 
Fmoc 9-Fluorenylmethoxycarbonyl quat. quaternary 
Fn Fibronectin r.t. room temperature 
h hours Rf Retention faktor 
HATU  O-(7-azabenzotriazol-1-yl)-tetramethyl- 
uronium hexafluorophosphate 
RMSD Root Mean Square Deviation 
ROESY Rotating Frame NOE spectroscopy TFE Trifluoroethanol 
sat. saturated THF  tetrahydrofurane 
SPPS  solid phase peptide synthesis TIS  triisopropylsilane 
tBu  tert-butyl TMS  trimethylsilyl 
TEA triethylamine TOCSY Total Correlation Spectroscopy 
tert tertiary tol toluene 
Tf  triflate UV Utraviolet Spectroscopy 
TFA trifluoroacetic acid δ Chemical shift 
 
